

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/12, C07K 14/47, A61K 31/70,</b> <b>35/12, 38/13, C07K 16/18, G01N 33/574,</b> <b>C12Q 1/68</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/20587</b>  <b>(43) International Publication Date:</b> 13 April 2000 (13.04.00)
<b>(21) International Application Number:</b> PCT/US99/22873  <b>(22) International Filing Date:</b> 4 October 1999 (04.10.99)  <b>(30) Priority Data:</b> 09/166,300           5 October 1998 (05.10.98)       US 09/166,350           5 October 1998 (05.10.98)       US  <b>(71) Applicant:</b> LUDWIG INSTITUTE FOR CANCER RE- SEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US).  <b>(72) Inventors:</b> OBATA, Yuichi; Chikusa-Ku, Nagoya 464 (JP). GOUT, Ivan; 91 Riding House Street, London W1P 8BT (GB). TURECI, Ozlem; Innere Medizin 1, D-66421 Hom- burg/Saar (DE). SAHIN, Ugar; Innere Medizin 1, D-66421 Homburg/Saar (DE). PFREUNDSCHUH, Michael; Innere Medizin 1, D-66421 Homburg/Saar (DE). SCANLAN, Matthew, J.; 1275 York Avenue, New York, NY 10021 (US). STOCKERT, Elisabeth; 1275 York Avenue, New York, NY 10021 (US). CHEN, Yao-Tseng; 525 East 68th Street, New York, NY 10021 (US). OLD, Lloyd, J.; 605 Third Avenue, New York, NY 10158 (US). JAGER, Elke; Hohl 2-28, D-60488 Frankfurt am Main (DE). KNUTH, Alex; Hohl 2-28, D-60488 Frankfurt am Main (DE).	<b>(74) Agent:</b> VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).  <b>(81) Designated States:</b> AU, CA, CN, JP, KR, NZ, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished          upon receipt of that report.</i>	
<b>(54) Title:</b> CANCER ASSOCIATED ANTIGENS AND USES THEREFOR		
<b>(57) Abstract</b>  <p>Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in renal cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with renal cancer. The invention provides, <i>inter alia</i>, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



### **Summary of the Invention**

Autologous antibody screening has now been applied to renal cancer using antisera from cancer patients. Numerous cancer associated antigens have been identified. The invention provides, *inter alia*, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and CTLs which recognize the proteins and peptides. Fragments including functional fragments and variants of the foregoing also are provided. Kits containing the foregoing molecules additionally are provided. The foregoing can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

Prior to the present invention, only a handful of cancer associated genes had been identified in the past 20 years. The invention involves the surprising discovery of several genes, some previously known and some previously unknown, which are expressed in individuals who have cancer. These individuals all have serum antibodies against the proteins (or fragments thereof) encoded by these genes. Thus, abnormally expressed genes are recognized by the host's immune system and therefore can form a basis for diagnosis, monitoring and therapy.

The invention involves the use of a single material, a plurality of different materials and even large panels and combinations of materials. For example, a single gene, a single protein encoded by a gene, a single functional fragment thereof, a single antibody thereto, etc. can be used in methods and products of the invention. Likewise, pairs, groups and even panels of these materials and optionally other cancer associated antigen genes and/or gene products can be used for diagnosis, monitoring and therapy. The pairs, groups or panels can involve 2, 3, 4, 5 or more genes, gene products, fragments thereof or agents that recognize such materials. A plurality of such materials are not only useful in monitoring, typing, characterizing and diagnosing cells abnormally expressing such genes, but a plurality of such materials can be used therapeutically. An example of the use of a plurality of such materials for the prevention, delay of onset, amelioration, etc. of cancer cells, which express or will express such genes prophylactically or acutely. Any and all combinations of the genes, gene products, and materials which recognize the genes and gene products can be tested and identified for use according to the invention. It would be far too lengthy to recite all such combinations; those skilled in the art, particularly in view of the teaching contained herein,

## **CANCER ASSOCIATED ANTIGENS AND USES THEREFOR**

### **Field of the Invention**

The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with a variety of cancers. The invention also relates to agents which bind the nucleic acids or polypeptides. The nucleic acid molecules, polypeptides coded for by such molecules and peptides derived therefrom, as well as related antibodies and cytolytic T lymphocytes, are useful, *inter alia*, in diagnostic and therapeutic contexts.

### **Background of the Invention**

The mechanism by which T cells recognize foreign materials has been implicated in cancer. A number of cytolytic T lymphocyte (CTL) clones directed against autologous melanoma antigens, testicular antigens, and melanocyte differentiation antigens have been described. In many instances, the antigens recognized by these clones have been characterized.

The use of autologous CTLs for identifying tumor antigens requires that the target cells which express the antigens can be cultured *in vitro* and that stable lines of autologous CTL clones which recognize the antigen-expressing cells can be isolated and propagated. While this approach has worked well for melanoma antigens, other tumor types, such as epithelial cancers including breast and colon cancer, have proved refractory to the approach.

More recently another approach to the problem has been described by Sahin et al. (*Proc. Natl. Acad. Sci. USA* 92:11810-11813, 1995). According to this approach, autologous antisera are used to identify immunogenic protein antigens expressed in cancer cells by screening expression libraries constructed from tumor cell cDNA. Antigen-encoding clones so identified have been found to have elicited an high-titer humoral immune response in the patients from which the antisera were obtained. Such a high-titer IgG response implies helper T cell recognition of the detected antigen. These tumor antigens can then be screened for the presence of MHC/HLA class I and class II motifs and reactivity with CTLs

Presently there is a need for additional cancer antigens for development of therapeutics and diagnosis applicable to a greater number of cancer patients having various cancers.

will readily be able to determine which combinations are most appropriate for which circumstances.

As will be clear from the following discussion, the invention has *in vivo* and *in vitro* uses, including for therapeutic, diagnostic, monitoring and research purposes. One aspect of the invention is the ability to fingerprint a cell expressing a number of the genes identified according to the invention by, for example, quantifying the expression of such gene products.

Such fingerprints will be characteristic, for example, of the stage of the cancer, the type of the cancer, or even the effect in animal models of a therapy on a cancer. Cells also can be screened to determine whether such cells abnormally express the genes identified according to the invention.

The invention, in one aspect, is a method of diagnosing a disorder characterized by expression of a cancer associated antigen precursor coded for by a nucleic acid molecule. The method involves the steps of contacting a biological sample isolated from a subject with an agent that specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an MHC, preferably an HLA, molecule, wherein the nucleic acid molecule is a NA Group 1 nucleic acid molecule, and determining the interaction between the agent and the nucleic acid molecule, the expression product or fragment of the expression product as a determination of the disorder.

In one embodiment the agent is selected from the group consisting of (a) a nucleic acid molecule comprising NA Group 1 nucleic acid molecules or a fragment thereof, (b) a nucleic acid molecule comprising NA Group 3 nucleic acid molecules or a fragment thereof, (c) a nucleic acid molecule comprising NA Group 5 nucleic acid molecules or a fragment thereof, (d) an antibody that binds to an expression product, or a fragment thereof, of NA group 1 nucleic acids, (e) an antibody that binds to an expression product, or a fragment thereof, of NA group 3 nucleic acids, (f) an antibody that binds to an expression product, or a fragment thereof, of NA group 5 nucleic acids, (g) an agent that binds to a complex of an MHC, preferably HLA, molecule and a fragment of an expression product of a NA Group 1 nucleic acid, (h) an agent that binds to a complex of an MHC, preferably HLA, molecule and a fragment of an expression product of a NA group 3 nucleic acid, and (i) an agent that binds to a complex of an MHC, preferably HLA, molecule and a fragment of an expression product of a NA Group 5 nucleic acid.

The disorder may be characterized by expression of a plurality of cancer associated

antigen precursors. Thus the methods of diagnosis may include use of a plurality of agents, each of which is specific for a different human cancer associated antigen precursor (including at least one of the cancer associated antigen precursors disclosed herein), and wherein said plurality of agents is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 such agents.

In each of the above embodiments the agent may be specific for a human cancer associated antigen precursor that is selected from the group consisting of breast, gastric, lung, prostate, renal, colon, thyroid, Hodgkin's disease, and hepatocarcinoma cancer associated antigen precursors.

In another aspect the invention is a method for determining regression, progression or onset of a condition characterized by expression of abnormal levels of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule. The method involves the steps of monitoring a sample, from a subject who has or is suspected of having the condition, for a parameter selected from the group consisting of (i) the protein, (ii) a peptide derived from the protein, (iii) an antibody which selectively binds the protein or peptide, and (iv) cytolytic T cells specific for a complex of the peptide derived from the protein and an MHC molecule, as a determination of regression, progression or onset of said condition. In one embodiment the sample is a body fluid, a body effusion or a tissue.

In another embodiment the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of (a) an antibody which selectively binds the protein of (i), or the peptide of (ii), (b) a protein or peptide which binds the antibody of (iii), and (c) a cell which presents the complex of the peptide and MHC molecule of (iv). In a preferred embodiment the antibody, the protein, the peptide or the cell is labeled with a radioactive label or an enzyme. The sample in a preferred embodiment is assayed for the peptide.

According to another embodiment the nucleic acid molecule is one of the following: a NA Group 3 molecule or a NA Group 5 molecule. In yet another embodiment the protein is a plurality of proteins, the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins. In certain embodiments the protein is a plurality of proteins, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and wherein the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of

proteins.

The invention in another aspect is a pharmaceutical preparation for a human subject. The pharmaceutical preparation includes an agent which when administered to the subject enriches selectively the presence of complexes of an HLA molecule and a human cancer associated antigen, and a pharmaceutically acceptable carrier, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule which comprises a NA Group 1 molecule. In one embodiment the nucleic acid molecule is a NA Group 3 nucleic acid molecule.

The agent in one embodiment comprises a plurality of agents, each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen. Preferably the plurality is at least two, at least three, at least four or at least 5 different such agents.

In certain embodiments, the agent comprises a plurality of agents, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen.

In another embodiment the agent is selected from the group consisting of (1) an isolated polypeptide comprising the human cancer associated antigen, or a functional variant thereof, (2) an isolated nucleic acid operably linked to a promoter for expressing the isolated polypeptide, or functional variant thereof, (3) a host cell expressing the isolated polypeptide, or functional variant thereof, and (4) isolated complexes of the polypeptide, or functional variants thereof, and an HLA molecule.

The agent may be a cell expressing an isolated polypeptide. In one embodiment the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof. In another embodiment the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof, and wherein the cell expresses an HLA molecule that binds the polypeptide. The cell can express one or both of the polypeptide and HLA molecule recombinantly. In preferred embodiments the cell is nonproliferative. In other preferred embodiments, the isolated polypeptide is or includes a kinectin polypeptide. In yet another embodiment the agent is at least two, at least three, at least four or at least five different polypeptides, each representing a different human cancer associated antigen or functional variant thereof.

The agent in one embodiment is a PP Group 2 polypeptide. In other embodiments the agent is a PP Group 3 polypeptide or a PP Group 4 polypeptide.

In an embodiment each of the pharmaceutical preparations described herein also includes an adjuvant.

According to another aspect the invention, a composition is provided which includes an isolated agent that binds selectively a PP Group 1 polypeptide. In separate embodiments the agent binds selectively to a polypeptide selected from the following: a PP Group 2 polypeptide, a PP Group 3 polypeptide, a PP Group 4 polypeptide, and a PP Group 5 polypeptide. In other embodiments, the agent is a plurality of different agents that bind selectively at least two, at least three, at least four, or at least five different such polypeptides. In each of the above described embodiments the agent may be an antibody. In a preferred embodiment, at least one of polypeptides is kinectin or a fragment thereof.

In another aspect the invention is a composition of matter composed of a conjugate of the agent of the above-described compositions of the invention and a therapeutic or diagnostic agent. Preferably the conjugate is of the agent and a therapeutic or diagnostic that is an antineoplastic.

The invention in another aspect is a pharmaceutical composition which includes an isolated nucleic acid molecule selected from the group consisting of: (1) NA Group 1 molecules, and (2) NA Group 2 molecules, and a pharmaceutically acceptable carrier. In one embodiment the isolated nucleic acid molecule comprises a NA Group 3 or NA Group 4 molecule. In another embodiment the isolated nucleic acid molecule comprises at least two isolated nucleic acid molecules coding for two different polypeptides, each polypeptide comprising a different cancer associated antigen. In preferred embodiments, at least one of the polypeptides is a kinectin polypeptide.

Preferably the pharmaceutical composition also includes an expression vector with a promoter operably linked to the isolated nucleic acid molecule. In another embodiment the pharmaceutical composition also includes a host cell recombinantly expressing the isolated nucleic acid molecule.

According to another aspect of the invention a pharmaceutical composition is provided. The pharmaceutical composition includes an isolated polypeptide comprising a PP Group 1 or a PP Group 2 polypeptide, and a pharmaceutically acceptable carrier. In one embodiment the isolated polypeptide comprises a PP Group 3 or a PP Group 4 polypeptide.

In another embodiment the isolated polypeptide comprises at least two different polypeptides, each comprising a different cancer associated antigen at least one of which is encoded by a NA group 1 molecule as disclosed herein. In separate embodiments the isolated polypeptides are selected from the following: PP Group 3 polypeptides or HLA binding fragments thereof and PP Group 5 polypeptides or HLA binding fragments thereof.

In an embodiment each of the pharmaceutical compositions described herein also includes an adjuvant.

Another aspect the invention is an isolated nucleic acid molecule comprising a NA Group 3 molecule. Another aspect the invention is an isolated nucleic acid molecule comprising a NA Group 4 molecule.

The invention in another aspect is an isolated nucleic acid molecule selected from the group consisting of (a) a fragment of a nucleic acid selected from the group of nucleic acid molecules consisting of SEQ ID Nos numbered below and comprising all nucleic acid sequences among SEQ ID NOs 1-11 and 22-46, of sufficient length to represent a sequence unique within the human genome, and identifying a nucleic acid encoding a human cancer associated antigen precursor, (b) complements of (a), provided that the fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of (1) sequences having the GenBank accession numbers of Table 1, (2) complements of (1), and (3) fragments of (1) and (2).

In one embodiment the sequence of contiguous nucleotides is selected from the group consisting of: (1) at least two contiguous nucleotides nonidentical to the sequences in Table 1, (2) at least three contiguous nucleotides nonidentical to the sequences in Table 1, (3) at least four contiguous nucleotides nonidentical to the sequences in Table 1, (4) at least five contiguous nucleotides nonidentical to the sequences in Table 1, (5) at least six contiguous nucleotides nonidentical to the sequences in Table 1, or (6) at least seven contiguous nucleotides nonidentical to the sequences in Table 1.

In another embodiment the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, 200 nucleotides, 1000 nucleotides and every integer length therebetween.

In yet another embodiment the molecule encodes a polypeptide which, or a fragment

of which, binds a human HLA receptor or a human antibody.

Another aspect of the invention is an expression vector comprising an isolated nucleic acid molecule of the invention described above operably linked to a promoter.

According to one aspect the invention is an expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 1 or Group 2 molecule. In another aspect the invention is an expression vector comprising a NA Group 1 or Group 2 molecule and a nucleic acid encoding an MHC, preferably HLA, molecule.

In yet another aspect the invention is a host cell transformed or transfected with an expression vector of the invention described above.

In another aspect the invention is a host cell transformed or transfected with an expression vector comprising an isolated nucleic acid molecule of the invention described above operably linked to a promoter, or an expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 1 or 2 molecule and further comprising a nucleic acid encoding HLA.

According to another aspect of the invention an isolated polypeptide encoded by the isolated nucleic acid molecules the invention, described above, is provided. These include PP Group 1-5 polypeptides. The invention also includes a fragment of the polypeptide which is immunogenic. In one embodiment the fragment, or a portion of the fragment, binds HLA or a human antibody. In still another aspect the invention provides as isolated polypeptide comprising a fragment of a kinectin polypeptide which is immunogenic.

The invention includes in another aspect an isolated fragment of a human cancer associated antigen precursor which, or portion of which, binds HLA or a human antibody, wherein the precursor is encoded by a nucleic acid molecule that is a NA Group 1 molecule. In one embodiment the fragment is part of a complex with HLA. In another embodiment the fragment is between 8 and 12 amino acids in length. In another embodiment the invention includes an isolated polypeptide comprising a fragment of the polypeptide of sufficient length to represent a sequence unique within the human genome and identifying a polypeptide that is a human cancer associated antigen precursor.

According to another aspect of the invention a kit for detecting the presence of the expression of a cancer associated antigen precursor is provided. The kit includes a pair of isolated nucleic acid molecules each of which consists essentially of a molecule selected from the group consisting of (a) a 12-32 nucleotide contiguous segment of the nucleotide sequence



of any of the NA Group 1 molecules and (b) complements of ("a"), wherein the contiguous segments are nonoverlapping. In one embodiment the pair of isolated nucleic acid molecules is constructed and arranged to selectively amplify an isolated nucleic acid molecule that is a NA Group 3 molecule. Preferably, the pair amplifies a human NA Group 3 molecule.

According to another aspect of the invention a method for treating a subject with a disorder characterized by expression of a human cancer associated antigen precursor is provided. The method includes the step of administering to the subject an amount of an agent, which enriches selectively in the subject the presence of complexes of an HLA molecule and a human cancer associated antigen, effective to ameliorate the disorder, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules, (b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules, (c) a nucleic acid molecule comprising NA group 5 nucleic acid molecules.

In one embodiment the disorder is characterized by expression of a plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which enriches selectively in the subject the presence of complexes of an HLA molecule and a different human cancer associated antigen. Preferably the plurality is at least 2, at least 3, at least 4, or at least 5 such agents. In a preferred embodiment, at least one of the human cancer associated antigens is kinectin or a fragment thereof.

In another embodiment the agent is an isolated polypeptide selected from the group consisting of PP Group 1, PP Group 2, PP Group 3, PP Group 4, and PP group 5 polypeptides.

In yet another embodiment the disorder is cancer.

According to another aspect the invention is a method for treating a subject having a condition characterized by expression of a cancer associated antigen precursor in cells of the subject. The method includes the steps of (i) removing an immunoreactive cell containing sample from the subject, (ii) contacting the immunoreactive cell containing sample to the host cell under conditions favoring production of cytolytic T cells against a human cancer associated antigen which is a fragment of the precursor, (iii) introducing the cytolytic T cells to the subject in an amount effective to lyse cells which express the human cancer associated antigen, wherein the host cell is transformed or transfected with an expression vector comprising an isolated nucleic acid molecule operably linked to a promoter, the isolated

nucleic acid molecule being selected from the group of nucleic acid molecules consisting of NA Group 1, NA Group 2, NA Group 3, NA Group 4, NA Group 5.

In one embodiment the host cell recombinantly expresses an HLA molecule which binds the human cancer associated antigen. In another embodiment the host cell endogenously expresses an HLA molecule which binds the human cancer associated antigen.

The invention includes in another aspect a method for treating a subject having a condition characterized by expression of a cancer associated antigen precursor in cells of the subject. The method includes the steps of (i) identifying a nucleic acid molecule expressed by the cells associated with said condition, wherein said nucleic acid molecule is a NA Group 1 molecule (ii) transfecting a host cell with a nucleic acid selected from the group consisting of (a) the nucleic acid molecule identified, (b) a fragment of the nucleic acid identified which includes a segment coding for a cancer associated antigen, (c) deletions, substitutions or additions to (a) or (b), and (d) degenerates of (a), (b), or (c); (iii) culturing said transfected host cells to express the transfected nucleic acid molecule, and; (iv) introducing an amount of said host cells or an extract thereof to the subject effective to increase an immune response against the cells of the subject associated with the condition. Preferably, the antigen is a human antigen and the subject is a human. In certain preferred embodiments the nucleic acid molecule is a kinectin nucleic acid molecule.

In one embodiment the method also includes the step of (a) identifying an MHC molecule which presents a portion of an expression product of the nucleic acid molecule, wherein the host cell expresses the same MHC molecule as identified in (a) and wherein the host cell presents an MHC binding portion of the expression product of the nucleic acid molecule.

In another embodiment the method also includes the step of treating the host cells to render them non-proliferative.

In yet another embodiment the immune response comprises a B-cell response or a T cell response. Preferably the response is a T-cell response which comprises generation of cytolytic T-cells specific for the host cells presenting the portion of the expression product of the nucleic acid molecule or cells of the subject expressing the human cancer associated antigen.

In another embodiment the nucleic acid molecule is a NA Group 3 molecule.

Another aspect of the invention is a method for treating or diagnosing or monitoring a

subject having a condition characterized by expression of an abnormal amount of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule. The method includes the step of administering to the subject an antibody which specifically binds to the protein or a peptide derived therefrom, the antibody being coupled to a therapeutically useful agent, in an amount effective to treat the condition.

In one embodiment the antibody is a monoclonal antibody. Preferably the monoclonal antibody is a chimeric antibody or a humanized antibody.

In another aspect the invention is a method for treating a condition characterized by expression in a subject of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule. The method involves the step of administering to a subject at least one of the pharmaceutical compositions of the invention described above in an amount effective to prevent, delay the onset of, or inhibit the condition in the subject. In one embodiment the condition is cancer. In another embodiment the method includes the step of first identifying that the subject expresses in a tissue abnormal amounts of the protein.

The invention in another aspect is a method for treating a subject having a condition characterized by expression of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule. The method includes the steps of (i) identifying cells from the subject which express abnormal amounts of the protein; (ii) isolating a sample of the cells; (iii) cultivating the cells, and (iv) introducing the cells to the subject in an amount effective to provoke an immune response against the cells.

In one embodiment the method includes the step of rendering the cells non-proliferative, prior to introducing them to the subject.

In another aspect the invention is a method for treating a pathological cell condition characterized by abnormal expression of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule. The method includes the step of administering to a subject in need thereof an effective amount of an agent which inhibits the expression or activity of the protein.

In one embodiment the agent is an inhibiting antibody which selectively binds to the protein and wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or a fragment thereof. In another embodiment the agent is an antisense nucleic acid molecule which selectively binds to the nucleic acid molecule which encodes the protein. In yet another important embodiment the nucleic acid molecule is a NA Group 3 nucleic acid

molecule. In other preferred embodiments, the nucleic acid molecule is a kinectin nucleic acid molecule.

The invention includes in another aspect a composition of matter useful in stimulating an immune response to a plurality of proteins encoded by nucleic acid molecules that are NA Group 1 molecules. The composition is a plurality of peptides derived from the amino acid sequences of the proteins, wherein the peptides bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein. In preferred embodiments, at least one of the proteins is kinectin.

In one embodiment at least a portion of the plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto. In another embodiment the composition of matter includes an adjuvant. In another embodiment the adjuvant is a saponin, GM-CSF, or an interleukin. In still another embodiment, the compositions also includes at least one peptide useful in stimulating an immune response to at least one protein which is not encoded by nucleic acid molecules that are NA Group 1 molecules, wherein the at least one peptide binds to one or more MHC molecules.

According to another aspect the invention is an isolated antibody which selectively binds to a complex of: (i) a peptide derived from a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule and (ii) and an MHC molecule to which binds the peptide to form the complex, wherein the isolated antibody does not bind to (i) or (ii) alone.

In one embodiment the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or a fragment thereof.

The invention also involves the use of the genes, gene products, fragments thereof, agents which bind thereto, and so on in the preparation of medicaments. A particular medicament is for treating cancer and a more particular medicament is for treating breast cancer, lung cancer, renal cancer, colon cancer, prostate cancer or gastric cancer.

### **Detailed Description of the Invention**

In the above summary and in the ensuing description, lists of sequences are provided. The lists are meant to embrace each single sequence separately, two or more sequences together where they form a part of the same gene, any combination of two or more sequences which relate to different genes, including and up to the total number on the list, as if each and every combination were separately and specifically enumerated. Likewise, when mentioning

fragment size, it is intended that a range embrace the smallest fragment mentioned to the full-length of the sequence (less one nucleotide or amino acid so that it is a fragment), each and every fragment length intended as if specifically enumerated. Thus, if a fragment could be between 10 and 15 in length, it is explicitly meant to mean 10, 11, 12, 13, 14, or 15 in length.

The summary and the claims mention antigen precursors and antigens. As used in the summary and in the claims, a precursor is substantially the full-length protein encoded by the coding region of the isolated DNA and the antigen is a peptide which complexes with MHC, preferably HLA, and which participates in the immune response as part of that complex. Such antigens are typically 9 amino acids long, although this may vary slightly.

As used herein, a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. In all embodiments human cancer antigens and human subjects are preferred.

The present invention in one aspect involves the cloning of cDNAs encoding human cancer associated antigen precursors using autologous antisera of subjects having renal cancer. The sequences of the clones representing genes identified according to the methods described herein are presented in the attached Sequence Listing. Of the foregoing, it can be seen that some of the clones are considered completely novel as no nucleotide or amino acid homologies to coding regions were found in the databases searched. Other clones are novel but have some homology to sequences deposited in databases (mainly EST sequences). Nevertheless, the entire gene sequence was not previously known. In some cases no function was suspected and in other cases, even if a function was suspected, it was not known that the gene was associated with cancer. In all cases, it was not known or suspected that the gene encoded a cancer antigen which reacted with antibody from autologous sera. Analysis of the clone sequences by comparison to nucleic acid and protein databases determined that still other of the clones surprisingly are closely related to other previously-cloned genes. The sequences of these related genes is also presented in the Sequence Listing. The nature of the foregoing genes as encoding antigens recognized by the immune systems of cancer patients is, of course, unexpected.

The invention thus involves in one aspect cancer associated antigen polypeptides, genes encoding those polypeptides, functional modifications and variants of the foregoing, useful fragments of the foregoing, as well as diagnostics and therapeutics relating thereto.

Homologs and alleles of the cancer associated antigen nucleic acids of the invention

can be identified by conventional techniques. Thus, an aspect of the invention is those nucleic acid sequences which code for cancer associated antigen precursors. Because this application contains so many sequences, the following chart is provided to identify the various groups of sequences discussed in the claims and in the summary:

### Nucleic Acid Sequences

NA Group 1. (a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of a nucleic acid sequence selected from the group consisting of nucleic acid sequences among SEQ ID NOs: 1-11 and 22-46 and which code for a cancer associated antigen precursor,

(b) deletions, additions and substitutions which code for a respective cancer associated antigen precursor,

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

NA Group 2. Fragments of NA Group 1, which codes for a polypeptide which, or a portion of which, binds an MHC molecule to form a complex recognized by a an autologous antibody or lymphocyte.

NA Group 3. The subset of NA Group 1 where the nucleotide sequence is selected from the group consisting of:

(a) previously unknown human nucleic acids coding for a human cancer associated antigen precursor (i.e. nucleic acid sequences among SEQ ID NOs: 1-11),

(b) deletions, additions and substitutions which code for a respective human cancer associated antigen precursor,

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

NA Group 4. Fragments of NA Group 3, which code for a polypeptide which, or a portion of which, binds to an MHC molecule to form a complex recognized by an autologous antibody or lymphocyte.

NA Group 5. A subset of NA Group 1, comprising human cancer associated antigens that react with allogeneic cancer antisera.

#### Polypeptide Sequences

- PP Group 1. Polypeptides encoded by NA Group 1.
- PP Group 2. Polypeptides encoded by NA Group 2
- PP Group 3. Polypeptides encoded by NA Group 3.
- PP Group 4. Polypeptides encoded by NA Group 4.
- PP Group 5. Polypeptides encoded by NA Group 5.

The term "stringent conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH<sub>2</sub>PO<sub>4</sub>(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the DNA is transferred is washed, for example, in 2 x SSC at room temperature and then at 0.1 - 0.5 x SSC/0.1 x SDS at temperatures up to 68°C.

There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of cancer associated antigen nucleic acids of the invention (e.g., by using lower stringency conditions). The skilled artisan also is familiar with the methodology for screening

cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In general homologs and alleles typically will share at least 75% nucleotide identity and/or at least 90% amino acid identity to the sequences of cancer associated antigen nucleic acid and polypeptides, respectively, in some instances will share at least 90% nucleotide identity and/or at least 95% amino acid identity and in still other instances will share at least 95% nucleotide identity and/or at least 99% amino acid identity. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland) that can be obtained through the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST system available at <http://www.ncbi.nlm.nih.gov>, using default settings. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using the MacVector sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

In screening for cancer associated antigen genes, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal. In screening for the expression of cancer associated antigen nucleic acids, Northern blot hybridizations using the foregoing conditions (see also the Examples) can be performed on samples taken from breast cancer patients or subjects suspected of having a condition characterized by expression of breast cancer associated antigen genes. Amplification protocols such as polymerase chain reaction using primers which hybridize to the sequences presented also can be used for detection of the cancer associated antigen genes or expression thereof.

The renal cancer associated genes correspond to SEQ ID NOs. 1-11 and 22-35. Kinectin cancer associated sequences correspond to SEQ ID Nos:36-46. The preferred cancer associated antigens for the methods of diagnosis disclosed herein are those which were found to react with allogeneic cancer antisera (i.e. NA Group 5). Encoded polypeptides (e.g., proteins), peptides and antisera thereto are also preferred for diagnosis.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the



purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating breast cancer associated antigen polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. In preferred embodiments, these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as antigenicity, enzymatic activity, receptor binding, formation of complexes by binding of peptides by MHC class I and class II molecules, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

For example, modified nucleic acid molecules which encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of

modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.

The invention also provides isolated unique fragments of cancer associated antigen nucleic acid sequences or complements thereof. A unique fragment is one that is a 'signature' for the larger nucleic acid. It, for example, is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the cancer associated antigen nucleic acids defined above (and human alleles). Those of ordinary skill in the art may apply no more than routine procedures to determine if a fragment is unique within the human genome. Unique fragments, however, exclude fragments completely composed of the nucleotide sequences of any of GenBank accession numbers listed in Table 1 or other previously published sequences as of the filing date of the priority documents for sequences listed in a respective priority document or the filing date of this application for sequences listed for the first time in this application which overlap the sequences of the invention.

A fragment which is completely composed of the sequence described in the foregoing GenBank deposits is one which does not include any of the nucleotides unique to the sequences of the invention. Thus, a unique fragment must contain a nucleotide sequence other than the exact sequence of those in GenBank or fragments thereof. The difference may be an addition, deletion or substitution with respect to the GenBank sequence or it may be a sequence wholly separate from the GenBank sequence.

Unique fragments can be used as probes in Southern and Northern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, or for generating immunoassay components. Likewise, unique fragments can be employed to produce nonfused fragments of the cancer associated antigen polypeptides,

useful, for example, in the preparation of antibodies, and in immunoassays. Unique fragments further can be used as antisense molecules to inhibit the expression of cancer associated antigen nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of cancer associated antigen sequences and complements thereof will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 or more bases long, up to the entire length of the disclosed sequence. As mentioned above, this disclosure intends to embrace each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 8 nucleotides short of the end, and ending anywhere from nucleotide number 8, 9, 10 and so on for each sequence, up to the very last nucleotide (provided the sequence is unique as described above).

Virtually any segment of the polypeptide coding region of novel cancer associated antigen nucleic acids, or complements thereof, that is 18 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from other sequences in the human genome of the fragment to those on known databases typically is all that is necessary, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

Especially preferred include nucleic acids encoding a series of epitopes, known as "polytopes". The epitopes can be arranged in sequential or overlapping fashion (*see, e.g.*, Thomson et al., *Proc. Natl. Acad. Sci. USA* 92:5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15:1280-1284, 1997), with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired. The polytope is processed to generate individual epitopes which are recognized by the immune system for generation of immune responses.

Thus, for example, peptides derived from a polypeptide having an amino acid sequence encoded by one of the nucleic acid disclosed herein, and which are presented by MHC molecules and recognized by CTL or T helper lymphocytes, can be combined with peptides from one or more other cancer associated antigens (e.g. by preparation of hybrid

nucleic acids or polypeptides) to form "polytopes". The two or more peptides (or nucleic acids encoding the peptides) can be selected from those described herein, or they can include one or more peptides of previously known cancer associated antigens. Exemplary cancer associated peptide antigens that can be administered to induce or enhance an immune response are derived from tumor associated genes and encoded proteins including MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12, MAGE-13, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, BAGE-1, RAGE-1, LB33/MUM-1, PRAME, NAG, MAGE-B2, MAGE-B3, MAGE-B4, tyrosinase, brain glycogen phosphorylase, Melan-A, MAGE-C1, MAGE-C2, NY-ESO-1, LAGE-1, SSX-1, SSX-2 (HOM-MEL-40) SSX-4, SSX-5, SCP-1 and CT-7. See, for example, PCT application publication no. WO96/10577. Other examples will be known to one of ordinary skill in the art (for example, see Coulic, *Stem Cells* 13:393-403, 1995), and can be used in the invention in a like manner as those disclosed herein. One of ordinary skill in the art can prepare polypeptides comprising one or more peptides and one or more of the foregoing cancer associated peptides, or nucleic acids encoding such polypeptides, according to standard procedures of molecular biology.

Thus polytopes are groups of two or more potentially immunogenic or immune response stimulating peptides which can be joined together in various arrangements (e.g. concatenated, overlapping). The polytope (or nucleic acid encoding the polytope) can be administered in a standard immunization protocol, e.g. to animals, to test the effectiveness of the polytope in stimulating, enhancing and/or provoking an immune response.

The peptides can be joined together directly or via the use of flanking sequences to form polytopes, and the use of polytopes as vaccines is well known in the art (see, e.g., Thomson et al., *Proc. Acad. Natl. Acad. Sci USA* 92(13):5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15(12):1280-1284, 1997; Thomson et al., *J. Immunol.* 157(2):822-826, 1996; Tam et al., *J. Exp. Med.* 171(1):299-306, 1990). For example, Tam showed that polytopes consisting of both MHC class I and class II binding epitopes successfully generated antibody and protective immunity in a mouse model. Tam also demonstrated that polytopes comprising "strings" of epitopes are processed to yield individual epitopes which are presented by MHC molecules and recognized by CTLs. Thus polytopes containing various numbers and combinations of epitopes can be prepared and tested for recognition by CTLs

and for efficacy in increasing an immune response.

It is known that tumors express a set of tumor antigens, of which only certain subsets may be expressed in the tumor of any given patient. Polytopes can be prepared which correspond to the different combination of epitopes representing the subset of tumor rejection antigens expressed in a particular patient. Polytopes also can be prepared to reflect a broader spectrum of tumor rejection antigens known to be expressed by a tumor type. Polytopes can be introduced to a patient in need of such treatment as polypeptide structures, or via the use of nucleic acid delivery systems known in the art (see, e.g., Allsopp et al., *Eur. J. Immunol.* 26(8):1951-1959, 1996). Adenovirus, pox virus, Ty-virus like particles, adeno-associated virus, plasmids, bacteria, etc. can be used in such delivery. One can test the polytope delivery systems in mouse models to determine efficacy of the delivery system. The systems also can be tested in human clinical trials.

In instances in which a human HLA class I molecule presents tumor rejection antigens derived from cancer associated nucleic acids, the expression vector may also include a nucleic acid sequence coding for the HLA molecule that presents any particular tumor rejection antigen derived from these nucleic acids and polypeptides. Alternatively, the nucleic acid sequence coding for such a HLA molecule can be contained within a separate expression vector. In a situation where the vector contains both coding sequences, the single vector can be used to transfect a cell which does not normally express either one. Where the coding sequences for a cancer associated antigen precursor and the HLA molecule which presents it are contained on separate expression vectors, the expression vectors can be cotransfected. The cancer associated antigen precursor coding sequence may be used alone, when, e.g. the host cell already expresses a HLA molecule which presents a cancer associated antigen derived from precursor molecules. Of course, there is no limit on the particular host cell which can be used. As the vectors which contain the two coding sequences may be used in any antigen-presenting cells if desired, and the gene for cancer associated antigen precursor can be used in host cells which do not express a HLA molecule which presents a cancer associated antigen. Further, cell-free transcription systems may be used in lieu of cells.

As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a cancer associated antigen polypeptide, to reduce the expression of cancer associated antigens. This is desirable in virtually any medical condition wherein a reduction of expression of cancer associated antigens is

desirable, e.g., in the treatment of cancer. This is also useful for *in vitro* or *in vivo* testing of the effects of a reduction of expression of one or more cancer associated antigens.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the sequences of nucleic acids encoding breast cancer associated antigen, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although the

listed sequences are cDNA sequences, one of ordinary skill in the art may easily derive the genomic DNA corresponding to the cDNA of a cancer associated antigen. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to nucleic acids encoding cancer associated antigens. Similarly, antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as

arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding breast cancer associated antigen polypeptides, together with pharmaceutically acceptable carriers.

Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art, as further described below.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate autonomously or integrated in the genome in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not



been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g.,  $\beta$ -galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al.,

*Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a breast cancer associated antigen polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr Virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 $\alpha$ , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an Adeno.P1A recombinant for the expression of an antigen is disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996). Additional vectors for delivery of nucleic acid are provided below.

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of a vector and one or more of the previously discussed cancer associated antigen nucleic acid molecules. Other components may be added, as desired, as long as the previously mentioned nucleic acid molecules, which are required, are included. The invention also includes kits for amplification of a cancer associated antigen nucleic acid, including at least one pair of amplification primers which hybridize to a cancer associated antigen nucleic acid. The primers preferably are 12-32 nucleotides in length and are non-overlapping to prevent formation of "primer-dimers". One of the primers will hybridize to one strand of the cancer associated antigen nucleic acid and the second primer will hybridize to the complementary strand of the cancer associated antigen nucleic acid, in an arrangement which permits

amplification of the cancer associated antigen nucleic acid. Selection of appropriate primer pairs is standard in the art. For example, the selection can be made with assistance of a computer program designed for such a purpose, optionally followed by testing the primers for amplification specificity and efficiency.

The invention also permits the construction of cancer associated antigen gene "knock-outs" in cells and in animals, providing materials for studying certain aspects of cancer and immune system responses to cancer.

The invention also provides isolated polypeptides (including whole proteins and partial proteins) encoded by the foregoing cancer associated antigen nucleic acids. Such polypeptides are useful, for example, alone or as fusion proteins to generate antibodies, as components of an immunoassay or diagnostic assay or as therapeutics. Cancer associated antigen polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

A unique fragment of a cancer associated antigen polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of cancer associated antigens will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 or 12 or more amino acids including each integer up to the full length).

Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include interaction with antibodies, interaction with other polypeptides or fragments thereof, selective binding of nucleic acids or proteins, and enzymatic activity. One important activity is the ability to act as a signature for identifying the polypeptide. Another is the ability to complex with HLA and to provoke in a human an

immune response. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known databases typically is all that is necessary.

The invention embraces variants of the cancer associated antigen polypeptides described above. As used herein, a "variant" of a cancer associated antigen polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a cancer associated antigen polypeptide. Modifications which create a cancer associated antigen variant can be made to a cancer associated antigen polypeptide 1) to reduce or eliminate an activity of a cancer associated antigen polypeptide; 2) to enhance a property of a cancer associated antigen polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) to provide a novel activity or property to a cancer associated antigen polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to provide equivalent or better binding to an HLA molecule. Modifications to a cancer associated antigen polypeptide are typically made to the nucleic acid which encodes the cancer associated antigen polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the cancer associated antigen amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant cancer associated antigen polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a cancer associated antigen polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

In general, variants include cancer associated antigen polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its desired physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide

linkages. Similarly, certain amino acids can be changed to enhance expression of a breast cancer associated antigen polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a cancer associated antigen polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant cancer associated antigen polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a cancer associated antigen gene or cDNA clone to enhance expression of the polypeptide. The activity of variants of cancer associated antigen polypeptides can be tested by cloning the gene encoding the variant cancer associated antigen polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the variant cancer associated antigen polypeptide, and testing for a functional capability of the cancer associated antigen polypeptides as disclosed herein. For example, the variant cancer associated antigen polypeptide can be tested for reaction with autologous or allogeneic sera as disclosed in the Examples. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

The skilled artisan will also realize that conservative amino acid substitutions may be made in cancer associated antigen polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., the variants retain the functional capabilities of the cancer associated antigen polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size

characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the cancer associated antigen polypeptides include conservative amino acid substitutions of in the amino acid sequences of proteins disclosed herein. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

For example, upon determining that a peptide derived from a cancer associated antigen polypeptide is presented by an MHC molecule and recognized by CTLs (e.g., as described in the Examples), one can make conservative amino acid substitutions to the amino acid sequence of the peptide, particularly at residues which are thought not to be direct contact points with the MHC molecule. For example, methods for identifying functional variants of HLA class II binding peptides are provided in a published PCT application of Strominger and Wucherpfennig (PCT/US96/03182). Peptides bearing one or more amino acid substitutions also can be tested for concordance with known HLA/MHC motifs prior to synthesis using, e.g. the computer program described by D'Amaro and Drijfhout (D'Amaro et al., *Human Immunol.* 43:13-18, 1995; Drijfhout et al., *Human Immunol.* 43:1-12, 1995). The substituted peptides can then be tested for binding to the MHC molecule and recognition by CTLs when bound to MHC. These variants can be tested for improved stability and are useful, *inter alia*, in vaccine compositions.

Conservative amino-acid substitutions in the amino acid sequence of cancer associated antigen polypeptides to produce functionally equivalent variants of cancer associated antigen polypeptides typically are made by alteration of a nucleic acid encoding a cancer associated antigen polypeptide. Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a cancer associated antigen polypeptide. Where amino acid substitutions are made to a small unique

fragment of a cancer associated antigen polypeptide, such as an antigenic epitope recognized by autologous or allogeneic sera or cytolytic T lymphocytes, the substitutions can be made by directly synthesizing the peptide. The activity of functionally equivalent fragments of cancer associated antigen polypeptides can be tested by cloning the gene encoding the altered cancer associated antigen polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered cancer associated antigen polypeptide, and testing for a functional capability of the cancer associated antigen polypeptides as disclosed herein. Peptides which are chemically synthesized can be tested directly for function, e.g., for binding to antisera recognizing associated antigens.

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of the cancer associated antigen protein molecules. A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated cancer associated antigen molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce polypeptide. Those skilled in the art also can readily follow known methods for isolating cancer associated antigen polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The isolation and identification of cancer associated antigen genes also makes it possible for the artisan to diagnose a disorder characterized by expression of cancer associated antigens. These methods involve determining expression of one or more cancer associated antigen nucleic acids, and/or encoded cancer associated antigen polypeptides and/or peptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes. In the latter situation, such determinations can be carried out by screening patient antisera for recognition of the polypeptide.

The invention also makes it possible isolate proteins which bind to cancer associated antigens as disclosed herein, including antibodies and cellular binding partners of the cancer

associated antigens. Additional uses are described further herein.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from cancer associated antigen polypeptides. A dominant negative polypeptide is an inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not phosphorylate the target proteins can reduce phosphorylation of the target proteins in response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, given the teachings contained herein of renal cancer associated antigens, especially those which are similar to known proteins which have known activities, one of ordinary skill in the art can modify the sequence of the cancer associated antigens by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

The invention also involves agents such as polypeptides which bind to cancer associated antigen polypeptides. Such binding agents can be used, for example, in screening assays to detect the presence or absence of cancer associated antigen polypeptides and complexes of cancer associated antigen polypeptides and their binding partners and in purification protocols to isolated cancer associated antigen polypeptides and complexes of



cancer associated antigen polypeptides and their binding partners. Such agents also can be used to inhibit the native activity of the cancer associated antigen polypeptides, for example, by binding to such polypeptides.

The invention, therefore, embraces peptide binding agents which, for example, can be antibodies or fragments of antibodies having the ability to selectively bind to cancer associated antigen polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')<sub>2</sub> fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3).

The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies

while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. See, e.g., U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205.

Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')<sub>2</sub>, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')<sub>2</sub> fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

Thus, the invention involves polypeptides of numerous size and type that bind specifically to cancer associated antigen polypeptides, and complexes of both cancer associated antigen polypeptides and their binding partners. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the cancer associated antigen

polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the cancer associated antigen polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the cancer associated antigen polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the cancer associated antigen polypeptides. Thus, the cancer associated antigen polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the cancer associated antigen polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of cancer associated antigen and for other purposes that will be apparent to those of ordinary skill in the art.

As detailed herein, the foregoing antibodies and other binding molecules may be used for example to identify tissues expressing protein or to purify protein. Antibodies also may be coupled to specific diagnostic labeling agents for imaging of cells and tissues that express cancer associated antigens or to therapeutically useful agents according to standard coupling procedures. Diagnostic agents include, but are not limited to, barium sulfate, iocetamic acid, iopanoic acid, ipodate calcium, diatrizoate sodium, diatrizoate meglumine, metrizamide, tyropanoate sodium and radiodiagnostics including positron emitters such as fluorine-18 and carbon-11, gamma emitters such as iodine-123, technitium-99m, iodine-131 and indium-111, nuclides for nuclear magnetic resonance such as fluorine and gadolinium. Other diagnostic agents useful in the invention will be apparent to one of ordinary skill in the art. As used herein, "therapeutically useful agents" include any therapeutic molecule which desirably is targeted selectively to a cell expressing one of the cancer antigens disclosed herein, including antineoplastic agents, radioiodinated compounds, toxins, other cytostatic or cytolytic drugs, and so forth. Antineoplastic therapeutics are well known and include: aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubicin, doxorubicin, taxol, etoposide, fluorouracil, interferon- $\alpha$ , lomustine, mercaptopurine,

methotrexate, mitotane, procarbazine HCl, thioguanine, vinblastine sulfate and vincristine sulfate. Additional antineoplastic agents include those disclosed in Chapter 52, Antineoplastic Agents (Paul Calabresi and Bruce A. Chabner), and the introduction thereto, 1202-1263, of Goodman and Gilman's "The Pharmacological Basis of Therapeutics", Eighth Edition, 1990, McGraw-Hill, Inc. (Health Professions Division). Toxins can be proteins such as, for example, pokeweed anti-viral protein, cholera toxin, pertussis toxin, ricin, gelonin, abrin, diphtheria exotoxin, or *Pseudomonas* exotoxin. Toxin moieties can also be high energy-emitting radionuclides such as cobalt-60.

In the foregoing methods, antibodies prepared according to the invention also preferably are specific for the renal cancer associated antigen/MHC complexes described herein.

When "disorder" is used herein, it refers to any pathological condition where the cancer associated antigens are expressed. An example of such a disorder is cancer, breast, colon, gastric, renal, prostate and lung cancers as particular examples.

Samples of tissue and/or cells for use in the various methods described herein can be obtained through standard methods such as tissue biopsy, including punch biopsy and cell scraping, and collection of blood or other bodily fluids by aspiration or other methods.

In certain embodiments of the invention, an immunoreactive cell sample is removed from a subject. By "immunoreactive cell" is meant a cell which can mature into an immune cell (such as a B cell, a helper T cell, or a cytolytic T cell) upon appropriate stimulation. Thus immunoreactive cells include CD34<sup>+</sup> hematopoietic stem cells, immature T cells and immature B cells. When it is desired to produce cytolytic T cells which recognize a cancer associated antigen, the immunoreactive cell is contacted with a cell which expresses a cancer associated antigen under conditions favoring production, differentiation and/or selection of cytolytic T cells; the differentiation of the T cell precursor into a cytolytic T cell upon exposure to antigen is similar to clonal selection of the immune system.

Some therapeutic approaches based upon the disclosure are premised on a response by a subject's immune system, leading to lysis of antigen presenting cells, such as breast cancer cells which present one or more cancer associated antigens. One such approach is the administration of autologous CTLs specific to a cancer associated antigen/MHC complex to a subject with abnormal cells of the phenotype at issue. It is within the ability of one of ordinary skill in the art to develop such CTLs *in vitro*. An example of a method for T cell

differentiation is presented in International Application number PCT/US96/05607. Generally, a sample of cells taken from a subject, such as blood cells, are contacted with a cell presenting the complex and capable of provoking CTLs to proliferate. The target cell can be a transfectant, such as a COS cell. These transfectants present the desired complex of their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells are widely available, as are other suitable host cells. Specific production of CTL clones is well known in the art. The clonally expanded autologous CTLs then are administered to the subject.

Another method for selecting antigen-specific CTL clones has recently been described (Altman et al., *Science* 274:94-96, 1996; Dunbar et al., *Curr. Biol.* 8:413-416, 1998), in which fluorogenic tetramers of MHC class I molecule/peptide complexes are used to detect specific CTL clones. Briefly, soluble MHC class I molecules are folded *in vitro* in the presence of  $\beta_2$ -microglobulin and a peptide antigen which binds the class I molecule. After purification, the MHC/peptide complex is purified and labeled with biotin. Tetramers are formed by mixing the biotinylated peptide-MHC complex with labeled avidin (e.g. phycoerythrin) at a molar ratio of 4:1. Tetramers are then contacted with a source of CTLs such as peripheral blood or lymph node. The tetramers bind CTLs which recognize the peptide antigen/MHC class I complex. Cells bound by the tetramers can be sorted by fluorescence activated cell sorting to isolate the reactive CTLs. The isolated CTLs then can be expanded *in vitro* for use as described herein.

To detail a therapeutic methodology, referred to as adoptive transfer (Greenberg, *J. Immunol.* 136(5): 1917, 1986; Riddel et al., *Science* 257: 238, 1992; Lynch et al, *Eur. J. Immunol.* 21: 1403-1410, 1991; Kast et al., *Cell* 59: 603-614, 1989), cells presenting the desired complex (e.g., dendritic cells) are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain of the abnormal cells presenting the particular complex. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that at least some of the subject's abnormal cells present the relevant HLA/cancer associated antigen complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expressing DNA of the pertinent sequences, in

this case a cancer associated antigen sequence. Once cells presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient, where the sample contains CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that a cancer associated antigen is being presented, and the subject is an appropriate candidate for the therapeutic approaches set forth *supra*.

Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked *in vivo*, using a number of approaches. One approach is the use of non-proliferative cells expressing the complex. The cells used in this approach may be those that normally express the complex, such as irradiated tumor cells or cells transfected with one or both of the genes necessary for presentation of the complex (i.e. the antigenic peptide and the presenting HLA molecule). Chen et al. (*Proc. Natl. Acad. Sci. USA* 88: 1110-1114, 1991) exemplifies this approach, showing the use of transfected cells expressing HPVE7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred. For example, nucleic acids which encode a cancer associated antigen polypeptide or peptide may be operably linked to promoter and enhancer sequences which direct expression of the cancer associated antigen polypeptide or peptide in certain tissues or cell types. The nucleic acid may be incorporated into an expression vector. Expression vectors may be unmodified extrachromosomal nucleic acids, plasmids or viral genomes constructed or modified to enable insertion of exogenous nucleic acids, such as those encoding cancer associated antigen, as described elsewhere herein. Nucleic acids encoding a cancer associated antigen also may be inserted into a retroviral genome, thereby facilitating integration of the nucleic acid into the genome of the target tissue or cell type. In these systems, the gene of interest is carried by a microorganism, e.g., a Vaccinia virus, pox virus, herpes simplex virus, retrovirus or adenovirus, and the materials de facto "infect" host cells. The cells which result present the complex of interest, and are recognized by autologous CTLs, which then proliferate.

A similar effect can be achieved by combining the cancer associated antigen or a stimulatory fragment thereof with an adjuvant to facilitate incorporation into antigen presenting cells *in vivo*. The cancer associated antigen polypeptide is processed to yield the peptide partner of the HLA molecule while a cancer associated antigen peptide may be presented without the need for further processing. Generally, subjects can receive an

intradermal injection of an effective amount of the cancer associated antigen. Initial doses can be followed by booster doses, following immunization protocols standard in the art. Preferred cancer associated antigens include those found to react with allogeneic cancer antisera, shown in the examples below.

The invention involves the use of various materials disclosed herein to "immunize" subjects or as "vaccines". As used herein, "immunization" or "vaccination" means increasing or activating an immune response against an antigen. It does not require elimination or eradication of a condition but rather contemplates the clinically favorable enhancement of an immune response toward an antigen. Generally accepted animal models can be used for testing of immunization against cancer using a cancer associated antigen nucleic acid. For example, human cancer cells can be introduced into a mouse to create a tumor, and one or more cancer associated antigen nucleic acids can be delivered by the methods described herein. The effect on the cancer cells (e.g., reduction of tumor size) can be assessed as a measure of the effectiveness of the cancer associated antigen nucleic acid immunization. Of course, testing of the foregoing animal model using more conventional methods for immunization include the administration of one or more cancer associated antigen polypeptides or peptides derived therefrom, optionally combined with one or more adjuvants and/or cytokines to boost the immune response. Methods for immunization, including formulation of a vaccine composition and selection of doses, route of administration and the schedule of administration (e.g. primary and one or more booster doses), are well known in the art. The tests also can be performed in humans, where the end point is to test for the presence of enhanced levels of circulating CTLs against cells bearing the antigen, to test for levels of circulating antibodies against the antigen, to test for the presence of cells expressing the antigen and so forth.

As part of the immunization compositions, one or more cancer associated antigens or stimulatory fragments thereof are administered with one or more adjuvants to induce an immune response or to increase an immune response. An adjuvant is a substance incorporated into or administered with antigen which potentiates the immune response. Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes. Adjuvants of many kinds are well known in the art. Specific examples of adjuvants include monophosphoryl lipid A (MPL, SmithKline Beecham), a congener obtained after purification

and acid hydrolysis of *Salmonella minnesota* Re 595 lipopolysaccharide; saponins including QS21 (SmithKline Beecham), a pure QA-21 saponin purified from *Quillja saponaria* extract; DQS21, described in PCT application WO96/33739 (SmithKline Beecham); QS-7, QS-17, QS-18, and QS-L1 (So et al., *Mol. Cells* 7:178-186, 1997); incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol. Preferably, the peptides are administered mixed with a combination of DQS21/MPL. The ratio of DQS21 to MPL typically will be about 1:10 to 10:1, preferably about 1:5 to 5:1 and more preferably about 1:1. Typically for human administration, DQS21 and MPL will be present in a vaccine formulation in the range of about 1 µg to about 100 µg. Other adjuvants are known in the art and can be used in the invention (*see, e.g. Goding, Monoclonal Antibodies: Principles and Practice*, 2nd Ed., 1986). Methods for the preparation of mixtures or emulsions of peptide and adjuvant are well known to those of skill in the art of vaccination.

Other agents which stimulate the immune response of the subject can also be administered to the subject. For example, other cytokines are also useful in vaccination protocols as a result of their lymphocyte regulatory properties. Many other cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-12) which has been shown to enhance the protective effects of vaccines (*see, e.g., Science* 268: 1432-1434, 1995), GM-CSF and IL-18. Thus cytokines can be administered in conjunction with antigens and adjuvants to increase the immune response to the antigens.

There are a number of immune response potentiating compounds that can be used in vaccination protocols. These include costimulatory molecules provided in either protein or nucleic acid form. Such costimulatory molecules include the B7-1 and B7-2 (CD80 and CD86 respectively) molecules which are expressed on dendritic cells (DC) and interact with the CD28 molecule expressed on the T cell. This interaction provides costimulation (signal 2) to an antigen/MHC/TCR stimulated (signal 1) T cell, increasing T cell proliferation and effector function. B7 also interacts with CTLA4 (CD152) on T cells and studies involving CTLA4 and B7 ligands indicate that the B7-CTLA4 interaction can enhance antitumor immunity and CTL proliferation (Zheng P., et al. *Proc. Natl. Acad. Sci. USA* 95 (11):6284-6289 (1998)).

B7 typically is not expressed on tumor cells so they are not efficient antigen presenting cells (APCs) for T cells. Induction of B7 expression would enable the tumor cells to stimulate more efficiently CTL proliferation and effector function. A combination of B7/IL-6/IL-12



costimulation has been shown to induce IFN-gamma and a Th1 cytokine profile in the T cell population leading to further enhanced T cell activity (Gajewski et al., *J. Immunol.*, 154:5637-5648 (1995)). Tumor cell transfection with B7 has been discussed in relation to *in vitro* CTL expansion for adoptive transfer immunotherapy by Wang et al., (*J. Immunol.*, 19:1-8 (1986)). Other delivery mechanisms for the B7 molecule would include nucleic acid (naked DNA) immunization (Kim J., et al. *Nat Biotechnol.*, 15:7:641-646 (1997)) and recombinant viruses such as adeno and pox (Wendtner et al., *Gene Ther.*, 4:7:726-735 (1997)). These systems are all amenable to the construction and use of expression cassettes for the coexpression of B7 with other molecules of choice such as the antigens or fragment(s) of antigens discussed herein (including polytopes) or cytokines. These delivery systems can be used for induction of the appropriate molecules *in vitro* and for *in vivo* vaccination situations. The use of anti-CD28 antibodies to directly stimulate T cells *in vitro* and *in vivo* could also be considered. Similarly, the inducible co-stimulatory molecule ICOS which induces T cell responses to foreign antigen could be modulated, for example, by use of anti-ICOS antibodies (Hutloff et al., *Nature* 397:263-266, 1999).

Lymphocyte function associated antigen-3 (LFA-3) is expressed on APCs and some tumor cells and interacts with CD2 expressed on T cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Parra et al., *J. Immunol.*, 158:637-642 (1997), Fenton et al., *J. Immunother.*, 21:2:95-108 (1998)).

Lymphocyte function associated antigen-1 (LFA-1) is expressed on leukocytes and interacts with ICAM-1 expressed on APCs and some tumor cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Fenton et al., *J. Immunother.*, 21:2:95-108 (1998)). LFA-1 is thus a further example of a costimulatory molecule that could be provided in a vaccination protocol in the various ways discussed above for B7.

Complete CTL activation and effector function requires Th cell help through the interaction between the Th cell CD40L (CD40 ligand) molecule and the CD40 molecule expressed by DCs (Ridge et al., *Nature*, 393:474 (1998), Bennett et al., *Nature*, 393:478 (1998), Schoenberger et al., *Nature*, 393:480 (1998)). This mechanism of this costimulatory signal is likely to involve upregulation of B7 and associated IL-6/IL-12 production by the DC (APC). The CD40-CD40L interaction thus complements the signal 1 (antigen/MHC-TCR)

and signal 2 (B7-CD28) interactions.

The use of anti-CD40 antibodies to stimulate DC cells directly, would be expected to enhance a response to tumor antigens which are normally encountered outside of a inflammatory context or are presented by non-professional APCs (tumor cells). In these situations Th help and B7 costimulation signals are not provided. This mechanism might be used in the context of antigen pulsed DC based therapies or in situations where Th epitopes have not been defined within known TRA precursors.

A cancer associated antigen polypeptide, or a fragment thereof, also can be used to isolate their native binding partners. Isolation of such binding partners may be performed according to well-known methods. For example, isolated cancer associated antigen polypeptides can be attached to a substrate (e.g., chromatographic media, such as polystyrene beads, or a filter), and then a solution suspected of containing the binding partner may be applied to the substrate. If a binding partner which can interact with cancer associated antigen polypeptides is present in the solution, then it will bind to the substrate-bound cancer associated antigen polypeptide. The binding partner then may be isolated.

It will also be recognized that the invention embraces the use of the cancer associated antigen cDNA sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., dendritic cells, B cells, CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include keratinocytes, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The invention also contemplates delivery of nucleic acids, polypeptides or peptides for vaccination. Delivery of polypeptides and peptides can be accomplished according to standard vaccination protocols which are well known in the art. In another embodiment, the delivery of nucleic acid is accomplished by *ex vivo* methods, i.e. by removing a cell from a subject, genetically engineering the cell to include a breast cancer associated antigen, and reintroducing the engineered cell into the subject. One example of such a procedure is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a

functional copy of a gene into a cell(s) of a subject, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. *In vivo* nucleic acid delivery using vectors such as viruses and targeted liposomes also is contemplated according to the invention.

In preferred embodiments, a virus vector for delivering a nucleic acid encoding a cancer associated antigen is selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-like particle. Examples of viruses and virus-like particles which have been used to deliver exogenous nucleic acids include: replication-defective adenoviruses (e.g., Xiang et al., *Virology* 219:220-227, 1996; Eloit et al., *J. Virol.* 71:5375-5381, 1997; Chengalvala et al., *Vaccine* 15:335-339, 1997), a modified retrovirus (Townsend et al., *J. Virol.* 71:3365-3374, 1997), a nonreplicating retrovirus (Irwin et al., *J. Virol.* 68:5036-5044, 1994), a replication defective Semliki Forest virus (Zhao et al., *Proc. Natl. Acad. Sci. USA* 92:3009-3013, 1995), canarypox virus and highly attenuated vaccinia virus derivative (Paoletti, *Proc. Natl. Acad. Sci. USA* 93:11349-11353, 1996), non-replicative vaccinia virus (Moss, *Proc. Natl. Acad. Sci. USA* 93:11341-11348, 1996), replicative vaccinia virus (Moss, *Dev. Biol. Stand.* 82:55-63, 1994), Venezuelan equine encephalitis virus (Davis et al., *J. Virol.* 70:3781-3787, 1996), Sindbis virus (Pugachev et al., *Virology* 212:587-594, 1995), and Ty virus-like particle (Allsopp et al., *Eur. J. Immunol* 26:1951-1959, 1996). In preferred embodiments, the virus vector is an adenovirus.

Another preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus is capable of infecting a wide range of cell types and species and can be engineered to be replication-deficient. It further has advantages, such as heat and lipid solvent stability, high transduction frequencies in cells of diverse lineages, including hematopoietic cells, and lack of superinfection inhibition thus allowing multiple series of transductions. The adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type adeno-associated virus

infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

In general, other preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA.

Adenoviruses and retroviruses have been approved for human gene therapy trials. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., "Gene Transfer and Expression, A Laboratory Manual," W.H. Freeman Co., New York (1990) and Murry, E.J. Ed. "Methods in Molecular Biology," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Preferably the foregoing nucleic acid delivery vectors: (1) contain exogenous genetic material that can be transcribed and translated in a mammalian cell and that can induce an immune response in a host, and (2) contain on a surface a ligand that selectively binds to a receptor on the surface of a target cell, such as a mammalian cell, and thereby gains entry to the target cell.

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid-CaPO<sub>4</sub> precipitates, transfection of nucleic acids associated with DEAE, transfection or infection with the foregoing viruses including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a

ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. Preferred antibodies include antibodies which selectively bind a cancer associated antigen, alone or as a complex with a MHC molecule. Especially preferred are monoclonal antibodies. Where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids.

When administered, the therapeutic compositions of the present invention can be administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents.

The therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal. When antibodies are used therapeutically, a preferred route of administration is by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing antibodies are well known to those of skill in the art. Generally, such systems should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope binding capacity (see, for example, Sciarra and Cutie, "Aerosols," in Remington's Pharmaceutical Sciences, 18th edition, 1990, pp 1694-1712; incorporated by reference). Those of skill in the art can readily determine the various parameters and conditions for producing antibody aerosols without resort to undue experimentation. When using antisense preparations of the invention, slow intravenous administration is preferred.

The compositions of the invention are administered in effective amounts. An "effective amount" is that amount of a cancer associated antigen composition that alone, or together with further doses, produces the desired response, e.g. increases an immune response to the cancer associated antigen. In the case of treating a particular disease or condition

characterized by expression of one or more cancer associated antigens, such as renal cancer, the desired response is inhibiting the progression of the disease. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods of the invention discussed herein. The desired response to treatment of the disease or condition also can be delaying the onset or even preventing the onset of the disease or condition.

Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

The pharmaceutical compositions used in the foregoing methods preferably are sterile and contain an effective amount of cancer associated antigen or nucleic acid encoding cancer associated antigen for producing the desired response in a unit of weight or volume suitable for administration to a patient. The response can, for example, be measured by determining the immune response following administration of the cancer associated antigen composition via a reporter system by measuring downstream effects such as gene expression, or by measuring the physiological effects of the cancer associated antigen composition, such as regression of a tumor or decrease of disease symptoms. Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response.

The doses of cancer associated antigen compositions (e.g., polypeptide, peptide, antibody, cell or nucleic acid) administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that

patient tolerance permits.

In general, for treatments for eliciting or increasing an immune response, doses of cancer associated antigen are formulated and administered in doses between 1 ng and 1 mg, and preferably between 10 ng and 100 µg, according to any standard procedure in the art. Where nucleic acids encoding cancer associated antigen of variants thereof are employed, doses of between 1 ng and 0.1 mg generally will be formulated and administered according to standard procedures. Other protocols for the administration of cancer associated antigen compositions will be known to one of ordinary skill in the art, in which the dose amount, schedule of injections, sites of injections, mode of administration (e.g., intra-tumoral) and the like vary from the foregoing. Administration of cancer associated antigen compositions to mammals other than humans, e.g. for testing purposes or veterinary therapeutic purposes, is carried out under substantially the same conditions as described above.

Where cancer associated antigen peptides are used for vaccination, modes of administration which effectively deliver the cancer associated antigen and adjuvant, such that an immune response to the antigen is increased, can be used. For administration of a cancer associated antigen peptide in adjuvant, preferred methods include intradermal, intravenous, intramuscular and subcutaneous administration. Although these are preferred embodiments, the invention is not limited by the particular modes of administration disclosed herein. Standard references in the art (e.g., *Remington's Pharmaceutical Sciences*, 18th edition, 1990) provide modes of administration and formulations for delivery of immunogens with adjuvant or in a non-adjuvant carrier.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like.

Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

A renal cancer associated antigen composition may be combined, if desired, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.

The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of breast cancer associated antigen polypeptides or nucleic acids, which is preferably isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be



employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA.

As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

As used herein with respect to polypeptides, "isolated" means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.

### Examples

#### Example 1: SEREX screening of renal cancer cell line 1973/10.4

A standard cDNA library was prepared using 5 µg of poly A<sup>+</sup> RNA derived from the cell line 1973/10.4. A primary (unamplified) cDNA library was immunoscreened (5 x 10<sup>5</sup> clones per library) by standard SEREX methodology, with absorbed autologous patient serum at 1:200 dilution [Sahin, U. et al., *Proc Natl Acad Sci USA* 92:11810-3 (1995); Chen, Y.T. et al. *Proc Natl Acad Sci USA*. 94:1914-8 (1997)]. Excluding false-positive clones encoding immunoglobulin gene fragments, clones were purified and sequence analyzed. Comparisons of the sequences showed that these clones represented cDNAs from 22 distinct genes, designated NY-REN-45 through NY-LU-66 (Table A and Sequence Listing (SEQ ID NOs:1-21)). A homology search through the GenBank/EMBO databases revealed that 14 of the 22 genes corresponded to previously known molecules, and 8 others were unknown genes, with sequence identity limited only to short segments of known genes or to expressed sequence tags (ESTs).

Analysis of isolated clones:

#### I. NY-REN clones which are known gene products

Designation	Gene/Sequence Identity	Accession Number	SEQ ID NO
NY-REN-46	lactate dehydrogenase B	Y00711	22
NY-REN-47	ERK tyrosine kinase	D31661	23
NY-REN-48	PINCH protein	U09284	24
NY-REN-51	BBP/53BP2	U58334	25
NY-REN-52	steroid receptor coactivator	U59302	26
NY-REN-53	KIAA0336 mRNA tag	AB002334	27
NY-REN-54	E6 oncogenic protein-associated protein	X98033	28
NY-REN-55	murine NEK1 protein kinase homologue	S45828	29

NY-REN-56	6-phospho-fructokinase	D49817	30
NY-REN-59	lactate dehydrogenase A	X02152	31
NY-REN-61	KIAA0081 mRNA tag	D42039	32
NY-REN-63	DDB p127-associated protein	AF035950	33
NY-REN-65	HREV107 protein	X92814	34
NY-REN-66	acidic ribosomal phosphoprotein 2	M17887	35

## II. Novel gene products

<u>Clone</u>	<u>SEQ ID NO:</u>	<u>Size</u>	<u>Tissue mRNA expression</u>	<u>Protein SEQ ID NO:</u>
NY-REN-45	1	4.0kb	Ubiquitous	12
NY-REN-49	2	1.1kb	Ubiquitous	13
NY-REN-50	3	1.8kb	Ubiquitous	14
NY-REN-57	4,5	2.9kb	Ubiquitous	15, 16
NY-REN-58	6	1.9kb	Ubiquitous	17
NY-REN-60	7	4.0kb	Ubiquitous	18
NY-REN-62	8,9	2.7kb	Ubiquitous	19, 20
NY-REN-64	10,11	3.0kb	Ubiquitous	21

## III. Clones which react with autologous sera only:

NY-REN-47

NY-REN-49

NY-REN-50

## IV. Clones which react with sera from normal control donors

### Frequency of sera reactivity

<u>Clone</u>	<u>normal</u>	<u>cancer patient</u>
NY-REN-46	4/4	6/14
NY-REN-48	14/14	17/17
NY-REN-51	1/12	3/17

- 52 -

NY-REN-52	4/12	7/17
NY-REN-53	4/19	10/31
NY-REN-54	5/8	7/7
NY-REN-55	3/19	6/31
NY-REN-56	3/19	7/31
NY-REN-57	1/19	3/31
NY-REN-58	1/12	2/17
NY-REN-59	1/19	4/31
NY-REN-61	3/19	5/31
NY-REN-62	1/19	4/31
NY-REN-63	2/19	12/31
NY-REN-64	3/19	6/31
NY-REN-65	2/19	2/31

V. Clones which react with sera from cancer patients only (failed to react with 19 normal patient serum samples). These clones are preferred for therapeutic and diagnostic applications.

	<u>Frequency of reactivity</u>
NY-REN-32	3/31
NY-REN-45	3/31
NY-REN-57	2/31
NY-REN-60	5/31
NY-REN-66	2/31

#### VI. Additional allogeneic screening of NY-REN renal SEREX clones

Renal SEREX clones were tested for reactivity with sera from the normal and various cancer patients listed below.

---

Sera

<u>Clone</u>	<u>normal</u>	<u>colon</u>	<u>renal</u>	<u>lung</u>	<u>breast</u>
NY-REN-3	0/26	7/37	8/32	0/23	1/26
NY-REN-12	0/19	0/16	3/32	0/15	0/16
NY-REN-19	0/19	0/16	2/32	0/15	0/16
NY-REN-21	0/16	3/16	3/32	1/15	0/16
NY-REN-25	0/15	0/16	5/32	0/15	0/16
NY-REN-31	0/14	0/16	5/32	0/15	0/16
NY-REN-32	0/14	2/16	3/32	0/15	0/16
NY-REN-37	0/15	0/16	2/32	0/15	0/16
NY-REN-45	0/14	0/16	3/32	1/15	0/16
NY-REN-57	0/19	0/16	2/32	0/15	0/16
NY-REN-60	0/19	0/16	7/32	0/15	0/16
NY-REN-66	0/19	0/16	2/32	0/15	0/16

### **Example 2: SEREX screening of tumor cells and testis libraries**

Standard cDNA libraries were prepared using poly A<sup>+</sup> RNA derived from the various cancer sources, as well as testis. The cDNA libraries were immunoscreened by standard SEREX methodology, with absorbed autologous patient serum [Sahin, U. et al., *Proc Natl Acad Sci USA* 92:11810-3 (1995); Chen, Y.T. et al. *Proc Natl Acad Sci USA* 94:1914-8 (1997)]. Excluding false-positive clones encoding immunoglobulin gene fragments, clones were purified and sequence analyzed. Comparisons of the sequences showed that these clones all were substantially identical to the kinectin cDNA (GenBank Accession number L25616).

**Table A: Kinectin clones isolated by SEREX**

<u>Clone designation</u>	<u>SEQ ID NO</u>	<u>Library</u>	<u>Patient sera for screen</u>
NGO-St-47	36	Gastric tumor	autologous
TS-64-5'	37	Testis	seminoma
HOM-TSOv3-41 (5')	38	Testis	seminoma
HOM-TSOv3-41 (3')	39	Testis	seminoma
HOM-HD2-2(3')	40	Hodgkin's disease	autologous
HOM-HD2-232(3')	41	Hodgkin's disease	autologous
Thy4 (3')	42	Thyroid tumor	autologous

Thy4 (3')	42	Thyroid tumor	autologous
Thy5 (3')	43	Thyroid tumor	autologous
Thy8 (3')	44	Thyroid tumor	autologous
Thy10 (3')	45	Thyroid tumor	autologous
NGO-Br-1	46	Breast cancer	autologous

In addition, a hepatocarcinoma library screened with autologous sera also identified several clones which were sequenced and found to be substantially identical to kinectin.

#### Allotyping (gastric cancer)

12/12 gastric cancer patient sera recognized kinectin

0/27 normal individual sera recognized kinectin

Therefore it was determined that recognition of kinectin was diagnostic for cancer patients.

#### **Example 3: Preparation of recombinant cancer associated antigens**

To facilitate screening of patients' sera for antibodies reactive with cancer associated antigens, for example by ELISA, recombinant proteins are prepared according to standard procedures. In one method, the clones encoding cancer associated antigens are subcloned into a baculovirus expression vector, and the recombinant expression vectors are introduced into appropriate insect cells. Baculovirus/insect cloning systems are preferred because post-translational modifications are carried out in the insect cells. Another preferred eukaryotic system is the *Drosophila* Expression System from Invitrogen. Clones which express high amounts of the recombinant protein are selected and used to produce the recombinant proteins. The recombinant proteins are tested for antibody recognition using serum from the patient which was used to isolated the particular clone, or in the case of cancer associated antigens recognized by allogeneic sera, by the sera from any of the patients used to isolate the clones or sera which recognize the clones' gene products.

Alternatively, the cancer associated antigen clones are inserted into a prokaryotic expression vector for production of recombinant proteins in bacteria. Other systems, including yeast expression systems and mammalian cell culture systems also can be used.

#### **Example 4: Preparation of antibodies to cancer associated antigens**

The recombinant cancer associated antigens produced as in Example 4 above are used to generate polyclonal antisera and monoclonal antibodies according to standard procedures. The antisera and antibodies so produced are tested for correct recognition of the cancer associated antigens by using the antisera/antibodies in assays of cell extracts of patients known to express the particular cancer associated antigen (e.g. an ELISA assay). These antibodies can be used for experimental purposes (e.g. localization of the cancer associated antigens, immunoprecipitations, Western blots, etc.) as well as diagnostic purposes (e.g., testing extracts of tissue biopsies, testing for the presence of cancer associated antigens).

**Example 5: Expression of cancer associated antigens in cancers of similar and different origin.**

The expression of one or more of the cancer associated antigens is tested in a range of tumor samples to determine which, if any, other malignancies should be diagnosed and/or treated by the methods described herein. Tumor cell lines and tumor samples are tested for cancer associated antigen expression, preferably by RT-PCR according to standard procedures. Northern blots also are used to test the expression of the cancer associated antigens. Antibody based assays, such as ELISA and western blot, also can be used to determine protein expression. A preferred method of testing expression of cancer associated antigens (in other cancers and in additional same type cancer patients) is allogeneic serotyping using a modified SEREX protocol (as described above).

In all of the foregoing, extracts from the tumors of patients who provided sera for the initial isolation of the cancer associated antigens are used as positive controls. The cells containing recombinant expression vectors described in the Examples above also can be used as positive controls.

The results generated from the foregoing experiments provide panels of multiple cancer associated nucleic acids and/or polypeptides for use in diagnostic (e.g. determining the existence of cancer, determining the prognosis of a patient undergoing therapy, etc.) and therapeutic methods (e.g., vaccine composition, etc.).

**Example 6: HLA typing of patients positive for cancer associated antigens**

To determine which HLA molecules present peptides derived from the cancer associated antigens of the invention, cells of the patients which express the cancer associated

antigens are HLA typed. Peripheral blood lymphocytes are taken from the patient and typed for HLA class I or class II, as well as for the particular subtype of class I or class II. Tumor biopsy samples also can be used for typing. HLA typing can be carried out by any of the standard methods in the art of clinical immunology, such as by recognition by specific monoclonal antibodies, or by HLA allele-specific PCR (e.g. as described in WO97/31126).

**Example 7: Characterization of cancer associated antigen peptides presented by MHC class I and class II molecules.**

Antigens which provoke an antibody response in a subject may also provoke a cell-mediated immune response. Cells process proteins into peptides for presentation on MHC class I or class II molecules on the cell surface for immune surveillance. Peptides presented by certain MHC/HLA molecules generally conform to motifs. These motifs are known in some cases, and can be used to screen the renal cancer associated antigens for the presence of potential class I and/or class II peptides. Summaries of class I and class II motifs have been published (e.g., Rammensee et al., *Immunogenetics* 41:178-228, 1995). Based on the results of experiments such as those described above, the HLA types which present the individual breast cancer associated antigens are known. Motifs of peptides presented by these HLA molecules thus are preferentially searched.

One also can search for class I and class II motifs using computer algorithms. For example, computer programs for predicting potential CTL epitopes based on known class I motifs has been described (*see, e.g.*, Parker et al., *J. Immunol.* 152:163, 1994; D'Amato et al., *Human Immunol.* 43:13-18, 1995; Drijfhout et al., *Human Immunol.* 43:1-12, 1995). Computer programs for predicting potential T cell epitopes based on known class II motifs has also been described (*see, e.g.* Sturniolo et al., *Nat Biotechnol* 17(6):555-61, 1999). HLA binding predictions can conveniently be made using an algorithm available via the Internet on the National Institutes of Health World Wide Web site at URL <http://bimas.dcrt.nih.gov>. See also the website of: SYFPEITHI: An Internet Database for MHC Ligands and Peptide Motifs (access via <http://www.uni-tuebingen.de/uni/kxi/> or <http://134.2.96.221/scripts/hlaserver.dll/EpPredict.htm>). Methods for determining HLA class II peptides and making substitutions thereto are also known (e.g. Strominger and Wucherpfennig (PCT/US96/03182)).



**Example 8: Identification of the portion of a cancer associated polypeptide encoding an antigen**

To determine if the cancer associated antigens isolated as described above can provoke a cytolytic T lymphocyte response, the following method is performed. CTL clones are generated by stimulating the peripheral blood lymphocytes (PBLs) of a patient with autologous normal cells transfected with one of the clones encoding a cancer associated antigen polypeptide or with irradiated PBLs loaded with synthetic peptides corresponding to the putative protein and matching the consensus for the appropriate HLA class I molecule (as described above) to localize an antigenic peptide within the cancer associated antigen clone (see, e.g., Knuth et al., *Proc. Natl. Acad. Sci. USA* 81:3511-3515, 1984; van der Bruggen et al., *Eur. J. Immunol.* 24:3038-3043, 1994). These CTL clones are screened for specificity against COS cells transfected with the cancer associated antigen clone and autologous HLA alleles as described by Brichard et al. (*Eur. J. Immunol.* 26:224-230, 1996). CTL recognition of a cancer associated antigen is determined by measuring release of TNF from the cytolytic T lymphocyte or by  $^{51}\text{Cr}$  release assay (Herin et al., *Int. J. Cancer* 39:390-396, 1987). If a CTL clone specifically recognizes a transfected COS cell, then shorter fragments of the cancer associated antigen clone transfected in that COS cell are tested to identify the region of the gene that encodes the peptide. Fragments of the cancer associated antigen clone are prepared by exonuclease III digestion or other standard molecular biology methods. Synthetic peptides are prepared to confirm the exact sequence of the antigen.

Optionally, shorter fragments of cancer associated antigen cDNAs are generated by PCR. Shorter fragments are used to provoke TNF release or  $^{51}\text{Cr}$  release as above.

Synthetic peptides corresponding to portions of the shortest fragment of the cancer associated antigen clone which provokes TNF release are prepared. Progressively shorter peptides are synthesized to determine the optimal cancer associated antigen tumor rejection antigen peptides for a given HLA molecule.

A similar method is performed to determine if the cancer associated antigen contains one or more HLA class II peptides recognized by T cells. One can search the sequence of the cancer associated antigen polypeptides for HLA class II motifs as described above. In contrast to class I peptides, class II peptides are presented by a limited number of cell types. Thus for these experiments, dendritic cells or B cell clones which express HLA class II molecules preferably are used.

**Table 1: Sequence homologies**

SEQ ID NO.: 1

AB002794, U46118RNU46118U19482AF026216AB002739, AB002730, AB002728,  
AF058796, AB002777, AF020187, AF009411, AB015609, AF006627, M95076, U43527,  
AB002741, U25846, AF006628, AF019043, D83352, U10355, M99575, U48288,  
AF090440, AB007504, U82480, Y15794, AJ005572, AF029349, L10111, S80963,  
U38894, L41731, AF022733, AJ225108, Y11879, AF001688, U33214, Z97178,  
AF009413, AF019907, AF016371, X71980, AF001522, M77169, AF023132, D83476,  
AJ009675, U90554, AF069324, AF048691, Z34799, AF004947, U60149, AF022732,  
AF019887, L02937, U55848, AF011331, AF045770, AF043533, X69524, M32882,  
U08214, U50847, AF017364, U35364, Y14339, AJ005969, U90555, U44430, U74296,  
AF001501, AJ223316, D78609, U41060, Z54362, AF034387, U62398, AB005545,  
AB002533, Y13865, AF009959, L02938, U10555, AL010246, AC003041, U37699,  
S75970, AF071010, Z81311, AB003681, X16353, AB002731, X53081, D63450,  
D10911, D90115, X97065, Z82275, AB016891, Y09455, X77990, , W58357, W07820,  
AA188593, W81046, AA858164, AI018124, AI139112, AA769634, W00437, D80849,  
AA448160, N98650, T31293, H15307, H51146, N29314, AA770301, AA187822,  
AA978299, T31823, AA936410, AA993194, N41386, W45601, W81099, C05691,  
D60153, AA780119, AA929004, R68608, Z43271, N37024, AA974718, AA928663,  
T30120, AA936583, H51109, N20251, W92917, T36035, AA480197, Z24908, N79450,  
AA872019, AA902275, N59810, R13443, AA740162, AA937759, N72168, AA970708,  
T36257, AA433833, H15700, D51185, AA249138, R37356, W93028, Z28641,  
AA371494, N72757, AA719126, N56164, T31790, D57384, Z41959, N58984,  
AA847848, AA587009, Z39343, AA654834, AA505490, Z38243, D20344, AA252395,  
AA025593, H70133, R09101, AA159862, AI032981, Z28355, C75020, AI139642,  
D82421, AI126922, C75170, AI016032, C18748, C75478, AI129334, C75472,  
AA310765, D63057, C05952, AA357303, C16591, D82132, L48852, D82799, C75176,  
AI124552, AA669404, U30155, C75118, AA374918, C75108, C05853, U30151,  
D57346, AI127548, AA918527, AA317816, AA573490, R21699, AA917928, R36311,  
AA361522, AA701252, AI085492, H44387, AA156256, AA587935, AA976510,  
AA515269, W73374, T27986, N34493, AA737770, N32609, N32612, H64420, ,  
AA415243, AA113717, AA117350, AA242502, AA117343, AA545256, AA795651,  
AA106372, U31322, AA681967, AA221922, AA600546, AA050610, AU018628, C80932,  
AA920654, AA863834, AI099036, AA183239, AI115182, AA590910, W65628,  
AA162291, , AA109440, AI052952, AA999324, AI105714, AI026280, AI072678,  
AA964820, AA754198, AA944557, AI045710, C94989, AA471630, AA933231,  
AA509077, AA257557, AA509328, AA109365, AA963207, AA435473, AA999306,  
AA406684, AI105662, AA509174, AI108597, AA109374, AA925182, AA471671,  
AA088161, AA752812, AA626989, AA406924, AA840999, AA509033, C94899,  
AA406875, AA842672, AA123619, AA072471, AA509339, AA933108, AI110259,  
AA842135, N99262, AA661430, AA842512, AA180648, AI066048, AA559515,  
AA406761, AA109423, AF074736, AA257676, D87312, AA257488, AA114390,  
AI087701, W06665, W32852, AA123649, AA842505, AA509330, AA908025, AA257279,  
AI105717, AA406673, AA627018, AA406850, AA161668, AA114453, AA109372,  
AA257572, AA803997, AA406943, AA257495, AA842019, AA661368, AI082949,  
AA842888, W06539, AA118223, AA406986, AA471717, AI096212, AA257707,  
AA257649, AI053126, AA508950, AA713366, W69049, AA965381, AA208680,  
AI057997, AA161707, AI058071, AA675858, AA257513, AI083337, AA406908,  
AI083256, AA659956, AA842532, AA754036, AA753165, W18199, AI109620,  
AI058022, AI064026, AA471431, AA032116, AA754544, AI108146, C42045,  
AA843025, AI109103, AA509237, AA161620, AA257665, AA471605, W84932,  
AA841358, AA843040, AA471695, AA003471, AA840977, AA509267, AA841711,  
AA471488, AA257699, N98079, AA454318, W04102, AA842874, N99754, AA509307,  
AA751845, AA661358, AA508954, AA406746, AA842720, W23363, AA508951,  
AI068913, AA417420, AI108220, AA508946, AA471497, AA842911, AA842501,  
AA123614, AA509218, AA547812, AA752986, AA752003, AA406839, AA508993,  
AA161747, AA509008, AA180623, AA508986, AA842627, AA753129, AA509214,  
AA406733, AI105737, N74818, AA753300, AA430818, AA417415, AA114426, R46936,  
AA979824, AA246112, AA753138, AI058077, AA842464, AA966639, AA842265,  
AA509025, AA601853, W15128, AA660039, AA842275, AA454424, AA180651,

AA842423, AA257507, AI063375, AA180692, AA051990, W15094, AA180620, W00308, AA406729, AA257712, AA257445, AA433148, C48534, AA495533, C08939, AA406845, AA933362, AA509242, AA842023, W29144, AI087490, AA842237, AA601823, W06538, AI087739, AI087524, AA842164, AA842642, AA471553, AA842419, AI113700, AA675813, AI083003, AI021727, AI083274, AI083309, W32823, AA253962, AA114520, AA430792, C47230, AA842674, AI053141, D75937, AA843034, W68979, AI105681, W91819, AA756971, AA509104, AA111828, AI109720, AI110161, AA933311, AA180602, AA842093, R86419, AI058057, AA186285, AA406891, AI105725, AA406888, AA649397, N94700, W51718, AA547916, AA840646, U74116, AA257756, AI082996, W91818, N74830, AA123585, AA118224, AA454446, AA841367, AA509109, AA842387, AI052833, AA751998, AA123634, AA257327, AA803962, AA842493, AA471448, AA406716, AA841361, AA840661, AA713447, AA406754, AA257695, AA841403, AA751834, AA406947, AI096182, AI105734, W15132, W59918, AA089352, AA180566, AA257427, AA406980, AA471469, AA509264, AA509032, AA749469, AA752028, AA754167, AA754646, AA842335, AA842574, AI065957, AI065970, AI096289, AA109379, AA109472, AA114484, AA161689, AA430830, AA406948, AA433246, AA454371, AA471492, AA471703, AA752086, AA842624, AI096185, R47079, R86415, AA161711, AA161655, AA180549, AA257424, AA257437, AA257749, AA433393, AA471419, AA471602, AA430922, AA661401, AA752034, AA752066, AA842384, AI082936, AI083329, AI105677, Z33912, AA109362, AA109417, AA051807, AA430797, AA406799, AA430806, AA495548, AA661116, AI082951, AI105685, AI114069, R47062, W59884, AA109292, AA751829, AA754172, AA842257, AI082934, AI082958, AA180706, AA471516, AA508962, AA751563, AA751816, AA753137, AA753167, AA840972, AA842079, AA874756, AI105522, AI108824, AA180588, AA406676, AA471392, AA509142, AA840909, AA842175, AI066854, R47172, AA161565, AA257643, AA753161, AA471447, AA680450, AA752897, AA753237, AA842230, AA842544, AA161635, AA454428, AA508933, AA509309, C41215, AA842585, D73786, D75990, D75808, AA627049, N74809, AA257682, AA257517, AA257668, AA471470, AA509251, AA509051, AA990913, C39627, C41200, C42101, C46071, C48450, AA840970, AA842156, AA430902, AA842216, AA007706, AA406765, AA180574, AA842310, AI067585, AI077003, AA756933, AA114501, AA406690, AA454440, AA661371, AA056797, AA114372, AA180676, AI082955, AA406735, AA675746, AA752005, W29142, AA109261, AA842401, AA842602, AA246079, AI043420, AA626993, AA123655, AA257716, AA406931, AA791379, AI105668, AA842538, R47669, AA088150, AA109308, AA738555, AA123638, AA180582, AA123597, AA471535, AA180728, AA161741, AA186201, AA430817, AA433170, AA454407, AA471686, AA161596, AA509110, AA675874, AA471540, Z26577, AA753093, AI066829, D37716, AA627017, N99292, AA508936, AA257656, AA406768, AA471587, H39287, AA842431, AA161715, AA509204, AA979935

SEQ ID NO.: 2, AF086243, AE001154, X62889, , W67765, W67764, AA947751, AI141491, W76469, AA906091, AA872676, AA349825, H77545, H91001, W72232, AA948309, AA361403, R57582, AA337188, AA215714, AA481093, T75310, AA976452, , AI120744, AA462558, AI158491, AA014020, AA285990, AA051044, AA473453, AA896862, W56907, AA218305, AA020167, W85164, AA017810, W30604, AA541978, W20894, AA023164, AA760425, AA024084, AA840044, , AA231755, T20644, C45833, T24185, C68940, D37618, AA964657, AI011924

SEQ ID NO.: 3, L08501, Z97205, Z48950, AF010400, AC005162, L08502, D50608, , AA707653, AA861639, AA292496, AA702524, AI097367, AI138504, AI147933, AI141836, AI075247, N63868, W88668, AA703146, AA625621, AA292247, AI032848, AA005331, AA699781, AA427941, D31111, D31113, N92013, AA884207, AA044752, R70900, R16693, AA906542, R35112, AA481286, D80100, AA235512, AA960995, AA867982, D59403, W88874, AA558590, R10048, AA719917, H43573, R49500, AA744780, AA047136, AA789101, AA906332, AA747301, AA830606, AA434559, AA236698, AA328889, N98469, W17299, W46605, AA258082, AI078045, R11930, W74577, AA703312, AI082727, R45189, N76461, AA010500, W63646, W38891, AA490651, AA558805, W87891, AA160849, AA618177, AA776126, AA161281, , AA822308, AA499768, AA028780, AA183100, AA276783, AA120227, AA200285, AA212541, AA116265, AA821616, AA265629, AA108594, W61565, AA030311, W42275, AA419903, AA268027, AA028211, AA518504, AA125394, , C92235, C92002, C29917, AI145662, C65317, AA901847, AI137443, Z14719, D35515, R90625, H76970,

SEQ ID NO.: 4, AL031178, Y11905, AF031904, M34309, M29366, L33953, L33952,

- 60 -

L33956, L33954, L33957, U41289, X13369, AL022072, AJ223074, AF078695, AC004683, X17267, AF025526, AF071798, AC005274, AB004537, X68248, AF035537, AF056116, AB009052, AL023286, AF058701, L20725, AF001308, U22438, , AA211485, AA579574, AI078750, AA568661, AA604128, H49462, AA767424, H97012, AA565823, H49463, AA827171, T87152, F22114, AA748475, T31504, Z42997, T89930, R02581, H75949, T87057, AA322268, R02700, AA005034, AA576177, AI014302, AA348159, T83607, AA322497, AA211532, AA019517, R27657, AA026869, N67589, T83782, AA129383, Z39829, AA814308, AA425564, H67997, AA004420, AA644513, AA007691, T62593, AA333601, H75334, AI057250, T62521, N73865, AA004558, AA004484, AA007690, AA910241, AA456251, AA004568, AA341266, T28757, AA132360, AA781316, AA456942, AA782765, AA662593, AA461351, AA885220, N33840, AA843737, T62232, AA608559, AA643270, R44662, AI074863, AI051088, N63305, W24955, AA085886, W31918, AA047466, AA178965, AA369890, AA515015, N79466, AA768162, AA864694, AA811390, AA834531, AA293263, AA768335, AA749083, T57520, AA292001, AI085512, AA969032, AI027062, AA595663, AA827242, AA744475, , AA472485, AA097011, AA959170, AA647546, AA986669, AI006628, W12604, AI122356, AA571721, AA433697, AA880171, AA015463, AA116290, C87721, AA437983, AA990395, AA265925, W14785, W89262, AA059703, AA413613, AI020231, AA667024, AA407526, AA221491, AA222523, C76436, AA409700, W35766, , AA859485, H33704, T46512, C25899, T41882, C26586, C92302, AA660448, C94493, C25527, D35045, D33727, F14543, D37473, T45969, AA040979, D68274, T38420, AA228607, AA660541, T38283, AA842575, C71889, T38745, D68465, T46732, AA598393, C23775, C64798, AA042714, F19972, C65873, N97974, AA114425, AA900456

SEQ ID NO.: 5, U29344, S80437, M76767, X62889, M84761, J03514, X62888, X13415, X13135, U05714, AC004013, U58675, S47635, Z81533, AC005250, AC003661, AB008567, Y13444, X96401, AF026487, AF026488, , AA781445, AI037943, AI129371, C15883, AI073336, AA904077, AA569042, AI039428, AA568701, AA058907, AA911112, AA234022, N95359, AA565390, AA082427, AA588430, D60358, AA045488, AA084417, N72089, AI143390, R51974, AA081439, AA635907, T47621, AA579930, AA995057, AA827039, AA872490, AA588319, AA069032, AA062768, AA534011, W96404, H06082, AA938900, AA971262, AA836547, AA251544, AA250742, AA830405, AA906492, AA102653, R38286, AA258075, H83302, H38522, R61787, R33742, R24094, AI052406, AA931452, R23634, R39640, AA974568, AI028383, AA312451, AA148800, AI138982, R36172, AA926921, , AA472563, AA914598, AA423256, AA476186, AA041992, W84938, AA797706, AA709956, AA544361, AI006075, AA717202, AA008602, AA033399, AA472306, AI037430, AI152943, AA475582, AA471742, AA530292, AA277496, AA718588, AA823112, AA822771, AA710973, AA981780, AA718846, AA797557, AA510746, AI036049, AA543891, AA606513, AA981758, AA822268, AA413161, AA472201, AA646527, AA213036, AA168254, AA718549, AA458342, AA119418, AA879925, AA050917, AA718814, AA793638, AA177849, AA575627, AA537367, AI121788, AA203946, AA413157, AA517432, AA867736, AI037420, W30436, , Z71851, AA957415, AI112847, AA955881, AA963915, AI043663, C95061, AI009894, AA957229, AI044678

SEQ ID NO.: 6, AC002426, AC004674, AC004675, AC004006, L12157, U20839, U46028, U20835, AC004058, X67115, X76266, M25485, U59759, AC005172, U70848, AF042274, X14724, L31840, L41679, , W52480, AA863014, W56770, AA286755, AA164604, W52777, AA814246, AA765427, AA873647, AA360577, AI139274, AA770312, AA732557, AA568651, AA164603, W56724, AA194905, AA865009, R16884, R08110, F07672, AA577790, T11467, AA502489, AA366688, AA480628, AA516318, AA090005, AA081908, F01265, AA780686, , AA466811, AA465808, AA197646, AI157174, AA153086, AA197667, AA066612, AA058086, AA024186, AA110104, AA880419, AA870161, AA153880, AA072995, , AI031052, AI043934, AA849320, D15181, U95093, AI096188, T09655, C62926, AA996434, AA925202, AA817271, AA901051, R03660, AA948980, AA658709, AA899446, AA957150, AA800160, T76196, AA891787

SEQ ID NO.: 7, X63547, X63546, AF017306, U44839, U20657, AF017305, AJ001589, L21998, D21270, Z48245, U63834, Z68006, L04573, D63819, AC005266, AF025468, M94131, , AI056961, C15588, AA373847, AA887911, N87070, R39133, AA226825, AA353972, AA325352, R88378, AA490675, AA456219, AA701415, AA046611, AA456224, , AA065652, AA221447, AA710221, AA717401, AA254049,

AA041745, AA510261, AA170745, AA656404, AA572506, AA174539, AA217630, ,  
AI134284, C58457, C11202, AA413362, AA728532

SEQ ID NO.: 8, AB016886, Z92811, AL021481, U52078, L46702, U23515, AC005555,  
Z84814, Z93016, D21138, X57513, L07144, D83711, M28488, U15974, U52513,  
AF026939, L19120, J05258, Z13985, Z70691, U59227, , AA190526, AA764854,  
AI014655, H88220, AA622877, N32046, H89609, AA682362, AA464420, AA375477,  
AA284905, AA257109, N80276, H89373, N92393, AA884334, AA778708, AA766209,  
AA535677, W46414, AA770266, AA983635, AA721113, H88219, R87349, AA628091, ,  
AI116513, AA183589, AI035517, AA209952, AA184622, AI097904, AA016440,  
AA162370, AA939521, AA162376, AA718152, AA048154, AA253815, AA795350, ,  
AA996981, C44448, C41783, C44695, C44039, C62421, C47063, C45014, D36613,  
C60872, C50136, C69177, AI055708, D27648, C65648, AI114022, AI064663,  
AI107213, AA395461, AA800126, AA891487, T01611, C27943, AI113482, C83830

SEQ ID NO.: 9, L43510, U71249, L11275, X73541, Z28317, AB008270, X75652,  
U05987, U85262, U24189, Z46676, X70823, AC004981, D11079, X56121, M58053,  
U33636, Z92773, U23168, D31662, , R15557, F01629, N71722, AA252548,  
AA806751, T59557, AA612671, AA329585, AA295675, AA166990, AA128100, H46363,  
AA125810, , AA396888, AA408999, AA270873, AA144722, AA863954, W10303, ,  
C38016, N96746, Z37622, AA395862, C38756, F15295, N99294, W68877, C44749,  
C24349, F15569, AA113611, AA689147, N96676, C73598, F15564, L46559, W06235,  
T09718, H77154, T14151, AI082914, AA650815, AA728021, AA072559, C92112,  
T46743, C61743, AA550223, C12798, AA275531, AA681003, T75878, AI100047,  
T75882, AA848187, T44109, AA542686, H21339

SEQ ID NO.: 10, Z81595, U41372, U01317, AE000696, AC002057, X66250, L11665,  
D13438, U29377, Z50028, U40953, AA114228, AI025080, R80188, W28745,  
AA381819, AA381991, Z44165, H75915, AI124743, H08139, AA375957, AA381750,  
AA166751, R42511, T26985, , AA471592, AA661387, AA606231, D35147

SEQ ID NO.: 11, X76498, Z97632, AC004232, AC005184, AC002545, AC003991.

## EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

All references disclosed herein are incorporated by reference in their entirety.

We claim:

**Claims**

1. A method of diagnosing a disorder characterized by expression of a human cancer associated antigen precursor coded for by a nucleic acid molecule, comprising:
  - contacting a biological sample isolated from a subject with an agent that specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an HLA molecule, wherein the nucleic acid molecule is a NA Group 1 nucleic acid molecule, and
  - determining the interaction between the agent and the nucleic acid molecule or the expression product as a determination of the disorder.
2. The method of claim 1, wherein the agent is selected from the group consisting of
  - (a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules or a fragment thereof,
  - (b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules or a fragment thereof,
  - (c) a nucleic acid molecule comprising NA group 5 nucleic acid molecules or a fragment thereof,
  - (d) an antibody that binds to an expression product of NA group 1 nucleic acids,
  - (e) an antibody that binds to an expression product of NA group 3 nucleic acids,
  - (f) an antibody that binds to an expression product of NA group 5 nucleic acids,
  - (g) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 1 nucleic acid,
  - (h) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 3 nucleic acid, and
  - (i) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 5 nucleic acid.
3. The method of claim 1, wherein the disorder is characterized by expression of a plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which is specific for a different human cancer associated antigen precursor, and wherein said plurality of agents is at least 2, at least 3, at least 4, at least 4, at least 6, at least 7, or at least 8, at least 9 or at least 10 such agents.

4. The method of claims 1-3, wherein the agent is specific for a human cancer associated antigen precursor that is selected from the group consisting of breast, gastric, lung, prostate, renal, colon, thyroid, Hodgkin's disease, and hepatocarcinoma cancer associated antigen precursors.
5. A method for determining regression, progression or onset of a condition characterized by expression of abnormal levels of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule, comprising  
monitoring a sample, from a patient who has or is suspected of having the condition, for a parameter selected from the group consisting of
  - (i) the protein,
  - (ii) a peptide derived from the protein,
  - (iii) an antibody which selectively binds the protein or peptide, and
  - (iv) cytolytic T cells specific for a complex of the peptide derived from the protein and an MHC molecule,as a determination of regression, progression or onset of said condition.
6. The method of claim 5, wherein the sample is a body fluid, a body effusion or a tissue.
7. The method of claim 5, wherein the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of
  - (a) an antibody which selectively binds the protein of (i), or the peptide of (ii),
  - (b) a protein or peptide which binds the antibody of (iii), and
  - (c) a cell which presents the complex of the peptide and MHC molecule of (iv).
8. The method of claim 7, wherein the antibody, the protein, the peptide or the cell is labeled with a radioactive label or an enzyme.
9. The method of claim 5, comprising assaying the sample for the peptide.
10. The method of claim 5, wherein the nucleic acid molecule is a NA Group 3 molecule.

11. The method of claim 5, wherein the nucleic acid molecule is a NA Group 5 molecule.
12. The method of claim 5, wherein the protein is a plurality of proteins, the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins, at least one of which is a cancer associated protein encoded by a NA Group 1 molecule.
13. The method of claim 5, wherein the protein is a plurality of proteins, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and wherein the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins.
14. A pharmaceutical preparation for a human subject comprising  
an agent which when administered to the subject enriches selectively the presence of complexes of an HLA molecule and a human cancer associated antigen, and  
a pharmaceutically acceptable carrier, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule comprises a NA Group 1 molecule.
15. The pharmaceutical preparation of claim 14, wherein the agent comprises a plurality of agents, each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen, wherein at least one of the human cancer associated antigens is encoded by a NA Group 1 molecule.
16. The pharmaceutical preparation of claim 15, wherein the plurality is at least two, at least three, at least four or at least 5 different such agents.
17. The pharmaceutical preparation of claim 14, wherein the nucleic acid molecule is a NA Group 3 nucleic acid molecule.
18. The pharmaceutical preparation of claim 14, wherein the agent comprises a plurality of



agents, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen.

19. The pharmaceutical preparation of claim 14, wherein the agent is selected from the group consisting of

- (1) an isolated polypeptide comprising the human cancer associated antigen, or a functional variant thereof,
- (2) an isolated nucleic acid operably linked to a promoter for expressing the isolated polypeptide, or functional variant thereof,
- (3) a host cell expressing the isolated polypeptide, or functional variant thereof, and
- (4) isolated complexes of the polypeptide, or functional variant thereof, and an HLA molecule.

20. The pharmaceutical preparation of claims 14-19, further comprising an adjuvant.

21. The pharmaceutical preparation of claim 14, wherein the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof, and wherein the cell is nonproliferative.

22. The pharmaceutical preparation of claim 14, wherein the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof, and wherein the cell expresses an HLA molecule that binds the polypeptide.

23. The pharmaceutical preparation of claim 21 or 22, wherein the isolated polypeptide comprises a kinectin polypeptide.

24. The pharmaceutical preparation of claim 14, wherein the agent is at least two, at least three, at least four or at least five different polypeptides, each coding for a different human cancer associated antigen or functional variant thereof, wherein at least one of the human cancer associated antigens is encoded by a NA Group 1 molecule.

25. The pharmaceutical preparation of claim 24, wherein the at least one of the human cancer associated antigens is kinectin or a fragment thereof.
26. The pharmaceutical preparation of claim 14, wherein the agent is a PP Group 2 polypeptide.
27. The pharmaceutical preparation of claim 14, wherein the agent is a PP Group 3 polypeptide or a PP Group 4 polypeptide.
28. The pharmaceutical preparation of claim 22, wherein the cell expresses one or both of the polypeptide and HLA molecule recombinantly.
29. The pharmaceutical preparation of claim 22, wherein the cell is nonproliferative.
30. A composition comprising  
an isolated agent that binds selectively a PP Group 1 polypeptide.
31. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 2 polypeptide.
32. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 3 polypeptide.
33. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 4 polypeptide.
34. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 5 polypeptide.
35. The composition of claims 30-34, wherein the agent is a plurality of different agents that bind selectively at least two, at least three, at least four, or at least five different such polypeptides.

36. The composition of claim 35, wherein the at least one of polypeptides is kinectin or a fragment thereof.
37. The composition of claims 30-34, wherein the agent is an antibody.
38. The composition of claim 315 wherein the agent is an antibody.
39. A composition of matter comprising  
a conjugate of the agent of claims 30-34 and a therapeutic or diagnostic agent.
40. A composition of matter comprising  
a conjugate of the agent of claim 35 and a therapeutic or diagnostic agent.
41. The composition of matter of claim 39, wherein the conjugate is of the agent and a therapeutic or diagnostic that is a toxin.
42. A pharmaceutical composition comprising an isolated nucleic acid molecule selected from the group consisting of NA Group 1 molecules and NA Group 2 molecules, and a pharmaceutically acceptable carrier.
43. The pharmaceutical composition of claim 42, wherein the isolated nucleic acid molecule comprises a NA Group 3 or NA Group 4 molecule.
44. The pharmaceutical composition of claim 42, wherein the isolated nucleic acid molecule comprises at least two isolated nucleic acid molecules coding for two different polypeptides, each polypeptide comprising a different human cancer associated antigen.
45. The pharmaceutical composition of claim 44, wherein at least one of the polypeptides is a kinectin polypeptide.
46. The pharmaceutical composition of claims 42-45 further comprising an expression

vector with a promoter operably linked to the isolated nucleic acid molecule.

47. The pharmaceutical composition of claims 42-45 further comprising a host cell recombinantly expressing the isolated nucleic acid molecule.
48. A pharmaceutical composition comprising  
an isolated polypeptide comprising a PP Group 1 or a PP Group 2 polypeptide, and  
a pharmaceutically acceptable carrier.
49. The pharmaceutical composition of claim 48, wherein the isolated polypeptide comprises a PP Group 3 or a PP Group 4 polypeptide.
50. The pharmaceutical composition of claim 48, wherein the isolated polypeptide comprises at least two different polypeptides, each comprising a different human cancer associated antigen.
51. The pharmaceutical composition of claim 50, wherein at least one human cancer associated antigen is kinectin.
52. The pharmaceutical composition of claim 48, wherein the isolated polypeptides are PP Group 11 polypeptides or HLA binding fragments thereof.
53. The pharmaceutical composition of claim 48, wherein the isolated polypeptides are PP Group 12 polypeptides or HLA binding fragments thereof.
54. The pharmaceutical composition of claims 48-53, further comprising an adjuvant.
55. An isolated nucleic acid molecule comprising a NA Group 3 molecule.
56. An isolated nucleic acid molecule comprising a NA Group 4 molecule.
57. An isolated nucleic acid molecule selected from the group consisting of

(a) a fragment of a nucleic acid molecule having a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs. 1-11 and 22-46, of sufficient length to represent a sequence unique within the human genome, and identifying a nucleic acid encoding a human cancer associated antigen precursor,

(b) complements of (a),

provided that the fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of

- (1) sequences having the GenBank accession numbers of Table 1,
- (2) complements of (1), and
- (3) fragments of (1) and (2).

58. The isolated nucleic acid molecule of claim 50, wherein the sequence of contiguous nucleotides is selected from the group consisting of:

- (1) at least two contiguous nucleotides nonidentical to the sequence group,
- (2) at least three contiguous nucleotides nonidentical to the sequence group,
- (3) at least four contiguous nucleotides nonidentical to the sequence group,
- (4) at least five contiguous nucleotides nonidentical to the sequence group,
- (5) at least six contiguous nucleotides nonidentical to the sequence group,
- (6) at least seven contiguous nucleotides nonidentical to the sequence group.

59. The isolated nucleic acid molecule of claim 57, wherein the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, and 200 nucleotides.

60. The isolated nucleic acid molecule of claim 57, wherein the molecule encodes a polypeptide which, or a fragment of which, binds a human HLA receptor or a human antibody.

61. An expression vector comprising an isolated nucleic acid molecule of any of claims 55-60 operably linked to a promoter.

62. An expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 2 molecule.
63. An expression vector comprising a NA Group 1 or Group 2 molecule and a nucleic acid encoding an HLA molecule.
64. A host cell transformed or transfected with an expression vector of claim 61.
65. A host cell transformed or transfected with an expression vector of claims 62 or 63.
66. A host cell transformed or transfected with an expression vector of claim 61 and further comprising a nucleic acid encoding HLA.
67. A host cell transformed or transfected with an expression vector of claim 62 and further comprising a nucleic acid encoding HLA.
68. An isolated polypeptide encoded by the isolated nucleic acid molecule of claim 55 or claim 56.
69. A fragment of the polypeptide of claim 68 which is immunogenic.
70. An isolated polypeptide comprising a fragment of a kinectin polypeptide which is immunogenic.
71. The fragment of claims 69 or 70, wherein the fragment, or a portion of the fragment, binds HLA or a human antibody.
72. An isolated fragment of a human cancer associated antigen precursor which, or portion of which, binds HLA or a human antibody, wherein the precursor is encoded by a nucleic acid molecule that is a NA Group 1 molecule.

73. The fragment of claim 72, wherein the fragment is part of a complex with HLA.
74. The fragment of claim 73, wherein the fragment is between 8 and 12 amino acids in length.
75. An isolated polypeptide comprising a fragment of the polypeptide of claim 68 of sufficient length to represent a sequence unique within the human genome and identifying a polypeptide that is a human cancer associated antigen precursor.
76. A kit for detecting the presence of the expression of a human cancer associated antigen precursor comprising  
a pair of isolated nucleic acid molecules each of which consists essentially of a molecule selected from the group consisting of (a) a 12-32 nucleotide contiguous segment of the nucleotide sequence of any of the NA Group 1 molecules and (b) complements of ("a"), wherein the contiguous segments are nonoverlapping.
77. The kit of claim 76, wherein the pair of isolated nucleic acid molecules is constructed and arranged to selectively amplify an isolated nucleic acid molecule that is a NA Group 3 molecule.
78. A method for treating a subject with a disorder characterized by expression of a human cancer associated antigen precursor, comprising  
administering to the subject an amount of an agent, which enriches selectively in the subject the presence of complexes of an HLA molecule and a human cancer associated antigen, effective to ameliorate the disorder, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule selected from the group consisting of
- (a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules,
  - (b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules,
  - (c) a nucleic acid molecule comprising NA group 5 nucleic acid molecules.
79. The method of claim 78, wherein the disorder is characterized by expression of a

plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which enriches selectively in the subject the presence of complexes of an HLA molecule and a different human cancer associated antigen, wherein at least one of the human cancer associated antigens is encoded by a NA Group 1 molecule.

80. The method of claim 79, wherein at least one of the human cancer associated antigens is kinectin or a fragment thereof.

81. The method of claim 79, wherein the plurality is at least 2, at least 3, at least 4, or at least 5 such agents.

82. The method of claims 78-81, wherein the agent is an isolated polypeptide selected from the group consisting of PP Group 1, PP Group 2, PP Group 3, PP Group 4, and PP Group 5.

83. The method of claims 78-81, wherein the disorder is cancer.

84. The method of claims 82, wherein the disorder is cancer.

85. A method for treating a subject having a condition characterized by expression of a human cancer associated antigen precursor in cells of the subject, comprising:

- (i) removing an immunoreactive cell containing sample from the subject,
- (ii) contacting the immunoreactive cell containing sample to the host cell under conditions favoring production of cytolytic T cells against a human cancer associated antigen which is a fragment of the precursor,
- (iii) introducing the cytolytic T cells to the subject in an amount effective to lyse cells which express the human cancer associated antigen, wherein the host cell is transformed or transfected with an expression vector comprising an isolated nucleic acid molecule operably linked to a promoter, the isolated nucleic acid molecule being selected from the group of nucleic acid molecules consisting of NA Group 1, NA Group 2, NA Group 3, NA Group 4, and NA Group 5.



86. The method of claim 85, wherein the host cell recombinantly expresses an HLA molecule which binds the human cancer associated antigen.
87. The method of claim 85, wherein the host cell endogenously expresses an HLA molecule which binds the human cancer associated antigen.
88. A method for treating a subject having a condition characterized by expression of a human cancer associated antigen precursor in cells of the subject, comprising:
- (i) identifying a nucleic acid molecule expressed by the cells associated with said condition, wherein said nucleic acid molecule is a NA Group 1 molecule;
  - (ii) transfecting a host cell with a nucleic acid selected from the group consisting of (a) the nucleic acid molecule identified, (b) a fragment of the nucleic acid identified which includes a segment coding for a human cancer associated antigen, (c) deletions, substitutions or additions to (a) or (b), and (d) degenerates of (a), (b), or (c);
  - (iii) culturing said transfected host cells to express the transfected nucleic acid molecule, and;
  - (iv) introducing an amount of said host cells or an extract thereof to the subject effective to increase an immune response against the cells of the subject associated with the condition.
89. The method of claim 88, wherein the nucleic acid molecule is a kinectin nucleic acid molecule.
90. The method of claim 88, further comprising identifying an MHC molecule which presents a portion of an expression product of the nucleic acid molecule, wherein the host cell expresses the same MHC molecule as identified and wherein the host cell presents an MHC binding portion of the expression product of the nucleic acid molecule.
91. The method of claim 88, wherein the immune response comprises a B-cell response or a T cell response.
92. The method of claim 91, wherein the response is a T-cell response which comprises

generation of cytolytic T-cells specific for the host cells presenting the portion of the expression product of the nucleic acid molecule or cells of the subject expressing the human cancer associated antigen.

93. The method of claim 88, wherein the nucleic acid molecule is a NA Group 3 molecule.
94. The method of claims 88 or 90, further comprising treating the host cells to render them non-proliferative.
95. A method for treating or diagnosing or monitoring a subject having a condition characterized by expression of an abnormal amount of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule, comprising  
administering to the subject an antibody which specifically binds to the protein or a peptide derived therefrom, the antibody being coupled to a therapeutically useful agent, in an amount effective to treat the condition.
96. The method of claim 95, wherein the antibody is a monoclonal antibody.
97. The method of claim 96, wherein the monoclonal antibody is a chimeric antibody or a humanized antibody.
98. A method for treating a condition characterized by expression in a subject of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising  
administering to a subject a pharmaceutical composition of any one of claims 14-29 and 42-547 in an amount effective to prevent, delay the onset of, or inhibit the condition in the subject.
99. The method of claim 98, wherein the condition is cancer.
100. The method of claim 98, further comprising first identifying that the subject expresses

in a tissue abnormal amounts of the protein.

101. The method of claim 99, further comprising first identifying that the subject expresses in a tissue abnormal amounts of the protein.

102. A method for treating a subject having a condition characterized by expression of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising

- (i) identifying cells from the subject which express abnormal amounts of the protein;
- (ii) isolating a sample of the cells;
- (iii) cultivating the cells, and
- (iv) introducing the cells to the subject in an amount effective to provoke an immune response against the cells.

103. The method of claim 102, further comprising rendering the cells non-proliferative, prior to introducing them to the subject.

104. A method for treating a pathological cell condition characterized by aberrant expression of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising

administering to a subject in need thereof an effective amount of an agent which inhibits the expression or activity of the protein.

105. The method of claim 104, wherein the agent is an inhibiting antibody which selectively binds to the protein and wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or an antibody fragment.

106. The method of claim 104, wherein the agent is an antisense nucleic acid molecule which selectively binds to the nucleic acid molecule which encodes the protein.

107. The method of claim 104, wherein the nucleic acid molecule is a NA Group 3 nucleic acid molecule.

108. The method of claim 104, wherein the nucleic acid molecule is a kinectin nucleic acid molecule.

109. A composition of matter useful in stimulating an immune response to a plurality of a proteins encoded by nucleic acid molecules that are NA Group 1 molecules, comprising  
a plurality of peptides derived from the amino acid sequences of the proteins, wherein the peptides bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein.

110. The composition of matter of claim 109, wherein at least a portion of the plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto.

111. The composition of matter of claim 109, wherein at least one of the proteins is kinectin.

112. The composition of matter of claim 110, further comprising an adjuvant.

113. The composition of matter of claim 112, wherein said adjuvant is a saponin, GM-CSF, or an interleukin.

114. The composition of matter of claim 109, further comprising at least one peptide useful in stimulating an immune response to at least one protein which is not encoded by nucleic acid molecules that are NA Group 1 molecules, wherein the at least one peptide binds to one or more MHC molecules.

115. An isolated antibody which selectively binds to a complex of:

- (i) a peptide derived from a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule and
  - (ii) and an MHC molecule to which binds the peptide to form the complex,
- wherein the isolated antibody does not bind to (i) or (ii) alone.

116. The antibody of claim 115, wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a fragment thereof.

## SEQUENCE LISTING

&lt;110&gt; Ludwig Institute for Cancer Research

<120> Cancer Associated Antigens  
and Uses Therefor

&lt;130&gt; L0461/7050WO

&lt;140&gt; US 09/166,300

&lt;141&gt; 1997-10-05

&lt;140&gt; US 09/166,350

&lt;141&gt; 1997-10-05

&lt;160&gt; 45

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;211&gt; 4422

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

gattattctg	gaggaagatg	accttcattt	tatggttatg	tgtgtgtgtc	tgtgtgtctt	60
tggaataata	tatataattt	tttcaaatag	gaagccaaca	tatcaagtga	tgaattaaag	120
tatgctgcag	aatatatatt	ctaaaactac	aaaaaaagtca	ctgaatatca	aaatgataca	180
gcttatacat	atagttactg	tgacaagtga	cagactgcta	gttcagaatt	caaaaatcct	240
ttcctagttt	gtgagataat	gggctaaaatt	ccttctgcct	gccactgggg	caaagcaaat	300
tgcttttagtt	tttgatgaga	gttcttagaa	gtttgttggt	attccttcat	ccacagcatc	360
cattgttgaa	ataaccattt	tcagttgtga	tgccttaact	aagaagccaa	ttgttagcct	420
gaaatgcaat	cttggtagcc	agtttcaatg	aagctagaga	ttagtcagaa	aaagttagct	480
gttgggcttt	agaaagggat	tttgagtcct	gncattttcta	cttggggagca	ttttggagca	540
gattaagctt	tcagtataaa	aacaagtggc	tacctgatgg	aaacttttct	taccttata	600
gggaaactga	gcacaagctg	aatgatattg	tctgctgcaa	aaaaaaaacaa	acaaaaaaa	660
aacaaaacaa	aaaacaaaaa	aaaaaaaaaa	aaaacctcgt	gccgaattcg	gcacgagggg	720
aagccccgtg	cacccccccg	cctccggccg	ccgcccgcgc	gctggccctg	cagccgtcgc	780
cgctgcctcg	ggctacagcc	ccgggctcgg	cggtcccggc	tggggaagga	gggcggcgag	840
cgcgctccga	gccgcgggag	atggcgggag	ggcactgcgg	cagcttcccc	gcggcggcgg	900
ccggcagcgg	cgagatcgtc	caactgaacg	taggggggac	cagatttagt	acctcaagac	960
aaactcttat	gtggattcca	gattcttttt	tttccagttt	gctgagtggg	agaatttcaa	1020
cacttcgaga	tgaactgggt	gctatatatt	ttgatagaga	tccagcagca	tttgcaccca	1080
ttttaaattt	tcttcggaca	aaagaactag	acttaagggg	agtgagtatt	aatgtttctca	1140
ggcatgaagc	agaattttac	gggatcactc	cattagtaag	aaggcttctc	ttatgtgaag	1200
aattggagcg	ttcctcttgt	ggcagtgctc	tttttcatgg	ttacttgccc	ccaccaggta	1260
ttcctagtcg	taaaataaac	aacacagtca	gatctgctga	ttctaggaat	ggtctaaatt	1320
ctacagaagg	tgaagcccg	ggaatggta	cacagcctgt	tctctctgga	acgggagaa	1380
aaactgttag	gctaggattt	cctgtggatc	cacgaaaagg	gctaatagta	gctggccatc	1440
acaactggat	tgtagctgca	tatgccattt	ttgctgngtg	gtacagaatc	aaagaatcct	1500
caggatggca	gcaagtgttt	acgagcccat	atlttgattg	gactatcgaa	cgagtagcct	1560
taaattgcaaa	ggtggttgg	gggccacatg	gagacaaaga	caaaatggtt	gctgttgctt	1620
cagagagtag	catcatcttg	tggagtgttc	aggatggggg	aagtgggaagt	gaaattggag	1680
tgttcagcct	gggtgttctt	gtagatgctc	tcttctttat	tggttaaccag	ttggtggcca	1740
cgagtcatac	agggaaaagt	ggagtgtgga	atgctgtcac	tcagcactgg	caggttcaag	1800
atgttggttc	tataactagt	tatgacactg	ctggatcatt	ccttctgctt	ggatgtaaca	1860
atggatcaat	gatattacata	gatattcaga	agttcccttt	gcgaatgaaa	gataatgatc	1920
ttcttgtaac	tgaactgtat	catgatcctt	caaatgatgc	tattactgct	ctgagtgttt	1980
acctcacacc	caaaacaagt	gtcagtggtg	actggatcga	gatcgccctat	ggtacgagct	2040
ctggagcagt	acgagtgatt	gtacaacacc	cagagacagt	tgggtcaggt	cctcagcttt	2100
ttcagacttt	cacagttcac	cgaagtcccg	taacaaaaat	catgctatca	gagaagcatc	2160
ttgtatcagt	ctgtgcagat	aataatcatg	tccggacgtg	gacagtaaca	cgattcngag	2220
gaatgatctc	tactcagcca	ggttctactc	cttttagcgtc	attcaagata	ctatccctgg	2280
aggagacaga	aagtcatggt	agctattcct	ctggaaaatga	cataggacct	tttgagagac	2340
gagacgatca	acaggtgttt	atccagaaa	ttgttcccat	caccaacaaa	ctatttgtaa	2400
gactctcatc	gactggaaaa	agaatatgtg	agatccaggc	tggttgactgt	actacaatat	2460
cctcattttac	agtgagggaa	tgtgagggat	ccagtaggat	gggctcaaga	ccaaggcgct	2520

	acttggttcac	aggccataca	aatggcagta	ttcaaatgtg	ggatctgacc	actgctatgg	2580
	atatggttaa	caaaagtga	gataaggatg	taggtggtcc	aaccgaagaa	gagctactca	2640
	aattactcga	tcaatgtgat	ttgagcacat	ctcgctgtgc	tactcctaac	atcagttccag	2700
	caacttccgt	agttcagcat	agccacttac	gagaatcaaa	ttctagcctt	cagcttcagc	2760
5	accatgatac	cacccatgaa	gcagctactt	acggttccat	gagggccttac	agagaaagt	2820
	ctttattagc	aagggcaaga	aggactgaga	gctttcacag	ttatagggac	ttccagacta	2880
	ttaatttgaa	cagaaatgta	gaaagagctg	tccctgaaaa	tggttaacttg	ggtccaatac	2940
	aagctgaagt	gaaaggggca	acaggggaat	gtaatatatc	tgagagaaa	tctcctggag	3000
	tagaaataaa	aagtttgaga	gaattggata	gtggattgga	agtgcataaa	atagctgaag	3060
10	gtttttcaga	atccaagaaa	aggtcatcag	aagatgaaaa	tgaaaaataaa	atagagttaa	3120
	ggaagaaaag	aggatttgaa	gggggaggat	tccttggaa	aaagaaaagt	ccctatctgg	3180
	catcatcacc	aagtacttcc	gatggaggaa	ctgactcacc	tggtactgcg	tccccatctc	3240
	ctacaaagac	tactccatct	cctcggcata	aaaaaagtga	ttcttcagggt	caggagtaca	3300
	gcttgtgaaa	actcaccaaa	atgaatagtt	gtttcgggta	catttagatg	aaagttaa	3360
15	tttactgaat	ttcagtagat	tagtttttac	actaaaactt	tacaagataa	aattggactt	3420
	catttagtat	ctttttaaca	gaattacttg	gaataatgag	atacaataat	catatctctt	3480
	ttgacatttt	ggaaattttt	ttaatttttac	aagtacattt	aacagatcat	ttataaagca	3540
	ggagtccatt	ttaacactta	ccgacttttt	ttggtttgga	aacatattac	cacgtcttaa	3600
	taggatgggtg	cccatatagg	tgagcatccc	tttagatcat	gggaaccagc	agactgcatt	3660
20	cctaactctc	attatgcctg	agacttgtct	tacaatgtta	cctttaagt	aatcacataa	3720
	ttgtctttgg	aacttggtct	cccaacactt	attgtgattg	caaagtgttt	accagatatt	3780
	tgatgaggtg	ctatgtttgt	gaaaaacata	tcatgttaatt	caaaaacact	attgatattg	3840
	aataccagat	accactatgt	agtaagtctt	ttaggatgat	tttaatttag	tcgtgcgtca	3900
	ttttctgatt	ctcatcattg	ggagatctta	aatcttagca	agcattagca	atattaaatg	3960
25	ccaaaattcc	attgaaactt	tcaagttgga	gcaattgtct	gtgtttgaaa	agatgaaata	4020
	aaaataataa	tcaagggcaa	agctttgagt	gcccagaagg	gaaagctgta	ccagttgcta	4080
	acctgtcttg	tttcaggagc	caccatgttt	ttttttcagt	gttancaaca	atcatgataa	4140
	ttaaattaaa	acnctagttt	gttcacttgt	aggactgcag	ttctgaattt	tgggttaaag	4200
	gttttggtg	ctgtaagaat	gtgaatttga	atgtattttg	aattgtaaga	gcaaaagaac	4260
30	gtttttgtac	aatttttttt	catttaattg	gaatgatctt	caggtttcta	caaatagggt	4320
	aattgtaaat	ttaaagcatt	agcattttatt	ggtgaataat	gtatatatcc	ccattccaag	4380
	aaatataagt	gagtgaagtt	gaaataaaat	ctttaaaatt	ta		4422

&lt;210&gt; 2

&lt;211&gt; 502

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

40	gctagcttcg	gcgcggatcc	ctgggcgtcc	gtacgtcgga	gtccttcgtc	ctccagggtc	60
	cctgttcttt	gcgccagcgg	gaaccactat	ctctgcactc	ctgggggttt	gttacatggc	120
	tgctttcctc	aaaatgagtg	ttagtgtcaa	tttcttcaga	cctttcacca	gggttttggg	180
	gccatttacc	cttcatagga	agagaaataa	cttaacaatt	ttgcagagat	acatgtcttc	240
	caaaaatacca	gctgttactt	atcctaataa	tgagagtaca	cgcccttctg	aagagctaga	300
45	gttggtgata	tggaataact	ccatgaaatc	tagtggtcaa	gaagaatgtg	tttcaacaat	360
	ctcaagcagt	aaggatgaag	atcctctagc	tgccacaga	gagttcattg	agatgtggag	420
	attgcttggc	agagaagtag	cagaacacat	cactgaagaa	gagctcaaaa	cccttatgga	480
	atgtgtttct	aacacagcaa	aa				502

&lt;210&gt; 3

&lt;211&gt; 1948

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

55	ccatgtgagg	gaggggccc	ctcctgcttg	gtgacagagt	cagcacgcgg	tggcctgcag	60
	ttcctccagc	agtgtgaccg	ggaggatctg	gtggaattgg	ctctgcctca	gctggctcag	120
	gttgtgaccg	tgtatgagtt	tcttctgatg	aaggttgaaa	aagatcatct	agcaaagcct	180
	tttttcccag	ctatatataa	ggaatttgaa	gagttgcata	aaatggttaa	gaaaatgtgc	240
60	caagattacc	tcagtagttc	tggtctgtgt	tcccaggaga	ccctggaaat	aaacaatgat	300
	aaggttgctg	agtcattagg	aatcacagaa	ttcctacgga	agaaagaaat	acaccagac	360
	aaccttggac	ccaagcacct	cagccgagac	atggatgggg	agcagctaga	gggagctagc	420
	agcgagaaga	gggaacgtga	ggctgcggag	gagggactgg	cctcagtgaa	aaggcccaga	480
	agagaagccc	tgtccaacga	taccactgaa	tctcttgctg	ccaacagcag	aggccgggag	540
65	aagcccaggc	ccttgcatgc	tttgcccgcg	ggtttttccc	ctccagtaaa	tgtgactgtc	600
	tctcccgtt	ctgaagaaag	ccatacaacg	acggtttctg	gtggcaatgg	gagcgtgttc	660
	caggcggggc	cgcagcttca	ggcactggct	aacttagaag	ccaggagggg	gtctatagg	720

	gctgctctct	catccccgga	tgtcagtggg	ctgcctgttt	atgctcagtc	aggagagcct	780
	aggaggctga	cccaggcaca	ggtggcagcg	tttcttgagg	agaatgcttt	ggaacactct	840
	tcagaccagg	acacctggga	cagcctgagg	agcccgggtt	tctgcagccc	tttgtcatct	900
	ggtgggtggag	cagagtccct	gccgcctggg	gggcctggac	atgcagaggc	aggacacctc	960
5	ggcaaggttt	gtgacttcca	cctgaaccac	cagcagccca	gccccaccag	cgtcctgcct	1020
	acagagggtg	cagccccctc	gcttgagaaa	attttgtctg	tggatagcgt	ggcagtggac	1080
	tgtgcctaca	ggactgtgcc	caagccaggg	cctcagcctg	gcccacatgg	atcactattg	1140
	actgaagggt	gtctcagaag	cctttcgggg	gacttgaacc	ggttcccctg	tgggatggag	1200
	gtgcactctg	gccagagaga	actggagagc	gtggttgcgt	tcggcggaagc	catggctttg	1260
10	aaatttccaa	tgggagccat	gagttactgt	ctcagggaca	gaagcagatt	tttattcaga	1320
	cttccgatgg	gcttatcttg	tccccctccag	gtacaatagt	gtctcaggag	gaggacattg	1380
	tcacagtgc	tgatgcagag	gggcgtgcct	gcggatgggc	ccgctagaag	gagttcctct	1440
	agaagctgtg	gagtcgggtc	tcaccgcgag	agccctcaca	gtgaagtgga	gtcagatcct	1500
	agattcgtct	gatttttatcc	agagaagggtc	tatggcaagc	aatgtatat	tttctaattg	1560
15	gaatattgca	cagatgaacc	ttttatattat	aaagaataat	gtctttctgc	cctgctgtct	1620
	acatttttct	atggagcttg	tcataataat	agcagatatt	acctgatcag	gaatccctgt	1680
	ggcgcgtctg	acgctcatga	gtttttcatg	atggtgatga	gtagcactgc	actgtcacct	1740
	gatgattggc	cctgctccgt	ttcccttctc	tcctgggaga	tatgctgctt	ttccaccaga	1800
	cttgctccat	actagaagct	tcttttgggt	tcaattaaaa	agaaaataag	ctagtcattc	1860
20	tgggcagcat	tttattgata	gaagggggaa	aaagtcattt	ctacttgcat	gattttttta	1920
	attaaattaa	attaaattaa	tttaaaaaa				1948

&lt;210&gt; 4

&lt;211&gt; 1486

25 &lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

	ccgcggcggc	gtccgggggtc	tccagtaggg	ctgaogctcc	ggtgctcgca	caatcccccg	60
30	cctcgggctg	caacggggcgt	ccctccactc	cccagagccc	cggcagccgc	cgccacccca	120
	gcgcgccccg	atctggcccc	ctgcccccg	aagatggctg	ccgtacgccc	ggcccgcagt	180
	tattgcogct	gcctgggtgc	cttctccgac	cgagaactct	gctaagctcc	gctgcagaga	240
	caggcaggag	tagacaccgc	gacacccagc	acccctcctc	cggggggcgg	tgcagagggg	300
	gcacggagag	cccctcgagc	gcagcaggcc	gccccgccag	catggcagaa	gctgaggaag	360
35	attgtcattc	tgatactgtc	agagcagatg	atgatgaaga	aaatgaaagt	cctgctgaaa	420
	cagatctgca	ggcacaactc	cagatgttcc	gagctcagtg	gatgtttgaa	cttgctccag	480
	gtgtaagctc	tagcaattta	gaaaatcgac	cttgccagag	agcaagaggc	tctctccaga	540
	aaacatcggc	agataccaaa	ggaaaacaa	aacaggcaaa	agaagaaaa	gctcgagaac	600
	tcttcctaaa	agcagtagaa	gaagaacaaa	atggagctct	ctatgaagcc	atcaagtttt	660
40	atcgtagggc	tatgcaactt	gtacctgata	tagagttcaa	gattacttat	acccggtctc	720
	cagatggtga	tggcggttga	aacagctaca	ttgaagataa	tgatgatgac	agcaaaatgg	780
	cagatctctt	gtcctacttc	cagcagcaac	tcacatttca	ggagtctgtg	cttaactctg	840
	gtcagcctga	gcttgagagc	agtcagattc	acatatcagt	gctgccaatg	gaggtcctga	900
	tgtacatctt	ccgatgggtg	gtgtctagtg	acttggacct	cagatcattg	gagcagttgt	960
45	cgctgggtgtg	cagaggattc	tacatctgtg	ccagagaccc	tgaatatatg	cgtctggcct	1020
	gcttgaaggt	tgggggcaga	agctgtatta	aacttgttcc	gtacacgtcc	tggagagaga	1080
	tgtttttaga	acggcctcgt	gttcggtttg	atggcgtgta	tatcagtaaa	accacatata	1140
	ttcgtcaagg	ggaacagtct	cttgatgggt	tctatagagc	ctggcaccaa	gtggaatatt	1200
	acaggtacat	aagattcttt	cctgatggcc	atgtgatgat	gttgacaacc	cctgaagagc	1260
50	ctcagtcctat	tgttccacgt	ttaagaacta	gggaatacca	ggactgatgc	caattctact	1320
	gggtcactat	cgcttggcac	aagacacaga	ccatcagacc	caaagtattt	tgctgtaata	1380
	actaagaaaa	aaagggaagaa	aaaccacttg	gactataaat	acccgatatt	ttcgtcgggg	1440
	tccctgtacc	aaagaagccg	aatcagaagt	tttcatgnng	gggctn		1486

&lt;210&gt; 5

&lt;211&gt; 774

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

	tgcgccaccc	cacccccacc	cacccccgcc	atgcaacggg	attgaagggt	cctgccgggtg	60
	ggaccctgtc	ccgcccagtg	ccactgcccc	ccgaggctgc	tagacgtagg	tgttaggcac	120
	gtcccaccca	ccgcgcgcct	cccacggcac	ctcggggaca	ccagagctgc	cgacttggag	180
	actcctggtc	tgtgaagagc	cggtgggtgc	cgtgcccgca	ggaactgggc	tgggcctcgt	240
65	gcgcgcgtgg	ggtctgcgct	tgggtctttct	gtgcttggat	ttgcatattt	attgcattgc	300
	tggtagagac	ccccaggcct	gtccaccctg	ccaagactcc	tcaggcagcg	tgtgggtccc	360
	gcactctgcc	cccatttccc	cgatgtcccc	tgcggggcgcg	ggcagccacc	caagcctgct	420



	ggctgcgggc	ccctctcggc	caggcattgg	ctcagcccg	tgagtggggg	gtcgtggggc	480
	agtcgccgag	gagctggggc	cctgcacag	cacacagggc	ccggccacac	ccagcggccc	540
	cccgacacagc	caccggtggg	gtgctgccct	tatgcccggc	gccgggcacc	aactccatgt	600
	ttgggtgtttg	tctgtgtttg	tttttcaaga	aatgattcaa	attgctgctt	ggatttttgaa	660
5	atttactgtg	actgtcagtg	tacacgtctg	gaccccggtt	cattttttaca	ccaatttggt	720
	aaaaatgctg	ctctcagcct	cccacaatta	aaccgcatgt	gatctccaaa	aaaa	774

&lt;210&gt; 6

&lt;211&gt; 2936

10 &lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

	cgtaaccctt	agtcccaatg	cctccgtaag	cggagttgag	tgggtgcctg	tggttggagc	60
15	tgtggaggtg	tccccggtgg	cgagcgcggc	cagaactgag	gtcacttaag	ttttccgtgt	120
	gcgggttgca	aggagcgtgc	gtgctgctgg	tatagggagg	acacctctgg	attgaggatc	180
	ttatgacctg	cttttagagga	aggtataatt	tggcttcctg	agattctgcc	ttagcaagaa	240
	aggagtggga	aatacccttg	gaaagaaaaac	taaaacagta	agaaagccaa	aacttatttt	300
	tacatgggtg	tcagcacatt	taccgatatg	gacacttttc	ccaataattt	tcctcctggt	360
20	ggagacagtg	gattgacagg	ttctcagtcg	gagttccaga	aaatgttaat	tgatgaaagg	420
	ttacgatgtg	agcatcataa	agctaattat	cagacactga	aggctgaaca	cacaaggttg	480
	cagaatgaac	atgtaaaagt	acaaaaatgaa	ctcaagcacc	tgtttaatga	aaagcaaat	540
	cagcagggaa	aacttcagct	cctgcttgaa	gaactaagag	gagaattagt	agagaaaact	600
	aaagatttag	aagaaatgaa	actgcagata	ttactccca	aaaattggaa	ttgctaagag	660
25	cccaaataca	acaagaatta	gaaactccaa	tgagagaacg	ttttaggaat	ctagatgaag	720
	aggtagaaaa	gtatagagct	gtatataata	agcttcgcta	tgaacataca	tttctcaagt	780
	cagaatttga	acaccagaag	gaagagtatg	cacgtatttt	agatgaagga	aaaataaaat	840
	atgaatcaga	gattgcaaga	ctggaggaag	ataaagaaga	actacgtaac	cagctgctta	900
	atgttgatct	cacaaaagac	agcaaacgag	tggaacaact	tgctcgagaa	aaagtctatt	960
30	tgtgtcaaaa	attaaaaggt	ttagaggctg	aagtagcgga	attaaaggct	gaaaaggaga	1020
	attctgaggc	tcagggtgaa	aatgcccmaa	gaatacaggt	gcggcagttg	gctgagatgc	1080
	aggctacagt	cagatccctg	ggggctgaaa	aacaatcagc	taatttacgg	gcagaaacgc	1140
	tggaaaaaga	gctacaatca	agcagtgaac	aaaatacctt	tttaattaat	aaattgcata	1200
	aagctgaacg	agaaataaat	acattgtcca	gtaaagttaa	agaacttaaa	cattcaaaca	1260
35	aactggaat	aacagacatc	aaactggaga	cagcaagagc	taagagttag	ctagaaaagag	1320
	aaaggaataa	gcttcaaagt	gaactggatg	gattacagtc	agacaatgaa	attctcaaaag	1380
	cagctgttga	acatcacaaa	gtgctcttag	tagaaaagga	tcgtgaatta	atacgtaaaag	1440
	tacaagctgc	caaagaagaa	ggttatcaaa	aacttgtggt	attacaagat	gaaaagttag	1500
	aactcgagaa	cagattagca	gatttggaga	aaatgaaagt	ggaacatgat	gtctggaggc	1560
40	aatctgaaaa	ggatcagtat	gaagagaaat	tgccggcttc	acagatggca	gaagagatca	1620
	ccaggaagga	gcttcagagt	gttaggttaa	aacttcagca	acaaaattgtg	actattgaaa	1680
	atgcagagaa	ggaaaaaaat	gaaaattctg	acctaataca	gcaaatcagt	agtttgcaga	1740
	tccaagtgc	ttcacttgca	cagtcagaga	atgacttgct	gaattcaaac	caaatgctga	1800
	aggaaatggt	ggagagatta	aaacaagaat	gccgaaat	tagaagccaa	gctgaaaaag	1860
45	cgcaactaga	agctgaaaag	acattggaag	agaaacagat	acagtgggtg	gaagaaaagc	1920
	ataagcttca	tgaccgtatc	acagacagag	aagaaaagta	caatcaagct	aaggagaaac	1980
	tgacgcgagc	tgcaattggc	cagaaaaaga	gaaaatctct	tcatgaaaac	aaattgaaaa	2040
	gactacaaga	gaaagtagaa	gtcttgaggg	caaagaaaga	agaattggaa	acagaaatca	2100
	ggtcttaaat	agacaaaatg	ttcctttgaa	gactatacaa	ggcttcaaaa	aagactaaaa	2160
50	gatatacaga	gaagacataa	tgaatttcga	agtctaattt	tggttcctaa	catgcctcca	2220
	acagcatcta	tcaatcctgt	tagctttcag	tcacagcca	tggttccaag	catggaacta	2280
	ccatttctct	ctcatatgca	ggaggaacaa	catcaaaggg	aactctctct	acttcgcaaa	2340
	agactagaag	aactggaaac	aacacaaaga	aaacaactag	aggaacttgg	atcttccgga	2400
	gaatgatgtt	cttgagagac	aggcagatca	aaagaggtga	agttggtgac	tcagtaaaac	2460
55	ttgacatttt	aacctgtggc	atttagatac	tttttactgt	ttgccaaaac	acttgaatgt	2520
	gcctcaagaa	aaggtaccta	ctacatgctg	tattgtatga	ctgtcaggat	tttaagatta	2580
	tacaagtga	agaaattctc	agaaattctc	agagatat	agaatatttg	acaatggttt	2640
	gagaatgtaa	aacaaaaagg	aactagttag	agtcaagttt	taaaaatttt	actttgttga	2700
	atTTTTTTTT	ttggcatttt	gagtgaaata	taactatcat	taattctctc	ttcatctttg	2760
60	agatgcttgg	ccataacagg	gtccatacac	atcttctggt	ttactatata	caaaaactgt	2820
	agttgaaaaa	agatgacaat	ttaaaagtca	gcctaaagaa	tgtaaaggta	tctatatata	2880
	aaaggctacc	ttttctaaaa	tctgtgtgca	cataattaaa	gagcttaatt	tttaaa	2936

&lt;210&gt; 7

&lt;211&gt; 1387

65 &lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

	aaaggtctaca	tcattaacac	tagaaggagg	acgattaaaa	cgaactccac	agctgattca	60
	tgggaagagac	tatgaaatgg	tcccagaacc	tgtgtggaga	gcactttatc	actgggtatgg	120
5	agcaaaccctg	gccttaccta	gaccagttat	caagaacagc	aagacagaca	ttccagagct	180
	ggaattatctt	ccccgctatc	ttctcttcc	gagacagcag	cctgccactc	ggacacagca	240
	gtctaacatc	tgggtgaata	tgggaaatgt	accttctccg	aatgcacctt	taaagcgggt	300
	attagcctat	acaggctgtt	ttagtccaat	gcagaccatc	aaggaaattc	acgaatatct	360
	atctcaaagg	ctgcgcatta	aagaggaaga	tatgcgcctg	tggctataca	acagtggaga	420
10	ctaccttact	cttctggatg	atgaggatca	taaattggaa	tatttgaaaa	tccaggatga	480
	acaacacctg	gtaattgaag	ttcgcaacaa	agatatgagt	tggcctgagg	agatgtcttt	540
	tatagcaaat	agtagtaaaa	tagatagaca	caaggttccc	acagaaaagg	gagccacagg	600
	tctaagcaat	ctgggaaaca	catgcttcat	gaactcaagc	atccagtgtg	ttagtaaacac	660
	acagccactg	acacagtatt	ttatctcagg	gagacatctt	tatgaactca	acaggacaaa	720
15	tcccattgggt	atgaaggggc	atatggctaa	atgctatggt	gatttagtgc	aggaactttg	780
	gagtggaaact	cagaagaatg	ttgccccatt	aaagcttcgg	tggaccatag	caaaatatgc	840
	tcccagggttt	aatgggtttc	agcaacagga	ctcccaagaa	cttctggctt	ttctcttgga	900
	tgggtcttcac	gaagatctta	atcgagtcca	tgaaaagcca	tatgtggaac	tgaaggacag	960
	tgatgggcga	ccagactggg	aagttagctgc	agaggcctgg	gacaaccatc	taagaagaaa	1020
20	tagatcaatt	gttgtggatt	tgttccatgg	gcagctaaga	tctcaagtaa	aatgcaagac	1080
	atgtgggcat	ataagtgtcc	gatttgaccc	tttcaatttt	ttgtctttgc	caactaccaat	1140
	ggacagttat	atgcacttag	aaataacagt	gattaagtta	gatggtacta	cccctgtacg	1200
	gtatggacta	agactgaata	tggatgaaaa	gtacacaggt	ttaaaaaaac	agctgagtga	1260
	tctctgtgga	cttaattcag	aacaaatcct	tctagcagaa	gtacatgggt	ccaacataaa	1320
25	gaacttttct	caggacaacc	caaaaagtac	cgaacttctc	agtgaagtgg	gatttttttg	1380
	tgtgccca						1387

&lt;210&gt; 8

&lt;211&gt; 749

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

30

&lt;400&gt; 8

	gccccacatg	gctggagcgc	ggcggagggtg	agccggccgc	ccgcccgcag	acgccccagc	60
35	ctactgcgcc	cgagtcccg	ggccccagtg	gcgcctcagc	tctgcggtgc	cgaggcccaa	120
	cggctcgatc	gctgcccgc	gccagcatgt	tgggcgcccc	ggacgagagc	tccgtgcggg	180
	tggctgtcag	aataagacca	cagcttgcca	aagagaagat	tgaaggatgc	catatttgta	240
	catctgtcac	accaggagag	cctcaggtct	tcctagggaa	agataaggct	tttacttttg	300
	actatgtatt	tgacattgac	tcccagcaag	agcagatcta	cattcaatgt	atagaaaaac	360
40	taattgaagg	ttgctttgaa	ggataacaatg	ctacagtttt	tgcttatgga	caaactggag	420
	ctggtaaaa	atacacaatg	ggaacaggat	ttgatgttaa	cattgttgag	gaagaactgg	480
	gtattatttc	tcgagctgtt	aaacaccttt	ttaagagtat	tgaagaaaaa	aaacacatag	540
	caattaaaaa	tgggttctct	gctccagatt	ttaaagtga	tgccccattc	ttagagctct	600
	ataatgaaga	ggtccttgac	ttatttgata	ccactcgtga	tattgatgca	aaaaagtaaa	660
45	aatcaaatat	aagaattcat	gaagattcaa	ctggagggaa	tttatactgt	gggcgtttcc	720
	aacacgtact	gtgaatacac	aatcnagag				749

&lt;210&gt; 9

&lt;211&gt; 686

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

50

&lt;400&gt; 9

	tggaaattat	agacctagca	aaaaaagatt	tagagaaggt	tgnaaaagaaa	agaaaagagg	60
55	aagnaaaaaa	gtgtggctgg	taaagaggat	aatacagaca	ctgaccaaga	gaagaaagaa	120
	gaaaagggtg	tttcggaaag	agaaacccaa	tgaattagaa	gtggaagaaa	gtcaagaagt	180
	gagtgatcat	gaggatgaag	aagaggagga	ggaggaggag	gaagatgaca	ttgatggggg	240
	tgaaagtctt	gatgaatcag	attctgaatc	agatgaaaaa	gccnattatc	aagcagactt	300
	ggcaaacatt	acttgtgaaa	ttgcaattaa	gcaaaaagctg	attgatgaac	tagaaaaacag	360
60	ccagaaaaaga	ctgcagactc	tgaaaaagca	gtatgaagag	aagntaatga	tgctgcaaca	420
	taaaattcgg	gatactcagc	ttgaaagaga	ccagggtgctt	caaaacttag	gctcggtaga	480
	atcttactca	gaagaaaaag	caaaaaaagt	taggtctgaa	tatgaaaaaga	aactccaagc	540
	catgaacaaa	gaactgcaga	gacttcaagc	agctcaaaaa	gaacatgcaa	ggttgcttaa	600
	aaatcagttc	cagtatgaaa	agcnattgaa	gaaattgcag	caggatgtga	tggaaatgaa	660
65	aaaaacaaa	gttcgcctaa	tgaaaa				686

&lt;210&gt; 10

<211> 833  
 <212> DNA  
 <213> Homo sapiens

5           <400> 10  
 gttcttctgt cgccggcttc agcagcccgc gcccgggcag gaatagaaga tgaacaaacc 60  
 cataacacca tcaacatatg tgcgctgcct caatgtttgga ctaatttagga agctgtcaga 120  
 ttttattgat cctcaagaag gatggaagaa gttagctgta gctattaaaa aacctctgg 180  
 10 tgatgataga tacaatcagt ttcacataag gagatttgaa gcattacttc aaactggaaa 240  
 aagtccact tctgaattac tgtttgactg gggcaccaca aattgcacag ttggtgatct 300  
 tgtggatctt ttgatccaaa atgaattttt tgctcctgcg agtcttttgc tcccagatgc 360  
 tgttcccaaa actgctaata cactaccttc taaagaagct ataacagttc agcaaaaaca 420  
 gatgcctttc tgtgacaaa acaggacatt gatgacacct gtgcagaatc ttgaacaaag 480  
 ctatatgcca cctgactcct caagtccaga aaataaaagt ttagaagtta gtgatacacg 540  
 15 ttttcacagt ttttcatttt atgaattgaa gaatgtcaca aataactttg atgaacgacc 600  
 catttctggt ggtggttaata aaatgggaga gggaggattt ggagttgtat ataaagggct 660  
 acgtaaaata cacaactgtg gcagtgaag aagcttgcag caatggttga cattactact 720  
 gaaggaaactg aaaccagcag tttgatccaa gaaaataaaa gtaatgggca aaagtgggtca 780  
 accatggaaa aacttttagta ggaacctact tgggttttct caagtggatg gga 833

<210> 11  
 <211> 799  
 <212> DNA  
 <213> Homo sapiens

25           <400> 11  
 taaaaatata cccttngatg atacctgccataaatgatata gtcccattat tagattatgt 60  
 tacatgccaa agtttaaaagg aatttgggca gatccagtta aggttcctta aacaacntca 120  
 30 ctttgagact gttgaaaggg cctgacctaa tccaagtga ccccttgcaa gaagaattct 180  
 ccttgtaagc cttgaagaag tatgtgagag ggccacattg gctaaaacct aaaggtggcc 240  
 tctaggagat gagacctacc ttccagttgt cagcaagcag gaaaaaaaaa ttgggacctc 300  
 agttgcaacc acaaggaaact gaattctgcc aaaaatntga gtcagcttag aagagtactc 360  
 caagcttcag atgataacca cagcctgggc tgacacctgg atttagcttt gcatgatcct 420  
 35 cagtatgaga atctatctgt tctgtgctgg acttctaata tatagaactg tgagataatg 480  
 ggtcacattg gctggatgtg gtggctcata cctgtaaatc ccagcacttt gggaggccga 540  
 ggcaggcaga tcacctgagg tcaagagttc aagaccggcc tggccaacat ggtgaaaccc 600  
 cgtctntact aaaaatacaa aaattagacg agcgtggtgg tggacacctg tagtcccagc 660  
 tgcttgggag gctgaggcag gagactagct ggaaccaggg aggtagaggt tgcagtgagc 720  
 40 tgagatcgtg ccactgcact ccagcctggg tgacagagtg agactccatc ataaataaat 780  
 aaataataaa atgggtcnc 799

<210> 12  
 <211> 812  
 <212> PRT  
 <213> Homo sapiens

45           <400> 12  
 Met Ala Gly Gly His Cys Gly Ser Phe Pro Ala Ala Ala Ala Gly Ser  
 1                           5                           10                           15  
 50 Gly Glu Ile Val Gln Leu Asn Val Gly Gly Thr Arg Phe Ser Thr Ser  
                          20                           25                           30  
 Arg Gln Thr Leu Met Trp Ile Pro Asp Ser Phe Phe Ser Ser Leu Leu  
                          35                           40                           45  
 55 Ser Gly Arg Ile Ser Thr Leu Arg Asp Glu Thr Gly Ala Ile Phe Ile  
                          50                           55                           60  
 Asp Arg Asp Pro Ala Ala Phe Ala Pro Ile Leu Asn Phe Leu Arg Thr  
                          65                           70                           75                           80  
 Lys Glu Leu Asp Leu Arg Gly Val Ser Ile Asn Val Leu Arg His Glu  
                          85                           90                           95  
 60 Ala Glu Phe Tyr Gly Ile Thr Pro Leu Val Arg Arg Leu Leu Leu Cys  
                          100                           105                           110  
 Glu Glu Leu Glu Arg Ser Ser Cys Gly Ser Val Leu Phe His Gly Tyr  
                          115                           120                           125  
 65 Leu Pro Pro Pro Gly Ile Pro Ser Arg Lys Ile Asn Asn Thr Val Arg  
                          130                           135                           140  
 Ser Ala Asp Ser Arg Asn Gly Leu Asn Ser Thr Glu Gly Glu Ala Arg  
                          145                           150                           155                           160

Gly Asn Gly Thr Gln Pro Val Leu Ser Gly Thr Gly Glu Glu Thr Val  
 165 170 175  
 Arg Leu Gly Phe Pro Val Asp Pro Arg Lys Val Leu Ile Val Ala Gly  
 180 185 190  
 5 His His Asn Trp Ile Val Ala Ala Tyr Ala His Phe Ala Tyr Arg Ile  
 195 200 205  
 Lys Glu Ser Ser Gly Trp Gln Val Phe Thr Ser Pro Tyr Leu Asp  
 210 215 220  
 10 Trp Thr Ile Glu Arg Val Ala Leu Asn Ala Lys Val Val Gly Gly Pro  
 225 230 235 240  
 His Gly Asp Lys Asp Lys Met Val Ala Val Ala Ser Glu Ser Ser Ile  
 245 250 255  
 Ile Leu Trp Ser Val Gln Asp Gly Gly Ser Gly Ser Glu Ile Gly Val  
 260 265 270  
 15 Phe Ser Leu Gly Val Pro Val Asp Ala Leu Phe Phe Ile Gly Asn Gln  
 275 280 285  
 Leu Val Ala Thr Ser His Thr Gly Lys Val Gly Val Trp Asn Ala Val  
 290 295 300  
 20 Thr Gln His Trp Gln Val Gln Asp Val Val Pro Ile Thr Ser Tyr Asp  
 305 310 315 320  
 Thr Ala Gly Ser Phe Leu Leu Leu Gly Cys Asn Asn Gly Ser Ile Tyr  
 325 330 335  
 Tyr Ile Asp Met Gln Lys Phe Pro Leu Arg Met Lys Asp Asn Asp Leu  
 340 345 350  
 25 Leu Val Thr Glu Leu Tyr His Asp Pro Ser Asn Asp Ala Ile Thr Ala  
 355 360 365  
 Leu Ser Val Tyr Leu Thr Pro Lys Thr Ser Val Ser Gly Asn Trp Ile  
 370 375 380  
 30 Glu Ile Ala Tyr Gly Thr Ser Ser Gly Ala Val Arg Val Ile Val Gln  
 385 390 395 400  
 His Pro Glu Thr Val Gly Ser Gly Pro Gln Leu Phe Gln Thr Phe Thr  
 405 410 415  
 Val His Arg Ser Pro Val Thr Lys Ile Met Leu Ser Glu Lys His Leu  
 420 425 430  
 35 Val Ser Val Cys Ala Asp Asn Asn His Val Arg Thr Trp Thr Val Thr  
 435 440 445  
 Arg Phe Gly Met Ile Ser Thr Gln Pro Gly Ser Thr Pro Leu Ala Ser  
 450 455 460  
 40 Phe Lys Ile Leu Ser Leu Glu Glu Thr Glu Ser His Gly Ser Tyr Ser  
 465 470 475 480  
 Ser Gly Asn Asp Ile Gly Pro Phe Gly Glu Arg Asp Asp Gln Gln Val  
 485 490 495  
 Phe Ile Gln Lys Val Val Pro Ile Thr Asn Lys Leu Phe Val Arg Leu  
 500 505 510  
 45 Ser Ser Thr Gly Lys Arg Ile Cys Glu Ile Gln Ala Val Asp Cys Thr  
 515 520 525  
 Thr Ile Ser Ser Phe Thr Val Arg Glu Cys Glu Gly Ser Ser Arg Met  
 530 535 540  
 50 Gly Ser Arg Pro Arg Arg Tyr Leu Phe Thr Gly His Thr Asn Gly Ser  
 545 550 555 560  
 Ile Gln Met Trp Asp Leu Thr Thr Ala Met Asp Met Val Asn Lys Ser  
 565 570 575  
 Glu Asp Lys Asp Val Gly Gly Pro Thr Glu Glu Glu Leu Lys Leu  
 580 585 590  
 55 Leu Asp Gln Cys Asp Leu Ser Thr Ser Arg Cys Ala Thr Pro Asn Ile  
 595 600 605  
 Ser Pro Ala Thr Ser Val Val Gln His Ser His Leu Arg Glu Ser Asn  
 610 615 620  
 60 Ser Ser Leu Gln Leu Gln His His Asp Thr Thr His Glu Ala Ala Thr  
 625 630 635 640  
 Tyr Gly Ser Met Arg Pro Tyr Arg Glu Ser Pro Leu Leu Ala Arg Ala  
 645 650 655  
 Arg Arg Thr Glu Ser Phe His Ser Tyr Arg Asp Phe Gln Thr Ile Asn  
 660 665 670  
 65 Leu Asn Arg Asn Val Glu Arg Ala Val Pro Glu Asn Gly Asn Leu Gly  
 675 680 685  
 Pro Ile Gln Ala Glu Val Lys Gly Ala Thr Gly Glu Cys Asn Ile Ser

690 695 700  
 Glu Arg Lys Ser Pro Gly Val Glu Ile Lys Ser Leu Arg Glu Leu Asp  
 705 710 715 720  
 Ser Gly Leu Glu Val His Lys Ile Ala Glu Gly Phe Ser Glu Ser Lys  
 5 Lys Arg Ser Ser Glu Asp Glu Asn Glu Asn Lys Ile Glu Phe Arg Lys  
 725 730 735  
 Lys Gly Gly Phe Glu Gly Gly Gly Phe Leu Gly Arg Lys Lys Val Pro  
 740 745 750  
 Tyr Leu Ala Ser Ser Pro Ser Thr Ser Asp Gly Gly Thr Asp Ser Pro  
 10 755 760 765  
 Gly Thr Ala Ser Pro Ser Thr Lys Thr Thr Pro Ser Pro Arg His  
 770 775 780 785  
 Lys Lys Ser Asp Ser Ser Gly Gln Glu Tyr Ser Leu 800  
 15 805 810

<210> 13  
 <211> 167  
 <212> PRT  
 <213> Homo sapiens

20  
 <400> 13  
 Leu Ala Ser Ala Arg Ile Pro Gly Arg Pro Tyr Val Gly Val Leu Arg  
 1 5 10 15  
 25 Pro Pro Gly Ser Leu Phe Phe Ala Pro Ala Gly Thr Thr Ile Ser Ala  
 20 25 30  
 Leu Leu Gly Phe Cys Tyr Met Ala Ala Phe Leu Lys Met Ser Val Ser  
 35 35 40 45  
 Val Asn Phe Phe Arg Pro Phe Thr Arg Phe Leu Val Pro Phe Thr Leu  
 50 55 60  
 His Arg Lys Arg Asn Asn Leu Thr Ile Leu Gln Arg Tyr Met Ser Ser  
 65 70 75 80  
 Lys Ile Pro Ala Val Thr Tyr Pro Lys Asn Glu Ser Thr Arg Pro Ser  
 85 90 95  
 35 Glu Glu Leu Glu Leu Asp Lys Trp Lys Thr Thr Met Lys Ser Ser Val  
 100 105 110  
 Gln Glu Glu Cys Val Ser Thr Ile Ser Ser Ser Lys Asp Glu Asp Pro  
 115 120 125  
 Leu Ala Ala Thr Arg Glu Phe Ile Glu Met Trp Arg Leu Leu Gly Arg  
 40 130 135 140  
 Glu Val Pro Glu His Ile Thr Glu Glu Glu Leu Lys Thr Leu Met Glu  
 145 150 155 160  
 Cys Val Ser Asn Thr Ala Lys  
 165

<210> 14  
 <211> 452  
 <212> PRT  
 <213> Homo sapiens

50  
 <400> 14  
 Pro Cys Glu Gly Gly Ala Arg Ser Cys Leu Val Thr Glu Ser Ala Arg  
 1 5 10 15  
 55 Gly Gly Leu Gln Phe Leu Gln Gln Cys Asp Arg Glu Asp Leu Val Glu  
 20 25 30  
 Leu Ala Leu Pro Gln Leu Ala Gln Val Val Thr Val Tyr Glu Phe Leu  
 35 40 45  
 Leu Met Lys Val Glu Lys Asp His Leu Ala Lys Pro Phe Phe Pro Ala  
 50 55 60  
 Ile Tyr Lys Glu Phe Glu Leu His Lys Met Val Lys Lys Met Cys  
 65 70 75 80  
 Gln Asp Tyr Leu Ser Ser Ser Gly Leu Cys Ser Gln Glu Thr Leu Glu  
 85 90 95  
 Ile Asn Asn Asp Lys Val Ala Glu Ser Leu Gly Ile Thr Glu Phe Leu  
 100 105 110  
 65 Arg Lys Lys Glu Ile His Pro Asp Asn Leu Gly Pro Lys His Leu Ser  
 115 120 125

Arg Asp Met Asp Gly Glu Gln Leu Glu Gly Ala Ser Ser Glu Lys Arg  
 130 135 140  
 Glu Arg Glu Ala Ala Glu Gly Leu Ala Ser Val Lys Arg Pro Arg  
 145 150 155 160  
 5 Arg Glu Ala Leu Ser Asn Asp Thr Thr Glu Ser Leu Ala Ala Asn Ser  
 165 170 175  
 Arg Gly Arg Glu Lys Pro Arg Pro Leu His Ala Leu Pro Ala Gly Phe  
 180 185 190  
 10 Ser Pro Pro Val Asn Val Thr Val Ser Pro Arg Ser Glu Glu Ser His  
 195 200 205  
 Thr Thr Thr Val Ser Gly Gly Asn Gly Ser Val Phe Gln Ala Gly Pro  
 210 215 220  
 Gln Leu Gln Ala Leu Ala Asn Leu Glu Ala Arg Gly Ser Ile Gly  
 225 230 235 240  
 15 Ala Ala Leu Ser Ser Arg Asp Val Ser Gly Leu Pro Val Tyr Ala Gln  
 245 250 255  
 Ser Gly Glu Pro Arg Arg Leu Thr Gln Ala Gln Val Ala Ala Phe Pro  
 260 265 270  
 20 Gly Glu Asn Ala Leu Glu His Ser Ser Asp Gln Asp Thr Trp Asp Ser  
 275 280 285  
 Leu Arg Ser Pro Gly Phe Cys Ser Pro Leu Ser Ser Gly Gly Gly Ala  
 290 295 300  
 Glu Ser Leu Pro Pro Gly Gly Pro Gly His Ala Glu Ala Gly His Leu  
 305 310 315 320  
 25 Gly Lys Val Cys Asp Phe His Leu Asn His Gln Gln Pro Ser Pro Thr  
 325 330 335  
 Ser Val Leu Pro Thr Glu Val Ala Ala Pro Pro Leu Glu Lys Ile Leu  
 340 345 350  
 30 Ser Val Asp Ser Val Ala Val Asp Cys Ala Tyr Arg Thr Val Pro Lys  
 355 360 365  
 Pro Gly Pro Gln Pro Gly Pro His Gly Ser Leu Leu Thr Glu Gly Cys  
 370 375 380  
 Leu Arg Ser Leu Ser Gly Asp Leu Asn Arg Phe Pro Cys Gly Met Glu  
 385 390 395 400  
 35 Val His Ser Gly Gln Arg Glu Leu Glu Ser Val Val Ala Val Gly Glu  
 405 410 415  
 Ala Met Ala Leu Lys Phe Pro Met Gly Ala Met Ser Tyr Cys Leu Arg  
 420 425 430  
 40 Asp Arg Ser Arg Phe Leu Phe Arg Leu Pro Met Gly Leu Ser Cys Pro  
 435 440 445  
 Leu Gln Val Gln  
 450  
 45 <210> 15  
 <211> 321  
 <212> PRT  
 <213> Homo sapiens  
 <400> 15  
 50 Met Ala Glu Ala Glu Glu Asp Cys His Ser Asp Thr Val Arg Ala Asp  
 1 5 10 15  
 Asp Asp Glu Glu Asn Glu Ser Pro Ala Glu Thr Asp Leu Gln Ala Gln  
 20 25 30  
 55 Leu Gln Met Phe Arg Ala Gln Trp Met Phe Glu Leu Ala Pro Gly Val  
 35 40 45  
 Ser Ser Ser Asn Leu Glu Asn Arg Pro Cys Arg Ala Ala Arg Gly Ser  
 50 55 60  
 Leu Gln Lys Thr Ser Ala Asp Thr Lys Gly Lys Gln Glu Gln Ala Lys  
 65 70 75 80  
 60 Glu Glu Lys Ala Arg Glu Leu Phe Leu Lys Ala Val Glu Glu Glu Gln  
 85 90 95  
 Asn Gly Ala Leu Tyr Glu Ala Ile Lys Phe Tyr Arg Arg Ala Met Gln  
 100 105 110  
 65 Leu Val Pro Asp Ile Glu Phe Lys Ile Thr Tyr Thr Arg Ser Pro Asp  
 115 120 125  
 Gly Asp Gly Val Gly Asn Ser Tyr Ile Glu Asp Asn Asp Asp Asp Ser  
 130 135 140

Lys Met Ala Asp Leu Leu Ser Tyr Phe Gln Gln Gln Leu Thr Phe Gln  
 145 150 155 160  
 Glu Ser Val Leu Lys Leu Cys Gln Pro Glu Leu Glu Ser Ser Gln Ile  
 165 170 175  
 5 His Ile Ser Val Leu Pro Met Glu Val Leu Met Tyr Ile Phe Arg Trp  
 180 185 190  
 Val Val Ser Ser Asp Leu Asp Leu Arg Ser Leu Glu Gln Leu Ser Leu  
 195 200 205  
 10 Val Cys Arg Gly Phe Tyr Ile Cys Ala Arg Asp Pro Glu Ile Trp Arg  
 210 215 220  
 Leu Ala Cys Leu Lys Val Trp Gly Arg Ser Cys Ile Lys Leu Val Pro  
 225 230 235 240  
 Tyr Thr Ser Trp Arg Glu Met Phe Leu Glu Arg Pro Arg Val Arg Phe  
 245 250 255  
 15 Asp Gly Val Tyr Ile Ser Lys Thr Thr Tyr Ile Arg Gln Gly Glu Gln  
 260 265 270  
 Ser Leu Asp Gly Phe Tyr Arg Ala Trp His Gln Val Glu Tyr Tyr Arg  
 275 280 285  
 20 Tyr Ile Arg Phe Phe Pro Asp Gly His Val Met Met Leu Thr Thr Pro  
 290 295 300  
 Glu Glu Pro Gln Ser Ile Val Pro Arg Leu Arg Thr Arg Glu Tyr Gln  
 305 310 315 320  
 Asp

<210> 16  
 <211> 172  
 <212> PRT  
 <213> Homo sapiens

30 <400> 16  
 Ala Cys Pro Thr His Pro Pro Pro Pro Thr Ala Pro Arg Gly His Gln  
 1 5 10 15  
 35 Ser Cys Arg Leu Gly Asp Ser Trp Ser Val Lys Ser Arg Trp Cys Pro  
 20 25 30  
 Cys Pro Gln Glu Leu Gly Trp Ala Ser Cys Ala Arg Gly Val Cys Ala  
 35 40 45  
 Trp Ser Phe Cys Ala Trp Ile Cys Ile Phe Ile Ala Leu Leu Val Glu  
 50 55 60  
 40 Thr Pro Arg Pro Val His Pro Ala Lys Thr Pro Gln Ala Ala Cys Gly  
 65 70 75 80  
 Ser Arg Thr Leu Pro Pro Phe Pro Arg Cys Pro Leu Arg Ala Arg Ala  
 85 90 95  
 45 Ala Thr Gln Ala Cys Trp Leu Arg Pro Pro Leu Gly Gln Ala Leu Ala  
 100 105 110  
 Gln Pro Ala Glu Trp Gly Val Val Gly Gln Ser Pro Arg Ser Trp Ala  
 115 120 125  
 Pro Ala Gln Ala His Arg Ala Arg Pro His Pro Ala Ala Pro Arg Thr  
 130 135 140  
 50 Ala Thr Arg Gly Val Leu Pro Leu Cys Pro Ala Pro Gly Thr Asn Ser  
 145 150 155 160  
 Met Phe Gly Val Cys Leu Cys Leu Phe Phe Lys Lys  
 165 170

<210> 17  
 <211> 472  
 <212> PRT  
 <213> Homo sapiens

60 <400> 17  
 Met Arg Glu Arg Phe Arg Asn Leu Asp Glu Glu Val Glu Lys Tyr Arg  
 1 5 10 15  
 Ala Val Tyr Asn Lys Leu Arg Tyr Glu His Thr Phe Leu Lys Ser Glu  
 20 25 30  
 65 Phe Glu His Gln Lys Glu Glu Tyr Ala Arg Ile Leu Asp Glu Gly Lys  
 35 40 45  
 Ile Lys Tyr Glu Ser Glu Ile Ala Arg Leu Glu Glu Asp Lys Glu Glu

50 55 60  
 Leu Arg Asn Gln Leu Leu Asn Val Asp Leu Thr Lys Asp Ser Lys Arg  
 65 70 75 80  
 Val Glu Gln Leu Ala Arg Glu Lys Val Tyr Leu Cys Gln Lys Leu Lys  
 85 90 95  
 Gly Leu Glu Ala Glu Val Ala Glu Leu Lys Ala Glu Lys Glu Asn Ser  
 100 105 110  
 Glu Ala Gln Val Glu Asn Ala Gln Arg Ile Gln Val Arg Gln Leu Ala  
 115 120 125  
 10 Glu Met Gln Ala Thr Val Arg Ser Leu Gly Ala Glu Lys Gln Ser Ala  
 130 135 140  
 Asn Leu Arg Ala Glu Arg Leu Glu Lys Glu Leu Gln Ser Ser Ser Glu  
 145 150 155 160  
 15 Gln Asn Thr Phe Leu Ile Asn Lys Leu His Lys Ala Glu Arg Glu Ile  
 165 170 175  
 Asn Thr Leu Ser Ser Lys Val Lys Glu Leu Lys His Ser Asn Lys Leu  
 180 185 190  
 Glu Ile Thr Asp Ile Lys Leu Glu Thr Ala Arg Ala Lys Ser Glu Leu  
 195 200 205  
 20 Glu Arg Glu Arg Asn Lys Leu Gln Ser Glu Leu Asp Gly Leu Gln Ser  
 210 215 220  
 Asp Asn Glu Ile Leu Lys Ala Ala Val Glu His His Lys Val Leu Leu  
 225 230 235 240  
 25 Val Glu Lys Asp Arg Glu Leu Ile Arg Lys Val Gln Ala Ala Lys Glu  
 245 250 255  
 Glu Gly Tyr Gln Lys Leu Val Val Leu Gln Asp Glu Lys Leu Glu Leu  
 260 265 270  
 Glu Asn Arg Leu Ala Asp Leu Glu Lys Met Lys Val Glu His Asp Val  
 275 280 285  
 30 Trp Arg Gln Ser Glu Lys Asp Gln Tyr Glu Glu Lys Leu Arg Ala Ser  
 290 295 300  
 Gln Met Ala Glu Glu Ile Thr Arg Lys Glu Leu Gln Ser Val Arg Leu  
 305 310 315 320  
 35 Lys Leu Gln Gln Gln Ile Val Thr Ile Glu Asn Ala Glu Lys Glu Lys  
 325 330 335  
 Asn Glu Asn Ser Asp Leu Lys Gln Gln Ile Ser Ser Leu Gln Ile Gln  
 340 345 350  
 Val Thr Ser Leu Ala Gln Ser Glu Asn Asp Leu Leu Asn Ser Asn Gln  
 355 360 365  
 40 Met Leu Lys Glu Met Val Glu Arg Leu Lys Gln Glu Cys Arg Asn Phe  
 370 375 380  
 Arg Ser Gln Ala Glu Lys Ala Gln Leu Glu Ala Glu Lys Thr Leu Glu  
 385 390 395 400  
 45 Glu Lys Gln Ile Gln Trp Leu Glu Glu Lys His Lys Leu His Asp Arg  
 405 410 415  
 Ile Thr Asp Arg Glu Glu Lys Tyr Asn Gln Ala Lys Glu Lys Leu Gln  
 420 425 430  
 Arg Ala Ala Ile Ala Gln Lys Lys Arg Lys Ser Leu His Glu Asn Lys  
 435 440 445  
 50 Leu Lys Arg Leu Gln Glu Lys Val Glu Val Leu Glu Ala Lys Lys Glu  
 450 455 460  
 Glu Leu Glu Thr Glu Ile Arg Ser  
 465 470  
  
 55 <210> 18  
 <211> 462  
 <212> PRT  
 <213> Homo sapiens  
  
 60 <400> 18  
 Lys Ala Thr Ser Leu Thr Leu Glu Gly Gly Arg Leu Lys Arg Thr Pro  
 1 5 10 15  
 Gln Leu Ile His Gly Arg Asp Tyr Glu Met Val Pro Glu Pro Val Trp  
 20 25 30  
 65 Arg Ala Leu Tyr His Trp Tyr Gly Ala Asn Leu Ala Leu Pro Arg Pro  
 35 40 45  
 Val Ile Lys Asn Ser Lys Thr Asp Ile Pro Glu Leu Glu Leu Phe Pro



50 55 60  
 Arg Tyr Leu Leu Phe Leu Arg Gln Gln Pro Ala Thr Arg Thr Gln Gln  
 65 70 75 80  
 Ser Asn Ile Trp Val Asn Met Gly Asn Val Pro Ser Pro Asn Ala Pro  
 85 90 95  
 Leu Lys Arg Val Leu Ala Tyr Thr Gly Cys Phe Ser Arg Met Gln Thr  
 100 105 110  
 Ile Lys Glu Ile His Glu Tyr Leu Ser Gln Arg Leu Arg Ile Lys Glu  
 115 120 125  
 10 Glu Asp Met Arg Leu Trp Leu Tyr Asn Ser Glu Asn Tyr Leu Thr Leu  
 130 135 140  
 Leu Asp Asp Glu Asp His Lys Leu Glu Tyr Leu Lys Ile Gln Asp Glu  
 145 150 155 160  
 15 Gln His Leu Val Ile Glu Val Arg Asn Lys Asp Met Ser Trp Pro Glu  
 165 170 175  
 Glu Met Ser Phe Ile Ala Asn Ser Ser Lys Ile Asp Arg His Lys Val  
 180 185 190  
 Pro Thr Glu Lys Gly Ala Thr Gly Leu Ser Asn Leu Gly Asn Thr Cys  
 195 200 205  
 20 Phe Met Asn Ser Ser Ile Gln Cys Val Ser Asn Thr Gln Pro Leu Thr  
 210 215 220  
 Gln Tyr Phe Ile Ser Gly Arg His Leu Tyr Glu Leu Asn Arg Thr Asn  
 225 230 235 240  
 25 Pro Ile Gly Met Lys Gly His Met Ala Lys Cys Tyr Gly Asp Leu Val  
 245 250 255  
 Gln Glu Leu Trp Ser Gly Thr Gln Lys Asn Val Ala Pro Leu Lys Leu  
 260 265 270  
 Arg Trp Thr Ile Ala Lys Tyr Ala Pro Arg Phe Asn Gly Phe Gln Gln  
 275 280 285  
 30 Gln Asp Ser Gln Glu Leu Leu Ala Phe Leu Leu Asp Gly Leu His Glu  
 290 295 300  
 Asp Leu Asn Arg Val His Glu Lys Pro Tyr Val Glu Leu Lys Asp Ser  
 305 310 315 320  
 35 Asp Gly Arg Pro Asp Trp Glu Val Ala Ala Glu Ala Trp Asp Asn His  
 325 330 335  
 Leu Arg Arg Asn Arg Ser Ile Val Val Asp Leu Phe His Gly Gln Leu  
 340 345 350  
 Arg Ser Gln Val Lys Cys Lys Thr Cys Gly His Ile Ser Val Arg Phe  
 355 360 365  
 40 Asp Pro Phe Asn Phe Leu Ser Leu Pro Leu Pro Met Asp Ser Tyr Met  
 370 375 380  
 His Leu Glu Ile Thr Val Ile Lys Leu Asp Gly Thr Thr Pro Val Arg  
 385 390 395 400  
 45 Tyr Gly Leu Arg Leu Asn Met Asp Glu Lys Tyr Thr Gly Leu Lys Lys  
 405 410 415  
 Gln Leu Ser Asp Leu Cys Gly Leu Asn Ser Glu Gln Ile Leu Leu Ala  
 420 425 430  
 Glu Val His Gly Ser Asn Ile Lys Asn Phe Pro Gln Asp Asn Pro Lys  
 435 440 445  
 50 Ser Thr Glu Leu Leu Ser Glu Val Gly Phe Phe Gly Val Pro  
 450 455 460

&lt;210&gt; 19

&lt;211&gt; 243

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 19

60 Pro Thr Trp Leu Glu Arg Gly Gly Gly Glu Pro Ala Ala Arg Pro Gln  
 1 5 10 15  
 Thr Pro Gln Pro Thr Ala Pro Glu Ser Arg Gly Pro Ser Gly Ala Ser  
 20 25 30  
 Ala Leu Arg Cys Arg Gly Pro Thr Ala Arg Ser Leu Pro Ala Ala Ser  
 35 40 45  
 65 Met Leu Gly Ala Pro Asp Glu Ser Ser Val Arg Val Ala Val Arg Ile  
 50 55 60  
 Arg Pro Gln Leu Ala Lys Glu Lys Ile Glu Gly Cys His Ile Cys Thr

65  
 Ser Val Thr Pro Gly Glu Pro Gln Val Phe Leu Gly Lys Asp Lys Ala  
 85 90 95  
 5 Phe Thr Phe Asp Tyr Val Phe Asp Ile Asp Ser Gln Gln Glu Gln Ile  
 100 105 110  
 Tyr Ile Gln Cys Ile Glu Lys Leu Ile Glu Gly Cys Phe Glu Gly Tyr  
 115 120 125  
 Asn Ala Thr Val Phe Ala Tyr Gly Gln Thr Gly Ala Gly Lys Thr Tyr  
 130 135 140  
 10 Thr Met Gly Thr Gly Phe Asp Val Asn Ile Val Glu Glu Glu Leu Gly  
 145 150 155 160  
 Ile Ile Ser Arg Ala Val Lys His Leu Phe Lys Ser Ile Glu Glu Lys  
 165 170 175  
 15 Lys His Ile Ala Ile Lys Asn Gly Leu Pro Ala Pro Asp Phe Lys Val  
 180 185 190  
 Asn Ala Gln Phe Leu Glu Leu Tyr Asn Glu Glu Val Leu Asp Leu Phe  
 195 200 205  
 Asp Thr Thr Arg Asp Ile Asp Ala Lys Ser Lys Lys Ser Asn Ile Arg  
 210 215 220  
 20 Ile His Glu Asp Ser Thr Gly Gly Asn Leu Tyr Cys Gly Arg Phe Gln  
 225 230 235 240  
 His Val Leu

25 <210> 20  
 <211> 223  
 <212> PRT  
 <213> Homo sapiens

30 <400> 20  
 Gly Asn Tyr Arg Pro Ser Lys Lys Arg Phe Arg Glu Gly Lys Glu Lys  
 1 5 10 15  
 Lys Arg Gly Lys Lys Val Trp Leu Val Lys Arg Ile Ile Gln Thr Leu  
 20 25 30  
 35 Thr Lys Arg Arg Lys Lys Lys Arg Val Phe Arg Lys Glu Lys Pro Asn  
 35 40 45  
 Glu Leu Glu Val Glu Glu Ser Gln Glu Val Ser Asp His Glu Asp Glu  
 50 55 60  
 40 Glu Glu Glu Glu Glu Glu Glu Glu Asp Asp Ile Asp Gly Gly Glu Ser  
 65 70 75 80  
 Ser Asp Glu Ser Asp Ser Glu Ser Asp Glu Lys Ala Tyr Gln Ala Asp  
 85 90 95  
 Leu Ala Asn Ile Thr Cys Glu Ile Ala Ile Lys Gln Lys Leu Ile Asp  
 100 105 110  
 45 Glu Leu Glu Asn Ser Gln Lys Arg Leu Gln Thr Leu Lys Lys Gln Tyr  
 115 120 125  
 Glu Glu Lys Met Met Leu Gln His Lys Ile Arg Asp Thr Gln Leu Glu  
 130 135 140  
 50 Arg Asp Gln Val Leu Gln Asn Leu Gly Ser Val Glu Ser Tyr Ser Glu  
 145 150 155 160  
 Glu Lys Ala Lys Lys Val Arg Ser Glu Tyr Glu Lys Lys Leu Gln Ala  
 165 170 175  
 Met Asn Lys Glu Leu Gln Arg Leu Gln Ala Ala Gln Lys Glu His Ala  
 180 185 190  
 55 Arg Leu Leu Lys Asn Gln Ser Gln Tyr Glu Lys Leu Lys Lys Leu Gln  
 195 200 205  
 Gln Asp Val Met Glu Met Lys Lys Thr Lys Val Arg Leu Met Lys  
 210 215 220

60 <210> 21  
 <211> 206  
 <212> PRT  
 <213> Homo sapiens

65 <400> 21  
 Met Asn Lys Pro Ile Thr Pro Ser Thr Tyr Val Arg Cys Leu Asn Val  
 1 5 10 15

Gly Leu Ile Arg Lys Leu Ser Asp Phe Ile Asp Pro Gln Glu Gly Trp  
 20 25 30  
 Lys Lys Leu Ala Val Ala Ile Lys Lys Pro Ser Gly Asp Arg Tyr  
 35 40 45  
 5 Asn Gln Phe His Ile Arg Arg Phe Glu Ala Leu Leu Gln Thr Gly Lys  
 50 55 60  
 Ser Pro Thr Ser Glu Leu Phe Asp Trp Gly Thr Thr Asn Cys Thr  
 65 70 75 80  
 10 Val Gly Asp Leu Val Asp Leu Leu Ile Gln Asn Glu Phe Phe Ala Pro  
 85 90 95  
 Ala Ser Leu Leu Leu Pro Asp Ala Val Pro Lys Thr Ala Asn Thr Leu  
 100 105 110  
 Pro Ser Lys Glu Ala Ile Thr Val Gln Gln Lys Gln Met Pro Phe Cys  
 115 120 125  
 15 Asp Lys Asp Arg Thr Leu Met Thr Pro Val Gln Asn Leu Glu Gln Ser  
 130 135 140  
 Tyr Met Pro Pro Asp Ser Ser Ser Pro Glu Asn Lys Ser Leu Glu Val  
 145 150 155 160  
 20 Ser Asp Thr Arg Phe His Ser Phe Ser Phe Tyr Glu Leu Lys Asn Val  
 165 170 175  
 Thr Asn Asn Phe Asp Glu Arg Pro Ile Ser Val Gly Gly Asn Lys Met  
 180 185 190  
 Gly Glu Gly Gly Phe Gly Val Val Tyr Lys Gly Leu Arg Lys  
 195 200 205

<210> 22  
 <211> 1260  
 <212> DNA  
 <213> Homo sapiens

30 <400> 22  
 cttctccgca cgactgttac agaggtctcc agagccttct ctctcctgtg caaaatggca 60  
 actcttaagg aaaaactcat tgcaccagtt gcggaagaag aggcaacagt tccaaacaat 120  
 aagatcactg tagtggtgtg tggacaagtt ggtatggcgt gtgctatcag cattctggga 180  
 35 aagtctcttg ctgatgaact tgctcttctg gatgttttgg aagataagct taaaggagaa 240  
 atgatggatc tgcagcatgg gagcttattt cttcagacac ctaaaattgt ggcagataaa 300  
 gattattctg tgaccgccaa ttctaagatt gtagtggtaa ctgcaggagt ccgtcagcaa 360  
 gaaggggaga gtcggctcaa tctggtgcag agaaatgtta atgtcttcaa attcattatt 420  
 cctcagatcg tcaagtacag tcctgattgc atcataattg tggtttccaa cccagtggac 480  
 40 attcttacgt atgttacctg gaaactaagt ggattacca aacaccgcgt gattggaagt 540  
 ggatgtaatc tggattctgc tagatttcgc taccttatgg ctgaaaaact tggcattcat 600  
 cccagcagct gccatggatg gattttgggg gaacatggcg actcaagtgt ggctgtgtg 660  
 agtgggtgta atgtggcagg tgtttctctc caggaattga atccagaaat gggaactgac 720  
 aatgatagtg aaaattggaa ggaagtgc ataatggtg ttgaaagtgc ctatgaagtc 780  
 45 atcaagctaa aaggatatac caactgggct attggattaa gtgtggctga tcttattgaa 840  
 tccatgttga aaaatctatc caggattcat cccgtgtcaa caatggtaaa ggggatgtat 900  
 ggcattgaga atgaagtctt cctgagcctt ccatgtatcc tcaatgcccg gggattaacc 960  
 agcgttatca accagaagct aaaggatgat gaggttgctc agctcaagaa aagtgcagat 1020  
 accctgtggg acatccagaa ggacctaataa gacctgtgac tagtgagctc taggctgtag 1080  
 50 aaatttaaaa actacaatgt gattaactcg agcctttagt tttcatccat gtacatggat 1140  
 cacagtttgc tttgatcttc ttcaatatgt gaatttgggc tcacagaatc aaagcctatg 1200  
 cttggtttta tgcttgcaat ctgagctctt gaacaaataa aattaactat tgtagtgtga 1260

<210> 23  
 <211> 3151  
 <212> DNA  
 <213> Homo sapiens

60 <400> 23  
 taacacagtt gtgaaaagag atggatgtgg gttccagctc tagccctgcc tgtgtgcaat 60  
 tatgcagaaa cgctaattga ctccactaca gcgactgctg agctgggctg gatggtgcat 120  
 cctccatcag gtgagggaaga ggtgagtggc tacgatgaga acatgaacac gatccgcacg 180  
 taccaggtgt gcaacgtggt tgagtcaagc cagaacaact ggctacggac caagtattatc 240  
 cgggcgccgtg gcgcccaccg catccacgtg gagatgaagt ttccggtgctg tgactgcagc 300  
 65 agcatcccca gcgtgcctgg ctccctgcaag gagaccttca acctctatta ctatgaggct 360  
 gactttgact cggccaccaa gaccttcccc aactggatgg agaatccatg ggtgaagggtg 420  
 gataccattg cagccgacga gagcttctcc cagggtggacc tgggtgaccg cgtcatgaaa 480

	atcaacaccg	aggtgcgag	cttcggacct	gtgtcccgca	gcggcttcta	cctggccttc	540
	caggactatg	gcggctgcat	gtccctcatc	gccgtgctgt	tcttctaccg	caagtgcctc	600
	cgcctcatcc	agaatggcgc	catcttccag	gaaaccctgt	cgggggctga	gagcacatcg	660
5	ctgggtggctg	cccggggcag	ctgcatcgcc	aatgcccgaag	aggtggatgt	acccatcaag	720
	ctctactgta	acggggacgg	cgagtggctg	gtgcccacat	ggcgctgcat	gtgcaaagca	780
	ggcttcgagg	ccgttgagaa	tggcaccgtc	tgcgaggtt	gtccatctgg	gactttcaag	840
	gccaaccaag	gggatgaggc	ctgtacccac	tgtcccatca	acagccggac	cacttctgaa	900
	ggggccacca	actgtgtctg	ccgcaatggc	tactacagag	cagacctgga	ccccctggac	960
	atgccctgca	caaccatccc	ctccgcgccc	caggctgtga	ttccagtggt	caatgagacc	1020
10	tccctcatgc	tggagtggac	ccctccccgc	gactccggag	gccgagagga	cctcgtctac	1080
	aacatcatct	gcaagagctg	tggctcgggc	cggggtgcct	gcacccgctg	cggggacaaat	1140
	gtacagtacg	caccacgcca	gctaggcctg	accgagccac	gcattttacat	cagtgcctg	1200
	ctggcccaca	cccagttacac	cttcgagatc	caggctgtga	acggcggttac	tgaccagagc	1260
	cccttctcgc	ctcagttcgc	ctctgtgaac	atcaccacca	accaggcagc	tccatcgcca	1320
15	gtgtccatca	tgcacaggt	gagccgcacc	gtggacagca	ttaccctgtc	gtgggtccag	1380
	ccagaccagc	ccaatggcgt	gacccctggc	tatgagctgc	agtactatga	gaagcaggag	1440
	ctcagtgagt	acaacgccac	agccataaaa	agccccacca	acacggtcac	cgtgcagggc	1500
	ctcaaagccg	gcgccatcta	tgtcttccag	gtgcccggac	gcaccgtggc	aggctacggg	1560
20	cgctacagcg	gcaagatgta	cttcagacc	atgacagaag	ccgattacca	gacaagcatc	1620
	caggagaagt	tgcactcat	catcggtctc	tggcccgctg	gcctggtctt	cctcattgct	1680
	gtggttgta	tgcacatcgt	gtgtaacaga	cgggggtttg	agcgtgctga	ctcggagtac	1740
	acggacaagc	tgcaacacta	caccagtggc	cacatgaccc	caggcatgaa	gatctacatc	1800
	gatcctttca	cctacgagga	ccccaacgag	gcagtgcggg	agtttgccaa	ggaaattgac	1860
25	atctcctgtg	tcaaaattga	gcaggtgata	ggagcagggg	agtttgccga	ggtctgcagt	1920
	ggccacctga	agctgccagg	caagagagag	atctttgtgg	ccatcaagac	gctcaagctg	1980
	ggctacacgg	agaagcagcg	ccgggacttc	ctgagcgaag	cctccatcat	gggccagttc	2040
	gaccatccca	acgtcatcca	cctggagggg	gtcgtgacca	agagcacacc	tgtgatgatc	2100
	atcaccgagt	tcattggagaa	tggctccctg	gactccttcc	tccggcaaaa	cgatgggcag	2160
	ttcacagtca	tccagctggt	gggcatgctt	cggggcatcg	cagctggcat	gaagtacctg	2220
30	gcagacatga	actatgttca	ccgtgacctg	gctgcccgcg	acatcctcgt	caacagcaac	2280
	ctgggtctgca	aggtgtcgga	ctttgggctc	tcacgcttcc	tagaggacga	tacctcagac	2340
	cccactaca	ccagtgcctt	gggcggaag	atccccatcc	gctggacagc	cccgggaagcc	2400
	atccagtacc	ggaagttcac	ctcggcaggt	gatgtgtgga	gctacggcat	tgtcatgtgg	2460
	gaggtgatgt	cctatgggga	gcggccctac	tgggacatga	ccaaccagga	tgtaatcaat	2520
35	gccattgagc	aggactatcg	gctgccaccg	cccatggact	gcccagctgc	cctgcaccaa	2580
	ctcatgctgg	actgttggca	gaaggaccgc	aaccacccgc	ccaagttcgg	ccaaattgtc	2640
	aacacgtag	acaagatgat	ccgcaatccc	aacagcctca	aagccatggc	gccccctctc	2700
	tctggcatca	acctgcccgt	gctggaccgc	acgatccccg	actacaccag	ctttaacacg	2760
	gtggacgagt	ggctgaaggc	catcaagatg	gggcagtaca	aggagagcct	cgccaatgcc	2820
40	ggcttcacct	cctttgacgt	cgtgtctcag	atgatgatgg	aggacattct	ccgggttggg	2880
	gtcacttttg	ctggccacca	gaaaaaaatc	ctgaacagta	tccaggtgat	gcgggagcag	2940
	atgaaccaga	ttcagttctg	ggaggtttga	cattccactg	cctcggtcca	cctcttctct	3000
	caagccccgc	ccctctctgc	ccactgtccg	gccctcctgg	tgctctatcc	actgcagggc	3060
45	cagccactcg	ccaggaggcc	acgggcacgg	gaagaacca	gcgggtgccag	ccacgagacg	3120
	tcaccaagaa	aacatgcaac	tcaaacgacg	g			3151

&lt;210&gt; 24

&lt;211&gt; 1234

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

	tagttcaaga	caacagagac	aaagctaaga	tgagggaagtt	ctgtacagtt	taggaaatag	60
55	aggctttcaa	agataattcg	cagtgatgtg	aaactggcct	cccaagccct	gataacaaca	120
	tggccaacgc	cctggccagc	gccacttgcg	agcgtgcaa	gggcccgttt	gcgcccgtg	180
	agaagatcgt	gaacagtaat	ggggagctgt	accatgagca	gtgtttcgtg	tgcgctcagt	240
	gcttccagca	gattccagaa	ggactcttct	atgagtttga	aggaagaaag	tactgtgaac	300
	atgactttca	gatgctcttt	gccccctgct	gtcatcagtg	tgggtgaattc	atcattggcc	360
	gagttatcaa	agccatgaat	aacagctggc	atccggagtg	cttccgctgt	gacctctgcc	420
60	aggaagtctt	ggcagatata	gggtttgtca	agaatgctgg	gagacacctg	tgtcggccct	480
	gtcataatcg	tgagaaagcc	agaggccttg	ggaaatacat	ctgccagaaa	tgccatgcta	540
	tcacogatga	gcagcctctg	atattcaaga	acgaccctta	ccatccagac	catttcaact	600
	gcgccaactg	cggaagaggag	ctgactgcgc	atgcacggga	gctgaaaggg	gagctatact	660
	gcctcccatg	ccatgataaa	atgggggtcc	ccatctgtgg	tgcttgccga	cggcccactg	720
65	aagggcgctg	ggtgaacgct	atgggcaagc	agtggcatgt	ggagcatttt	gtttgtgcca	780
	agtgtgagaa	accctttctt	ggacatcgcc	attatgagag	gaaaggcctg	gcatattgtg	840
	aaactcacta	taaccagcta	tttgggtgatg	tttgcttcca	ctgcaatcgt	gttatagaag	900

5	gtgatgtggt	ctctgctctt	aataaggcct	ggtgctgtaa	ctgctttgcc	tgttctacct	960
	gcaacactaa	attaacactc	aagaataagt	ttgtggagtt	tgacatgaag	ccagtctgta	1020
	agaagtgcta	tgagatttcc	attggagctg	aagaaaagac	ttaagaaact	agctgagacc	1080
	ttaggaagga	aataagttcc	tttatttttt	cttttctatg	caagataaga	gattaccaac	1140
	attacttgct	ttgatctacc	catattttaa	gctatatctc	aaagcagttg	agagaagagg	1200
	acctatatga	atggttttat	gtcatttttt	taaa			1234
	<210> 25						
	<211> 4534						
10	<212> DNA						
	<213> Homo sapiens						
	<400> 25						
15	gtcacgagcg	tcgaagagac	aaagccgcgt	cagggggccc	ggccggggcg	ggggagcccc	60
	gggcttggtg	gtgccccagc	ccgcgcggag	ggcccttcgg	acccgcgcgc	cgccgctgcc	120
	gccgcccgcg	cctcgcaaca	ggtccggggc	gcctcgctct	ccgctcccct	ccccgcctc	180
	cgcgaccctc	cggggcacct	cagctcgccc	ggggccgcag	tctggccacc	cgcttccatg	240
	cggttcgggt	ccaagatgat	gccgatgttt	cttaccgtgt	atctcagtaa	caatgagcag	300
20	cacttcacag	aagttccagt	tactccagaa	acaatatgca	gagacgtggg	ggatctgtgc	360
	aaagaacccg	gcgagagtga	ttgccatttg	gctgaagtgt	gggtgtggctc	tgtagagata	420
	gagtttcatc	atgtttggcca	ggatggtctc	gatctcctga	ccttgtgatc	cgctgcctc	480
	ggcctcccaa	agtgtctggat	tacaggtgtg	agccaccacg	atcagcctct	agtgtttaaa	540
	aaagaacgtc	cagttgcgga	taattgagca	atgtttgatg	ttcttcaacg	atttgggaagt	600
25	cagaggaacg	aagttcgctt	cttccctcgt	catgaacgcc	cccctggcag	ggacattgtg	660
	agtggaccaaa	gatctcagga	tccaagttta	aaaagaaatg	gtgtaaaagt	tcctggtgaa	720
	tatcgaagaa	aggagaacgg	tggttaatat	cctaggatgg	atctgactct	tgctgaactt	780
	caggaaatgg	catctcgcca	gcagcaacag	attgaagccc	agcaacaatt	gctggcaact	840
	aaggaacacg	gcttaaagtt	tttgaaacaa	caagatcagc	gacaacagca	acaagttgct	900
30	gagcaggaga	aacttaaaag	gctaaaagaa	atagctgaga	atcaggaagc	taagctaaaa	960
	aaagtggagag	cacttaaaag	ccacgtggaa	cagaagagac	taagcaatgg	gaaacttgtg	1020
	gaggaaaattg	aacagatgaa	taatttggtc	cagcaaaaac	agagggagct	cgctcctggc	1080
	gtgtcaaaaag	tagaagaact	gaccaggcag	ctagagatgc	tcaagaacgg	caggatcgac	1140
	agccaccatg	acaatcagtc	tgcatgtggc	gagcttgatc	gcctctataa	ggagctgcag	1200
35	ctaagaaaca	aattgaatca	agagcagaat	gccaaagctac	aacaacagag	ggagtgtttg	1260
	aataagcgta	attcagaagt	ggcagtcatg	gataagcgtg	ttaatgagct	gagggaccgg	1320
	ctgtggaaga	agaaggcagc	tctacagcaa	aaagaaaatc	taccagtttc	atctgatgga	1380
	aatcttcccc	agcaagccgc	gtcagcccca	agccgtgtgg	ctgcagtagg	tccttatatc	1440
	cagtcattcta	ctatgcctcg	gatgcctcca	agccctgaat	tgctggtgaa	gccagccctg	1500
40	ccggatgggt	ccttggtcat	tcaggcttca	gagggggccg	tgaaaataca	gacactcccc	1560
	aacatgagat	ctggggctgc	ttcacaactc	aaaggctcta	aaatccatcc	agttggccct	1620
	gattggagtc	cttcaaatgc	agatcttttc	ccaagccaag	gctctgcttc	tgtacctcaa	1680
	agcactggga	atgctctgga	tcaagttgat	gatggagagg	ttccgctgag	ggagaaagag	1740
	aagaaagtgc	gtccgtttctc	aatgtttgat	gcagtagacc	agtccaatgc	cccacttccc	1800
45	tttggtactc	tgaggaagaa	ccagagcagt	gaagatatct	tgccgggatgc	tcagggttgc	1860
	aataaaaaatg	tggtctaaagt	accacctcct	gttcctacaa	aaccaaaca	gattaatttg	1920
	ccttattttg	gacaaactaa	tcagccacct	tcagacatta	agccagacgg	aagttctcag	1980
	cagttgtcaa	cagttgttcc	gtccatggga	actaaaccaa	aaccagcagg	gcagcagccg	2040
	agagtgtctgc	tatctcccag	cataccttcg	gttggccaag	accagaccct	ttctccaggt	2100
	tctaagcaag	aaagtccacc	tgctgctgcc	gtccggccct	ttactcccca	gccttccaaa	2160
50	gacaccttac	ttccaccctt	cagaaaaccc	cagaccgtgg	cagcaagttc	aatatatatt	2220
	atgtatacgc	aacagcaggc	gccaggaaaa	aacttccagc	aggctgtgca	gagcgcgttg	2280
	accaagactc	ataccagagg	gccacacttt	tcaagtgtat	atggtaagcc	tgtaattgct	2340
	gctgcccaga	atcaacagca	gcacccagag	aacattttatt	ccaatagcca	gggcaagcct	2400
55	ggcagtcag	aacctgaaac	agagcctggt	tcttcagttc	aggagaacca	tgaaaacgaa	2460
	agaattcctc	ggccactcag	cccactaaa	ttactgcctt	tcttatctaa	tccttaccga	2520
	aaccagagtg	atgctgacct	agaagcctta	cgaaagaaac	tgtctaacgc	accaaggcct	2580
	ctaaagaaaac	gtagttctat	tacagagcca	gagggctcta	atggggccaa	tattcagaag	2640
	ctttttatata	agaggaccac	catagcgccc	atggagacca	tctctgtccc	atcataccca	2700
60	tccaagtacg	cttctgtgac	tgccagctca	gaaagcccag	tagaaatcca	gaatccatat	2760
	ttacatgtgg	agcccgaata	ggaggtgggc	tctctgggtc	ctgaatcatt	gtccccagag	2820
	gatgtgggga	atgccagtac	agagaacagt	gacatgccag	ctccttctcc	aggccttgat	2880
	tatgagcctg	agggagtccc	agacaacagc	ccaaatctcc	agaataaacc	agaagaacca	2940
	aatccagagg	ctccacatgt	gcttgatgtg	tacctggagg	agtaccctcc	ataccacccc	3000
65	ccaccatacc	catctgggga	gcctgaaggg	cccggagaa	actcggtgag	catgcccgcg	3060
	cctgaaatca	ccgggcaggt	ctctctgcct	cctggtaaaa	ggacaaactt	gcgtaaaact	3120
	ggctcagagc	gtatcgctca	tggaatgagg	gtgaaattca	accccttgc	tttactgcta	3180
	gattcgtctt	tggagggaga	atttgacctt	gtacagagaa	ttattttatga	ggttgatgac	3240

	ccaagcctgc	ccaatgatga	aggcatcaag	gctcttcaca	atgctgtgtg	tgcaggccac	3300
	acagaaatcg	ttaagttcct	ggtacagttt	ggtgtaaatg	ttaaagctgc	tgatagtgtat	3360
	ggatggactc	cattacattg	tgctgcctca	tgtaacaacg	tccaagtgtg	taagtttttg	3420
5	gtggagtcag	gagccgctgt	gtttgccatg	acctacagtg	acatgcagac	tgctgcagat	3480
	aagtgcgagg	aaatggagga	aggctacact	cagtgtctcc	aattttcttta	tgaggttcag	3540
	gagaagatgg	gcataatgaa	taaaggagtc	atztatgcgc	tttgggatta	tgaacctcag	3600
	aatgatgatg	agctgcccac	gaaagaagga	gactgcatag	caatcatcca	cagggaagac	3660
	gaagatgaaa	tcgaatggtg	gtgggcgcg	cttaatgata	aggaggata	tggtccacgt	3720
10	aacttgctgg	gactgtaccc	aagaattaaa	ccaagacaaa	ggagcttggc	ctgaaacttc	3780
	cacacagaat	tttagtcaat	gaagaattaa	tctctgttaa	gaagaagtaa	tacgattatt	3840
	tttggcaaaa	atctcacaag	acttatttta	atgacaatgt	agcttgaaag	cgatgaagaa	3900
	tgctctctaga	agagaatgaa	ggattgaaga	attcaccatt	agaggacatt	tagcgtgatg	3960
	aaataaagca	tctacgtcag	caggccatac	tggtgtgggg	caaagggtgc	cgtgtagca	4020
	ctcagataag	tatacagcga	caatcctgtt	ttctacaaga	atcctgtcta	gtaaatagga	4080
15	tcattttattg	ggcagttggg	aaatcagctc	tctgtcctgt	tgagtgtttt	cagcagctgc	4140
	tcctaaacca	gtcctcctgc	cagaaaggac	cagtgcctgc	acatcgctgt	ctctgattgt	4200
	ccccggcacc	agcaggcctt	gggctcact	gaaggctcga	aggcactgca	caccttgtat	4260
	attgtcagtg	aagaacgtta	gttggtgtgc	agtgaacaat	aactttatta	tatgagtttt	4320
20	tgtagcatct	taagaattat	acatatgttt	gaaatattga	aactaagcta	cagtaccagt	4380
	aattagatgt	agaatcttgt	ttgtaggctg	aattttaatc	tgtattttatt	gtcttttgta	4440
	tctcagaaat	tagaaacttg	ctacagactt	acccgtaata	tttgtcaaga	tcatagctga	4500
	ctttaaaaac	agttgtaata	aactttttga	tgct			4534
	<210> 26						
25	<211> 4660						
	<212> DNA						
	<213> Homo sapiens						
	<400> 26						
30	ggggcttaga	aattaacagg	ttgtttatat	aattggcctt	aaatgaggtg	agagtgaaga	60
	gactagagcc	atctctggaa	aacatcatta	tcccattccc	cggaagcta	ccctctggaa	120
	ctcaagattt	gaccatatct	gttttgagga	ttcattatga	acaaagaagt	ctcccagggtg	180
	tgaagttttt	caacatgagt	ggcctcgggg	acagttcatc	cgacctgct	aaccagact	240
	cacataagag	gaaaggatcg	ccatgtgaca	cactggcatc	aagcacggaa	aagaggcgca	300
35	gggagcaaga	aaataaatat	ttagaagaac	tagctgagtt	actgtctgcc	aacattagtg	360
	acattgacag	cttgagtgtg	aaaccagaca	aatgcaagat	tttgaagaaa	acagtcgac	420
	agatacagct	aatgaagaga	atggaacaag	agaaatcaac	aactgatgac	gatgtacaga	480
	aatcagacat	ctcatcaagt	agtcaaggag	tgatagaaaa	ggaatccttg	ggaccccttc	540
	ttttggaggc	tttggatgga	ttttcttttg	ttgtgaactg	tgaagggaga	attgtatttg	600
40	tgtcagagaa	tgtaaccagc	tacttaggtt	acaatcagga	ggaattaatg	aataccagcg	660
	tctacagcat	actgcacgtg	ggggatcatg	cagaatttgt	gaagaatctg	ctacccaaat	720
	cactagtaaa	tggagttcct	tggcctcaag	aggcaacacg	acgaaatagc	cataccttta	780
	actgcaggat	gctaattcac	cctccagatg	agccagggac	cgagaaccaa	gaagcttgcc	840
	agcgttatga	agtaatgcag	tggttccactg	tgtcacagcc	aaaatcaatt	caagaggatg	900
45	gagaagattt	ccagtcattg	ctgattttgta	ttgcacggcg	attacctcgg	cctccagcta	960
	ttacgggtgt	agaattcctt	atgaccaagc	aagatactac	aggtaaaatc	atctctattg	1020
	atactagttc	cctgagagct	gctggcagaa	ctggttgagg	agattttagt	aggaagtgc	1080
	tttatgcttt	tttccaacct	cagggcagag	aacctcttta	tgccagacag	ctgtttccaag	1140
	aagtgatgac	tctgtggcact	gcctccagcc	cctcctatag	attcatattg	aatgatggga	1200
50	caatgcttag	cgccacacac	aagtgtaaac	tttgctaccc	tcaaagtcca	gacatgcaac	1260
	ctttcatcat	gggaattcat	atcatcgaca	gggagcacag	tgggctttct	cctcaagatg	1320
	acactaatte	tggaaatgtca	attccccgag	taaatccctc	ggtcaatcct	agtatctctc	1380
	cagctcatgg	tgtggctcgt	tcatccacat	tgccaccatc	caacagcaac	atggtatcca	1440
	ccagaataaa	ccgccagcag	agctcagacc	ttcatagcag	cagtcatagt	aattctagca	1500
55	acagccaagg	aagtttcgga	tgctcaccgg	gaagtcagat	tgtagccaat	gttgcccttaa	1560
	accaaggaca	ggccagttca	cagagcagta	atccctcttt	aaacctcaat	aattctccta	1620
	tggaaaggtac	aggaattatcc	ctagcacagt	tcatgtctcc	aaggagacag	gttacttctg	1680
	gattggcaac	aaggcccgagg	atgccaaaca	attcctttcc	tcctaataat	tcgacattaa	1740
	gctctcccgt	tggcatgaca	agtagtgcc	gtaataataa	taaccgatct	tattcaaaaca	1800
60	tcccagtaac	atcttttacag	ggatgaatg	aaggacccaa	taactccgtt	ggcttctctg	1860
	ccagttctcc	agtcctcagg	cagatgagct	cacagaattc	acctagcaga	ttaaataatc	1920
	aacctgcaaa	agctgagtc	aaagataaca	aagagattgc	ctcaatttta	aatgaataag	1980
	ttcaatctga	caacagctct	agtgatggca	aacctctgga	ttcagggtct	ctgcataaca	2040
	atgacagact	ttcagatgga	gacagtaaat	actctcaaac	cagtcacaaa	ctagtgcagc	2100
65	ttttgacaac	aactgccgaa	cagcagttac	ggcatgctga	tatagacaca	agctgcaaa	2160
	atgtcctgtc	ttgcacaggc	acttccaact	ctgctctctg	taactcttca	ggaggttctt	2220
	gtccctcttc	tcatagctca	ttgacagaac	ggcataaaat	tctacaccgg	ctcttacagg	2280

	agggtagccc	ctcagatatc	accactttgt	ctgtcagagcc	tgataaaaag	gacagtgcac	2340
	ctactttctgt	gtcagtgact	ggacaggtac	aaggaaactc	cagtataaaa	ctagaactgg	2400
	atgcttcaaa	gaaaaaagaa	tcaaaaagacc	atcagctcct	acgctatctt	ttagataaag	2460
5	atgagaaaga	tttaagatca	actccaaacc	tgagcctgga	tgatgtaaag	gtgaaagtgg	2520
	aaaagaaaga	acagatggat	ccatgtaata	caaaccacac	cccaatgacc	aaacccactc	2580
	ctgaggaat	aaaactggag	gcccagagcc	agttttacagc	tgaccttgac	cagtttgatc	2640
	agttactgcc	cacgctggag	aaggcagcac	agttgccagg	cttatgtgag	acagacagga	2700
	tggatggtgc	ggtcaccagt	gtaaccatca	aatcggagat	cctgccagct	tcacttcagt	2760
	ccgccactgc	cagacccact	tccaggctaa	atagattacc	tgagctggaa	ttggaagcaa	2820
10	ttgataacca	at ttggacaa	ccaggaacag	gcgatcagat	tccatggaca	aataatacag	2880
	tgacagctat	aaatcagagt	aaatcagaag	accagtgtat	tagctcaca	ttagatgagc	2940
	ttctctgtcc	accacaaca	gtagaaggga	gaaatgatga	gaaggctctt	cttgaacagc	3000
	tgggtatcctt	ccttagtggc	aaagatgaaa	ctgagctagc	tgaactagac	agagctctgg	3060
	gaattgacaa	acttggtcag	gggggtggat	tagatgtatt	atcagagaga	tttccaccac	3120
15	aacaagcaac	gccacctttg	atcatggaag	aaagacccaa	cctttatttc	cagccttact	3180
	cttctccttc	tctactgccc	aatctcccta	gccctttcca	aggcatggtc	aggcaaaaac	3240
	cttcaactggg	gacgatgcct	gttcaagtaa	cacctccccg	agggtgctttt	tcacctggca	3300
	tgggcatgca	gcccaggcaa	actctaatac	gacctccggc	tgacaccta	cagcttcgac	3360
	ttcaactaca	gcagcgatta	cagggacaac	agcagttgat	acacaaaaat	cggcaagcta	3420
20	tcttaaacca	gtttgcagca	actgctcctg	ttggcatcaa	tatgagatca	ggcatgcaac	3480
	agcaaattac	acctcagcca	cccctgaatg	ctcaaagtgt	ggcacaacgt	cagcgggaac	3540
	tgtacagtca	acagcaccga	cagaggcagc	taatacagca	gcaaagagcc	atgcttatga	3600
	ggcagcaaaag	ctttgggaac	aacctccctc	cctcatcttg	actaccagtt	caaatgggga	3660
	acccccgtct	tctcagggt	gctccacagc	aattccctta	tccaccaa	tatggtacaa	3720
25	atccaggaac	cccacctgct	tctaccagcc	cgttttcaca	actagcagca	aatcctgaag	3780
	catccttggc	caaccgcaac	agcatggtga	gcagaggcat	gacaggaaac	ataggaggac	3840
	agtttggcac	tggaaatcaat	cctcagatgc	agcagaatgt	cttccagtat	ccaggagcag	3900
	gaatggttcc	ccaaggtgag	gccaactttg	tctcatctct	aagccctggg	agctccatgg	3960
	tgccgatgcc	aatccctcct	cctcagagtt	ctctgctcca	gcaaactcca	cctgcctccg	4020
30	ggtatcagtc	accagacatg	aaggcctggc	agcaaggagc	gataggaaac	aacaatgtgt	4080
	tcagtcaagc	tgtccagaac	cagcccacgc	ctgcacagcc	aggagtatac	aacaacatga	4140
	gcataccgtg	ttccatggca	ggtggaaata	cgaatgttca	gaacatgaac	ccaatgatgg	4200
	cccagatgca	gatgagctct	ttgcagatgc	caggaaatga	cactgtgtgc	cctgagcaga	4260
	taaatgatcc	cgactgaga	cacacaggcc	tctactgcaa	ccagctctca	tccactgacc	4320
35	ttctcaaaac	agaagcagat	ggaacccagg	tgcaacaggt	tcaggtgttt	gctgacgtcc	4380
	agtgtacagt	gaatctggta	ggcggggacc	cttacctgaa	ccagcctggt	ccactgggaa	4440
	ctcaaaagcc	cacgtcagga	ccacagaccc	cccaggccca	gcagaagagc	ctccttcagc	4500
	agctactgac	tgaataacca	cttttaagg	aatgtgaaat	ttaaataata	gacatacaga	4560
40	gatatacaaa	tatattatat	at ttttctga	gatttttgat	atctcaatct	gcagccattc	4620
	ttcaggtcgt	agcatttggg	gcaaaaaaaa	aaaaaaaaaa			4660

&lt;210&gt; 27

&lt;211&gt; 6773

&lt;212&gt; DNA

45 &lt;213&gt; Homo sapiens

&lt;400&gt; 27

	gcggctggtt	gcgggcccgc	ggcgggctgg	cggagatgga	ggatcttgtt	caagatgggg	60
50	tggcttcacc	agctaccctt	gggaccggga	aatctaagaa	ttggagaaag	aaattgaaga	120
	actcagatca	aaacctgtta	ctgaagggaac	tggtgatatt	attaaggcat	taactgaacg	180
	tctggatgct	cttcttctgg	aaaaagcaga	gactgagcaa	cagtgtcttt	ctctgaaaaa	240
	ggaaaatata	aaaatgaagc	aagaggttga	ggattctgta	acaaagatgg	gagatgcaca	300
	taaggagttg	gaacaatcac	atataaacta	tgtgaaagaa	attgaaaatt	tgaaaaatga	360
55	ggtgatggca	gtacgttcca	aatacagtga	agacaaagct	aacttacaaa	agcagctgga	420
	agaagcaatg	aatacgcaat	tagaactttc	agaacaactt	aaatttcaga	acaactctga	480
	agataatgtt	aaaaaactac	aagaagagat	tgagaaaatt	aggccaggct	ttgaggagca	540
	aattttatat	ctgcaaaagc	aattagacgc	taccactgat	gaaaagaagg	aaacagttac	600
	tcaactccaa	aatatcattg	aggctaattc	tcagcattac	caaaaaata	ttaatagttt	660
	gcaggaagag	cttttacagt	tgaaagctat	acaccaagaa	gaggtgaaag	agttgatgtg	720
60	ccagattgaa	gcatcagcta	aggaacatga	agcagagata	aataagttga	acgagctaaa	780
	agagaactta	gtaaaacaat	gtgaggcaag	tgaaaagaac	atccagaaga	aatatgaatg	840
	tgagtttaga	aatttaagga	aagccacctc	aaatgcaaac	caagacaatc	agatatgttc	900
	tattctcttg	caagaaaata	cattttgtaga	acaagttaga	aatgaaaaag	tcaaacactt	960
	agaagatacc	ttaaaagaac	ttgaatctca	acacagtatc	ttaaaagatg	aggtaactta	1020
65	tatgaataat	cttaagttaa	aacttgaaat	ggatgctcaa	catataaagg	atgagttttt	1080
	tcatgaacgg	gaagacttag	agtttaaaat	taatgaatta	ttactagcta	aagaagaaca	1140
	gggctgtgta	attgaaaaat	taaaatctga	gctagcaggt	ttaaataaac	agttttgcta	1200

	tactgtagaa	cagcataaca	gagaagtaca	gagtcttaag	gaacaacatc	aaaaagaaat	1260
	atcagaacta	aatgagacat	ttttgtcaga	ttcagaaaaa	gaaaaattaa	cattaatgtt	1320
	tgaaatacag	ggtctttaag	aacagtgtga	aaacctacag	caagaaaagc	aagaagcaat	1380
	tttaaattat	gagagtttac	gagagattat	ggaaatttta	caaacagaac	tgggggaatc	1440
5	tgctggaaaa	ataagtcaag	agttcgaatc	aatgaagcaa	cagcaagcat	ctgatgttca	1500
	tgaactgcag	cagaagctca	gaactgcttt	tactgaaaaa	gatgcccttc	tcgaaactgt	1560
	gaatcgctc	cagggagaaa	atgaaaagtt	actatctcaa	caagaattgg	taccagaact	1620
	tgaaaaatcc	ataaagaacc	ttcaagaaaa	gaatggagta	tacttactta	gtctcagtca	1680
	aagagatacc	atgttataaag	aattagaagg	aaagataaat	tctcttactg	aggaaaaaga	1740
10	tgattttata	aataaactga	aaaattccca	tgaagaaatg	gataatttcc	ataagaaatg	1800
	tgaaagggaa	gaaagattga	ttcttgaact	tggaagaaaa	gtagagcaaa	caatccagta	1860
	caacagtga	ctagaacaaa	aggtaaatga	attaacagga	ggactagagg	agacttttaa	1920
	agaaaaggat	caaaatgacc	aaaaactaga	aaaacttatg	gttcaaataa	aagttctctc	1980
	tgaagacaaa	gaagtattgt	cagctgaagt	gaagtctctt	tatgaggaaa	acaataaact	2040
15	cagttcagaa	aaaaaacagt	tgagtaggga	tttggagggt	tttttgtctc	aaaaagaaga	2100
	tgttatcctt	aaagaacata	ttactcaatt	agaaaagaaa	cttcagttaa	tggttgaaga	2160
	gcaagataat	ttaaataaac	tgcttgaaaa	tgagcaagtt	cagaagttat	ttgttaaaac	2220
	tcagttgtat	ggttttctta	aagaaatggg	atcagaagtt	tcagaagaca	gtgaagagaa	2280
	agatgttgtt	aatgtcctac	aggcagctcg	tgaatccttg	gcaaaaaata	atgaggaaaa	2340
20	atgcaacctg	gcttttcagc	gtgatgaaaa	agtattagag	ttagaaaaag	agattaaagt	2400
	ccttcaagaa	gagagtgtag	ttcagtgatg	agaacttaag	tctttattga	gagactatga	2460
	gcaagagaaa	gttctcttaa	ggaaagagtt	agaagaaata	cagtcagaaa	aagaggccct	2520
	gcagtcctgat	cttctagaaa	tgaagaatgc	taatgaaaaa	acaaggcttg	aaaaatcagaa	2580
	tcttttaatt	caagttgaag	aagtatctca	aacatgtagc	aaaagtgaag	tccataatga	2640
25	aaaagaaaaa	tgttttataa	aggaacatga	aaacctaaag	ccactactag	aacaaaaaga	2700
	attacgagat	aggagagcag	agttgatact	attaaaggat	tccttagcaa	aatcaccttc	2760
	tgtaaaaaat	gatcctctgt	cttcagtaaa	agagttggaa	gaaaaaatag	aaaatctgga	2820
	aaaagaatgc	aaagaaaagg	aggagaaaaa	aaataagata	aaattagttg	ccgtaaaggc	2880
	aaagaaagaa	ctagattcca	gcagaaaaag	gaccagact	gtgaagggaag	aacttgaatc	2940
30	tcttcgatca	gaaaaggacc	agttatctgc	ttccatgaga	gatctcattc	aaggagcaga	3000
	aagctataag	aatcttttat	tagaatatga	aaagcagtc	gagcaactgg	atgtggaaaa	3060
	agaacgtgct	aataattttg	agcatcgtat	tgaagacctt	acaagacaat	taagaaattc	3120
	gactttgcag	tgtgaaacaa	ttaattctga	taatgaagat	ctcctggctc	gtattgagac	3180
	attacagtct	aatgccaaat	tattagaagt	acagatttta	gaagtccaga	gagccaaagc	3240
35	aatggtagac	aaagaattag	aagctgaaaa	acttcagaaa	gaacagaaga	taaaggaaca	3300
	tgccactact	gtaaatgaac	ttgaagaact	tcaggtacaa	cttcaaaaag	aaaagaaaca	3360
	gcttcagaaa	accatgcaag	aattagagct	ggttaaaaaa	gatgcccaac	aaaccacatt	3420
	gtgaattatg	gaaatgactg	attatgaacg	tttgatgaaa	gaactaaatc	aaaagttaac	3480
	taataaaaaa	aacaagatag	aagatttggg	gcaagaaata	aaaattcaaa	aacagaaaca	3540
40	agaaacccta	caagaagaaa	taacttcatt	acagtcttca	gtacaacaat	atgaagaaaa	3600
	aaacacccaa	atcaagcaat	tgcttgtgaa	aaccaaaaag	gaactggcag	attcaaagca	3660
	agcagaaact	gatcacttaa	tacttcaagc	atctttaaaa	ggtgagctgg	aggcaagcca	3720
	gcagcaagta	gaagtctata	aaatacagct	ggctgaaata	acatcagaga	agcacaatat	3780
	ccacgagcac	ctgaaaacct	ctgcggaaca	gcaccagcgt	acgctaagtg	cataccagca	3840
45	gagagtgcac	gcactacagg	aagagtgcag	tgctgccaa	gcagaaaca	ctactgtaac	3900
	ctctgaattc	gagagctaca	aagtcagagt	tcataatgtt	ctaaaacaac	agaaaaataa	3960
	atctatgtct	caggctgaaa	ctgagggcgc	taaacagaag	agggaaacatc	tggaatgtct	4020
	gattgaccag	ctaaaaaatc	aattacaaga	tagccaaaat	aaccttacaga	ttaatgtatc	4080
	tgaacttcaa	acattgcagt	ctgaacatga	tacactgcta	gaaaggcaca	acaagatgct	4140
50	gcaggaaaact	gtgtccaaa	aggcggaact	ccgggaaaaa	ttgtgttcaa	tacagtcaga	4200
	gaacatgatg	atgaaatctg	aacatacaca	gactgtgagt	cagctaacat	cccagaacga	4260
	ggtccttcga	aatagcttcc	gagatcaagt	gcgacatttg	caggaagaac	acagaaagac	4320
	agtgagagaca	ttacagcagc	agctctccaa	gatggaaaga	cagctcttcc	agcttaagaa	4380
	tgaaccgacc	acaagaagcc	cagtttcttc	tcaaaactct	ttgaagaacc	ttcgagaaag	4440
55	gagaaacaca	gacctcccg	ttctagacat	gcacactgta	acccgggaag	agggagaagg	4500
	catggagaca	actgatacgg	agtctgtgtc	ttccgccagc	acatacacac	agtctttaga	4560
	cagctgctt	aactctccc	aaactaaact	tgagcctcca	ttatggcatg	ctgaattttac	4620
	caaagaagaa	ttggttcaga	agctcagttc	caccacaaaa	agtgagatc	acttaaacgg	4680
	cctgcttcgg	gaaacagaag	caaccaatgc	aattcttatg	gagcaaatta	agcttctcaa	4740
60	aagtgaataa	agaagattgg	aaaggaatca	agagcgagag	aagtctgcag	ctaacttgga	4800
	atacttgaag	aacgtcttgc	tgagttcat	tttcttgaaa	ccaggtagtg	aaagagagag	4860
	acttcttctt	gttataaata	cgatgttgca	gctcagcctc	gaagaaaaag	gaaaacttgc	4920
	tgcggttgct	caaggtgagg	aagaaaaatgc	ttcccgctct	tctggatggg	catcctatct	4980
	tcatagttgg	tctggacttc	gataggttga	tggaagggaat	atttttatta	accaaataga	5040
65	atctattttac	aaaaatggtt	cacgtatatt	accacaattc	ttttgtcaaa	aagtgtgtat	5100
	atatgtttgc	atctacatat	atttgtacat	ctatatgaca	gatgtatttt	aaaagtttca	5160
	tcttgaagta	aaagtacaac	agcttgaagt	ggttagtagca	ggccacagcc	ctctaactca	5220



	tgtgatttcc	catgcatgct	gccagaataa	aaccaccagg	aatgaattca	ctccccactt	5280
	ctctggaacc	tcaggaccgc	cccattttct	ggcagtagct	tgaattttga	agttaaacta	5340
	aattttggta	ccataccaac	tggaaattag	gctttaaaaa	taatgtttca	aggccagggt	5400
	tggtgattca	tgcctgaaat	cccactactt	tgggaggctg	aggctggaga	attgcttgag	5460
5	gctagtgage	tgtgactccc	actgcactcc	agctcgggga	acagagcgag	accttgtctc	5520
	taaaaataat	agtaataaaa	taaaaataac	gttttatgac	tatttattgc	aaggctcagag	5580
	ttacagattg	ttataaattg	ttgagaaatt	tttgtgatta	gaatatgaag	gaaaaagctt	5640
	tgttggtaaa	agtgcacatg	taaggggcta	tgaagtaaat	atgctgcagt	taattgtgct	5700
	aagttaaaat	acagtttagt	tatttgcctt	aaaataaact	cttctttttt	tctttaaagt	5760
10	atactatctc	aaaactcatt	atgttgtcag	agccctagag	ctggctagtg	taacactgac	5820
	tatgagttag	tgggcccacc	acttgagttg	agggtgattc	atgggtgtct	tccaggctct	5880
	tgatagggtg	tcactgcctg	caagccatga	atctgttttg	agaatcctct	ccattttccc	5940
	aaataaaaaa	ctatcacaa	agtgcactata	tcactcagca	ttggatctaa	atataaaaagt	6000
	ggtgctttca	gtgttttttg	cagatagtgt	tccataagct	ttccatcaga	agggatttta	6060
15	gacaccttag	aggctcgtgc	tacatcgtca	cagttcctcc	gaataacctt	aggtggtagt	6120
	gttacttgcc	tttgacacct	ctgcataatg	tttaatgact	agatccaaac	tgtgttgttc	6180
	ttaaatcaaa	aattggataa	tttgtaatat	ttatgtgtta	atcacacagt	atgctctctg	6240
	aagttctctt	aagccttcag	tttatactct	taatttaatt	ttctttctga	gctggagaac	6300
	tggctttgca	ctttggttac	acagaacatt	ggtttccaat	tcagtttaac	tgaattttgc	6360
20	tgctgatatg	ttgagtttgt	tctttaaaaa	atagctcata	tatctcatct	ttcctcctgt	6420
	cttagaagaa	cagacctaac	tagtgaatgt	attaatgaaa	atgcatctat	ttcagagctg	6480
	acatgaagag	tttagttttt	ttactttata	aactgtgaat	atgagtatgc	cagctgcata	6540
	cgatgtaact	aatcatatct	aaatatatct	cactttctct	ttgacttttag	accttttgaa	6600
	gtctgtataa	acttgttttg	aaatatagtc	tctgcttacg	aatgtcataa	caaaataatt	6660
25	ttttgcatga	taaaaaatta	ctttgattac	aaaaggcgta	ttctttcatg	gtttctgcaa	6720
	tgagaggaag	tgtaatgatt	attttaatat	ttctattaaa	tatgtttaac	tgt	6773
30	<210> 28						
	<211> 2619						
	<212> DNA						
	<213> Homo sapiens						
35	<400> 28						
	atggccacag	cttgtaaaag	atcaggagaa	cctcagttct	acgacattga	agctagccga	60
	atgaagcgag	cagctgcaaa	gcatcttaata	gaacgctact	accaccagtt	aactgagggc	120
	tgtggaaatg	aagcctgcac	gaatgagttt	tgtgcttctt	gtccaaacttt	tcttcgtatg	180
	gataataatg	cagcagctat	taaagccctc	gagctttata	agattaatgc	aaaactctgt	240
40	gatcctcatc	cctccaagaa	aggagcaagc	tcagcttacc	ttgagaactc	gaaaggtgcc	300
	cccaacaact	cctgctctga	gataaaaaatg	aacaagaaag	gcgctagaat	tgattttaaa	360
	gatgtgactt	acttaacaga	agagaaggta	tatgaaattc	ttgaattatg	tagagaaaaga	420
	gaggattatt	cccctttaat	ccgtgttatt	ggaagagttt	tttctagtgc	tgaggcattg	480
	gtacagagct	tccggaaggt	taacaacac	accaaggaag	aactgaaatc	tcttcaagca	540
45	aaagatgaag	acaaagatga	agatgaaaag	gaaaaagctg	catgtttctg	tgctgctatg	600
	gaagaagact	cagaagcatc	tcctcaagg	ataggtgata	gtcacagggt	agacaacaat	660
	ttgcaaaaaa	taggccttga	tgtatgtgtc	gtggatattg	atgccattag	aagggtctac	720
	accagattgc	tctctaata	aaaaattgaa	actgcctttc	tcaatgcact	tgtatatttg	780
	tcacctaacg	tggaaatgtg	cttgacgtat	cacaatgtat	actctcgaga	tcctaattat	840
50	ctgaatttgt	tcattatcgg	aatggagaat	agaaatctcc	acagtcctga	atatctggaa	900
	atggctttgc	cattattttg	caaagcgatg	agcaagctac	cccttgcagc	ccaagggaaa	960
	ctgatcagac	tgtggtctaa	atacaatgca	gaccagattc	ggagaatgat	ggagacattt	1020
	cagcaactta	ttactttata	agtcataagc	aatgaattta	acagtcgaaa	tctagtgaat	1080
	gatgatgatg	ccattgttgc	tgtctcgaag	tgtctgaaaa	tggtttacta	tgcaaatgta	1140
55	gtgggagggg	aagtggacac	aaatcacaa	gaagaagatg	atgaagagcc	catccctgag	1200
	tccagcgagc	tgacacttca	ggaacttttg	ggagaagaaa	gaagaaacaa	gaaaggtcct	1260
	cgagtggacc	ccctggaaac	tgaacttggt	tgtaaaaccc	tggattgtcg	aaaaccattt	1320
	atcccttttg	aagagtttat	taatgaacca	ctgaatgagg	ttctagaaat	ggataaagat	1380
	tatacttttt	tcaaagtaga	aacagagaa	aaattctctt	ttatgacatg	tccctttata	1440
60	ttgaatgctg	tcacaaagaa	tttgggatta	tattatgaca	atagaattcg	catgtacagt	1500
	gaacgaagac	tcactgttct	ctacagctta	gttcacaggc	agcagttgaa	tccatatttg	1560
	agactcaaa	ttagacgtga	ccatatcata	gatgatgcac	ttgtccggct	agagatgatc	1620
	gctatggaaa	atcctgcaga	cttgaagaag	cagttgtatg	tggaaatttg	aggagaacaa	1680
	ggagttgatg	agggaggtgt	ttccaaagaa	ttttttcagc	tggttgtgga	ggaaatcttc	1740
65	aatccagata	ttggtatgtt	cacatacgat	gaatctacaa	aattgttttg	gtttaatcca	1800
	tcttcttttg	aaactgagg	tcagtttact	ctgattggca	tagtactggg	tctggctatt	1860
	tacaataact	gtatactgga	tgtacatttt	cccatggttg	tctacaggaa	gctaattggg	1920

	aaaaaaggaa	cttttcgtga	cttgggagac	tctcaccag	ttctatatca	gagtttaaaa	1980
	gattttattgg	agtatgaagg	gaatgtggaa	gatgacatga	tgatcacttt	ccagatatca	2040
	cagacagatc	tttttggtaa	cccaatgatg	tatgatctaa	aggaaaatgg	tgataaaatt	2100
5	ccaattacaa	atgaaaacag	gaaggaattt	gtcaatcttt	attctgacta	cattctcaat	2160
	aaatcagtag	aaaaacagtt	caaggctttt	cggagaggtt	ttcatatggt	gaccaatgaa	2220
	tctcccttaa	agtacttatt	cagaccagaa	gaaattgaat	tgcttatatg	tggaagccgg	2280
	aatctagatt	tccaagcact	agaagaaact	acagaatatg	acggtggcta	taccagggac	2340
	tctgttctga	ttaggggagtt	ctgggaaatc	gttcattcat	ttacagatga	acagaaaaga	2400
10	ctcttcttgc	agttttacaac	gggcacagac	agagcacctg	tgggaggact	aggaaaatta	2460
	aagatgatta	tagccaaaaa	tggcccagac	acagaaaggt	tacctacatc	tcatacttgc	2520
	tttaatgtgc	ttttacttcc	ggaatactca	agcaaaagaa	aacttaaaga	gagattgttg	2580
	aaggccatca	cgtatgccaa	aggatttggc	atgctgtaa			2619
	<210> 29						
15	<211> 4263						
	<212> DNA						
	<213> Homo sapiens						
	<400> 29						
20	ggccggttccc	ctctcctcag	cagtagctct	atggtttccag	ggcggcaacg	tgcagcgtcc	60
	ttaccttgag	cctgtgcagt	tgccctcacc	ccggaatcca	tagtcaactgt	gacgaggcgg	120
	gaggacttgg	gcgacaggtg	gcctcccagt	cccacacgct	gcgggtccgc	gcctggccaa	180
	gccaccttga	cctgtgaaat	tgggggcggg	accagcaac	tccccctgtg	cagccgcggt	240
25	ttccaagggg	tcaggaaccg	ctgtgtttgt	ttcgctccgcg	tagccagggc	gggtcccgga	300
	gtactgtgcc	tgacccgacg	gtggcaagtc	tgacgcgtca	gccagagacc	ggtgccgggt	360
	gtaggagtgc	cagcctgggc	tgtgagcggc	tgctgggtag	acagacttgc	tttctcttac	420
	agcatgtcat	ttccaaaatg	catcgtggtg	cttctgcctt	aagtcctata	ggaagacact	480
	gccgccacta	gaccgggtgt	tatggtcgcc	actgttatte	tgactcaggt	cccgtgtcat	540
30	tgagcatatg	tatgaaaatg	ccttaggagg	gaaccatgga	gaagtatgtg	agactgcaga	600
	agattggaga	aggttcattt	ggaaaagctg	ttcttgttaa	atcgacagag	gatggcagac	660
	attatgtcat	caaggaaatt	aacatctcaa	gaatgtctga	taaagaaagg	caagaatcaa	720
	ggagagaagt	tgctgtattg	gcaaacatga	agcatccaaa	tattgtccaa	tataaagaat	780
	catttgaaga	aaatggctct	ctctacatag	taatggatta	ctgtgaagga	ggtgatttgt	840
	ttaaacgaat	aaatgctcag	aaaggcgctc	tgtttcaaga	agaccagatt	ttggactggg	900
35	ttgtgcagat	atgtttggct	ctgaagcatg	tacatgatag	aaaaattctt	caccgagaca	960
	taaagtcaga	gaacatatat	ctaaccaaaag	atgggacagt	gcagcttggg	gattttggaa	1020
	ttgctcgagt	tcttaatagt	actgtagagc	tggctcgaac	ttgcataggg	actccatact	1080
	acttgtcacc	tgaaatctgt	gaaaacaagc	cttataacaa	taaaagtgc	atttgggctt	1140
40	tgggctgtgt	cctttatgag	ttgtgtacac	ttaaacatgc	atttgaagct	ggaacacatga	1200
	aaaacctggt	actgaagata	atctccggat	cctttctctc	agtgtctcca	cattactcct	1260
	atgatctccg	cagcttgcgt	tctcagttat	ttaaaagaaa	tcctagggat	agaccatcag	1320
	tcaactccat	attggagaaa	ggttttatag	ctaaacgaat	cgaaaagttt	ctctccccctc	1380
	agcttattgc	agaagaattt	tgtctaaaaa	cactttcaaa	gtttggacca	cagcctctcc	1440
	caggtaaaag	accagcatca	ggacaagggtg	tcagttcttt	tgtccctgct	cagaaaaatca	1500
45	caaagcctgc	tgctaaatac	ggagtgcctt	taacatataa	gaagtatgga	gataaaaagt	1560
	tacttgagaa	aaaaccaccc	ccaaaacata	aacaggccca	tcaaattccc	gtgaagaaaa	1620
	tgaattctgg	agaagaaaag	aagaaaatgt	ctgaggaagc	agcaaaaaaa	agaaggttgg	1680
	aatttatatga	gaaagaaaag	aagcaaaagt	atcagattag	gttcctgaag	gctgagcaga	1740
	tgaagcggca	agagaagcag	cgggttgaga	ggataaatag	ggccagggga	caaggatgga	1800
50	ggaatgtttt	aagggtggtg	ggaagcgggtg	aagtaaaggc	ttcctttttt	ggcattggag	1860
	gggctgtctc	tccatcaccg	tgttctctctc	gaggccagta	tgaacattac	catgccattt	1920
	ttgaccaaatt	gcagcggcta	agagcagaag	ataatgaagc	aagatggaag	gggggaatct	1980
	atggtcagatg	gctcccagaa	aggcaaaaag	gacacttagc	tgtagagaga	gccaaaccaag	2040
	tggaagaatt	cctacagcgt	aaacgagaag	ctatgcagaa	taaagcccga	gccgaaggac	2100
55	acgtgggttta	tttggcaaga	ctgaggcaaaa	taagactaca	aaattttaat	gagcgccaac	2160
	agattaaagc	caaacttcgt	ggtgagaata	aagaagctga	tggtaccaaa	ggacaagaag	2220
	caactgaaga	gactgacatg	aggctcaaaa	agatggagtc	acttaaggcg	caaacaaatg	2280
	cacgtgctgc	tgtactaaaa	gaacagctgg	agcgaaaagc	aaaggaagct	tatgaaaagc	2340
	aaaagaaagt	atgggaagaa	catttggtgg	cgagggtaaa	aagctcagat	gttcctctgc	2400
60	ctttggaact	tcttgaaaca	ggtggttctc	catcaaagca	gcaggtgaag	cctgtcattt	2460
	ctgtgacttc	agctttgaaa	gaagtgggcc	tggatggaag	tttaactgat	acccaggaag	2520
	aagaaatgga	aaagagtaac	agtgtatttt	caagtaagcg	agaaatcctg	cgtaggctaa	2580
	atgaaaatct	taaagctcaa	gaggatgaaa	aggaaaaagca	gcatcactca	ggttcttgtg	2640
	agaccgttgg	tcacaaagat	gagagagagt	atgagacaga	aaatgccatt	tcctctgtac	2700
65	gcaagaagtg	ggagatggga	ggtcagcttg	tgattcctct	cgatgcagtg	acactggata	2760
	catccttctc	tgcaaccgaa	aaacatactg	tgggagaggt	tattaaatta	gattctaattg	2820
	gctctccaa	aaaagtctgg	gggaaaaacc	ctacagattc	tgtgtgaa	atacttggag	2880

	aagctgaatt	acagctatag	acagaactac	tagaaaaacac	atctttttaa	agtgagggtt	2940
	atgctgaaga	ggagaactac	aaacccttac	ttactgaaga	agagaatctg	cagtgcat	3000
	caaaagaaat	aaatccatca	gctactgttg	attctactga	aacgaaaagt	ccaaagttaa	3060
5	ctgagggtgc	tccacaaatg	tcagaaggaa	atgtggaaga	acctgatgat	ttggaacacg	3120
	aagttctaca	agagccaagt	agcacacaca	cagatgggag	tttgccacct	gttcttaatg	3180
	atgtgtggac	tagagagaag	gaagcagcta	aggaaactga	gttggaagat	aaggttgctg	3240
	tgcagcagag	tgaagtttgt	gaagatagaa	ttccagggaa	cgtggaccaa	tcctgtaagg	3300
	atcagagaga	tcctgcagta	gacgattctc	cgcagtctgg	ctgtgatgta	gagaagtcag	3360
10	tacagccaga	atcgattttc	cagaaagtgg	ttcattctaa	ggacttgaac	ttagttcagg	3420
	cagttcattg	ctcaccagaa	gaaccaattc	caattcgatc	tcactctgat	tctccaccaa	3480
	aaactaagag	caagaattcc	ttactgattg	gactttcaac	tggctctgtt	gatgcaaaca	3540
	atccaaagat	gctgaggacc	tgctcacttc	cagatcttcc	caagctgttc	agaaccctaa	3600
	tggacgttcc	cactgtgggg	gacgttcac	aagacagctc	tgaaatcgat	gagctggaag	3660
15	atgaaccaat	taaagaagg	ccttctgatt	ccgaagacac	tgtatttgaa	gaaactgaca	3720
	cagattttaca	agagcttcag	gcctcaatgg	agcagctgct	tagggagcaa	ccaggtgacg	3780
	aatacagtga	ggaggaagag	tctgttttaa	aaagcagcga	tgtggagcag	acagcaagag	3840
	ggacagatgc	cccagacgag	gaggacaacc	ccagcagcga	aagccctga	acgaggaatg	3900
	gcactcagat	aatagtgcg	ctgagaccac	tagtgaatgt	gaatatgaca	gtgtctttaa	3960
20	ccatttagag	gaactaagac	ttcacttgga	gcaagaaatg	ggctttgaaa	agttctttga	4020
	ggtttatgag	aaagtaaagg	ctattcatga	ggatgaagat	gaaaatattg	aaatttggtc	4080
	taacaatagt	gagaatattt	tgggcaatga	gcaccagcat	ctctatgcca	agattctgca	4140
	tttagtcatg	cagatggag	ccatcaggga	agataatgat	gaataatcct	caggacattc	4200
	tttaatatg	aactgtaaga	acacatttga	acttggtcca	taatacaagc	ttcctgggaa	4260
25	ata						4263
	<210> 30						
	<211> 1756						
	<212> DNA						
	<213> Homo sapiens						
30	<400> 30						
	tcgggagcag	ccgcgaagat	gccgttgga	ctgacgcaga	gccgagtgca	gaagatctgg	60
	gtgcccgtgg	accacaggcc	ctcgttgccc	agatcctgtg	ggccaaagct	gaccaactcc	120
35	cccaccgtca	tcgtcatgg	gggctcccc	gcccggggca	agacctacat	ctccaagaag	180
	ctgactcgct	acctcaactg	gattggcgct	cccacaaaag	tgttcaacgt	cggggagtat	240
	cgccgggagg	ctgtgaagca	gtacagctcc	tacaacttct	tcggccccga	caatgaggaa	300
	gccatgaaag	tccggaagca	atgtgcctta	gctgccttga	gagatgtcaa	aagctacctg	360
	gcgaaagaag	ggggacaaat	tgcggttttc	gatgccacca	atactactag	agagaggaga	420
40	cacatgatcc	ttcattttgc	caaagaaaat	gactttaaag	cgtttttcat	cgagtcggtg	480
	tgcgacgacc	ctacagttgt	ggcctccaat	atcatggaag	ttaaaatctc	cagcccggat	540
	tacaaagact	gcaactcggc	agaagccatg	gacgacttca	tgaagaggat	cagttgctat	600
	gaagccagct	accagcccct	cgaccccagc	aaatgcgaca	gggacttgtc	gctgatcaag	660
	gtgattgacg	tgggcccggg	gttcctgggt	aaccgggtgc	aggaccacat	ccagagccgc	720
45	atcggtgtact	acctgatgaa	catccacgtg	cagccgcgta	ccatctacct	gtgccggcac	780
	ggcgagaacg	agcacaacct	ccagggccgc	atcgggggcg	actcaggcct	gtccagccgg	840
	ggcaagaagt	ttgccagtgc	tctgagcaag	ttcgtggagg	agcagaacct	gaaggacctg	900
	cgcggtgtgga	ccagccagct	gaagagcacc	atccagacgg	ccgaggcgct	gcggctgccc	960
	tacgagcagt	ggaaggcgct	caatgagatc	gacgcgggcg	tctgtgagga	gctgacctac	1020
50	gaggagatca	gggacacct	ccctgaggag	tatgcgctgc	gggagcagga	caagtactat	1080
	taccgctacc	ccaccgggga	gtcctaccag	gacctggctc	agcgcttgga	gccagtgatc	1140
	atggagcttg	agcggcagga	gaatgtgctg	gtcatctgcc	accaggccgt	cctgcgctgc	1200
	ctgcttgctc	acttccctga	taagagtcca	gaggagatgc	cctacctgaa	atgccctctt	1260
	cacaccgtcc	tgaactgac	gcctgtcgct	tatggctgcc	gtgtggaatc	catctacctg	1320
55	aacgtggagt	cgtctgcac	acaccgggag	aggtcagagg	atgcaaagaa	gggacctaac	1380
	cgctcatga	gacgcaatag	tgtaacccc	ctagccagcc	ccgaacccac	caaaaagcct	1440
	cgcatcaaca	gctttgagga	gcatgtggcc	tccacctcgg	ccgccctgcc	cagctgcctg	1500
	cccccgagg	gtcccaagca	gctgocctga	caaaacctga	aaggctcccg	gagcagcgct	1560
	gactcctcca	ggaaacactg	aggcagacgt	gtcggttcca	ttccatttcc	atttctcgag	1620
60	cttagcttgt	gtcctgcctc	ccgcccaggg	caaaacgtat	cctgaggact	tcttccggag	1680
	aggggtgggt	ggagcagcgg	gggagccttg	gccgaagaga	accatgcttg	gcaccgtctg	1740
	tgtcccctcg	gcccgt					1756
	<210> 31						
	<211> 1661						
65	<212> DNA						
	<213> Homo sapiens						

<400> 31							
5	tgctgcagcc	gctgccgccg	attccggatc	tcattgccac	gcgcccccca	cgaccgcccc	60
	acgtgcattc	ccgattccctt	ttggttccaa	gtccaatatg	gcaactctaa	aggatcagct	120
	gatttataat	cttctaaagg	aagaacagac	cccccagaat	aagattacag	ttgttggggg	180
	tggtgctgtt	ggcatggcct	gtgccatcag	tatcttaatg	aaggacttgg	cagatgaact	240
	tgctcttggt	gatgtcatcg	aagacaaatt	gaagggagag	atgatggatc	tccaacatgg	300
10	cagccttttc	cttagaacac	caaagattgt	ctctggcaaa	gactataatg	taactgcaaa	360
	ctccaagctg	gtcattatca	cggctggggc	acgtcagcaa	gagggagaaa	gccgtcttaa	420
	tttgggtccag	cgtaacgtga	acatatttaa	attcatcatt	cctaattgtt	taaaatacag	480
	cccgaactgc	aagttgctta	ttgtttcaaa	tccagtggat	atcttgacct	acgtggcttg	540
	gaagataagt	ggttttccca	aaaaccgtgt	tattggaagt	ggttgcaatc	tggattcagc	600
15	ccgattccgt	tacctgatgg	gggaaaaggct	gggagttcac	ccattaagct	gtcatgggtg	660
	ggctcttggg	gaacatggag	attccagtgt	gcctgtatgg	agtggaatga	atgttgctgg	720
	tgtctctctg	aagactctgc	accagatttt	agggactgat	aaagataagg	aacagtggaa	780
	agaggttcac	aagcagggtg	ttgagagtgc	ttatgaggtg	atcaaactca	aaggctacac	840
	atcctgggct	attggactct	ctgtagcaga	tttggcagag	agtataatga	agaatcttag	900
20	gcgggtgcac	ccagtttcca	ccatgattaa	gggtctttac	ggaataaagg	atgatgtctt	960
	ccttagtggt	ccttgcatct	tgggacagaa	tggaaatctc	gacctgtgta	agtgactctt	1020
	gacttctgag	gaagaggccc	gtttgaagaa	gagtgcagat	acactttggg	ggatccaaaa	1080
	ggagctgcaa	ttttaaaagtc	ttctgatgtc	atatcatttc	actgtctagg	ctacaacagg	1140
	attctaggtg	gaggttggtc	atgttgctct	ttttatctga	tctgtgatta	aagcagtaat	1200
25	attttaagat	ggactgggaa	aaacatcaac	tccgtgaagt	agaaataaga	atggtttgta	1260
	aaatccacag	ctatatcctg	atgctggatg	gtattaatct	tgtgtagtct	tcaactggtt	1320
	agtgtgaaat	agttctgcca	cctctgacgc	accactgcc	atgctgtacg	tactgcattt	1380
	gccccctgag	ccaggtggat	gtttaccgtg	tgttatataa	cttcctggct	ccttcaactga	1440
	acatgcctag	tccaacattt	tttcccagtg	agtcacatcc	tgggatccag	tgtataaatc	1500
30	caatatcatg	tcttgtgcat	aattcttcca	aaggatctta	ttttgtgaac	tatatcagta	1560
	gtgtacatta	ccatataatg	taaaaagatc	tacatacaaa	caatgcaacc	aactatccaa	1620
	gtgttatacc	aactaaaacc	cccaataaac	cttgaacagt	g		1661
<210> 32							
<211> 4169							
<212> DNA							
<213> Homo sapiens							
<400> 32							
40	ggcggtttcc	aggtggggcg	gcaaggccgt	ggctctgctt	tgtgcctctg	acctgctgct	60
	gctgctgcta	ctgctaccac	cgctgggtc	ctgcggggcc	gaaggctcgc	ccgggacgcc	120
	cgacgagtct	acccacacct	cccggaagaa	gaagaaggat	attcgcgatt	acaatgatgc	180
	agacatggcg	cgtcttcttg	agcaatggga	gaaagatgat	gacattgaag	aaggagatct	240
	tccagagcac	aagagacctt	cagcacctgt	cgacttctca	aagatagacc	caagcaagcc	300
45	tgaagcata	ttgaaaatga	cgaaaaaagg	gaagactctc	atgatgtttg	tcactgtatc	360
	aggaagccct	actgagaagg	agacagagga	aattacgagc	ctctggcagg	gcagcctttt	420
	caatgccaac	tatgacgtcc	agaggttcat	tgtgggatca	gaccgtgcta	tcttcatgct	480
	tgcgcatggg	agctacgcct	gggagatcaa	ggactttttg	gtcgggtcaag	acaggtgtgc	540
	tgatgtaact	ctggagggcc	aggtgtaccc	cggcaaagga	ggaggaagca	aagagaaaaa	600
50	taaaacaaag	caagacaagg	gcaaaaaaaa	gaaggaaagg	gatctgaaat	ctcggctctt	660
	caaggaagaa	aatcgagctg	ggaataaaag	agaagacctg	tgatggggca	gcagtgaagc	720
	gctgtggggg	gacaggtgga	cgtggagagc	tctttgcccc	gctcctgggg	tgggagtggg	780
	ctcaggcaac	tgcacaccgg	atgacattct	agtgtcttct	agaaaggggt	tgccacatga	840
	ccagtttggt	gtcaaagaat	tactgcttaa	taggcttcaa	gtaagaagac	agatgttttc	900
55	taattaatac	tggacactga	caaattcatg	tttactataa	aatctcotta	catggaaatg	960
	tgactgtggt	gctttttccc	atttacactt	ggtagtcat	caactctact	gagattccac	1020
	tcccccccaa	gcacctgctg	tgattgggtg	gcctgctctg	atcagatagc	aaattctgat	1080
	cagagaagac	tttaaaactc	ttgacttaat	tgagtaaact	cttcatgcc	tatacatcat	1140
	tttcattatg	ttaaaggtaa	aatatgcttt	gtgaactcag	atgtctgtag	ccaggaagcc	1200
60	aggggtgtgta	aatccaaaat	ctatgcagga	aatgcggaga	atagaaaata	tgtcacttga	1260
	aatcctaagt	agttttgaat	ttctttgact	tgaatcttac	tcatcagtaa	gagaactctt	1320
	gggtgtctgtc	aggttttatg	tgggtctgtaa	agttaggggt	tctgttttgt	ttccttattt	1380
	aggaaagagt	actgctgggt	tgcagggggt	atatgtttcca	tttaatgtga	cagtttttaa	1440
	ggatttaagt	aggaatcag	agtcctttgc	agagtgtgac	agacgactca	ataacctcat	1500
65	ttgtttctaa	acatttttct	ttgataaagt	gcctaatact	gtgctttcgt	atagagtaac	1560
	atgatgtgct	actgttgatg	tctgattttg	ccgttcatgt	tagagcctac	tgtgaataag	1620
	agttagaaca	tttatataca	gatgtcattt	ctaagaacta	aaattctttg	ggaaaaaccc	1680
	tcaattgtga	ttttaataaa	ttaaaagtga	cacattacat	gggttagaaaa	tgtcagtgtt	1740
	aaagaatggg	acaaagtga	aagtgtatcc	ctctcttgcc	gcgggtggta	gcttgtccca	1800
70	gtggaagctg	ctgttaacaa	tttgtgcccc	cacatcccc	tccctgcccc	tccacccaaa	1860

```
<210> 33
<211> 859
<212> DNA
<213> Homo sapiens
```

atgc	agcttaccaa	ccatcgagtc	tgggactatg	ctggagataa	ctatgttcat	60
ggtg	caagtaaaac	agatggaaaa	atagtacagt	atgaatgtga	gggggatact	120
gaag	agaaaaataga	tgcctttacag	ttagagtatt	catatttact	aacaagccag	180
ttct	agcgaatcta	ctgggaaaac	aagatagttc	ggatagagaa	ggacacagca	240
atta	acaacatgaa	gaccaagttt	aaagaaacaa	ttgagaagtg	tgataatcta	300
aaac	taaatgatct	cctaaaagaa	aagcagtcctg	tggaaagaaa	gtgcactcag	360
taca	aagtggccaa	actcaccaac	gagctcaaag	aggagcagga	aatgaacaag	420
cgag	ccaaccaagt	cctcctgcag	aacaagctaa	aagaggagga	gagggtgctg	480
acct	gtgacccaaa	agatctgcag	atcacccaga	tccaggagca	gctgcgtgac	540
ttct	acctggagac	acagcagaag	atcaaccata	tgcttgccga	gaccgccgac	600
cagg	agggacagat	caacatcgcc	atggcctcgg	cctcgagccc	tgccctcttcg	660
agtg	ggaagttgcc	ctccaggaag	ggccgcagca	agaggggcaa	gtgaccttca	720
caga	caccctgag	actgtttctc	ctgacactgt	gagagtgtgc	tgggaccttc	780
atgt	gagggtgggc	cctaataagt	acaaagtgag	acgaaggccg	gccttcgtgg	840
agat	ggatgaggc					859

```
<210> 34
<211> 1070
<212> DNA
<213> Homo sapiens
```

	<400> 34						
	gcgattgctg	gggctgcagc	gctgcctccg	agaccgagag	tgggtggagc	gggtcttcct	60
	ggaaggggtgc	gataaggccg	ggcgaggtgc	ctgggatgct	tctccccttc	cgcgagggaag	120
5	agatctaatt	gggtagggcg	ggtgtagact	agcctgccga	gccgcccgt	ggcacctgca	180
	gcctcctggg	cgcccgcggg	cccggcgaga	aagttgttaa	agggagcgag	gtggttggtc	240
	ctgggggtccg	aggcgcgcct	ctcacgccct	gcccacacaga	agccgcagtc	ccgtgggggtc	300
	tggagacgca	gtttccttgt	taatgacaat	aaatccctgc	tccccctgcc	tcagacatct	360
	acgcagcgaa	atcgagcctg	gccttgaggg	tccacaccgc	gaggaagatg	cgtagcggcca	420
10	ttccagagcc	taagcctgga	gacctgattg	agatttttctg	ccctttctac	agacactggg	480
	ccatctatgt	tggcgatgga	tatgtgggtc	atctggcccc	tccaagtgaag	gtcgcaggag	540
	ctgggtgcagc	cagtgtcatg	tccgccttga	ctgacaaggc	catcgtgaag	aaggaattgc	600
	tgtatgatgt	ggccgggagt	gacaagtacc	aggtcaacaa	caaacatgat	gacaagtact	660
	cgccgctgcc	ctgcacgaaa	atcatccagc	ggcgcgagga	gctgggtggg	caggaggtgc	720
15	tctacaagct	gaccagtgaag	aactgcgagc	actttgtgaa	tgagctgcgc	tatggagtgc	780
	cccgcagtga	ccaggtcaga	gatgtcatca	tcgctgcaag	cgttgcagga	atgggcttgg	840
	cagccatgag	ccttatttga	gtcatgttct	caagaaacaa	gcgacaaaag	caataactga	900
	aaaagactgt	ctgtcagcga	tgactttata	catcaagggg	gtcttgtttt	gctagagagt	960
	ttgggggtttg	gtttgtggat	ttcattgtga	tttataataa	ggcttatttt	cacagaataa	1020
20	aataaagcaa	aacgagggag	gattttattg	ggggagtga	gccccaaaaa		1070
	<210> 35						
	<211> 460						
	<212> DNA						
25	<213> Homo sapiens						
	<400> 35						
	cttttctctc	catgtgcgca	cagaggtgcc	acgcgtgaga	cttctccgcc	gcctccgcgc	60
	cagacgccgc	cgcgatgcgc	taogtgcct	cctacctgct	ggctgcctta	gggggcaact	120
30	cctccccag	cgccaaggac	atcaagaaga	tcttgacag	cgtaggtatc	gaggcggacg	180
	acgaccggct	caacaagggt	atcagtgaag	tgaatggaaa	aaacattgaa	gacgtcattg	240
	cccagggtat	tggcaagctt	gccagtgtac	ctgctgggtg	ggctgtagcc	gtctctgctg	300
	ccccaggctc	tgcagccct	gctgctggtt	gtgccctgc	tcgagcagag	gagaagaaag	360
	atgagaagaa	ggaggagtct	gaagagtcag	atgatgacat	gggatttggc	ctttttgatt	420
35	aaattcctgc	tcccctgcaa	ataaagcctt	tttacacatc			460
	<210> 36						
	<211> 4416						
	<212> DNA						
40	<213> Homo sapiens						
	<400> 36						
	gccgcacagg	gttttatagg	atcacattga	caaaagtacc	atggagtgtt	atgagtcagc	60
	atattttatt	gttcttattc	cttcaatagt	tattacagta	attttcctct	tcttctggct	120
45	tttcatgaaa	gaaacattat	atgatgaagt	tcttgcaaaa	cagaaaagag	aacaaaagct	180
	tattcctacc	aaaacagata	aaaagaaaag	agaaaagaaa	aagaataaaa	agaaagaaat	240
	ccagaatgaa	aacctccatg	aatccgactc	tgagagtgt	cctcgagact	ttaaattatc	300
	agatgctttg	gcagtagaag	atgatcaagt	tgacactgtt	ccattgaatg	tcgttgaaac	360
	ttcaagtagt	gttagggaaa	gaaaaaagaa	ggaaaagaaa	caaaaagcctg	tgcttgaaga	420
50	gcaggtcatc	aaagaaaagt	acgcatacaa	gattcctggc	aaaaaagtag	aacctgtccc	480
	agttactaaa	cagcccaccc	ctccctctga	agcagctgcc	tcgaagaaga	aaccagggca	540
	gaagaagtct	aaaaatggaa	gcgatgacca	ggataaaaag	gtggaaactc	tcattggtacc	600
	atcaaaaagg	caagaagcat	tgccctccca	ccaagagact	aaacaagaaa	gtggatcagg	660
	gaagaagaaa	gcttcatcaa	agaaacaaaa	gacagaaaat	gtcttcgtag	atgaacccct	720
55	tattcatgca	actacttata	ttcctttgat	ggataatgct	gactcaagtc	ctgtggtaga	780
	taagagagag	gttattgatt	tgcttaaac	tgaccaagta	gaagggatcc	agaaatctgg	840
	gactaaaaaa	ctgaagaccg	aaactgacaa	agaaaatgct	gaagtgaagt	ttaaagattt	900
	tcttctgtcc	ttgaagacta	tgatgttttc	tgaagatgag	gctctttgtg	ttgtagactt	960
	gctaaaggag	aagtctggtg	taatacaaga	tgctttaaag	aagtcaagta	agggagaatt	1020
60	gactacgctt	atacatcagc	ttcaagaaaa	ggacaagtta	ctcgtgctg	tgaagggaaga	1080
	tgctgctgct	acaaaggatc	ggtgtaagca	gttaaccag	gaaatgatga	cagagaaaga	1140
	aagaagcaat	gtggttataa	caaggtgaa	agatcgaatt	ggaacattag	aaaaggaaca	1200
	taatgtattt	caaaacaaaa	tacatgtcag	ttatcaagag	actcaacaga	tcagatgaa	1260
	gtttcagcaa	gttcgtgagc	agatggaggc	agagatagct	cacttgaagc	aggaaaatgg	1320
65	tatactgaga	gatgcagtca	gcaacactac	aaatcaactg	gaaagcaagc	agtctgcaga	1380
	actaaataaa	ctacgccagg	attatgctag	gttggtgaat	gagctgactg	agaaaacagg	1440
	aaagctacag	caagaggaag	tccaaaagaa	gaatgctgag	caagcagcta	ctcagttgaa	1500
	ggttcaacta	caagaagctg	agagaagggtg	ggaagaagtt	cagagctaca	tcaggaagag	1560

	aacagcggaa	catgaggcag	cacagcaaga	tttacagagt	aaatttgtgg	ccaaagaaaa	1620
	tgaagtacag	agtctgcata	gtaagcttac	agataccttg	gtatcaaaac	aacagttgga	1680
	gcaaagacta	atgcagttta	tggaatcaga	gcagaaaagg	gtgaacaaag	aagagttctt	1740
5	acaaatgcag	gttcaggata	ttttggagca	gaatgaggct	ttgaaagctc	aaattcagca	1800
	gttccattcc	cagatagcag	cccagacctc	cgcttcagtt	ctagcagaag	aattacataa	1860
	agtgattgca	gaaaaggata	agcagataaa	acagactgaa	gattcttttag	caagtgaacg	1920
	tgatcgttta	acaagtaaa	aagaggaact	taaggatata	cagaatatga	atttcttatt	1980
	aaaagctgaa	gtgcagaaat	tacaggccct	ggcaaataag	caggctgctg	ctgcacatga	2040
10	attggagaag	atgcaacaaa	gtgtttatgt	taaagatgat	aaaataagat	tgctggaaga	2100
	gcaactacaa	catgaaattt	caaacaaaat	ggaagaattt	aagattctaa	atgaccaaaa	2160
	caaagcatta	aaatcagaag	ttcagaagct	acagactcct	gtttctgaac	agcctaataa	2220
	ggatgtttgt	gaacaaatgg	aaaaatgcac	tcaagaaaaa	gatgagaagt	taaagactgt	2280
	ggaagaatta	cttgaaactg	gacttattca	ggtaggcaact	aaagaagagg	agctgaatgc	2340
15	aataagaaca	gaaaattcat	ctctgacaaa	agaagttcaa	gacttaaaaag	ctaagcaaaa	2400
	tgatcagggt	tcttttgcct	ctctagttga	agaacttaag	aaagtgatcc	atgagaaaga	2460
	tggaaagatc	aagtctgtag	aagagcttct	ggaggcagaa	cttctcaaag	ttgctaacaa	2520
	ggagaaact	gttcaggatt	tgaacacagga	aataaagggt	ctaaaagaag	aaataggaaa	2580
	tgccagctt	gaaaaggctc	aacagttatc	tatcacttcc	aaagttcagg	agcttcagaa	2640
20	cttattaaaa	ggaaaagagg	aacagatgaa	taccatgaag	gctgttttgg	aagagaaga	2700
	gaaagacctt	gccaatacag	ggaagtgggt	acaggatcct	caagaagaaa	atgaatcttt	2760
	aaaagcacat	gttcagggaag	tagcacaaca	taacttgaaa	gaggcctctt	ctgcatcaca	2820
	gtttgaagaa	cttgagattg	tgttgaaaga	aaaggaaaaat	gaattgaaga	ggttagaagc	2880
	catgctaaaa	gagagggaga	gtgacttttc	tagcaaaaaca	cagctgttac	aggatgtaca	2940
25	agatgaaaac	aaattgttta	agtcccaaat	tgagcagctt	aaacaacaaa	actaccaaca	3000
	ggcatcttct	tttccccctc	atgaagaatt	attaaaagta	atttcagaaa	gagagaaaga	3060
	aataagtggg	ctctggaatg	agttagattc	tttgaaggat	gcagttgaac	accagaggaa	3120
	gaaaaacaa	gaaaggcagc	aacaggtgga	agctgttgag	ttggaggcta	aagaagtctt	3180
	caaaaaatta	tttccaaaag	tgtctgtccc	ttctaatttg	agttatgggt	aatgggtgca	3240
30	tggatttgaa	aaaaaggcaa	aagaatgtat	ggctggaact	tcagggtcag	aggaggttaa	3300
	ggttctagag	cacaagttga	aagaagctga	tgaaatgcac	acattgttac	agctagagt	3360
	tgaaaaatac	aaatccgtcc	ttgcagaaac	agaagggaatt	ttacagaagc	tacagagaag	3420
	tggttagcaa	gaagaaaata	aatggaaagt	taaggctgat	gaatcacaca	agactattaa	3480
	acagatgcag	tcattcattta	catcttcaga	acaagagcta	gagcgattaa	gaagcgaaaa	3540
35	taaggatatt	gaaaatctga	gaagagaacg	agaacatttg	gaaatggaac	tagaaaaggc	3600
	agagatggaa	cgatctacct	atgttacaga	agtcagagag	ttgaaggcac	agttaaatga	3660
	aacactcaca	aaacttagaa	ctgaacaaaa	tgaaagacag	aaggtagctg	gtgatttgca	3720
	taaggctcaa	gagtcactgg	agcttatcca	gtcaaaaata	gtaaaagctg	ctggagacac	3780
	tactgttatt	gaaaatagt	atgtttcccc	agaaacggag	tcttctgaga	aggagacaat	3840
40	gtctgtaagt	ctaaatcaga	ctgtaacaca	gttacagcag	ttgcttcagg	cggtaaacca	3900
	acagctcaca	aaggagaaag	agcactacca	ggtgttagag	tgaagtaatt	gggaaactgt	3960
	tcatttgagg	ataaaaaaag	cattgtatta	tattttgcca	aattaaagcc	ttatttatgt	4020
	tttcaccctt	tctactttgt	cagaaacact	gaacagagtt	ttgtcttttc	taatccttgt	4080
	tagactactg	atttaaaagaa	ggaaaaaaa	aagccaactc	tgtagacacc	ttcagagttt	4140
45	agttttataa	taaaaaactgt	ttgaataatt	agacctttac	attcctgaag	ataaacatgt	4200
	aatcttttat	cttattttgc	tcaataaaat	tgttcagaag	atcaaagtgg	ttaaagacaat	4260
	gtaaaattta	acattttta	actgatgttg	tacactgttt	tacttaacat	tttgggaagt	4320
	aactgcctct	gacttcaact	caagaaaaca	cttttttgtt	gctaattgtaa	tcggtttttg	4380
	taatggcgctc	agcaataaaa	aggatgctta	ttatttc			4416
50	<210> 37						
	<211> 628						
	<212> DNA						
	<213> Homo sapiens						
55	<220>						
	<221> unsure						
	<222> 284..284						
	<223> n = a, c, g or t						
60	<220>						
	<221> unsure						
	<222> 594..594						
	<223> n = a, c, g or t						
65	<220>						
	<221> unsure						
	<222> 597..597						

<223> n = a, c, g or t  
 <220>  
 <221> unsure  
 5 <222> 607..607  
 <223> n = a, c, g or t  
 <400> 37  
 10 ggcacgagaa gaagtctaaa aatggaagcg atgaccaggg ataaaaaggt ggaaactctc 60  
 atggtaccat caaaaaggca agaagcattg cccctccacc aagagactaa acaagaaagt 120  
 ggatcaggga agaagaaagc ttcataaaag aaacaaaaga cagaaaatgt ctctcgtagat 180  
 gaacccttta ttcatagcaac tacttatatt cctttgatgg ataatgctga ctcaagtcct 240  
 gtggtagata agagagaggt tatttatttg cttaaacctg accnagtaga agggatccag 300  
 15 aaatctggga ctaaaaaact gaagacccaa actgacaaaag aaaatgctga agtgaagttt 360  
 aaagattttc ttctgtcctt taagactatg atgttttctg aagatgaggc tctttgtggt 420  
 gtagacttgc taaaggagaa gtctcgtgta atacaagatg ctttaaagaa gtcaagtaag 480  
 ggagaattga ctacgcttat acatcagctt caagaaaagg accaagttac tcgctgctgt 540  
 gaaggaagat gctgctgcta caaaggatcc gtgtaagcag ttaccccagg aatnatncca 600  
 20 aagaaanaca gagcaatttg gtatacaa 628  
 <210> 38  
 <211> 730  
 <212> DNA  
 25 <213> Homo sapiens  
 <220>  
 <221> unsure  
 <222> 127..127  
 30 <223> n = a, c, g or t  
 <220>  
 <221> unsure  
 <222> 260..260  
 35 <223> n = a, c, g or t  
 <220>  
 <221> unsure  
 <222> 307..307  
 40 <223> n = a, c, g or t  
 <220>  
 <221> unsure  
 <222> 329..329  
 45 <223> n = a, c, g or t  
 <220>  
 <221> unsure  
 <222> 336..336  
 50 <223> n = a, c, g or t  
 <220>  
 <221> unsure  
 <222> 473..473  
 55 <223> n = a, c, g or t  
 <220>  
 <221> unsure  
 <222> 487..487  
 60 <223> n = a, c, g or t  
 <220>  
 <221> unsure  
 <222> 494..494  
 65 <223> n = a, c, g or t  
 <220>  
 <221> unsure



<222> 563..563  
 <223> n = a, c, g or t

5        <220>  
          <221> unsure  
          <222> 640..640  
          <223> n = a, c, g or t

10       <220>  
          <221> unsure  
          <222> 681..681  
          <223> n = a, c, g or t

15       <220>  
          <221> unsure  
          <222> 689..689  
          <223> n = a, c, g or t

20       <220>  
          <221> unsure  
          <222> 708..708  
          <223> n = a, c, g or t

25       <220>  
          <221> unsure  
          <222> 714..714  
          <223> n = a, c, g or t

30       <220>  
          <221> unsure  
          <222> 728..728  
          <223> n = a, c, g or t

35       <220>  
          <221> unsure  
          <222> 730..730  
          <223> n = a, c, g or t

40       <400> 38  
 aaagaattcg gcacgagtga agaccgaaac tgacaaagaa aatgctgaag tgaagtttaa 60  
 agattyyctt ctgtccttga agactatgat gttttctgaa gatgaggctc tttgtgttgt 120  
 agactyncta aaggagaagt ctggtgtaat acaagatgct ttaaagaagt caagtaaggg 180  
 agaattgact acgcttatac atcagcttca agaaaaggac aagtyactcg ctgctgtgaa 240  
 ggaagatgct gctgcyacan aggatcggtg taagcagtta acccaggaaa tgatgacaga 300  
 45       gaaaganaga agcaatgtgg ttataacang gatganagay cgaatyggaa cattagaaaa 360  
 ggracataat gtatyycaaa acaaaataca tgtcagtyat caagagacyc aacagatgca 420  
 gatgaagttt cagcaagttc gtgagcagat ggaggcagag atagcycact tgnagcagga 480  
 aaatggnata ctgngagaat gcagtcagca acactacaaa tcaactggaa agcaagcagt 540  
 ctgcagaact aaataaacta cgncaggatt atgctaggtt ggtgaatgag cctgactgag 600  
 50       aaacaggaaa gctacagcaa gaggaagtca aagaagaatn ctgagcaagc agctactcag 660  
 ttgaaggttc caactacacg nacgcctgng agaaggtggg ggaggcgntt cagngcctac 720  
 atcagggnngn  
 730

55       <210> 39  
          <211> 571  
          <212> DNA  
          <213> Homo sapiens

60       <220>  
          <221> unsure  
          <222> 37..37  
          <223> n = a, c, g or t

65       <220>  
          <221> unsure  
          <222> 42..42  
          <223> n = a, c, g or t

5           <220>  
            <221> unsure  
            <222> 64..64  
            <223> n = a, c, g or t

10           <220>  
            <221> unsure  
            <222> 67..67  
            <223> n = a, c, g or t

15           <220>  
            <221> unsure  
            <222> 73..73  
            <223> n = a, c, g or t

20           <220>  
            <221> unsure  
            <222> 86..99  
            <223> n = a, c, g or t

25           <220>  
            <221> unsure  
            <222> 106..107  
            <223> n = a, c, g or t

30           <220>  
            <221> unsure  
            <222> 117..117  
            <223> n = a, c, g or t

35           <220>  
            <221> unsure  
            <222> 139..139  
            <223> n = a, c, g or t

40           <220>  
            <221> unsure  
            <222> 153..153  
            <223> n = a, c, g or t

45           <220>  
            <221> unsure  
            <222> 243..243  
            <223> n = a, c, g or t

50           <220>  
            <221> unsure  
            <222> 257..257  
            <223> n = a, c, g or t

55           <220>  
            <221> unsure  
            <222> 264..264  
            <223> n = a, c, g or t

60           <220>  
            <221> unsure  
            <222> 319..319  
            <223> n = a, c, g or t

65           <220>  
            <221> unsure  
            <222> 337..337  
            <223> n = a, c, g or t

            <220>

<221> unsure  
<222> 341..341  
<223> n = a, c, g or t

5       <220>  
      <221> unsure  
      <222> 353..353  
      <223> n = a, c, g or t

10       <220>  
      <221> unsure  
      <222> 362..362  
      <223> n = a, c, g or t

15       <220>  
      <221> unsure  
      <222> 373..373  
      <223> n = a, c, g or t

20       <220>  
      <221> unsure  
      <222> 379..379  
      <223> n = a, c, g or t

25       <220>  
      <221> unsure  
      <222> 384..385  
      <223> n = a, c, g or t

30       <220>  
      <221> unsure  
      <222> 419..419  
      <223> n = a, c, g or t

35       <220>  
      <221> unsure  
      <222> 421..421  
      <223> n = a, c, g or t

40       <220>  
      <221> unsure  
      <222> 427..427  
      <223> n = a, c, g or t

45       <220>  
      <221> unsure  
      <222> 433.433  
      <223> n = a, c, g or t

50       <220>  
      <221> unsure  
      <222> 440..442  
      <223> n = a, c, g or t

55       <220>  
      <221> unsure  
      <222> 444..444  
      <223> n = a, c, g or t

60       <220>  
      <221> unsure  
      <222> 448..448  
      <223> n = a, c, g or t

65       <220>  
      <221> unsure  
      <222> 450..450

<223> n = a, c, g or t

<220>  
<221> unsure  
5 <222> 455..455  
<223> n = a, c, g or t

<220>  
<221> unsure  
10 <222> 486..486  
<223> n = a, c, g or t

<220>  
<221> unsure  
15 <222> 488..489  
<223> n = a, c, g or t

<220>  
<221> unsure  
20 <222> 493..493  
<223> n = a, c, g or t

<220>  
<221> unsure  
25 <222> 496..497  
<223> n = a, c, g or t

<220>  
<221> unsure  
30 <222> 500..500  
<223> n = a, c, g or t

<220>  
<221> unsure  
35 <222> 504..504  
<223> n = a, c, g or t

<220>  
<221> unsure  
40 <222> 506..507  
<223> n = a, c, g or t

<220>  
<221> unsure  
45 <222> 515..515  
<223> n = a, c, g or t

<220>  
<221> unsure  
50 <222> 520..520  
<223> n = a, c, g or t

<220>  
<221> unsure  
55 <222> 523..523  
<223> n = a, c, g or t

<220>  
<221> unsure  
60 <222> 525..526  
<223> n = a, c, g or t

<220>  
<221> unsure  
65 <222> 538..538  
<223> n = a, c, g or t

	<div>&lt;400&gt; 39</div> <div>aayacaatgc cttttttatc ctcaaataga rcagtttccc anttacttca ctcttacacc 60</div> <div>tggnagngct ctntctcett tgtgrnnnnn nnnnnnnnc ccccyntccg aatggtnctg 120</div> <div>5 taactgtgtt acagtctgnt ttaggcttac agncattgtc tccttctcag gaggctccgt 180</div> <div>ttctggggga acatcacttt tttcaataac agtagtgtct cccgcagctt ttactatttt 240</div> <div>tgntcggata agctccngtg actnttgagc cttatgcaaa tcaccagcta ccttctgtct 300</div> <div>ttcattttgt tcagttctna gttttgtggg tgtttcnttt nactgtgccy tcnactctct 360</div> <div>gncttctgta acntagggng gtcnntccct ctctgccttt tctagttccc tttcccaang 420</div> <div>10 ntctcgnctc cncccccagn nngncaanan ccgcnatttt tcgcttctta attcgggtcta 480</div> <div>gccccgnnc cgnagnngn aaangnnggc tgcanccggn ttannaggc ctgtgtgntt 540</div> <div>catcggcctt tacctttccc tttattttct t 571</div>
	<div>&lt;210&gt; 40</div> <div>&lt;211&gt; 644</div> <div>15 &lt;212&gt; DNA</div> <div>&lt;213&gt; Homo sapiens</div> <div>&lt;220&gt;</div> <div>&lt;221&gt; unsure</div> <div>20 &lt;222&gt; 415..415</div> <div>&lt;223&gt; n = a, c, g or t</div> <div>&lt;220&gt;</div> <div>&lt;221&gt; unsure</div> <div>25 &lt;222&gt; 525..526</div> <div>&lt;223&gt; n = a, c, g or t</div>
	<div>&lt;400&gt; 40</div> <div>30 atattttgga gcagaatgag gctttgaaag ctcaaattca gcagttccat tcccagatag 60</div> <div>cagcccagac ctccgcttca gttctagcag aagaattaca taaagtgatt gcagaaaagg 120</div> <div>ataagcagat aaaacagact gaagattctt tagcaagtga acgtgatcgt ttaacaagta 180</div> <div>aagaagagga acttaaggat atacagaata tgaatttctt attaaaagct gaagtgcaga 240</div> <div>aattacaggc cctggcaaatt gagcaggctg ctgctgcaca tgaattggag aagatgcaac 300</div> <div>35 acagtgttta tgttaaagat gataaaataa gattgctgga agagcaacta caacatgaca 360</div> <div>tttcaaacaa aatggaagaa ttttaagattc taaatgacca aaacaaagca ttaanatcag 420</div> <div>aagttcagaa gctacagact cttgtttctg aacagcctaa taaggatgtt gtggaacaca 480</div> <div>tggaataatg cattcaagaa aagatgagaa gttaaagact gtggnggatt acttgacact 540</div> <div>ggacttattc aggtggcaac taaagagagg agctgatgca tagacagaca ttcattctctg 600</div> <div>40 acaaagagtt caagacttac agctagcaaa tgatcaggtt cttg 644</div>
	<div>&lt;210&gt; 41</div> <div>&lt;211&gt; 566</div> <div>&lt;212&gt; DNA</div> <div>45 &lt;213&gt; Homo sapiens</div> <div>&lt;220&gt;</div> <div>&lt;221&gt; unsure</div> <div>&lt;222&gt; 47.47</div> <div>50 &lt;223&gt; n = a, c, g or t</div> <div>&lt;220&gt;</div> <div>&lt;221&gt; unsure</div> <div>&lt;222&gt; 59..59</div> <div>55 &lt;223&gt; n = a, c, g or t</div> <div>&lt;220&gt;</div> <div>&lt;221&gt; unsure</div> <div>&lt;222&gt; 91..91</div> <div>60 &lt;223&gt; n = a, c, g or t</div> <div>&lt;220&gt;</div> <div>&lt;221&gt; unsure</div> <div>&lt;222&gt; 104..104</div> <div>65 &lt;223&gt; n = a, c, g or t</div> <div>&lt;220&gt;</div> <div>&lt;221&gt; unsure</div>

<222> 441..441  
 <223> n = a, c, g or t

5

<220>  
 <221> unsure  
 <222> 448..448  
 <223> n = a, c, g or t

10

<220>  
 <221> unsure  
 <222> 457..457  
 <223> n = a, c, g or t

15

<220>  
 <221> unsure  
 <222> 525..525  
 <223> n = a, c, g or t

20

<220>  
 <221> unsure  
 <222> 539..539  
 <223> n = a, c, g or t

25

<220>  
 <221> unsure  
 <222> 564..564  
 <223> n = a, c, g or t

30

<400> 41	caacacaatc	tcaaggtctt	caaaactggga	tgcagaagag	gcctctntca	agttatgtng	60
	tgctacttcc	tgaacaaggg	cttgaaaaga	ntcaatggct	tctngaagag	cccgtaacca	120
	cttccccgta	ttggctaggg	ctttctcttt	ctcttccaaa	acagccttca	tgggattcat	180
	ctgtgcctct	tttcctttta	ataagttcyg	aagctcctga	actttggaag	tgatagataa	240
	cygttgagcc	ttttcaagct	ggacatttcc	tatttcttct	tttagagcct	ttatttcccg	300
35	tttcaaatacc	cgaacagttt	tctccttggt	agcaacattg	agaagtgccg	cctccagaag	360
	ctcttctaca	gacttgatct	ttcacctctc	tcatggatca	ctctcttaag	gtcttcaact	420
	agagaggcaa	aagaaccga	ncatttgnta	gttttangct	cgaacttctt	ttgtcagaga	480
	tgaattttct	gttcttattg	cattcagctc	ctcttcttta	ggtgncacca	gaataaggnc	540
40	agtgtcaaga	aattcttcca	cagnct				566

<210> 42  
 <211> 878  
 <212> DNA  
 <213> Homo sapiens

45

<220>  
 <221> unsure  
 <222> 595..595  
 <223> n = a, c, g or t

50

<220>  
 <221> unsure  
 <222> 756..756  
 <223> n = a, c, g or t

55

<220>  
 <221> unsure  
 <222> 766..766  
 <223> n = a, c, g or t

60

<220>  
 <221> unsure  
 <222> 815..815  
 <223> n = a, c, g or t

65

<220>  
 <221> unsure

<222> 818..818  
 <223> n = a, c, g or t

5  
 <220>  
 <221> unsure  
 <222> 827..827  
 <223> n = a, c, g or t

10  
 <220>  
 <221> unsure  
 <222> 831..831  
 <223> n = a, c, g or t

15  
 <220>  
 <221> unsure  
 <222> 853..853  
 <223> n = a, c, g or t

20  
 <220>  
 <221> unsure  
 <222> 866..866  
 <223> n = a, c, g or t

25  
 <400> 42  
 accttaacct cctctgacct gaagttccag ccatacatte ttttgccttt ttttcaatcc 60  
 atgcaaccat tcaccataac tcaaattaga agggacagac acctttggaa ataatttttt 120  
 gagaacttct ttagcctcca actcaacagc ttccacctgt tgctgccttt cattgttttt 180  
 cttcctctgg tgttcaactg catccttcaa agaactctaac tcattccaga gaccacttat 240  
 ttctttctct ctttctgaaa ttacttttaa taattcttca tgagggggaa aagaagatgc 300  
 30 ctggttgtag ttttgttgtt taagctgctc aatttgggac ttaaacaatt tgttttcatc 360  
 ttgtacatcc tgtaacagct gtgttttgct agaaagatca ctctccctct ctttttagcat 420  
 ggcttctaac ctcttcaatt cattttcctt ttctttcaac acaatctcaa gtcttcaaa 480  
 ctgtgatgca gaagaggcct ctttcaagtt atgttggtgct acttcctgaa catgtgcttt 540  
 taaaagattc attttcttct tgaagatcct gtaaccactt ccctgtattg gctangtctt 600  
 35 tctctttctc ttccaaaaca gccttcaagg tattcatctg ttccctcttt ccttttataaa 660  
 agttctgaag ctcttgaact ttggaagtga tagataactg ttgagccctt tcaagcctgg 720  
 acattcctaa ttctctcttt aaaagcctta attccngttt caaaaanccga aacagttttc 780  
 ccccttgtaa gcaactttga gaaattcggc tccanaancc ctctctanaga nttgatcttt 840  
 40 caacctttcc aanggattac tttccnaaag ttccttaa 878

<210> 43  
 <211> 620  
 <212> DNA  
 <213> Homo sapiens

45  
 <220>  
 <221> unsure  
 <222> 391..391  
 <223> n = a, c, g or t

50  
 <220>  
 <221> unsure  
 <222> 400..400  
 <223> n = a, c, g or t

55  
 <220>  
 <221> unsure  
 <222> 411..411  
 <223> n = a, c, g or t

60  
 <220>  
 <221> unsure  
 <222> 414.. 414  
 <223> n = a, c, g or t

65  
 <220>  
 <221> unsure

<222> 418..418  
<223> n = a, c, g or t

5       <220>  
      <221> unsure  
      <222> 421..421  
      <223> n = a, c, g or t

10       <220>  
      <221> unsure  
      <222> 427..428  
      <223> n = a, c, g or t

15       <220>  
      <221> unsure  
      <222> 435..435  
      <223> n = a, c, g or t

20       <220>  
      <221> unsure  
      <222> 446..446  
      <223> n = a, c, g or t

25       <220>  
      <221> unsure  
      <222> 454..455  
      <223> n = a, c, g or t

30       <220>  
      <221> unsure  
      <222> 463..463  
      <223> n = a, c, g or t

35       <220>  
      <221> unsure  
      <222> 465..465  
      <223> n = a, c, g or t

40       <220>  
      <221> unsure  
      <222> 471..471  
      <223> n = a, c, g or t

45       <220>  
      <221> unsure  
      <222> 480..480  
      <223> n = a, c, g or t

50       <220>  
      <221> unsure  
      <222> 484..484  
      <223> n = a, c, g or t

55       <220>  
      <221> unsure  
      <222> 490..490  
      <223> n = a, c, g or t

60       <220>  
      <221> unsure  
      <222> 493..493  
      <223> n = a, c, g or t

65       <220>  
      <221> unsure  
      <222> 500..500  
      <223> n = a, c, g or t



5       <220>  
           <221> unsure  
           <222> 514..515  
           <223> n = a, c, g or t

10       <220>  
           <221> unsure  
           <222> 524..524  
           <223> n = a, c, g or t

15       <220>  
           <221> unsure  
           <222> 539..539  
           <223> n = a, c, g or t

20       <220>  
           <221> unsure  
           <222> 568..568  
           <223> n = a, c, g or t

25       <220>  
           <221> unsure  
           <222> 573..574  
           <223> n = a, c, g or t

30       <220>  
           <221> unsure  
           <222> 581..581  
           <223> n = a, c, g or t

35       <220>  
           <221> unsure  
           <222> 600..600  
           <223> n = a, c, g or t

40       <220>  
           <221> unsure  
           <222> 604..604  
           <223> n = a, c, g or t

45       <220>  
           <221> unsure  
           <222> 608..608  
           <223> n = a, c, g or t

50       <220>  
           <221> unsure  
           <222> 616..616  
           <223> n = a, c, g or t

55       <220>  
           <221> unsure  
           <222> 619..619  
           <223> n = a, c, g or t

60       <400> 43  
           accttaacct cctctgaccc tgaattccag ccatacatte ttttgccttt ttttcaaate 60  
           catgcaacca ttcaccataa ctcaaattag aagggacaga cacctttgga aataattttt 120  
           tgagaacttc tttagcctcc aactcaacag cttccacctg ttgctgcctt tcattgtttt 180  
           tcttcctctg gtgttcaact gcatccttca aagaatctaa ctcatccag agaccactta 240  
           tttctttctc tctttctgaa attactttta ataattcttc atgaggggga aaagaagatg 300  
           cctgttggtg gttttgttgt ttaagctgct caatttgga cttaaacaat ttgttttcat 360  
           cctgtacatc ctgtaacagc tgtgttttgc naagaaagtn actccccctc nccnttanca 420  
 65       nggggttnca acctncttaa atacanttcc tttnncttta aananaatct naggttccctn 480  
           caanggtan tgnaaaaaan gcccttttca agtnnggttg tgcnacttcc tgaacatgng 540  
           ctttaagatc attttctctg aagatccngt acnnttcccg nattggtagg cttcccttcn 600

ttcnaaanag cttcangng

620

5           <210> 44  
            <211> 623  
            <212> DNA  
            <213> Homo sapiens

10           <220>  
            <221> unsure  
            <222> 25..25  
            <223> n = a, c, g or t

15           <220>  
            <221> unsure  
            <222> 409..409  
            <223> n = a, c, g or t

20           <220>  
            <221> unsure  
            <222> 412..412  
            <223> n = a, c, g or t

25           <220>  
            <221> unsure  
            <222> 414..414  
            <223> n = a, c, g or t

30           <220>  
            <221> unsure  
            <222> 423..423  
            <223> n = a, c, g or t

35           <220>  
            <221> unsure  
            <222> 426..426  
            <223> n = a, c, g or t

40           <220>  
            <221> unsure  
            <222> 435..435  
            <223> n = a, c, g or t

45           <220>  
            <221> unsure  
            <222> 444..444  
            <223> n = a, c, g or t

50           <220>  
            <221> unsure  
            <222> 450..450  
            <223> n = a, c, g or t

55           <220>  
            <221> unsure  
            <222> 454..454  
            <223> n = a, c, g or t

60           <220>  
            <221> unsure  
            <222> 459..459  
            <223> n = a, c, g or t

65           <220>  
            <221> unsure  
            <222> 490..490  
            <223> n = a, c, g or t

5 <220>  
 <221> unsure  
 <222> 508..508  
 <223> n = a, c, g or t

10 <220>  
 <221> unsure  
 <222> 511..511  
 <223> n = a, c, g or t

15 <220>  
 <221> unsure  
 <222> 515..515  
 <223> n = a, c, g or t

20 <220>  
 <221> unsure  
 <222> 524..524  
 <223> n = a, c, g or t

25 <220>  
 <221> unsure  
 <222> 545..545  
 <223> n = a, c, g or t

30 <220>  
 <221> unsure  
 <222> 555..555  
 <223> n = a, c, g or t

35 <220>  
 <221> unsure  
 <222> 564..564  
 <223> n = a, c, g or t

40 <220>  
 <221> unsure  
 <222> 600..600  
 <223> n = a, c, g or t

45 <220>  
 <221> unsure  
 <222> 611..611  
 <223> n = a, c, g or t

50 <400> 44  
 accttaacct cctctgaccc tgaantccag ccatacatte ttttgccctt ttttcaaate 60  
 catgcaacca ttcaccataa ctcaaattag aagggacaga cacctttgga aataattttt 120  
 tgagaacttc tttagcctcc aactcaacag ctccacctg ttgctgcctt tccttggaag 180  
 tcttggtcac ttgtcctgc agcatttttt cagttgatgc caatgcttcc attgcttccc 240  
 agtttttctc ccgaagggtca ttgtttttct tcctctgggtg ttcaactgca tccttcaaag 300  
 aatctaactc attccagaga ccacttattt ctttctctct ttctgaaatt acttttaata 360  
 attcttcatg aggggggaaaa gaagatgcct ggtgggaatt tgggtggttna ancnggccaa 420  
 ttnggnacct aaaaanatttg gttncactn gtanaccgng taaaaactgt gttttgctaa 480  
 55 aaagataacn cccctctct ttaagcangg nttcnaacct cttnattcat ttccttttct 540  
 tcaanaaatc tcagntctca aacngggatg caaaaagaggc tcttcaagtt aaggtgggcn 600  
 acttccggaa natggccttt aaa 623

60 <210> 45  
 <211> 625  
 <212> DNA  
 <213> Homo sapiens

65 <220>  
 <221> unsure  
 <222> 392..392  
 <223> n = a, c, g or t

5       <220>  
          <221> unsure  
          <222> 408..408  
          <223> n = a, c, g or t

10       <220>  
          <221> unsure  
          <222> 417..417  
          <223> n = a, c, g or t

15       <220>  
          <221> unsure  
          <222> 421..421  
          <223> n = a, c, g or t

20       <220>  
          <221> unsure  
          <222> 424..425  
          <223> n = a, c, g or t

25       <220>  
          <221> unsure  
          <222> 437..437  
          <223> n = a, c, g or t

30       <220>  
          <221> unsure  
          <222> 439..439  
          <223> n = a, c, g or t

35       <220>  
          <221> unsure  
          <222> 456..456  
          <223> n = a, c, g or t

40       <220>  
          <221> unsure  
          <222> 467..467  
          <223> n = a, c, g or t

45       <220>  
          <221> unsure  
          <222> 469..469  
          <223> n = a, c, g or t

50       <220>  
          <221> unsure  
          <222> 473..473  
          <223> n = a, c, g or t

55       <220>  
          <221> unsure  
          <222> 475..475  
          <223> n = a, c, g or t

60       <220>  
          <221> unsure  
          <222> 496..496  
          <223> n = a, c, g or t

65       <220>  
          <221> unsure  
          <222> 499..500  
          <223> n = a, c, g or t

          <220>

<221> unsure  
<222> 516..516  
<223> n = a, c, g or t

5 <220>  
<221> unsure  
<222> 524..524  
<223> n = a, c, g or t

10 <220>  
<221> unsure  
<222> 535..535  
<223> n = a, c, g or t

15 <220>  
<221> unsure  
<222> 538..538  
<223> n = a, c, g or t

20 <220>  
<221> unsure  
<222> 560..560  
<223> n = a, c, g or t

25 <220>  
<221> unsure  
<222> 582..582  
<223> n = a, c, g or t

30 <220>  
<221> unsure  
<222> 592..592  
<223> n = a, c, g or t

35 <220>  
<221> unsure  
<222> 594..594  
<223> n = a, c, g or t

40 <220>  
<221> unsure  
<222> 604..604  
<223> n = a, c, g or t

45 <400> 45  
accttaacct cctctgaccc tgaagtcag ccatacatc ttttgccctt ttttcaaatac 60  
catgcaacca ttcaccataa ctcaaattag aaggagacaga caccttttga aataattttt 120  
tgagaacttc tttagcctcc aactcaacag cttccacctg ttgctgcctt tcattgtttt 180  
50 ttttcctctg gtgttcaact gcacccctca aagaatctaa ctcatccag agaccactta 240  
tttctttctc tctttctgaa attactttta ataattcttc atgaggggga aaagaagatg 300  
cctgttggtg gttttgttgt ttaagctgct caatttgga cttaaacaat ttgttttcat 360  
ctgttacatc ctggtaacag ctgtgttttg cntagaaaag attactcncc ctctctnttt 420  
ncannngggt caaccnntna aattacattt cocttntctt aaacaanant ctngatttct 480  
tcaaactgtg atgcanaann ggctctttca agttangttg tgcnaacttc tgaanatntg 540  
55 ttttaaagat catttcttctn tgaaatccgt aaccacttcc cngtatgggc angncttccc 600  
ttcncttcaa aaaagcctca aggtg 625

<210> 46  
<211> 4416  
60 <212> DNA  
<213> Homo sapiens

<400> 46  
gccgcacagg gttttatagg atcacattga caaaagtacc atggagtttt atgagtcagc 60  
65 atattttatt gttcttattc cttcaatagt tattacagta attttcctct tcttctggct 120  
tttcatgaaa gaaacattat atgatgaagt tcttgcaaaa cagaaaagag aacaaaagct 180  
tattcctacc aaaacagata aaaagaaagc agaaaagaaa aagaataaaa agaaagaaat 240

	ccagaatgga	aacctccatg	aatccgactc	tgagagtgtg	cctcgagact	ttaaattatc	300
	agatgctttg	gcagtagaag	atgatcaagt	tgcacctgtt	ccattgaatg	tcgttgaaac	360
	ttcaagtagt	gttagggaaa	gaaaaaagaa	ggaaaagaaa	caaaagcctg	tgcttgaaaga	420
5	gcaggctcatc	aaagaaagtg	acgcatcaaa	gattcctggc	aaaaaagtag	aacctgtccc	480
	agttactaaa	cagcccaccc	ctccctctga	agcagctgcc	tcgaagaaga	aaccagggca	540
	gaagaagtct	aaaaatggaa	gcgatgacca	ggataaaaaag	gtggaaactc	tcatggtacc	600
	atcaaaaagg	caagaagcat	tgccctccca	ccaagagact	aaacaagaaa	gtggatcagg	660
	gaagaagaaa	gcttcatcaa	agaaacaaaa	gacagaaaat	gtcttcgtag	atgaaccctt	720
10	tattcatgca	actacttata	ttcctttgat	ggataatgct	gactcaagtc	ctgtggtaga	780
	taagagagag	gttattgatt	tgcttaaacc	tgaccaagta	gaagggatcc	agaaatctgg	840
	gactaaaaaa	ctgaagaccg	aaactgacaa	agataatgct	gaagtgaagt	ttaaagattt	900
	tcttctgtcc	ttgaagacta	tgatgttttc	tgaagatgag	gctctttgtg	ttgtagactt	960
	gctaaaggag	aagtctggtg	taatacaaga	tgctttaaag	aagtcaagta	agggagaatt	1020
	gactacgctt	atacatcagc	ttcaagaaaa	ggacaagtta	ctcgctgctg	tgaagggaaga	1080
15	tgctgctgct	acaaaggatc	ggtgtaagca	gttaacccag	gaaatgatga	cagagaaaga	1140
	aagaagcaat	gtgggttataa	caaggatgaa	agatcgaatt	ggaacattag	aaaaggaaca	1200
	taatgtattt	caaaacaaaa	tacatgtcag	ttatcaagag	actcaacaga	tgcatatgaa	1260
	gtttcagcaa	gttcgtgagc	agatggaggc	agagatagct	cacttgaagc	aggaaaaatgg	1320
	tataactgaga	gatgcagtca	gcaacactac	aaatcaactg	gaaagcaagc	agtctgcaga	1380
20	actaaataaa	ctacgccagg	attatgctag	gttgggtgaat	gagctgactg	agaaaaacagg	1440
	aaagctacag	caagaggaag	ttccaaaagaa	gaatgctgag	caagcagcta	ctcagttgaa	1500
	ggttcaacta	caagaagctg	agagaagggtg	ggaagaagtt	cagagctaca	tcaggaagag	1560
	aacagcggaa	catgaggcag	cacagcaaga	tttacagagt	aaatttgtgg	ccaaagaaaa	1620
	tgaagtacag	agtctgcata	gtaagcttac	agataccttg	gtatcaaaac	aacagttgga	1680
25	gcaaagacta	atgcagttaa	tggaatcaga	gcagaaaagg	gtgaacaaaag	aagagtctct	1740
	acaaatgcag	gttcaggata	ttttggagca	gaatgaggct	ttgaaagctc	aaattcagca	1800
	gttccattcc	cagatagcag	cccagacctc	cgcttcagtt	ctagcagaag	aattacataa	1860
	agtgattgca	gaaaaggata	agcagataaa	acagactgaa	gattcttttag	caagtgaacg	1920
	tgatcgttta	acaagtaaaag	aagaggaact	taaggatata	cagaatatga	atttcttatt	1980
30	aaaagctgaa	gtgcagaat	tacaggccct	ggcaaatgag	caggctgctg	ctgcacatga	2040
	attggagaag	atgcaacaaa	gtgtttatgt	taaaagatga	aaaataagat	tgctggaaga	2100
	gcaactacaa	catgaaattt	caaacaaaat	ggaagaattt	aagattctaa	atgacaaaaa	2160
	caaagcatta	aaatcagaag	ttcagaagct	acagactctt	gtttctgaac	agcctaataa	2220
	ggatgttgtg	gaacaaatgg	aaaaatgcac	tcaagaaaaa	gatgagaagt	taaagactgt	2280
35	ggaagaatta	gaactaaactg	gacttattca	ggtggcaact	aaagaagagg	agctgaatgc	2340
	aataagaaca	gaaaattcat	ctctgacaaa	agaagttcaa	gacttaaaaag	ctaagcaaaa	2400
	tgatcagggtt	tcttttgccct	ctctagttga	agaacttaag	aaagtgatcc	atgagaaaga	2460
	tggaaagatc	aagtctgtag	aagagcttct	ggaggcagaa	cttctcaaaag	ttgctaacaa	2520
	ggagaaaact	gttcaggatt	tgaacacagga	aataaaaggct	ctaaaagaag	aaataggaaa	2580
40	gtgccagctt	gaaaaggctc	aacagttatc	tatcacttcc	aaagttcagg	agcttcagaa	2640
	cttatttaaaa	ggaaaagagg	aacagatgaa	taccatgaag	gctgttttgg	aagagaaaga	2700
	gaaagaccta	gccaatcacg	ggaagtgggt	acaggatctt	caagaagaaa	atgaatcttt	2760
	aaaagcacat	gttcagggaag	tagcacaaca	taacttgaaa	gaggcctctt	ctgcatcaca	2820
	gtttgaagaa	cttgagattg	tggtgaaaga	aaagggaaat	gaattgaaga	ggttagaagc	2880
45	catgtataaaa	gagagggaga	gtgacttttc	tagcaaaaaca	cagctgttac	aggatgtaca	2940
	agatgaaaaac	aaattgttta	agtcccaaat	tgagcagctt	aaacaacaaa	actaccaaca	3000
	ggcatcttct	tttccccctc	atgaagaatt	attaaaagta	atttcagaaa	gagagaaaga	3060
	aataagtggt	ctctggaatg	agttagattc	tttgaaggat	gcagttgaac	accagaggaa	3120
	gaaaaacaat	gaaaggcagc	aacaggtgga	agctgttgag	ttggaggcta	aagaagttct	3180
50	caaaaaatta	tttccaaagg	tgtctgtccc	ttctaatttg	agttatggtg	aatggttgca	3240
	tggattttgaa	aaaaaggcaa	aagaatgtat	ggctggaact	tcagggtcag	aggaggttaa	3300
	ggttctagag	cacaagttga	aagaagctga	tgaatgcac	acattgttac	agctagagtg	3360
	tgaaaaatac	aaatccgtcc	ttgcagaaac	agaagggaatt	ttacagaagc	tacagagaag	3420
	tgttgagcaa	gaagaaaaata	aatggaaagt	taaggtcgat	gaatcacaca	agactattaa	3480
55	acagatgcag	tcatcattta	catcttcaga	acaagagcta	gagcgattaa	gaagcgaaaa	3540
	taaggatatt	gaaaaatctga	gaagagaacg	agaacatttg	gaaatggaac	tagaaaaaggc	3600
	agagatggaa	cgatctacct	atgttacaga	agtcagagag	ttgaaggcac	agttaaatga	3660
	aacactcaca	aaacttagaa	ctgaacaaaa	tgaagacag	aaggtagctg	gtgatttgca	3720
	taaggctcaa	cagtcactgg	agcttatcca	gtcaaaaata	gtaaaagctg	ctggagacac	3780
60	tactgttatt	gaaaatagtg	tactttcccc	agaaacggag	tcttctgaga	aggagacaat	3840
	gtctgtaagt	ctaaatcaga	ctgtaacaca	gttacagcag	ttgcttcagg	cggtaaaacca	3900
	acagctcaca	aaggagaaag	agcactacca	ggtgttagag	tgaagtaatt	gggaaactgt	3960
	tcatttgagg	ataaaaaaag	cattgtatta	tattttgccca	aattaaaagcc	ttattttatgt	4020
	tttcaccctt	tctactttgt	cagaaaacact	gaacagagtt	ttgtcttttc	taatccttgt	4080
65	tagactactg	atttaaagaa	ggaaaaaaaa	aagccaactc	tgtagacacc	ttcagagttt	4140
	agttttataa	taaaaaactgt	ttgaataatt	agacctttac	attcctgaag	ataaacatgt	4200
	aatcttttat	cttatttttgc	tcaataaaat	tgttcagaag	atcaaagtgg	taaagacaat	4260

gtaaaattta	acattttaat	actgatgttg	tacactgttt	tacttaacat	tttgggaagt	4320
aactgcctct	gacttcaact	caagaaaaca	cttttttggt	gctaatagtaa	tcggtttttg	4380
taatggcgtc	agcaaataaa	aggatgctta	ttattc			4416

5





## SEQUENCE LISTING

&lt;110&gt; Ludwig Institute for Cancer Research

<120> Cancer Associated Antigens  
and Uses Therefor

&lt;130&gt; L0461/7050WO

&lt;140&gt; US 09/166,300

&lt;141&gt; 1997-10-05

&lt;140&gt; US 09/166,350

&lt;141&gt; 1997-10-05

&lt;160&gt; 45

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;211&gt; 4422

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

gattattctg	gaggaagatg	accttcattt	tatggttatg	tgtgtgtgtc	tgtgtgtgtc	60
tggaaaaatn	tntataattt	ttttttttt	ggggggggg	tatcangtga	tgaattaaaq	120
tatgtgcag	aatatataatt	ctaaaaactac	aaaaaagtca	ctgaatalca	aatgatatac	180
gattatacat	atagttaactg	tgnnagtga	cagactgcta	gttcagaatt	caaanntcct	240
l.l.ccttagl.l.l.l	gtgagalaal	gggtctaaatt	ccttctgccl	gccaatgygg	caaaagcaat	300
tgccttagtt	ttgatgaga	gttccttagaa	gtttgttggg	attccttcct	ccacagcctc	360
cattgttgaa	atnccattt	tcncttctga	tcncttctga	aaagaagcaa	ttgttgcctt	420
gaaalgcac	cttggtagcc	agtttcaatg	aaagctagaga	ttagtcagaa	aaagttagct	480
gttgggcttt	agaaagggat	ttttagtctt	gncatttcta	cttgggagca	ttttggagca	540
gattaaagctt	tcnctataaa	naaaaglggc	laccclgatgg	aaacttttct	taactttala	600
gggaaactga	gcacaagctg	aatgatattg	tctgctgcaa	aaaaaaacaa	acaaaaaaaa	660
aaacaaacaa	aaaaaaacaa	aaaaaaacaa	aaaaaaacaa	gccaatctct	gccaatctct	720
aagctcccg	ccccccccc	cctccggcgg	cagccggccc	gctggccctg	cagccgtcgc	780
cgtgctcctg	ggctacagcc	cgggctctcg	cgtcccccgc	tggggaagg	gggcccctgg	840
cgtgctcctg	ggcgcggag	ahggggygag	ggccltgggg	cagcltcccc	ggggccggcg	900
ccggcagcgg	cagatcctg	caactgaacg	taggggggac	cagatttagt	acctcaagac	960
aaactcttat	gtggattcca	gattcttttt	ttttagttt	gctgaagtcg	agacttttaa	1020
cacttgcgg	tgaaactgg	gctacattta	ttgatagaga	tccagcagca	tttgcaccca	1080
ttttaaat	ttctcggaca	aaagaactag	acttaagggg	agtgaagtatt	aatgtttctc	1140
ggcatgaagc	agaaattttac	gggactcact	catttagtgg	aaagcltctc	tttctggaag	1200
aattggagcg	l.l.ccttctgt	ggcagtgctc	tttttcatgg	ttacttgccc	ccaccaggtc	1260
ttcctagtcg	taaaataaac	aaacacatcn	gacttctgta	ttctaggaat	ggctcctaat	1320
ctacagagag	tgaagcccg	ggaaatggta	cacagctctg	ttctctctga	aaagggagag	1380
aaactgttag	gctagggatt	cctgtggatc	cacgaagagt	gctaatagta	gctggccatc	1440
acaaactggat	tgtagctgca	tatgcctatt	ttgtctggtg	gtacagagtc	aaagaaatct	1500
caggatggga	gcasygttt	acgagcccat	atttggattg	gactatcgaa	caggtagctt	1560
taaatgcaaa	ggtggttgg	ggcccccctg	gggacaaaga	caaatggtt	gctgttgccl	1620
cagagagtag	cctcatcttg	l.ggagtgct	aggatggggg	aaglggaagt	gaaattggag	1680
tgttcagcct	gggtgttctt	gtagatgctc	tcttctttat	tggtaaccag	ttggtggcca	1740
cgagtcatac	agggaaaagt	ggagtgtgga	atgctgtcac	tcagcactcg	caggttcaay	1800
ahgtgtttcc	tatpantayl	katgacactg	ctggatcalt	ccttctgctt	ggatgtaaac	1860
atggatcaat	atattacata	gatatgcaga	agttcccttt	gogaatgaan	gatanctgac	1920
ttcttgtaac	tgaactgtat	cctgtgtctt	caaatgtctg	l.l.cctctgct	ctgagttggt	1980
actcagagag	caaaacaaal	gtcagtggtc	actggatcga	gataccttat	ggtaacagct	2040
ctggagcagt	acaggtgatt	gtacaacacc	cagagacagt	tgggtcaggt	cctcagcttt	2100
ttcagacttt	cacagttcac	cgaagtcccg	taaaaaaaat	catactatca	gaggaagcct	2160
ttgtatcagt	ctgtgcagat	ahaaalcal	l.cggagcgl	gacagtaaca	cgaattcngag	2220
gaattgatctc	l.l.cagcga	ggttctactc	ctttagcgtc	attcaagata	ctatcctctg	2280
aggagacaga	aagtcattggt	agctattctt	ctgggaatga	cataaggaat	tttggagagc	2340
gagacagatca	acaggtgcttt	alcccagaag	ttgttcccat	caccaacaaa	ctatttgtaa	2400
gactcctcctc	gactggaaaa	agaatatgtg	agatccaggg	tgttgaactgt	actacaatat	2460
cctcatttac	agtgaagga	tgtgaagga	caagtgaagt	gggclcaagg	ccaaagcgcl	2520

	acttgttccac	agggccataca	aalgggcaata	ttcaaatgtg	ggatctgacc	actgctatgg	2580
	atattgttta	caaaaagtga	gataaggatg	taggtgtgtc	aaccgaagaa	gagctactca	2640
	aattatctga	tcaatgtgat	ttgagcacat	ctogctglyc	taactccta	atcagkccay	2700
5	caacttccgt	agttcagcat	agccacttac	gagaatcaaa	tlclagcett	cagcttcagc	2760
	accatgatac	caccocatgaa	gcagctactt	acgggtccat	gaggccctac	agagaaggtc	2820
	ctttatttgc	aaggggcann	nggactgaga	gctttccan	ttatagggac	ttccagacta	2880
	ttattttgaa	cagaaatgfa	gnaaagactg	tcactgaaaa	tggttaactb	ggtccaatac	2940
	aagctgaagt	gaaaggggca	acaggggaat	glactatata	tgagagaaa	tcctcttggg	3000
10	taggaakaaa	aaqtttqgg	qanttgata	gtggattgga	agtgnatcaa	atagctgaag	3060
	gtttttcaga	atccaaagaaa	agglcaakcag	angatgaaaa	tgaaaaataa	atagagctta	3120
	ggaagaaagq	aggatttgaa	gggggaggat	tccttggaag	nnngannagt	ccctatctgg	3180
	catcatccac	aaglacctcc	gahgnggaa	ctgnctcacc	tggtactgag	ccccatctc	3240
	ctacaaagac	tactccatct	cctgggcata	aannangta	ttcttcaggt	caggagtaca	3300
15	gcttgtgaaa	actcaccaaa	atgaatagtt	gtttcgggta	cahtthgntg	aaagtttaac	3360
	ttlacnlgaa	ttcaglacat	laqctttttc	octannactt	tacaagataa	aal.tggactt	3420
	catttagtat	ctttttaaca	gaattacttg	gaataalyay	atcaatnat	catatctctt	3480
	ttgaactttt	qnaatttttt	ttantttttc	agttacattt	aacagatcat	tlhlaaagca	3540
	ggagtccatt	ctaanactta	ccgntttttt	tlgggtttgna	aacatattac	cagctcttaa	3600
20	taggatgggt	cccatatagg	tgagcatccc	tttagatcat	gggaaccag	agantgactt	3660
	actaatcttc	attatgccc	agactttgtc	tacaatgita	cctttaagtg	aatcacataa	3720
	ttgtcttttg	aacttgggtc	cccaacactt	atttgally	caahgthgtt	ccccgatatt	3780
	tgatgagttg	ctatgtttgt	qaaaaacata	tcagttaatt	caaaaaactt	attgatattg	3840
	aataccagat	accactatgt	agtaagtctt	ttaggaatgt	tttaatttag	tcgtgactca	3900
25	ttttctgatt	ctcatcattg	ggagatctta	natcttagca	agcattagca	alattaaatg	3960
	ccaaentlcc	altgnaactll	tcaggllgga	gnaahgtct	gtgtttgaaa	agatgaaata	4020
	aaaataataa	tcaggggcaa	agctttgagt	gcccagaagg	gaahgthgh	ccccctgrrla	4080
	acctgtcttg	tttcaggaga	caacatgttt	tttttccagt	gttancaaca	atcatgataa	4140
	ttaaaktaaa	acnccagttt	gttcaacttg	aggaclggag	ttctgaattt	tggttcaann	4200
30	gtttttggctg	ctgtaagaat	gtgaatttga	atgtattttg	aallglaaga	gcnaaaggaac	4260
	gttttttgtac	aatttttttt	cahttaacth	gactgatctt	caggtttcta	caaatagggt	4320
	aattgtaaat	ttaaagcatt	agcattttatt	ggtgaataal	glahkhaton	ccattctaa	4380
	aaatataagt	gagtgaagtt	gnaataaaat	cttlaaaatt	ta		4422
	<210> 2						
35	<211> 502						
	<212> DNA						
	<213> Homo sapiens						
	<400> 2						
40	getagcttgc	ggcgggatar	ntgggggctcc	ghanghcnqa	ntccttctgtc	ctccaggglr	60
	cctgtttctt	ggccagcggg	gaacacatat	ctctgcactc	ctgggggtttt	gllacatggc	120
	tactttcttc	aaaatgagtg	tttgtgtcaa	ttcttcaga	cctttcaacca	ggttttttgt	180
	gccattttacc	cttcctagga	agagaaataa	ctlaacaacl	ttgnaagagcl	acclgtcttc	240
45	caaaataacca	gctgtttact	atcctaaaaa	tgagagtaca	cggcctttctg	aagagctaga	300
	gttggtatay	tngnaactc	ccatgnaatc	lahgtgtcaa	gaaqnnatgt	tttcaacaacl	360
	ctcaagcag	aaggatgaag	atcctctagc	tgccaccaga	gagttcattg	agatgtggag	420
	attccttgcc	agagaagta	caqaaacacat	cactgaagaa	gagctcaaaa	cccttatggc	480
	atgtgtttct	aacacagcaa	aa				502
50	<210> 3						
	<211> 1948						
	<212> DNA						
	<213> Homo sapiens						
	<400> 3						
55	ccatgkyagg	gagggggccc	ctcclgccll	glgahngant	caqcaagggg	tqgctgag	60
	ttcctccagc	agtggtgacc	ggaggtatct	gtggaattgg	ctctgectca	gctggctcag	120
	gttgtgnccg	tgtatgagtt	tcttctgctg	aaqgttgnaa	aagatcatct	agcaagacrt	180
	ttttttccag	clataclak	ggaaatttgaa	gagtrgcalf	aaahggkkan	gnaaatgtgc	240
60	caagattacc	ttagtagttc	tggtctgtgt	tcacaggaga	ccctggaaat	aaacaatgat	300
	aaggttgcgt	agtcattagg	aatcacagaa	ttcctaagg	agaaagaaat	acacccagnc	360
	aaactttgnc	ccaaagccct	caqccggggc	ahqgtgtgng	agcagctaga	gggagctayc	420
	agcgagagga	gggnaacgha	ggclgcggag	gagggactuy	ctcagctgaa	aaqgcccaga	480
	agagaagccc	tgtccaacga	taccactgaa	tctcttgctg	ccaaacagcag	aggccggggag	540
65	aaqcccaagg	ccttgcatgc	tttgcccctc	ggtttttccc	ctccagtaaa	tgtgactgto	600
	tctcccnghl	clghagaaag	ccalacaaac	acggtttcl	gtngcaatg	gaagghgltc	660
	caggccgggccc	cgcagcttca	ggcactggct	aacttagaag	ccagggagggg	gltctataggt	720

	gctgcclclnt	catcccgga	tgtcagtguy	ctgcctgttt	atgctcagtc	aggagagnt	780
	aggagagctga	cccagggca	ggtggcagcg	tttccLggg	ngaagctll	ggacacactct	840
	lccagaccag	acacctggga	cagcctggcg	agcccggtt	tttgcagcc	ttlghcctct	900
5	ggtygtggag	cagcgtccct	gocgocctgg	ggynctnqac	atgcagaggn	aggacacclc	960
	ggcaagggttt	gtgacttccc	cttgaaccac	cagcagccc	gccccaccag	gttcttgcct	1020
	acagaggttg	cagccctccc	gcttgagaaa	atcttgtctg	tggatagcgt	ggcagtgga	1080
	tgtgcctaca	ggaactgtgc	caagccaggg	cllccagcctg	gcccacalgg	atcactattg	1140
	actgaayygl	glctnagaa	cctttcgggg	gacttgamin	gttccctcg	tggaatggag	1200
	gtgcactctg	gccagagaga	achygnqng	gtggttgctg	tgggnguan	catggctttg	1260
10	aaatttccan	tggagagccat	gagttactgt	ctcagggaca	gaagcagatt	ttttctcaga	1320
	cttcagatgg	gcllclclh	tccctccng	gtacaatagt	glctcagng	gaggacattg	1380
	tcacagtgac	tgatgcagag	ggcgclgcl	ngnratggc	ccgctagang	nggttccct	1440
	agaaactgtg	gagtcggtcg	tcaccggcag	agccclccc	gtgaagtgg	glcagatct	1500
	agattcgclcl	galclcltct	agaggaaggt	tatggcaagc	ahqctatatt	tttctaattg	1560
15	gaattttgca	cagatgaacc	ttttatttcl	aaagataat	gtttttctgc	ctcagatct	1620
	acattttclcl	atggagctt	tataataat	agcagatatt	acttctcag	gaatccctgt	1680
	ggcgcgctcg	acgctcatga	gttttclcl	ahqctatga	gtagcactgc	actgtcact	1740
	galgattggc	cctgctccgt	ttcccttct	tcctgggata	lclqctnct	ttccaccaga	1800
	cttgcctcat	actagaagct	clcltttgg	tcaattaaaa	agaaataag	ctagtcatto	1860
20	tgggcagcat	tttattgata	gaagggggaa	aaagcllclt	ctacttgcct	galclclcll	1920
	ahlaaattcc	actaaattaa	tttaaaaa				1980

&lt;210&gt; 4

&lt;211&gt; 1486

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

	ccgcggguy	gtccnngglt	tcacgtaggg	ctgaagctcc	gggtgctgca	aaahhcccc	60
30	cctcggtctg	caacggggct	cctccactc	cccgaylccc	gggnagccgc	ggccacccca	120
	gggagccccc	atctngccc	ctgcccgcg	aagatggctg	ccgtargccg	ggccuytagl	180
	tattgcgcct	gctcgttgcg	cttclccgac	cgagaaatct	gctangctcc	gctgcagaga	240
	caggcaggag	tagacacccg	gacacccagc	acccctcttc	ccggguyng	tccagngng	300
	gcaagggag	ccctcngng	gcagcagggc	gcccngccag	catggcagaa	gclgagggag	360
35	attgtcatlc	lgatcttyle	agagcagalg	ahgahyng	aatggaagt	cctgctgaaa	420
	cagatctgca	ggcacaactc	cagatgttcc	gagctcagtg	gatgtllgaa	attgclccag	480
	glgtaaagcl	tagcaattta	gaaactcgac	cttgcagang	agcaagaggo	tctctccaga	540
	aaacatcggc	agataccaaa	ggaaaacazg	aacagycasa	agaaaguan	gtccaguan	600
	tcttctctaan	agcagtagaa	gaagaaacaa	atggagctct	ctatgaagcc	atcaagtitt	660
40	atcgtagggc	talgcacatt	glacctgata	tagagllclaa	gattacttat	acccggtoto	720
	cagatggtga	tggcgttggg	aacagctaca	ttgaagataa	tgatgatgac	agaaahlyg	780
	cagatclclh	gtcctacttc	agcagcagac	hacatttcc	ngagtctgtg	cttaactgt	840
	gtcagcctga	gotttgagagc	agtcagatto	acatatcagt	gctgccaal	gnglccctga	900
	tgtacatclt	ccgatggng	gtgtctang	acttngacct	cagatcattg	gagcagttgt	960
45	cgttgggtg	cagaggtatc	tacatctgtg	ccagagaccc	tgaallalg	cgtctngcct	1020
	gcttgaaggt	ttggggcaga	agctgtatta	aaottgttcc	gtacacgtcc	tggagagaga	1080
	gttttttaga	agcccttugl	glcayttily	ahygclygh	tctcngtana	accacatata	1140
	ttcgtcaagg	ggaacagctc	cttgatgggt	tctatagagc	ctggcactaa	ghggaaahh	1200
	acaggtatct	aagattcttt	cctgntggcc	atgtgatgat	gttgacaacc	cctgaagagc	1260
50	ctcagtcctat	lgllccacgc	ltaagacta	gggaclacaa	ggactngatn	caattctact	1320
	nggtcaactat	cgttggcac	aagacacaga	ccatcagacc	caagatattt	lgclgtaata	1380
	actaagaaaa	aaaggaagaa	aaacacttly	gaetacant	acccatatt	ttcgtcgggg	1440
	tcctgtacc	aaagaagccg	aatcagaagt	tttcatynny	gggcll		1486

&lt;210&gt; 5

&lt;211&gt; 774

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

	tggcgggccc	cagcccccgc	atgaaagggg	attgaagggt	cctgcgggtg		60
	ggacccctgcl	cgagccagtg	cccllccccc	ccgagggclg	tagacgttag	tgttcgggnt	120
	gtccacccca	ccgcgcgcct	ccacggccac	ctcggggaca	ccagagctgc	ngacttggag	180
	actcctngtc	tgtgaagagc	cgttgggtcc	cgtgcgcgca	ggaaactggg	tgggcctcgt	240
65	ggcgcggtgg	ggtctcggcl	hgttcltclt	gtgcllggat	lhcactclh	attgcattgc	300
	tggtagagac	ccccagggct	gtccacccct	ccagactcc	tcaggcagcg	tgtgggtccc	360
	gcaactctgoc	cccatttccc	cgtatgtccc	tggggggcng	ggcagccacc	caagcctnct	420

	yggtgggggc	ccctotoggc	caggcattgg	ctcagccccg	tgaagtgggg	glcggggggc	480
	agtccccgag	gggtgtgggc	cctgncnagg	cacacagggg	nnngccacac	ccagggggcc	540
	cccgccacagc	cacccgtggg	glgclggggt	tatgcccggc	gcccgggggg	aaatccatgt	600
	ttnggtgtttg	tctgctgttg	tttttcaaga	aatgallccc	attgctgctt	ggattttgaa	660
5	atttactglia	actglicagtg	tccacgtctg	nnccccgttt	cal.ttttaca	ccaatttggg	720
	aaaaatgctg	ctctcagcct	cccacaattta	nnnnnctgtg	gatctccaaa	aaaa	774

&lt;210&gt; 6

&lt;211&gt; 2936

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

	cgtaacccctt	agtcaccaatg	cctcccgtaag	cggagcllgag	ttnggtgcttg	tggttggagc	60
15	tgtggaggtg	tccccgggtg	cgagcgcgggc	cagaactgcg	gttccclhann	ttttccglgl	120
	ncgggtttgc	nnnagcgtgc	gtnggtctnng	tatcgggaggg	acacotctgg	attgaggtatc	180
	ttatgaccta	cttttagagga	aggtataatt	tggcttccclg	gntttctgnc	ttagccaggaa	240
	aggagtggga	aatacccttg	gnnaganaanc	taaaacagta	agaaagccaa	aaatttatttt	300
	laccshggttg	lccagcccllk	lccuyalaly	gacaccltttc	ccantatttt	tcctctgtgt	360
20	ggagacagtg	gatttgacagg	ttctcagtcg	gagttccaga	nnatgtlcnkh	tnatgaaagg	420
	ttacgatgtg	agcttcctaa	agctanttat	nnagacactga	aggtgaaaca	cacaaggttg	480
	cagactgann	algttaagtl	acaaaatgaa	ctcaagcanc	hgtttaatga	annnnnnccl	540
	cagcaggaaa	aacttcagct	cctgcttgan	gnaactaagag	gagaatttagt	agagaaaaact	600
	nnngnclltag	aaqnaalga	actgcagata	ltaaclnnna	nnatttgnan	ttgctaaagg	660
25	cccassatac	acaagaatla	gaactctcaa	ttagagaaag	tttttaggaal	clagatgaag	720
	agntaganna	gtatatnact	ghatatnkh	ngnttngcta	tgaacttaca	ttctctcaggt	780
	cagaattltga	acacccagaag	gaagagtatg	caggtatttl	agclgnaayn	nnntaaaaat	840
	atgaatcaga	gattgcaaga	ctggaggaag	ataaagaaag	actacgtaac	cagctgotta	900
	atgtttgatct	cacannnanc	agcannnggg	hyyaacacact	tgtctagann	aaagtctattt	960
30	tgtgtccaaa	allaaaaggt	tttagaggtg	aaagtgcyya	allaaaagycl	gaaaaggaga	1020
	attctgaggg	tcaggttgaa	aatgccccaa	qantacaggt	goggcagttg	gctgaatnnc	1080
	agntnccnng	ccggttccclg	ggggctgaaa	acccclccgg	nnclhannng	gncagagctg	1140
	tggaaaazga	gctacaatca	agcagtgaa	taaaactcctt	tttaatttaac	aaattgcta	1200
	aaagtgaacg	agaantnnat	acattgtccc	ghanngtanp	nnacttaan	catttannnc	1260
35	aaatggaaat	aaacagcactc	aaactggaga	cagccagagc	taagagtgag	ctagaaagag	1320
	aaaggaaata	gcttcaaaagt	gaactggatg	gattacagtc	agacaatqaa	attctcannng	1380
	agntgtttga	acattnnnnna	gtgclcttag	tagaaaagga	lcy.lgallu	alacgtaaaag	1440
	tacaagctgc	caaaagaagaa	ggttatccaa	aaattgttgt	atttcaagat	gaaaggttag	1500
	aaatnngqna	caagattngca	galcllgaga	aaatgaaagl	ggaacalgal	gtctggagggc	1560
40	aatctgaaaa	ggatcagtat	gaagagaaat	tgggggttcc	acagatggca	gaagagntcn	1620
	ccaggaaagg	gcttcagagt	gttaggttaa	aaattcagca	annattgtg	actcllyaaa	1680
	atgtagagaa	nnnnnnnncl	gaaacltctg	acclaaaaca	gaaaal.cagl	agtttgaga	1740
	tcaaagtgar	ttcacttgca	cagtcagaga	atgaattgct	gaattcaaac	caaatgttgn	1800
	aggaataggt	ggagagatta	nnccnnngncl	gcccnnnclt	tnngagccnn	gclgaaaaag	1860
45	cgcaactlaga	agctgaaaaag	acatttgaag	agaaacagat	acagtggttg	gaagaannnt	1920
	ataagcttca	tgaacgtatc	acagacagag	nnqaaaagta	cnatcaagct	annngaaac	1980
	lpcggtgggc	tganncttgn	cagaaaaaga	gaaaalclcl	lncatgaaaa	aaattgaaaa	2040
	gaactacaaga	gaaagttagaa	gtotttgagg	caaaagaaaga	agaattggaa	acagannnn	2100
	ggnttttaat	nnacaaagtg	tttclclgaa	gacclatacaa	ggcttannnn	nnagclaaaa	2160
50	gatatacaga	gaagacataa	tgaatttoga	agctataattt	tggttccotaa	catgootccn	2220
	nnqantctca	tcaatccctg	tagcttthng	lncatcagcca	tggttcannng	ctggyaacta	2280
	ccatttccclc	ctcatatgca	ggaggaaacaa	catcaaaagg	aaactctctct	acttgcgaaa	2340
	agactagaag	aaactggaac	aaacannngn	nnacaactag	aggaacttgg	atcttctngn	2400
	naetgntgtt	cttggaqaac	nnngagallca	aaagaggtga	ngltggttgn	tcnqtaaaa	2460
55	ttgacclllll	nnclclgtggc	atttagatac	tttttactgt	ttgccaaaaac	acttgaatgt	2520
	gcttcaagaa	aaagttacct	ctacatgctg	tattgtatga	ctgtcaggat	tttaagctln	2580
	tacaagtga	gcatttaaaag	nnnatttclc	nnngatattt	nnnatttttg	acattgggttt	2640
	gagantgtac	nnccnnnnng	nnctagttag	agtcaagtlf	taaacltttt	actttgttgn	2700
	attttttttt	ttggcatttt	gagtgaaata	taactatcat	taattctctc	ttcatclclly	2760
60	agatgcttgg	ccataacagg	gtccatann	attttctngt	ttactatata	caaaaactgt	2820
	ngtlnaaaaa	ngutqccat	tlaaaaagta	guctaaagaa	ngtaaaagta	tctatatacn	2880
	aaaggtctacn	ttttclaaaa	tctgtgtgca	cataattaaa	gagcttaatt	tttaaa	2936

&lt;210&gt; 7

&lt;211&gt; 1387

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

	naaggtacac	tcatttAAAc	tagaaggagg	acgahtaaaa	cgaaacttacc	agctgattca	60
	Uyyaagggg	tatgaaatgg	tccchggg	tgtgtggaga	gnaottttatc	actggtatng	120
5	agcaaacctg	gnrtatocct	gaccagttat	nnnnnncagc	aaghnngnca	tcccagagct	180
	ggaattattt	ccccgctatc	ttctotttct	gagacagng	cctgccacLn	qnnacacagca	240
	glttaacatc	tgggtgaata	tgggnntngt	acottctctcg	mtgcacott	taaagnggg	300
	attagctat.	acggctqtt	ttagtcgaat	gcagacacatc	aaggaaallc	acnaatatct	360
	atctcaagg	ctgcgcaltt	nnagaggaaga	tatggccclg	tggtatataca	acagtnngna	420
10	clacettact	ottctggatg	atgaggatln	taatttggaa	talLllynnn	tccaggatga	480
	acaacacctg	gtaalLlggg	ttcgcaacaa	agatatgng	tqncctgagg	agatgtcttt	540
	tatacaaat	agtagtaaaa	tagalagann	cnnggttccc	acaynnngnn	gagccacagg	600
	tataagcaal	rtngnnnaaa	catgottcat	gaactLnnng	atccagttyt	Lhghznppn	660
	adagccactg	acacagLall	ttatctcagg	gagacatctt	Lrtganctca	acaggacaaa	720
15	tcccatttgg	atgaaggggc	atatggclnn	atqctatggt	gatlLlghnn	nggaactttg	780
	gagtggaacl	cnngnnnatg	ttgccccatt	aaagcttLnn	tggaccatag	caaaallLlg	840
	tcccagtttt	aatgggtttc	agcnnnggg	ctcccnaagaa	ctLclggclt	ttctcttggg	900
	lggtttctat	gaagatotta	atcgagtcca	tgaannngcc	tatgtggaa	Lgnagngcng	960
	tgatgggcga	ccagnttynn	aatagctgc	agaggcttyg	gnanncatc	taagagaaa	1020
20	tagatcaatt	gttgtggatt	tgttccalyy	gcgctaaaga	tctcaaglan	atgcnngac	1080
	atgtggncat	ataagtgtcc	gatttgaccc	ttLcaalltt	tigtottttgc	cactaccaat	1140
	ggacagttat	algcaclLnn	naataacagt	gattaagtta	galygtacta	ccctgtacg	1200
	gtatggacta	agactgaata	tggatgaann	ghcncaggt	ctaaaaaaac	agclgagtya	1260
	tctctgltgg	cttctctcag	naaaatctct	tctagcagaa	ghnnntngtt	ccacacataa	1320
25	gaactttct	caggacaacc	caaaaaglan	nnactttctc	agtgaagLgg	yatLlLlLlgn	1380
	lgttcca						1387

&lt;210&gt; 8

&lt;211&gt; 749

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

	gicccacatn	actggagcgc	ggcggaggtg	agccggccgc	ngnnngcnn	acgcccacgc	60
	ctactgcgcc	cgactcnnng	ggcccaangn	ngccctcagc	tctggcgtgc	cyagggccaa	120
35	cggtctgato	gctgcrcgcc	gccagcatgt	tyggcgcccc	ggacnngnng	tccgtggcgg	180
	lgyctgtcng	nataagacca	cagcttgcca	aagagaagat	tgaaggclgc	catatLltgt	240
	catctgtcac	accaggagag	ctLcagglct	LctLagggga	agatnaggt	tttacttttg	300
	actatgtatt	tnacattgac	tcccagcaag	agcagatcta	cattcaallgt	ntngnnnnnc	360
40	taattgaag	tlyclLlLgn	qyatccaalgy	ntnagtttt	tgttatgga	caaaactggag	420
	ctqgtaaaa	atacacaatg	ggaacaggat	ttgatgttaa	calLghthgg	qanngactng	480
	gtattalLl	tngagctqtt	naaaccttt	tttagagtat	tgaagaaaa	aaacacatag	540
	caattaaaa	tgggcttct	gtccagatt	ctaaalyaaa	hgcccatttc	tttagactct	600
	ataalyaag	ggtccttgac	ctntttgata	ccactcgiga	tattgatgca	aaaagLaaaa	660
45	aatcaaatat	aagaattcat	gaagattcaa	clgggggggn	tttatactgt	gggcgtttcc	720
	aaacngtact	gtgaatacag	aaconagag				749

&lt;210&gt; 9

&lt;211&gt; 686

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

	tggaaattat	agacctagca	aaaaaagatt	tagagaaggl	Lgnnnnggg	agnnnnngng	60
	aaglnnnnn	ntgtggctng	taaagaggat	aatacagaca	ctgaccaaga	gaagaaagaa	120
55	gaaaagggtg	tttcggann	nyaaaaccca	Lgnnttnnna	gtggaagaaa	gtcaagaggt	180
	ngtgtatcat	aaggatgaag	aaggaggaga	ggaggaggag	gaagclgccc	LhgnLggyny	240
	tgaagytct	natgaaatca	nttctgaatc	agntgaaaaa	gcnattatc	aagcagactt	300
	ggcaaacatt	acttglyga	Ltgcalttaa	gcnnnygttg	attgctgaac	taaaaaaacn	360
60	ccagpaaaga	ctgcagactc	tgaaaaagca	gtatgaagag	aagulaallg	Lgttgcannca	420
	txaaattcgg	gatactcagc	ttgaagagga	ccaggttgct	caaaacttag	gctcgytaga	480
	atcttactca	qaaatzaang	caaaaaaagt	taggtctgna	tatgaagaga	aaactcaagc	540
	catgaacaaa	gaactLgcag	gacttcaagc	agctLcaaaa	gaacatgcaa	gatttgcctta	600
	aaatcagttc	cagtatgaaa	agcnattgaa	gaatttgcag	caagclgLyg	Lggaaatgaa	660
65	aaaaacggng	gttcgcctan	tgaana				686

&lt;210&gt; 10

<211> 833  
 <212> DNA  
 <213> Homo sapiens

5 <400> 10  
 gttctttctgt cgcacggttc agcagccccc gcccgggcag caatagaaga lgaacnaacc 60  
 cctaacacca tcaacatctg hggcgtgcct caatgttggg ctacttagga agctgkcarq 120  
 ttttattggt cctcaagaag gatgggagaa gtttagctgn gctattaaa acccatctgy 180  
 tgatgataga kactatcagt ttacacatag nagatttgaq gctattactt aacttggaag 240  
 10 aagtcaccact tctgaalac tgtttgactg gggacccaca aatlyacacg ttggtgaleh 300  
 tgtggatctt ttgatccaaa atgaakttt tgcctcctgc aqtcttttgc lccragatgc 360  
 tgttcccaaa actgataata cactaccttc kaaaagagct atactagttc agcaaaaaaa 420  
 gahgcttttc tgtgacaaag acaggaactt gatgacact ctgcagaate kggacnaag 480  
 ctatatgcca cctgactcct caagtcacag aataaaaagt ctgcagaate kggacnaag 540  
 15 ttttcacagt ttttcattll atganttga gaalglacn aataactllg atgaacgacc 600  
 caltctcttt ggtggtata aaklygynq gggaggattc gnaattgtat ataaagggct 660  
 aagtaataaa caactctgtg gcaqtgaaag aagcttgcaq caatgghkq cattaactact 720  
 aaggaactg aacaccagag lthgactcaa gaaaataaaa gtaatgggca aaagtgtctc 780  
 accatggaaa aactttagta ggaacctact lgggtttttt caagtggatg qga 833

<210> 11  
 <211> 799  
 <212> DNA  
 <213> Homo sapiens

25 <400> 11  
 taaaaaleh ccttingatg atactgcca ctatgatat gtccallal tggattatgt 60  
 tacatgccaa agcttaaaag aatttgggca gatccagllk aggttcccta aacaaactca 120  
 30 ctttgagact gttgaaaggg cctgacckaa tccagtgaa cccclhgnn gaagaattct 180  
 ccttgtaagc cttgaanag tatgtgagag ggcchattq gctaaaaacc aaagghgnc 240  
 totaggagat gagacclac tthcatttgt cagcaagcag yaaaaaana ttgggacctc 300  
 agtgcanaa acaggaact gaattctgc aaaaatntga gtcagcllag aaagtactc 360  
 caagcttcag agtatccca cagcctggg tgacacclg atttagcttt gcatgaccl 420  
 35 cagtatgaga atctatctgt tctglyctgg aatttataa tatayactg tgagataatg 480  
 ggtaaccltq qctggatgtg gtggctcata cclghaate ccagcacttt ggggagccga 540  
 ggcaggcaga tcaactggg tcaagagttc aagaccggc hggccanct ggtgaaaccc 600  
 cgtctntact aaaaatacaa aaattlagag nycgttgttg tggacacclg hgtccacag 660  
 cgtttgggag gctgagcag ggaactagct ggaaccagg aggtagaggt tgcagtgcg 720  
 kggatctgt cactgcact ccagccclgg hgcagagtg agactccalc ataatant 780  
 40 aataaalaa atgggtcnc

<210> 12  
 <211> 812  
 <212> PRT  
 <213> Homo sapiens

45 <400> 12  
 Met Ala Gly Gly His Cys Gly Ser Phe Pro Ala Ala Ala Ala Gly Ser  
 1 5 10 15  
 50 Gly Glu Ile Val Cln Leu Asn Val Gly Gly Thr Arg Phe Ser Thr Ser  
 20 25 30  
 Arg Glu Thr Leu Met Trp Ile Pro Asp Ser Phe Phe Ser Ser Leu Leu  
 35 40 45  
 55 Ser Gly Arg Ile Ser Thr Leu Arg Asp Glu Thr Gly Ala Ile Phe Ile  
 50 55 60  
 Asp Arg Asp Pro Ala Ala Phe Ala Pro Ile Leu Asn Phe Leu Arg Thr  
 65 70 75 80  
 Lys Glu Leu Asp Leu Arg Gly Val Ser Ile Asn Val Leu Arg His Glu  
 85 90 95  
 60 Ala Glu Phe Tyr Gly Ile Thr Pro Leu Val Arg Arg Leu Leu Leu Cys  
 100 105 110  
 Glu Glu Leu Glu Arg Ser S r Cys Gly Ser Val Leu Phe His Gly Tyr  
 115 120 125  
 65 Leu Pro Pro Pro Gly Ile Pro Ser Arg Lys Ile Asn Asn Thr Val Arg  
 130 135 140  
 Ser Ala Asp Ser Arg Asn Gly Leu Asn Ser Thr Glu Gly Glu Ala Arg  
 145 150 155 160

	Gly	Asn	Gly	Thr	Gln	Pro	Val	Leu	Ser	Gly	Thr	Gly	Glu	Glu	Thr	Val
					165					170						175
	Arg	Leu	Gly	Phe	Pro	Val	Asp	Pro	Arg	Lys	Val	Leu	Ile	Val	Ala	Gly
			180						185							190
5	Ris	His	Asn	Trp	Ile	Val	Ala	Ala	Tyr	Ala	His	Phe	Ala	Tyr	Arg	Ile
			195					200					205			
	Lys	Glu	Ser	Ser	Gly	Trp	Gln	Gln	Val	Phe	Thr	Ser	Pro	Tyr	Leu	Asp
		210					215					220				
10	Trp	Thr	Ile	Glu	Arg	Val	Ala	Leu	Asn	Ala	Lys	Val	Val	Gly	Gly	Pro
	225					230					235					240
	His	Gly	Asp	Lys	Asp	Lys	Met	Val	Ala	Val	Ala	Ser	Glu	Ser	Ser	Ile
					245					250					255	
	Ile	Leu	Trp	Ser	Val	Gln	Asp	Gly	Gly	Ser	Gly	Ser	Glu	Ile	Gly	Val
			260					265						270		
15	Phe	Ser	Leu	Gly	Val	Pro	Val	Asp	Ala	Leu	Phe	Phe	Ile	Gly	Asn	Gln
			275					280					285			
	Leu	Val	Ala	Thr	Ser	His	Thr	Gly	Lys	Val	Gly	Val	Trp	Asn	Ala	Val
		290					295					300				
20	Thr	Gln	His	Trp	Gln	Val	Gln	Asp	Val	Val	Pro	Ile	Thr	Ser	Tyr	Asp
	305					310					315					320
	Thr	Ala	Gly	Ser	Phe	Leu	Leu	Leu	Gly	Cys	Asn	Asn	Gly	Ser	Ile	Tyr
					325					330					335	
	Tyr	Ile	Asp	Met	Gln	Lys	Phe	Pro	Leu	Arg	Met	Lys	Asp	Asn	Asp	Leu
			340						345					350		
25	Leu	Val	Thr	Glu	Leu	Tyr	His	Asp	Pro	Ser	Asn	Asp	Ala	Ile	Thr	Ala
			355					360					365			
	Leu	Ser	Val	Tyr	Leu	Thr	Pro	Lys	Thr	Ser	Val	Ser	Gly	Asn	Trp	Ile
		370					375					380				
30	Glu	Ile	Ala	Tyr	Gly	Thr	Ser	Ser	Gly	Ala	Val	Arg	Val	Ile	Val	Gln
	385					390					395					400
	His	Pro	Glu	Thr	Val	Gly	Ser	Gly	Pro	Gln	Leu	Phe	Gln	Thr	Phe	Thr
					405					410					415	
	Val	His	Arg	Ser	Pro	Val	Thr	Lys	Ile	Met	Leu	Ser	Glu	Lys	His	Leu
			420						425					430		
35	Val	Ser	Val	Cys	Ala	Asp	Asn	Asn	His	Val	Arg	Thr	Trp	Thr	Val	Thr
			435					440					445			
	Arg	Phe	Gly	Met	Ile	Ser	Thr	Gln	Pro	Gly	Ser	Thr	Pro	Leu	Ala	Ser
		450					455					460				
40	Phe	Lys	Ile	Leu	Ser	Leu	Glu	Glu	Thr	Glu	Ser	His	Gly	Ser	Tyr	Ser
	465					470					475					480
	Ser	Gly	Asn	Asp	Ile	Gly	Pro	Phe	Gly	Glu	Arg	Asp	Asp	Gln	Gln	Val
					485					490					495	
	Phe	Ile	Gln	Lys	Val	Val	Pro	Ile	Thr	Asn	Lys	Leu	Phe	Val	Arg	Leu
			500						505					510		
45	Ser	Ser	Thr	Gly	Lys	Arg	Ile	Cys	Glu	Ile	Gln	Ala	Val	Asp	Cys	Thr
			515					520					525			
	Thr	Ile	Ser	Ser	Phe	Thr	Val	Arg	Glu	Cys	Glu	Gly	Ser	Ser	Arg	Met
		530					535					540				
50	Gly	Ser	Arg	Pro	Arg	Arg	Tyr	Leu	Phe	Thr	Gly	His	Thr	Asn	Gly	Ser
	545					550					555					560
	Ile	Gln	Met	Trp	Asp	Leu	Thr	Thr	Ala	Met	Asp	Met	Val	Asn	Lys	Ser
					565					570					575	
	Glu	Asp	Lys	Asp	Val	Gly	Gly	Pro	Thr	Glu	Glu	Glu	Leu	Leu	Lys	Leu
			580						585					590		
55	Leu	Asp	Gln	Cys	Asp	Leu	Ser	Thr	Ser	Arg	Cys	Ala	Thr	Pro	Asn	Ile
			595					600					605			
	Ser	Pro	Ala	Thr	Ser	Val	Val	Gln	His	Ser	His	Leu	Arg	Glu	Ser	Asn
		610					615					620				
60	Ser	Ser	Leu	Gln	Leu	Gln	His	His	Asp	Thr	Thr	His	Glu	Ala	Ala	Thr
	625					630					635					640
	Tyr	Gly	Ser	Met	Arg	Pro	Tyr	Arg	Glu	Ser	Pro	Leu	Leu	Ala	Arg	Ala
					645					650					655	
	Arg	Arg	Thr	Glu	Ser	Phe	His	Ser	Tyr	Arg	Asp	Phe	Gln	Thr	Tle	Asn
			660						665					670		
65	Leu	Asn	Arg	Asn	Val	Glu	Arg	Ala	Val	Pro	Glu	Asn	Gly	Asn	Leu	Gly
		675						680					685			
	Pro	Ile	Gln	Ala	Glu	Val	Lys	Gly	Ala	Thr	Gly	Glu	Cys	Asn	Ile	Ser

590 695 700  
 Glu Arg Lys Ser Pro Gly Val Glu Ile Lys Ser Leu Arg Glu Leu Asp  
 705 720 715 720  
 Ser Gly Leu Glu Val His Lys Il Ala Glu Gly Phe Ser Glu Ser Lys  
 725 730 735  
 Lys Arg Ser Ser Glu Asp Glu Asn Glu Asn Lys Ile Glu Phe Arg Lys  
 740 745 750  
 Lys Gly Gly Phe Glu Gly Gly Gly Phe Leu Gly Arg Lys Lys Val Pro  
 755 760 765  
 Tyr Leu Ala Ser Ser Pro Ser Thr Ser Asp Gly Gly Thr Asp Ser Pro  
 770 775 780  
 Gly Thr Ala Ser Pro Ser Phe Thr Lys Thr Thr Pro Ser Pro Arg His  
 785 790 795 800  
 Lys Lys Ser Asp Ser Ser Gly Gln Glu Tyr Ser Leu  
 805 810

<210> 13  
 <211> 167  
 <212> PRT  
 <213> Homo sapiens

<400> 13  
 Leu Ala Ser Ala Arg Ile Pro Gly Arg Pro Tyr Val Gly Val Leu Arg  
 1 5 10 15  
 Pro Pro Gly Ser Leu Phe Phe Ala Pro Ala Gly Thr Thr Ile Ser Ala  
 20 25 30  
 Leu Leu Gly Phe Cys Tyr Met Ala Ala Phe Leu Lys Met Ser Val Ser  
 35 40 45  
 Val Asn Phe Phe Arg Pro Phe Thr Arg Phe Leu Val Pro Phe Thr Leu  
 50 55 60  
 His Arg Lys Arg Asn Asn Leu Thr Ile Leu Glu Arg Tyr Met Ser Ser  
 65 70 75 80  
 Lys Ile Pro Ala Val Thr Tyr Pro Lys Asn Glu Ser Thr Arg Pro Ser  
 85 90 95  
 Glu Glu Leu Glu Leu Asp Lys Trp Lys Thr Thr Met Lys Ser Ser Val  
 100 105 110  
 Gln Glu Glu Cys Val Ser Thr Ile Ser Ser Ser Lys Asp Glu Asp Pro  
 115 120 125  
 Leu Ala Ala Thr Arg Glu Phe Ile Glu Met Trp Arg Leu Leu Gly Arg  
 130 135 140  
 Glu Val Pro Glu His Ile Thr Glu Glu Glu Leu Lys Thr Leu Met Glu  
 145 150 155 160  
 Cys Val Ser Asn Thr Ala Lys  
 165

<210> 14  
 <211> 452  
 <212> PRT  
 <213> Homo sapiens

<400> 14  
 Pro Cys Glu Gly Gly Ala Arg Ser Cys Leu Val Thr Glu Ser Ala Arg  
 1 5 10 15  
 Gly Gly Leu Gln Phe Leu Gln Gln Cys Asp Arg Glu Asp Leu Val Glu  
 20 25 30  
 Leu Ala Leu Pro Gln Leu Ala Gln Val Val Thr Val Tyr Glu Phe Leu  
 35 40 45  
 Leu Met Lys Val Glu Lys Asp His Leu Ala Lys Pro Phe Phe Pro Ala  
 50 55 60  
 Ile Tyr Lys Glu Phe Glu Glu Leu His Lys Met Val Lys Lys Met Cys  
 65 70 75 80  
 Gln Asp Tyr Leu Ser Ser Ser Gly Leu Cys Ser Gln Glu Thr Leu Glu  
 85 90 95  
 Ile Asn Asn Asp Lys Val Ala Glu Ser Leu Gly Ile Thr Glu Phe Leu  
 100 105 110  
 Arg Lys Lys Glu Ile His Pro Asp Asn Leu Gly Pro Lys His Leu Ser  
 115 120 125



Arg Asp Met Asp Gly Glu Gln Leu Glu Gly Ala Ser Ser Glu Lys Arg  
 130 135 140  
 Glu Arg Glu Ala Ala Gln Glu Gly Leu Ala Ser Val Lys Arg Pro Arg  
 145 150 155 160  
 5 Arg Glu Ala Leu Ser Asn Asp Thr Thr Glu Ser Leu Ala Ala Asn Ser  
 165 170 175  
 Arg Gly Arg Glu Lys Pro Arg Pro Leu His Ala Leu Pro Ala Gly Phe  
 180 185 190  
 10 Ser Pro Pro Val Asn Val Thr Val Ser Pro Arg Ser Glu Glu Ser His  
 195 200 205  
 Thr Thr Thr Val Ser Gly Gly Asn Gly Ser Val Phe Glu Ala Gly Pro  
 210 215 220  
 Gln Leu Gln Ala Leu Ala Asn Leu Glu Ala Arg Arg Gly Ser Ile Gly  
 225 230 235 240  
 15 Ala Ala Leu Ser Ser Arg Asp Val Ser Gly Leu Pro Val Tyr Ala Gln  
 245 250 255  
 Ser Gly Glu Pro Arg Arg Leu Thr Gln Ala Gln Val Ala Ala Phe Pro  
 260 265 270  
 20 Gly Glu Asn Ala Leu Glu His Ser Ser Asp Gln Asp Thr Trp Asp Ser  
 275 280 285  
 Leu Arg Ser Pro Gly Phe Cys Ser Pro Leu Ser Ser Gly Gly Gly Ala  
 290 295 300  
 Glu Ser Leu Pro Pro Gly Gly Pro Gly His Ala Glu Ala Gly His Leu  
 305 310 315 320  
 25 Gly Lys Val Cys Asp Phe His Leu Asn His Gln Gln Pro Ser Pro Thr  
 325 330 335  
 Ser Val Leu Pro Thr Glu Val Ala Ala Pro Pro Leu Glu Lys Ile Leu  
 340 345 350  
 30 Ser Val Asp Ser Val Ala Val Asp Cys Ala Tyr Arg Thr Val Pro Lys  
 355 360 365  
 Pro Gly Pro Gln Pro Gly Pro His Gly Ser Leu Leu Thr Glu Gly Cys  
 370 375 380  
 Leu Arg Ser Leu Ser Gly Asp Leu Asn Arg Phe Pro Cys Gly Met Glu  
 385 390 395 400  
 35 Val His Ser Gly Gln Arg Glu Leu Glu Ser Val Val Ala Val Gly Glu  
 405 410 415  
 Ala Met Ala Leu Lys Phe Pro Met Gly Ala Met Ser Tyr Cys Leu Arg  
 420 425 430  
 40 Asp Arg Ser Arg Phe Leu Phe Arg Leu Pro Met Gly Leu Ser Cys Pro  
 435 440 445  
 Leu Gln Val Gln  
 450  
 <210> 15  
 <211> 321  
 <212> PRT  
 <213> Homo sapiens  
 <400> 15  
 50 Met Ala Glu Ala Glu Glu Asp Cys His Ser Asp Thr Val Arg Ala Asp  
 1 5 10 15  
 Asp Asp Glu Glu Asn Glu Ser Pro Ala Glu Thr Asp Leu Gln Ala Gln  
 20 25 30  
 55 Leu Gln Met Phe Arg Ala Gln Trp Met Phe Glu Leu Ala Pro Gly Val  
 35 40 45  
 Ser Ser Ser Asn Leu Glu Asn Arg Pro Cys Arg Ala Ala Arg Gly Ser  
 50 55 60  
 Leu Gln Lys Thr Ser Ala Asp Thr Lys Gly Lys Glu Glu Gln Ala Lys  
 65 70 75 80  
 60 Glu Glu Lys Ala Arg Glu Leu Phe Leu Lys Ala Val Glu Glu Glu Gln  
 85 90 95  
 Asn Gly Ala Leu Tyr Glu Ala Ile Lys Phe Tyr Arg Arg Ala Met Gln  
 100 105 110  
 65 Leu Val Pro Asp Ile Glu Phe Lys Ile Thr Tyr Thr Arg Ser Pro Asp  
 115 120 125  
 Gly Asp Gly Val Gly Asn Ser Tyr Il Glu Asp Asn Asp Asp Asp Ser  
 130 135 140

145  
 150  
 155  
 160  
 165  
 170  
 175  
 180  
 185  
 190  
 195  
 200  
 205  
 210  
 215  
 220  
 225  
 230  
 235  
 240  
 245  
 250  
 255  
 260  
 265  
 270  
 275  
 280  
 285  
 290  
 295  
 300  
 305  
 310  
 315  
 320

Lys Met Ala Asp Leu Leu Ser Tyr Phe Gln Gln Gln Leu Thr Phe Gln  
 Glu Ser Val Leu Lys Leu Cys Gln Pro Gln Leu Glu Ser Ser Gln Ile  
 His Ile Ser Val Leu Pro Met Glu Val Leu Met Tyr Ile Phe Arg Trp  
 Val Val Ser Ser Asp Leu Asp Leu Arg Ser Leu Glu Gln Leu Ser Leu  
 Val Cys Arg Gly Phe Tyr Ile Cys Ala Arg Asp Pro Glu Ile Trp Arg  
 Leu Ala Cys Leu Lys Val Trp Gly Arg Ser Cys Ile Lys Leu Val Pro  
 Tyr Thr Ser Trp Arg Glu Met Phe Leu Gln Arg Pro Arg Val Arg Phe  
 Asp Gly Val Tyr Ile Ser Lys Thr Thr Tyr Ile Arg Gln Gly Glu Gln  
 Ser Leu Asp Gly Phe Tyr Arg Ala Trp His Gln Val Glu Tyr Tyr Arg  
 Tyr Ile Arg Phe Phe Pro Asp Gly His Val Met Met Leu Thr Thr Pro  
 Glu Glu Pro Gln Ser Ile Val Pro Arg Leu Arg Thr Arg Glu Tyr Gln  
 Asp

25  
 30  
 <210> 16  
 <211> 172  
 <212> PRT  
 <213> Homo sapiens

35  
 40  
 45  
 50  
 55  
 60  
 65

<400> 16  
 Ala Cys Pro Thr His Pro Pro Pro Pro Thr Ala Pro Arg Gly His Gln  
 1 5 10 15  
 Ser Cys Arg Leu Gly Asp Ser Trp Ser Val Lys Ser Arg Trp Cys Pro  
 20 25 30  
 Cys Pro Gln Glu Leu Gly Trp Ala Ser Cys Ala Arg Gly Val Cys Ala  
 35 40 45  
 Trp Ser Phe Cys Ala Trp Ile Cys Ile Phe Ile Ala Leu Leu Val Glu  
 50 55 60  
 Thr Pro Arg Pro Val His Pro Ala Lys Thr Pro Gln Ala Ala Cys Gly  
 65 70 75 80  
 Ser Arg Thr Leu Pro Pro Phe Pro Arg Cys Pro Leu Arg Ala Arg Ala  
 85 90 95  
 Ala Thr Gln Ala Cys Trp Leu Arg Pro Pro Leu Gly Gln Ala Leu Ala  
 100 105 110  
 Gln Pro Ala Glu Trp Gly Val Val Gly Gln Ser Pro Arg Ser Trp Ala  
 115 120 125  
 Pro Ala Gln Ala His Arg Ala Arg Pro His Pro Ala Ala Pro Arg Thr  
 130 135 140  
 Ala Thr Arg Gly Val Leu Pro Leu Cys Pro Ala Pro Gly Thr Asn Ser  
 145 150 155 160  
 Met Phe Gly Val Cys Leu Cys Leu Phe Phe Lys Lys  
 165 170

55  
 60  
 <210> 17  
 <211> 472  
 <212> PRT  
 <213> Homo sapiens

60  
 65

<400> 17  
 Met Arg Glu Arg Phe Arg Asn Leu Asp Glu Glu Val Glu Lys Tyr Arg  
 1 5 10 15  
 Ala Val Tyr Asn Lys Leu Arg Tyr Glu His Thr Phe Leu Lys Ser Glu  
 20 25 30  
 Phe Glu His Gln Lys Glu Glu Tyr Ala Arg Ile Leu Asp Glu Gly Lys  
 35 40 45  
 Ile Lys Tyr Glu Ser Glu Ile Ala Arg Leu Glu Glu Asp Lys Glu Glu

	50		55		60
	Leu Arg Asn Gln Leu	Leu Asn Val Asp Leu Thr	Lys Asp Ser Lys Arg		
	65	70	75	80	
5	Val Glu Gln Leu Ala Arg Glu Lys Val Tyr Leu Cys Gln Lys Leu Lys				
	85	90	95		
	Gly Leu Glu Ala Glu Val Ala Glu Leu Lys Ala Gln Lys Glu Asn Ser				
	100	105	110		
	Glu Ala Gln Val Glu Asn Ala Gln Arg Ile Gln Val Arg Gln Leu Ala				
	115	120	125		
10	Glu Met Glu Ala Thr Val Arg Ser Leu Gly Ala Glu Lys Gln Ser Ala				
	130	135	140		
	Asn Leu Arg Ala Glu Arg Leu Glu Lys Glu Leu Gln Ser Ser Ser Glu				
	145	150	155		160
15	Gln Asn Thr Phe Leu Ile Asn Lys Leu His Lys Ala Glu Arg Glu Ile				
	165	170	175		
	Asn Thr Leu Ser Ser Lys Val Lys Glu Leu Lys His Ser Asn Lys Leu				
	180	185	190		
	Glu Ile Thr Asp Ile Lys Leu Glu Thr Ala Arg Ala Lys Ser Gln Leu				
	195	200	205		
20	Glu Arg Gln Arg Asn Lys Leu Gln Ser Glu Leu Asp Gly Leu Gln Ser				
	210	215	220		
	Asp Asn Glu Ile Leu Lys Ala Ala Val Glu His His Lys Val Leu Leu				
	225	230	235		240
25	Val Glu Lys Asp Arg Glu Leu Ile Arg Lys Val Gln Ala Ala Lys Glu				
	245	250	255		
	Glu Gly Tyr Gln Lys Leu Val Val Leu Gln Asp Glu Lys Leu Gln Leu				
	260	265	270		
	Glu Asn Arg Leu Ala Asp Leu Glu Lys Met Lys Val Glu His Asp Val				
	275	280	285		
30	Trp Arg Gln Ser Glu Lys Asp Gln Tyr Glu Glu Lys Leu Arg Ala Ser				
	290	295	300		
	Gln Met Ala Glu Glu Ile Thr Arg Lys Glu Leu Gln Ser Val Arg Leu				
	305	310	315		320
35	Lys Leu Gln Gln Gln Ile Val Thr Ile Glu Asn Ala Glu Lys Glu Lys				
	325	330	335		
	Asn Glu Asn Ser Asp Leu Lys Gln Gln Ile Ser Ser Leu Gln Ile Gln				
	340	345	350		
	Val Thr Ser Leu Ala Gln Ser Glu Asn Asp Leu Leu Asn Ser Asn Gln				
	355	360	365		
40	Met Leu Lys Glu Met Val Glu Arg Leu Lys Gln Glu Cys Arg Asn Phe				
	370	375	380		
	Arg Ser Gln Ala Glu Lys Ala Glu Leu Glu Ala Glu Lys Thr Leu Glu				
	385	390	395		400
45	Glu Lys Gln Ile Gln Trp Leu Glu Glu Lys His Lys Leu His Asp Arg				
	405	410	415		
	Ile Thr Asp Arg Glu Glu Lys Tyr Asn Gln Ala Lys Glu Lys Leu Gln				
	420	425	430		
	Arg Ala Ala Ile Ala Gln Lys Lys Arg Lys Ser Leu His Glu Asn Lys				
	435	440	445		
50	Leu Lys Arg Leu Gln Glu Lys Val Glu Val Leu Glu Ala Lys Lys Glu				
	450	455	460		
	Glu Leu Gln Thr Glu Ile Arg Ser				
	465	470			
55	<210> 18				
	<211> 462				
	<212> PRT				
	<213> Homo sapiens				
60	<400> 18				
	Lys Ala Thr Ser Leu Thr Leu Glu Gly Gly Arg Leu Lys Arg Thr Pro				
	1	5	10	15	
	Gln Leu Ile His Gly Arg Asp Tyr Glu Met Val Pro Gln Pro Val Trp				
	20	25	30		
65	Arg Ala Leu Tyr His Trp Tyr Gly Ala Asn Leu Ala Leu Pro Arg Pro				
	35	40	45		
	Val Ile Lys Asn Ser Lys Thr Asp Ile Pro Glu Leu Glu Leu Phe Pro				

50  
 Arg Tyr Leu Leu Phe Leu 55 Arg Gln Gln Pro Ala 60 Thr Arg Thr Gln Gln  
 65 Ser Asn Ile Trp Val Asn Met Gly Asn Val Pro Ser Pro Asn Ala Pro  
 80  
 85  
 90  
 95  
 100  
 105  
 110  
 115  
 120  
 125  
 130  
 135  
 140  
 145  
 150  
 155  
 160  
 165  
 170  
 175  
 180  
 185  
 190  
 195  
 200  
 205  
 210  
 215  
 220  
 225  
 230  
 235  
 240  
 245  
 250  
 255  
 260  
 265  
 270  
 275  
 280  
 285  
 290  
 295  
 300  
 305  
 310  
 315  
 320  
 325  
 330  
 335  
 340  
 345  
 350  
 355  
 360  
 365  
 370  
 375  
 380  
 385  
 390  
 395  
 400  
 405  
 410  
 415  
 420  
 425  
 430  
 435  
 440  
 445  
 450  
 455  
 460  
  
 <210> 19  
 <211> 243  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 19  
 Pro Thr Trp Leu Glu Arg Gly Gly Gly Glu Pro Ala Ala Arg Pro Gln  
 1 5 10 15  
 Thr Pro Gln Pro Thr Ala Pro Glu Ser Arg Gly Pro Ser Gly Ala Ser  
 20 25 30  
 Ala Leu Arg Cys Arg Gly Pro Thr Ala Arg Ser Leu Pro Ala Ala Ser  
 35 40 45  
 Met Leu Gly Ala Pro Asp Glu Ser Ser Val Arg Val Ala Val Arg Il  
 50 55 60  
 Arg Pro Gln Leu Ala Lys Glu Lys Ile Glu Gly Cys His Ile Cys Thr

55  
 Ser Val Thr Pro Gly Glu Pro Gln Val Phe Leu Gly Lys Asp Lys Ala  
 85  
 Phe Thr Phe Asp Tyr Val Phe Asp Ile Asp Ser Gln Gln Glu Gln Ile  
 100  
 Tyr Ile Gln Cys Ile Glu Lys Leu Ile Glu Gly Cys Phe Glu Gly Tyr  
 115  
 Asn Ala Thr Val Phe Ala Tyr Gly Gln Thr Gly Ala Gly Lys Thr Tyr  
 130  
 Thr Met Gly Thr Gly Phe Asp Val Asn Ile Val Glu Glu Glu Leu Gly  
 145  
 Ile Ile Ser Arg Ala Val Lys His Leu Phe Lys Ser Ile Gln Glu Lys  
 165  
 Lys His Ile Ala Ile Lys Asn Gly Leu Pro Ala Pro Asp Phe Lys Val  
 180  
 Asn Ala Gln Phe Leu Glu Leu Tyr Asn Glu Glu Val Leu Asp Leu Phe  
 195  
 Asp Thr Thr Arg Asp Ile Asp Ala Lys Ser Lys Lys Ser Asn Ile Arg  
 210  
 Ile His Glu Asp Ser Thr Gly Gly Asn Leu Tyr Cys Gly Arg Phe Gln  
 225  
 His Val Leu  
 230  
 235  
 240

25  
 <210> 20  
 <211> 223  
 <212> PRT  
 <213> Homo sapiens

30  
 Gly Asn Tyr Arg Pro Ser Lys Lys Arg Phe Arg Glu Gly Lys Glu Lys  
 1  
 Lys Arg Gly Lys Lys Val Trp Leu Val Lys Arg Ile Ile Gln Thr Leu  
 20  
 25  
 30  
 35  
 Thr Lys Arg Arg Lys Lys Lys Arg Val Phe Arg Lys Glu Lys Pro Asn  
 35  
 40  
 Glu Leu Glu Val Glu Glu Ser Gln Glu Val Ser Asp His Glu Asp Glu  
 50  
 Glu Glu Glu Glu Glu Glu Glu Asp Asp Ile Asp Gly Gly Glu Ser  
 65  
 Ser Asp Glu Ser Asp Ser Glu Ser Asp Glu Lys Ala Tyr Gln Ala Asp  
 85  
 Leu Ala Asn Ile Thr Cys Glu Ile Ala Ile Lys Gln Lys Leu Ile Asp  
 100  
 105  
 110  
 45  
 Glu Leu Glu Asn Ser Gln Lys Arg Leu Gln Thr Leu Lys Lys Gln Tyr  
 115  
 Glu Glu Lys Met Met Leu Gln His Lys Ile Arg Asp Thr Gln Leu Gln  
 130  
 135  
 140  
 50  
 Arg Asp Gln Val Leu Gln Asn Leu Gly Ser Val Glu Ser Tyr Ser Glu  
 145  
 Glu Lys Ala Lys Lys Val Arg Ser Glu Tyr Glu Lys Lys Leu Gln Ala  
 165  
 Met Asn Lys Glu Leu Gln Arg Leu Gln Ala Ala Gln Lys Glu His Ala  
 180  
 185  
 190  
 55  
 Arg Leu Leu Lys Asn Gln Ser Gln Tyr Glu Lys Leu Lys Lys Leu Gln  
 195  
 Gln Asp Val Met Glu Met Lys Lys Thr Lys Val Arg Leu Met Lys  
 210  
 215  
 220

60  
 <210> 21  
 <211> 206  
 <212> PRT  
 <213> Homo sapiens

65  
 Met Asn Lys Pro Ile Thr Pro Ser Thr Tyr Val Arg Cys Leu Asn Val  
 1  
 5  
 10  
 15

Gly Leu Ile Arg Lys Leu Ser Asp Phe Ile Asp Pro Gln Glu Gly Trp  
 20  
 Lys Lys Leu Ala Val Ala Ile Lys Lys Pro Ser Gly Asp Arg Tyr  
 35  
 5 Asn Gln Phe His Ile Arg Arg Phe Glu Ala Leu Leu Gln Thr Gly Lys  
 50  
 Ser Pro Thr Ser Glu Leu Leu Phe Asp Trp Gly Thr Thr Asn Cys Thr  
 65  
 Val Gly Asp Leu Val Asp Leu Leu Ile Gln Asn Glu Phe Phe Ala Pro  
 80  
 10 Ala Ser Leu Leu Leu Pro Asp Ala Val Pro Lys Thr Ala Asn Thr Leu  
 85  
 Pro Ser Lys Glu Ala Ile Thr Val Gln Gln Lys Gln Met Pro Phe Cys  
 100  
 15 Asp Lys Asp Arg Thr Leu Met Thr Pro Val Gln Asn Leu Glu Gln Ser  
 115  
 Tyr Met Pro Pro Asp Ser Ser Pro Glu Asn Lys Ser Leu Glu Val  
 130  
 20 Ser Asp Thr Arg Phe His Ser Phe Ser Phe Tyr Glu Leu Lys Asn Val  
 145  
 Thr Asn Asn Phe Asp Glu Arg Pro Ile Ser Val Gly Gly Asn Lys Met  
 160  
 Gly Glu Gly Gly Phe Gly Val Val Tyr Lys Gly Leu Arg Lys  
 175  
 25 195 200 205

&lt;210&gt; 22

&lt;211&gt; 1260

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

ottcttcgga cgaactgttac agaggtctct agagccttct ctctctctgtg cnaaatggca 60  
 actcttaagc annaactcat tgcaccagll cggymangag agqcaacagt tcccaaacat 120  
 35 aagatcaact tagtgggtgt tggcaggtt ggtatggcgt gtgtatkaa gtctctggga 180  
 aagtctctgt atgatgaact tgcagcatgg gactcttctt ctccagacac ccaaatctgt ggcagataaa 240  
 gattatctgt tgcacggcaa ttctaagall gctgctgttt ctccagacac ccaaatctgt ggcagataaa 300  
 gaagggggaga gtgggtctaa totggtgcag agaatgtta atgtcttcaa attcattatt 360  
 40 ontongatcg tcaagtacag tcttgatttc atcataattg tggtttccaa cccagtggtac 480  
 attcttaact atgttacct gaaactaagl gyalactaa nccaccggtt gatttgaagl 540  
 ggaatgaatc tggattctgc kagatttgcg taacttatgt ctgaasact tggcattcat 600  
 cccagtggtt qccatggatg gattttgggg gacactggcg actcaactgt ggcctgctgg 660  
 agtgggtgtg aagtggcagg tgtttctctc caggaaatgc atccagact atccagact 720  
 45 aatgatactg aaaaattggaa ggaatgtcat aagatggctg ttgaaaglgc ctatgaagtc 780  
 atccagctaa aaggatatac caactgggcl attgatttaa gtgtggctga tcttallgaa 840  
 tccatgttga annatctatc caggattcat cccgtgltaa ccttggttaa ggggatgtat 900  
 tgcattgaga atgaagtctt cclgagcctt ccatgtatcc tcaatgccc gggattaccc 960  
 50 agcgttctga accagaagct aaaggatgal gaggltgttc agctcaagaa aagtgcagat 1020  
 accctgtggg acclccaggg gacctaataa gacctgtgac taglgaagtc taggctgtag 1080  
 aaatttaaaa actacaatgt gattaactng ancttttagt ttcatccat gtacatggat 1140  
 cacaglttgc ttgatcttc ttcaatatgt gaallctggg tccacgaate aaagcctatg 1200  
 cctgggtttaa tcttgcaat ctgagctctt gaaccaataa aallactat tgtgtgtga 1260

&lt;210&gt; 23

&lt;211&gt; 3151

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

taacacagtt gtgaaaagag atggatgtgg gllmantec tagccctgcc tgtgtgcact 60  
 tatgcagaa cctaatgga ctccactaca ggcactgtgt agclgggtgt gatgtgcat 120  
 ootccatcag ggtgggaga ggtggttggc taagatgaga acatgaacac galccgcag 180  
 tcccaaggtgt gcaacgtgtt tgagtcaagc cagaaactat gactacggac caagtttatc 240  
 65 cggcgccglt ggcggccagg catccacgtg gagatgaagt tttcgggtgt tgaactgcagc 300  
 agcatcccca ggtgtgtctg ctccatgcaag gagaccttca acctctatla clatgaggtc 360  
 gactttgact cggccaccaa gaccllcccc aactggtatn agaatccatg ggtgaaggtg 420  
 galacacttg cagccgagca gagcttctcc caggctggac tgggtgaccc cgtcatgaaa 480

	atcmmenocg	ayytrqogqag	ctkaggacot	glutococga	qgggelirta	celggootto	540
	ngggactatn	goggotgcot	ntocctcabe	gogtyintg	tclktetaccg	caagtgecon	600
	cggatcater	agmacgggc	catnecocag	ganacocetg	ogggogetga	gagmratog	660
5	ctggtygctg	ccggggynag	ctgcalinon	aatgconaaq	ayntggatgl	acccatcaag	720
	ctotactqla	acggggacgy	enagtggclg	qtgoccalag	gglyntroat	ghgcaagca	780
	ggcttcagag	ccgttrqagaa	tggcnocgtc	tqunqaggtt	gtocatefuy	gaetttcwag	840
	qocaaconag	gggatgaggg	ctgtacccac	tgtcccatca	acwgnocqac	enettctqaa	900
	ggynocacca	actgtgtotg	enocantggc	lantacagag	agacactggg	ccccctggac	960
10	atgccttqca	caacombccc	ctccgcqccc	caggclntga	tl.tnaggtgt	aatgagacc	1020
	toectcalnq	tggagtggat	ccctcccccg	naetccggag	gcccagynna	celcgtctac	1080
	ancatcatef	qcnagagctg	tynotogggc	cggagtgecl	gcacccgclg	oggggacant	1140
	gtacagtaag	acncccccac	gclaygcttg	acggagccac	gcnittacat	nantgacctg	1200
	ctggcccccac	cccagtaaac	cttogagala	caggctglga	acggcgl.tac	tgannagagc	1260
15	cccttctcgc	ctcagttcgc	ctctgtgaac	al.nacccaca	cccaggcagc	tcacatggac	1320
	glgtccatca	tgnctcaggt	gagccgcacc	gtggamqoca	ttamctgtc	gl.ggtccacg	1380
	ccagacnagc	ccaatgggnt	gacccctggac	batgagctgc	agtaactcya	gaagcagynq	1440
	ctcagtgagl	acnacgccac	ayccataaaa	agmccaccca	acccggctcac	nttgcagggc	1500
	cl.naaagccg	ggcccatcta	tgtcl.lcnag	gtgcgggcac	gcacccgtgc	agynl.nccgg	1560
20	cgtacacgcn	gcagatgla	cttocagacc	atgcacagag	ccgattaccc	qacaagcala	1620
	caggagaaal	tgcacactcat	calnaggtcc	tggccnctg	gcctnntctt	celccttctgt	1680
	gtggttgtca	tgcacactcat	gtgtacacga	cnggggttllg	agcgtgclyq	ctcggagtae	1740
	acggacaaag	tgcacacclg	cccacagtggc	canatgaccc	cagggatgaa	gatctacatc	1800
	ytccctttca	cttacaggga	cccacagag	ccagtgngnn	agtl.lgcnaa	ggaaahhgac	1860
25	atclctctgtg	tcaaaahhga	gcaggtgala	qngcaggggy	ngttttggcga	ngtctcagcl	1920
	ggccaccllgn	agctgccacg	anagnagag	atcl.lctgtg	cnatccagac	gcttccngtcg	1980
	ggtacacgy	anagacagcg	ccggganttc	ctgagccyag	cttccatnat	gggccaagtle	2040
	gacatccca	acg.lcnatna	ccctggaggg	gtctgtacca	agagccacac	tctgatgate	2100
	atcacccgag	ctatggagaa	tggctccctg	gactcctttc	tcgggnnaaa	cga.tgggnag	2160
30	ttccacgtca	tcacgchqnt	gggcattgcl	cggggccatcg	naqctggcal	qanqtaoctg	2220
	gcagacalga	actatgttca	ccgtgagcll	gctgcaccca	acal.ctctct	caacagccac	2280
	ctgntctgca	aggtntcgga	cttttgggcll	tcacgcttll	tanaggacga	taoctcagac	2340
	ccacactaca	ccagtgccll	gynccgnaag	atmccatcc	gcllygacagc	ccccganncc	2400
	atccagtacc	gnaagttcac	ctcggclaat	natgtgtgaa	actacggcat	tgtcatgtgg	2460
35	gaggttntgt	ccatagggga	gcggccctac	tyygnatga	ccanncaqga	tgtlaahcant	2520
	gocattgagc	anagactatcg	gctgcacann	cccatggant	ccccagclgc	ccctgcaccaa	2580
	ctcalngctgg	actgllgyna	gaaggacccg	aaannccggc	ccaaqttcgg	ccaaal.lqtc	2640
	aaacacclag	acaagatgat	ccgcnatccc	aacagcccca	aagccalggc	gcccctctcc	2700
	tctggcatca	actgtccqct	gctggacccg	acgatccccc	antacaccag	cltlaaacag	2760
40	gtggacagat	ggctgaaggg	catcaagatg	gggcactaca	agggagactt	cggcaalggc	2820
	ggcttcaact	cccttgacgt	cgltyctcna	atgatgalyn	aggaactlll	ccgggttggg	2880
	gtcactttgg	ctggcnacca	gaaaaaaate	clgaaacngta	lccngntgat	gggggcyng	2940
	atgaaccaga	ttcagttctg	ggaggtttn	catctcaatn	ccctggclac	ccctctctcc	3000
	caagccocgc	ccctctctgc	ccacgtgcgc	qccctccctg	lntctctatc	anlyncgggc	3060
45	cagcnactcg	ccagggagyn	ccgggacccg	gaagaaacca	gcyyl.qccag	ccacyagacy	3120
	tcaccaagaa	aacatgcac	tcaaaacagc	g			3151

&lt;210&gt; 24

&lt;211&gt; 1234

&lt;212&gt; DNA

50 &lt;213&gt; Homo sapiens

&lt;400&gt; 24

	tagltcaaga	caanagagac	aaagotaaga	tggggaagtt	ctglanantt	taggaatatag	60
55	aggtttlcan	agataatlac	ayttrattgtg	aaactggcct	cccaagcccl	gtanccaaca	120
	tggccaacgc	actggccagc	gccacttgyy	aynctgcaa	gggcggcttt	ggccccgclg	180
	agaaytctgt	gaacmytaet	qgggagccgt	accatynna	gtgtttccglg	tncgctcagt	240
	gcttccagca	gttccacaga	gganctttct	atnagtttga	anagaagaag	tacthlygac	300
	atgaactttca	gatgctottt	gccccttgc	glnatcagtg	tyglgnatlc	atcattggcc	360
60	gagttatcaa	agccctnna	aacagctggc	atccggagtq	cttccgclhly	gaactctgoc	420
	aggaayttct	ggcagatalc	gggtttgtca	agaaatgctg	gnacacactg	lglngccct	480
	gtcataatcg	lmgaaagcc	agaggccctg	gganctacat	clgucanana	tgcactgcta	540
	tcakccatga	gcagccctn	atattcaaga	acgaccccll	ccatccagac	catttcaant	600
	ggcccaantn	cggaaggag	ctgac.lgccc	atgcacggga	gntnnaaggg	gagctalac	660
65	gnctcccatg	ccatgataaa	atgggggtcc	ccatclgtcg	tgttynngn	cgcccatcg	720
	aaggggcgct	ggtgaacgct	ntngccaagc	agtggcatgl	ggagcatttl	glttqtgcca	780
	agtgtgagaa	acccctttct	ggacalngcc	attatnagag	gaanngnctg	gcatalctgt	840
	aaactcacta	taanacagcta	cttgggtgatg	tttgettcca	ctgcacngt	gttatagaaq	900

5	gltgtgtgtgt ctcttctctt aataaggcct ggtgctgtaa ctgclttgce tglkctacct 960
	gcaacaccta attaaccttc aagaataagt tttgtgagtl tgacatgaag ccagttctyl 1020
	agaagtgtta hgagatttcc attggagctg aagaatgac tlgaqnaact agctgagacc 1080
	llggaagga aaknagtcc ttattttttt cttttctatg caagatnnaa gattacccac 1140
	attanttttc ttgatctacc catahttaaa gclctatctc nngcagtlg agagaagagg 1200
	acctatalyn atgtgtttat gtcatttttt taaa 1234
	<210> 25
	<211> 4534
10	<212> DNA
	<213> Homo sapiens
	<400> 25
15	gtcagcagcc tgaagagac aaagcttgcct caggggggccc ggccgggggcn ggggagcccn 60
	nggctcgttg gkcccccagc cngcggggag ggccttcagg ncccgcgccg ncccgctgca 120
	gcttgcgcgc cctcgcacaa ggtccggggc gcclcgctct ccgttccctt cccnngcate 180
	cggcaccctc oggggcacat cagctcggcc ggggggncag tctggccccc cgtttccakg 240
	cggttcgggt ccaagatgat tccgatgtll cttaacctyl atctcagtaa caatgagcag 300
20	cccttcacag angttccagt tntccagaa tccatctgca ywncgttgt ggtgkggctc tctagagcln 360
	aaagaccccg gcgagagtga ttgcattttg gotgaagtgt ggtgkggctc tctagagcln 420
	gagtttcake atgttcggcc gcatgtgttc gctctcctga ncttgtgac cgtctgctc 480
	gncctcccaa agkgtngat tacaggtgtg agcccccacg atcagctct agtgtllan 540
	aaagaccccg cagttgcgyn taatgagyn calgnccgoc tttctcaacg atttggaagt 600
25	cagaggaacy ngttccgtt ctccctcgt tocaaghtta aaaaqaantg gtgtaaaagi tctgtgtgaa 660
	aglggnccaa gatctcagga tccaghtta cctaggatgg atntgactt tgclyactt 720
	tatcgagaa cagaggaacg calctcgcga gcaagacag attgaagccc agcaacaalk notggcaat 780
	caggaatgg calctcgcga gcaagacag attgaagccc agcaacaalk notggcaat 840
	aaggacnng gcttaaatg lttgaacaa naagatcag atagclgna atcaggaagc acaaghtgct 900
	gagcaggaga ancttaaaag gclanagaa atagclgna atcaggaagc acaaghtgct 960
30	aaagtcgag cacttaangy ccacgtggan cagaagagac kagcaatgg gaaatttgtg 1020
	gaggaatllg anccgatgaa lantttgttc gacayggag agagggggt agagggggt 1080
	gtgtcaaaag tagunuaat tgcagtgcl aggttgcac gntctataa nnggatgac 1140
	agccnccatg acaatcagk agnycgaat gccaggtac gccaggtac gntctataa 1200
35	ctaagaaaca attcagant ggcagtcakg qtaagcgtg lhaatngct taccagllc 1260
	aaknagccta atccagant ggcagtcakg qtaagcgtg lhaatngct taccagllc 1320
	ctgtggagyn aagaggaagc agcaagcccg yntccctca tccagllc 1380
	aclnttcccg cagtcakcln ctatgcctg ctatgcctca tccagllc 1440
	cccgatggtt ccttngtcat tccagllc 1500
40	aacatgagat ctggggclg tccagllc 1560
	gatttgagtc ctccaatgc agatcttgc tccagllc 1620
	agcctgga agatcttgc tccagllc 1680
	aagaagclg gtccgttct tccagllc 1740
	tttggtactc ltaggaagaa tccagllc 1800
45	aakanaaatg tggctcaant tccagllc 1860
	ccttattttg gacaacln tccagllc 1920
	cagttgtcaa ngttgttcc tccagllc 1980
	agagtgctgc talctccag tccagllc 2040
	totaagunag aaagtccac tccagllc 2100
50	gacaccttac ttccacccct tccagllc 2160
	atgtatccg aacagcngc tccagllc 2220
	accaagctc ataccagag tccagllc 2280
	gctgcccaga atccacaga tccagllc 2340
	ggcagtcacg aacclgnaa tccagllc 2400
55	agaatccctc ggcactcag tccagllc 2460
	aaocagagly ctgctgacct tccagllc 2520
	ctanagaac gtatcttat tccagllc 2580
	cttctctatc agagagccc tccagllc 2640
	tccaagcln ctctgtgac tccagllc 2700
60	ttacatgttg agccgnaaa tccagllc 2760
	galgtgagg atgccagly tccagllc 2820
	tatgagclg angagtcoc tccagllc 2880
	aatccagag cctacactgt tccagllc 2940
	ccaccaacc catctggga tccagllc 3000
65	cotgaaatca ccnggcaggt tccagllc 3060
	gggtccagag gtatcgcln tccagllc 3120
	gattcgtctc tggagggag atttgcct tccagllc 3180
	gtacagagc 3240



	ccaagcctgc	ccaatgatga	aggeatcaag	gckettcaaa	atgctgltgt	tgaggecnc	3300
	aaagaaatcg	ttangtttct	ggtacagttt	ggtgtaaatg	taastgctgc	tgatagtgat	3360
	ggalggaactc	cattacalkk	tgctgctctc	tgtaacaacg	tccaagltgt	taagtttttg	3420
5	gtggagtcag	gagccgctgt	glttgcocat	acclacagtg	acatgcagac	tqctgcagat	3480
	aatgtgcagg	aaatggagga	aggtacact	cagtgcctcc	aatlketita	tgaghttcag	3540
	gagaagtgg	gcataatgaa	lwaaggagtc	alttatgcgc	tttgggattt	tgaacctcag	3600
	natgatgale	agctgcccac	gaaagwagga	gactgcctga	caatcatcca	cagggaaagac	3660
	gnaqatgaaa	tcgaatcgtt	gtgggcgcgc	cttaatgala	aggagggala	tgttccacgl	3720
	aacttgctg	gactgtaccc	naqaattaaa	ccaagacaaa	ggngcttggc	clqaaacttc	3780
10	cacacagaak	tttagtcaat	gaagaattaa	tctctgltta	gaagaaatga	tacgalatkh	3840
	lhtggcaaaa	atfllcccaag	acttatttla	atgacaatyl	agcttgaaag	ngatgaagaa	3900
	tgltttbtaga	agagaatgaa	ggattgaaga	alkacacatt	agaggaacatt	taqctgatg	3960
	aaataaagaa	tctacgtcag	caggacatcc	tgtgtlqagg	caaaagtgtc	ccgtglagcu	4020
	ctcagataag	lctacagoga	caatccctgt	ttctacaaga	atootgtclt	qtaaatagga	4080
15	tcatttattg	ggcagttyuy	naatcagctc	telgtccctgt	lyantgtitt	caguanctgc	4140
	tcctaannaa	gtccctcctc	cagaaagga	cagtgccttc	acatcgtnt	ctctgalleg	4200
	ccccggcacc	agcagccct	gggctcccl	gaaggtctga	aggaactgca	cccttgat	4260
	atlytcagtg	aagaacglha	gttqgttgtc	aglgaaacat	aactttatta	talagklttt	4320
	tgtagcalet	taagaattat	acalatatgt	gaatatctga	aactaagcha	cagtaccagt	4380
20	aattagatgt	agattcttgt	ttgtaggcty	atttttaate	tttattttatt	gntttttgta	4440
	tctcagaaat	tagaaacttg	clacagactt	acccglanta	tttgcagaag	tcatagetga	4500
	ctttaaaaac	agtttata	aactttttga	tgt			4534

&lt;210&gt; 26

&lt;211&gt; 4660

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

30	ggggtctaga	aal.khnnnag	ttgttttatat	aatllygcott	aaalynggtt	agagtgaaga	60
	gactagagnc	atctctggaa	aaacalcakha	tcccattccc	cgqgaagcta	ccctctggaa	120
	ctcaagattt	gaacatctct	gttttgagga	ttctctatga	acaaagwgt	ctcccaggtg	180
	tganghtttt	caacatgagt	gyckkcgqg	acagttcalr	cgacccctgct	anncccgact	240
	cacataagag	gnaaggatcg	ccatgtgaca	caclggcttc	aagcaccgga	nagaggcgca	300
35	gggagcaaga	aaataaalcl	l.khnnnag	tagctgaglt	actgtctgcc	aanattagtr	360
	acattgacag	cttgagtcta	aaaccagaca	antqcaaat	tllynnana	acagtcgact	420
	agatcacagct	ant.khnnnag	atggaacaa	agaaal.khnn	aactgatyan	catgtacaga	480
	aalk.khnnnag	ctcatcaagt	aglk.khnnnag	tgatagaaaa	gynatccctg	ggaccccl.kh	540
	ttttggaggg	tttggatgga	ttttctttty	llgtnaactg	tgannnggna	attgtatttg	600
40	tgtcagagaa	lghk.khnnnag	taacttaggtt	acaatcagga	ggaattaaty	atcccagcc	660
	tel.khnnnag	actgcaagtg	ggggal.khnn	cagaatttgt	gaggaatctg	ctaccaaaal	720
	cactagtann	tgaatttct	tggcctcaag	aggnnnnag	acgaal.khnn	ctacacttta	780
	acthccaggat	gctaattcau	nttccagctg	agccagggan	cgagaaccas	gaaychhgn	840
	agcgtt.khnn	ngtaatgcag	tgtttcaact	lgtcacagcc	aaatctcaatt	caagaggatg	900
45	ggaagatctt	ccaghtcat	ctgatttcta	ttgcacggcg	attacctcgy	ctccagctn	960
	ttccnggtgt	agaatcclll	l.khnnnag	aagatactac	nnqtaaaatc	atcl.khnnnag	1020
	atactagllk	ectgagagct	gctggcagaa	ctggttggga	agattt.khnn	aggaagtgc	1080
	tttatgtttt	tttccacact	ccgggagag	aaacatcl.kh	tgcagacag	clgh.khnnnag	1140
	agtgatgac	tctgtgcaact	gcck.khnnnag	ccctcatatag	alkcatattg	aatgatggga	1200
50	caatgcltar	cgccacacac	aagtgtaaac	tttgcctaccc	tcaaglk.khnn	gcatgcaac	1260
	ctttcatcat	gggaattcat	atcatcgaca	gggagcaahg	tgggtttct	ct.khnnnag	1320
	acactaatte	tggaaityta	alk.khnnnag	taaatccctc	ynhcaatcct	agtatctctc	1380
	cagctcatgg	tgtggctcgt	tcattccaccl	lghccaccatc	caacaynnag	atqgtatcca	1440
	ccagaa.khnn	ccggcagcag	agctcagacc	ttcal.khnnnag	cagtcatagt	aalk.khnnnag	1500
55	ccagccaagg	aagtk.khnnnag	tgctcaccgc	gaagtccagcl	tytanccaat	gttgcccttaa	1560
	accannngca	ggccagttca	l.khnnnag	alcctctctt	aaacctcaal	antctctcta	1620
	tggaaaggtac	aynatctctc	ctagccnagt	tcattgtctcc	nnqnaqacag	gttaactctg	1680
	gatttggcaac	aaggccccag	algccaaaah	attcctttcc	tccl.khnnnag	tgcacattaa	1740
	gctcl.khnnnag	tggcatgaca	agtagtgcct	gtaal.khnnnag	taacgatctc	tal.khnnnag	1800
60	tcocagtaac	alktttccag	qghatqatg	aaggacccaa	l.khnnnag	ggcttctctg	1860
	ccagttctcc	agtoctcag	cagatgagct	cahngaatte	acctagcag	ttaaatatac	1920
	accagannag	agctgagtc	aaagataaca	aagayakhgc	ctcaatttta	aatgaaa.khnn	1980
	ttcaatctga	caacagctct	ghgaltgna	naactctgga	tl.khnnnag	ctgcataaca	2040
	atg.khnnnag	ttcagatgga	gacagtaaat	act.khnnnag	cagtcacaaa	ctagtgcagc	2100
65	ttttgcagac	aactgcogaa	cagcagttac	ggcatgctga	tatagacaca	aglk.khnnnag	2160
	atgtcctgtc	ttgcacaggc	acttcaact	ctgctctg	l.khnnnag	ggaggttctt	2220
	gtccctcttc	tcatagcl.khnn	ttgcacagaa	ttgcataaat	tctacacag	ctcttacagg	2280

	agqqttagccc	ctcagatato	acccctttgt	ctgkcgagcc	tgataaaaaq	gacngtgoat	2340
	ctacttctgt	gtcagtgact	ggacaggtac	aaggaaactc	cagcataaaa	ctagaantng	2400
	atgcttcaaa	gnaaaagaa	ctaaaagacc	alcnqctcot	acgctatott	tlngqtasay	2460
5	atqagaanga	tttaagtca	actcnancc	tgagccctnn	tgatgtanng	gtgaaagtgg	2520
	aaaagaaanq	acagatgggt	ccatgtanta	ccaaacccaa	cccaatgacc	nanccaccc	2580
	ctgaggaaal	aaaactggag	ccccagagcc	agtttaacagc	tgaurttgac	cagkttigate	2640
	agttactgoc	cacgctggag	aaggccagcc	agttgcnnng	cttatgtgag	ccagacaggn	2700
	tggaatgknc	ngtoaccagl	ntaaoccalc	ccatggagat	ccclgcagct	tcacttcagt	2760
	cogocactgc	cgncccaact	ctnaggotaa	atagctcncc	tgagctggna	ttggaaagca	2820
10	ttgataacca	atttggacaa	ccaggnnccg	gogatcaghl	tcocatggaca	mtaataacag	2880
	tgacagctat	aaatcagagt	aaatcagang	ccccagtgtat	tgurtcacaa	ttayntgagc	2940
	ttctctgtct	ccccacaaca	gkagaaggga	gaatctgtga	gaaggctctt	cttgaaacagc	3000
	tqgtatcott	ccllkngtng	aaagakgaa	ctgagctagc	kgaaactagac	agagctctgg	3060
	gaakktgcaa	aotttgttcng	gggggtggal	knatgtatt	atcagngnna	tttccnccnc	3120
15	sacaagcaac	gcccactttg	alcatggag	aaagnnccnn	cottttacttc	cagccttanc	3180
	cttctcttto	tcctactgoc	aatclcnctc	gcccctttcca	agycctagtc	agggcaaaaac	3240
	cltactngng	gaogatgccl	gctoaagtaa	ccccctcccg	aggtgccltct	ccactggcc	3300
	tgggcatgcn	gcccaggcaa	actctannca	gaectccggc	tgacactaac	cnqcttogac	3360
	ttcactaca	gcagngatta	cagggacnnc	ngcagttgat	acnnccaaat	cggcaagcta	3420
20	tcctnaacca	gtttgcagun	actgtctctg	llygcatcaa	tatgagakca	ggcatgcann	3480
	agcaaatlac	acctcagcca	ccccgcaatg	ctcaaatytt	ggcacaacgt	cagcgggaac	3540
	tttactagta	acagcnccnn	cagagggcagc	tcatacagca	gcaaaagunc	atgcttctng	3600
	ggcagngang	ctttgggaac	ccccctcttc	ctcccltctng	notaccagtt	nnatggggc	3660
	acccccgtct	lntcaggggt	gctcnannc	aattcccta	ccnncccaac	tatgklncaa	3720
25	atcnaaggaac	ccccclgct	tctacagcc	ctllkthcaa	accagcagca	vatcctgaag	3780
	cactctlggn	ccacccgaac	aguntngtga	gcagagggcal	gnanngaaac	atagngngac	3840
	agtttgcaac	tggaalcnat	cctcagatgn	ngnngaatgt	cttcagylal	ccaggagcay	3900
	gaatgkthc	ccaagtgag	gccaactttg	ctccactcll	nnccctggg	agclnccng	3960
	tgccgatgoc	aalccntctt	cctcagagll	ctctnctcaa	gcaactcnn	ctgctctccg	4020
30	gklnkngtc	accagacatg	nnqgctggc	agcaaggng	nataggaaac	aaanctgtgt	4080
	tcagtcaagc	lgtccagaa	cagccnccgc	ctgcacagcc	aggaglnctc	aaacaactgc	4140
	gcataccgtt	ttccatggng	ngtgaaata	cgaalghtca	gnccatgaac	nnatngatgg	4200
	cccagctgna	gatgagctct	lctnngatgc	caggaatgaa	canlgtgtgc	cttagcngn	4260
	taaatgatcc	cgncttqga	cacacagyn	lntactgcaa	ccagctctca	lccactgaac	4320
35	ttctnaaaac	agaagcagal	gganccnagg	tgcaacaggl	lcnngtqttt	gctgacgknc	4380
	agtgtacagl	gnatctggta	ggcgggggnc	cttncctgaa	ccagcttytl	ccactgggaa	4440
	ctcaaaagcc	cagctnaggn	ccacagaccc	cccayunna	gcagaagago	ctccctnngc	4500
	agctactgnc	tgataacca	ctllknggg	aatgtgaaat	ttaaalenta	ngcatacaga	4560
	gatatacaaa	tatalcnat	atttttctga	galllkngat	atctaatct	gcagccatcc	4620
40	llknggttgt	agcatttggg	gcnaaaaaaa	aaaaaasaaa			4680

&lt;210&gt; 27

&lt;211&gt; 6773

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

	gggctgggtt	gggggngngc	ggcgggctgg	ggagaglynn	ngatcttgtt	caagatgggg	60
	lgggttccac	agctacccct	gggccccgga	aatctaagaa	ctyyngannq	aanntgaaga	120
50	actcagatca	aaactgtta	ctgaagggaac	lgytqwtatt	attaaggcat	taantgnaac	180
	tctqgatgt	cttcttctng	annagccaga	gactgagcaa	cngkgtcttt	ctctgaaaaa	240
	ggaaatctca	aaaatgaagc	aagaggttna	ngattctgta	acaaagatgy	ggcatgcaca	300
	taaggagttg	gnccnctcac	atataaacla	tytgaaagaa	attgaaaatt	tgaaanctga	360
	gttgatggca	gtacgkthca	aatncagtga	agacaaagcl	anclhctcaa	ngcagctgga	420
55	agaagcnatg	ntacgcgaat	tagaacttct	ngaanccctt	aaatttcaga	acnactctng	480
	agataatgtt	nnnannctac	aagaagagat	tgaghaaaat	ngccccaggt	ttgaggagca	540
	aaattttatat	ctgcannngc	atctagagcc	taccactgat	gaaaaagang	nnccagttac	600
	tcnactccaa	aatatcattg	agglancttc	tcagcattn	caaaaaata	tlcnkgttt	660
	gcagggaagag	cttttacagt	tgaaagctat	acaccanngn	nnngtgaana	agttgatgtg	720
60	ccagattgaa	gcclnngnta	aggaacatga	agcagagata	aalaaaglkga	ncngctaaa	780
	agngaaacta	gtaaacaat	glgagggngc	tgaaaagaa	atccagaaga	aalnkgatn	840
	tgagttgaaa	aattnagga	aagccacctc	aaalgcnngn	cnnngcaate	agatatgttc	900
	tattctcttg	caagaaanta	natttgtaga	acaaqtagta	aafgaaanng	tcnaccactt	960
	agsagatccc	ttaaaagAAC	ttgaatclca	annccgtatc	ttaaaagatg	agglancttc	1020
65	tatgaataat	cllknngttn	accttgaaat	ggatgctcaa	catatanaag	atgagttttt	1080
	tcctgaacgg	gaagacttaq	ngllknaaat	taatgaatta	ttactagcln	acgaangaaca	1140
	gggctgtgtca	attgaaaaat	taaaatctga	ngtanccgg	ttanataaac	agllkktgcln	1200

	tactgtcagaa	cagcataacn	ggnagtaacn	gngtcttaag	gncacacac	anacagaaat	1260
	atcagaacta	aatgagacat	tttlgtcaga	ttcagmnaa	gaaanattan	catlaahgtt	1320
	tgaaatacag	ggtctlaamq	naacgtgltq	aaacotacag	caagaaaagc	anagaagcaal	1380
5	tttaaahtet	gagagtttac	gngagattat	ggaantttta	canacagaac	tggngaatc	1440
	tgcctggaaan	ataagtoaac	agltcgaatc	aalgnaagca	cagcmngent	ctgalgttca	1500
	tgaactgcag	cagmngotca	gaactyrttt	tactgamaaa	natgcccLLU	tcgaactytl	1560
	gaatcgcctc	cagggaagaa	atgaaaagtt	mtatctocaa	canynatttg	tacccagact	1620
	tgaaaatacu	atonaqaaoc	ttcaggaaaa	gaatgngta	tacttaackla	gtotcagtea	1680
10	anagataacc	atgllammyq	nattagaagg	aaagataaat	letcttactg	agynunaga	1740
	tgetttttat	aataaactga	aanattccca	lgaaqpaaty	gataalttcc	ataagaantq	1800
	tgaagggaag	qmanagattg	ttcttgaaot	tgggaagaaa	ntagagcaaa	catccagta	1860
	caacngtgaa	ctagaaacna	aggtaaatga	mttaacagga	gynctagagg	agacklluno	1920
	agannngnt	caaaatgacc	anannctaga	aaaacttatg	gttcaamhyn	aagttctcln	1980
15	tgaagacann	naagttattgt	cagctngant	gaagtelckt	tacgaggaaa	anataaact	2040
	ongtttcagaa	aaaaannant	tgaatagggg	tttgagaggt	LLLLttttct	aaaaagaaag	2100
	tyttatcoct	aaagaacata	ltctotcaatt	agannngnaa	cttcagtliaa	hngttgaaga	2160
	gcaagalaal	ctaaataaac	tgccllgaaaa	tgaagcaagll	anagaattat	ttgcllunaa	2220
	tcagtttgtat	gylttttctta	aagaaatggg	atcagaagtt	tcagmngaa	gtgaagagaa	2280
20	agotgtttgt	aatgtctctac	aggtcagtg	tgaalccttg	gcaaaaataa	alagaggaaa	2340
	atgcannctg	gcttttccagc	gtgalygaaa	agtatttagag	ltananaaag	agallamgtq	2400
	cottcaagaa	gagahlyhag	ttcagtgtag	agmacttaag	tctttatllg	gagactatga	2460
	gcmagagaa	gttctottaa	ggaanngant	agaagaaala	aatgcagaaa	aagagggcct	2520
	gaggtctgat	clltctagaa	tgaagaatgc	lmtngnaaaa	acaagggcllg	annatcagaa	2580
25	lcttttaate	caagttgaag	aaghtctoca	aacatgtagc	mnaqcgaaa	tcclaaagc	2640
	aaaagaaann	tytttttatna	aggaacalgn	aaacotaaag	ccacLmntag	acaaaaaaga	2700
	attacagagat	agygagngny	anttgatact	allamnggat	tcotttagcaa	ahcacccttc	2760
	lglnnaaant	gatcctctgt	cttcngtana	agagtttgaa	gmanaatng	aaatctclyy	2820
	aaaagaatgc	annagaaagg	aggaagaaat	aanatagata	aaattagllg	ccctaaaggc	2880
30	anagaangaa	ctagattcca	gcnyaaanga	gaocacagac	ghyaaagaaq	aacttgaelr	2940
	tcttcagala	gaaanngacc	agttatctgc	ttccontgaga	gatctcalia	anngagcaga	3000
	angctetaag	aatclllllll	hagantatga	aaagcaghtc	gagcaactgg	atglygaaag	3060
	agmactgtct	aataaatttg	agcalngtat	tgaagacett	acmnyannat	taagaaatte	3120
	gactttgcay	hgtgaanonn	taaatcttga	lanhngant	ctcctggctc	qlattgagac	3180
35	mtacagctct	aatgccaaat	talhogaagt	acagatttta	ynaghcnan	gagccaaagc	3240
	aatggttaga	anagaattng	aagctgaaaa	achtcaqana	gaacagaaga	lanngyaaac	3300
	tgcactactc	gtaaatgaac	ttgaaagact	tcaggtacaa	nlhcnanng	aaaagaaaca	3360
	gtcllcnag	anactgcaag	aattagagcl	ggttaaaaag	gatgcccaac	anccacattt	3420
	gatgaatatg	ganahagctg	attatgaacg	tttgahgaaa	qanctaaatc	aaaagttaac	3480
40	tnatanaaac	aacaagatag	aagntttngn	gcaagaataa	anhalicnny	anacagaaca	3540
	agaaacccra	caagaaagaaa	taacttcaill	anngtcttca	gtacaacaat	atynngyaaa	3600
	aaacacccaaa	atcayayact	tgcctgtgaa	aaccaaaaaq	gaactggcag	attcaagaca	3660
	agynagaaact	gatcaacttaa	tacllcnagac	ntotttaaaa	gglyayclgg	nyngaaagcca	3720
	gcagcaaglu	naqctotata	aaatacayct	gqntngantn	acatcagaga	agcclaaal	3780
45	ccacgagcac	ctgannnncp	ntgcggaaca	gcaccagcyl	ngqctuanrg	cataccagca	3840
	gaggtgacaa	gcactacagg	aagaglycnng	tgcctgcacag	gcagaacaaq	ctactgttac	3900
	ctctgaatla	ngagactaca	aagtcagagt	tcalanhtgt	ctnaaaacaac	agaaaataaa	3960
	ntctatgtct	cagglcgaav	ntgagggcgc	taaacaaaga	nyygnaccto	tggaaatgct	4020
	gattgacocag	ctaaaaatca	aattacmny	taagccaaat	aacttacaga	llahgttatc	4080
50	tgaactcaac	mnttgcaagt	ctgaacatga	tacaclycla	gannggaca	acaagatgct	4140
	qanagaaact	gtgtccaaaq	aggrnyaaat	cogggaaaaa	ttgtgllcaa	taanqtona	4200
	gaacatbntg	atgaaatctg	aacatacana	gantngtgt	cagctaacat	cccagaacga	4260
	ggctccttng	aatngcttcc	gagatcaagt	gcyanalttn	ccqnanpaa	acagaagac	4320
	agtggagaca	llanngnygc	agctctccaa	gatggaagta	cagclntfkn	agcttaagaa	4380
55	tgaacogacc	acaagaagcc	caglllcnctc	tcacaaatct	ttgaagaacc	tlcngyannq	4440
	gagaaacmca	naoctccogc	ttotagacat	gcacmngty	anccqgnag	agggagaaqg	4500
	catggagaca	actgntwng	mtctgtgtc	ttccggcagc	acalacacac	ngtctttaga	4560
	gcagttgctt	aactctcccg	aaactaaac	lgagcttcca	ttatggcatg	ctgaattttac	4620
	caagaagaa	ttgtttcagn	agctcagttc	caccacaaa	ngtgcngqnc	acttaaacgg	4680
60	ontgottcgg	gaacacagay	anannnatgc	aatctttatg	gagcaaatla	agcltclcan	4740
	aaglygaata	agaagattgg	aaaggaatca	agagccgagq	angtctgng	ctaacctgga	4800
	atacttgaag	naqctcttgc	tgcagttcat	ttctttgaaa	anagghagty	aaagagagag	4860
	actctctcoct	gttalaaata	cyntlyhgc	gctcagccct	gaagaaaagg	gaaaacthgc	4920
	tgcggttngt	caaggtgagg	aagaaaatgc	ttcccgkhet	tctggatggg	catcttatct	4980
65	tcatagttgg	hctggaecttc	qntaggttga	tggaaaggaa	allllllall	anccaaataga	5040
	atctattttac	aaaaatgggt	nanatatatt	ancccaatcc	ttttgtcaaa	aahtgltghk	5100
	alattgtttgc	atctacatat	atttgyacat	cllaltgaca	gatgtatttt	aaaagtttca	5160
	tcttgaaqta	aanctacaa	agcttgaagt	gttgatagca	ggmnaagcc	ctctaactca	5220

	tgtgtatttcc	catgcttqct	gcacagaata	accacacagc	natgaattca	ctccccactt	5280
	ctctgggaac	tcaggacccg	ccattttctc	ggcaglkctg	tgaattttga	agtcanncto	5340
	aattttggtg	ccalancanc	tggaaattcg	gttttaaaaa	taatgtttca	agccacagtg	5400
5	tgggtgalkca	tgcotgaaat	ccccctactt	tgggngqctg	aggctnqnga	atlgcttqar	5460
	qctagtgage	ktqnaoctcc	actgcactcc	agctcgggyn	ccagagcngy	accttgtctc	5520
	tannntaat	agtaalaxaa	taaaaataac	glkbtatgac	cttttattgc	annqtcagag	5580
	ttacngtttg	ttataaatlg	ktqngaatt	tttglgctta	gaatntgaag	gaaaaagctt	5640
	tgttggtann	actgacatgt	taaggggcta	tgaagtaash	atgctgcagl	taatttgtct	5700
	nanttaaaat	acaghttagt	tatttgctct	naataaaact	ctctcttttt	tccllanngt	5760
10	atactatctc	aaaaactcalk	atgttgtcag	agccclnqng	ctggclngtn	taacactgac	5820
	tatgagttag	tgggcccacc	acllgagctt	aggtgattin	atgggtgtct	lncaggetct	5880
	tgatagggtg	lcnatgcctg	caagccalga	atctgtttct	agantctctc	ccaktllkcc	5940
	aanataaaaac	ctatncanac	agtgaactata	tcacclcagca	ttgyalctoa	atataaaagt	6000
	gggtgkctca	gtgtcttttg	cmgtatgtgt	tcocatagct	ttccatcaga	agggntttta	6060
15	ncacacottag	aggtcctgtg	tacatcgtta	cmgttctctc	gahtnccctt	aggtggllagt	6120
	gllacttqno	tttgacaccl	ntgcataatgt	tttaalgact	agatcccaan	tgtgttgttc	6180
	ttaaatcaaa	naattggataa	tttglakkt	ttatgtgtta	akacacacagt	atgclctctg	6240
	nantttctctt	aagcclhcaq	tttatactct	taallkntt	ttctllcthga	gctggagaac	6300
	tggctllhca	ctttggttac	cttggacact	ggtttccaal	tcagtttaac	lgnatttgc	6360
20	tgttgatact	ktqngtttgt	cttttaaaaa	akagctcata	katctcatct	ttctctclgt	6420
	cttaqaagaa	cagacchanc	tagtgaatgt	attaalgman	atgcactclak	ttcagagctg	6480
	acatgannag	tttagttttt	ttacllkntn	actgtgcat	akgqratgc	cagctgcakn	6540
	cgatgtaact	antnctatnt	aaatatatnt	cactllknt	ttgactllknt	accttttga	6600
25	ghctgtataa	acttgitttg	nahtatantc	tctgtctacg	antqtcataa	caaaalaxll	6660
	ttttgcalg	tcaaaaatta	ctttgattac	annnqngta	ttclllkntn	gtttctgcaa	6720
	tqagagggaag	tglakctgtt	nttttaatac	ttctatlann	tatgttttaac	lgl	6773
30	<210> 28						
	<211> 2619						
	<212> DNA						
	<213> Homo sapiens						
35	<400> 28						
	atnqccacag	cttgtaaaag	akcagggagga	ccctcagctctg	acgaacttga	agctagccga	60
	atgaagcagq	cagctgcaaa	gcactctaata	gannqctact	acacacagtl	annlgngngc	120
	tgttgaaalg	naqctgcnc	gaatgagttt	tgtgcttccc	qtccaaacttt	tcttctgtatg	180
40	gctaataatg	cagcagctat	lannqccctc	gagctttata	ayallkntgc	aaactctgt	240
	gatenctate	ccccaagaa	aggagcaagc	tcagcttacc	ttgagaactc	gannqgkgrc	300
	cccaacaact	cttgcctctga	nttcaaaatg	aacaagaaag	gngctngaat	tgattttaaa	360
	galgtqnot	acttaacaga	agagaaggla	lctgaacttc	ttgaattaly	tcagagagga	420
	gaggatcakt	cccttttaac	ccgtgtttatt	ggaagagllh	ttctctagtgc	tgaggaattg	480
	gtacagagct	tcgyyaaagl	lannnannnc	cccaagggaag	aactlganntr	cttctnagcn	540
45	aaagalkang	acaaagatga	agatgaaaag	gaannnqctg	catgttctgc	tgtgtctalg	600
	gaagaaganl	caggaacatc	ttccccaagg	ataggtgala	qctcacaggg	agacaaacat	660
	lctcaaaaat	taggcclhga	lgahtgkhtc	ntqgatatga	atgccallng	annqgtctac	720
	accagattgc	tctctaata	aaaaattgaa	actgnttttc	tcactgcaat	tglataattg	780
	tcacctaaag	tngaatgtga	cttgacgtat	cacaatgtat	antctctaga	tcttaattat	840
50	ctgaatttgt	tcattalccg	aalggagaa	agcaatctcc	acagtcclhga	atctctgga	900
	atggctttgc	cattattttg	caaagcgatg	agcaagclnc	cccttgacgc	ccaaaggaana	960
	ctgatcagac	ktqngtctaa	atncaatgca	gaccagattc	ggagactnnc	ggagacattt	1020
	cagcaactta	ttactttata	agtlcalaagc	antqnaattt	acagtcgaaa	lclagllgaal	1080
	gatgatnate	ccatttgttg	tgttctgaag	tgtclgannn	tggtttacta	tgcnaatgta	1140
55	gtgggagggg	annqngncc	aanctccact	gaagaagatg	algaagngnc	ontcctngn	1200
	lcnatgcagc	tgaactttca	ggaacttttg	ggaagagaa	gaagaaacaa	gaaaggtctt	1260
	cgagtgggnc	ccctngnaac	tgnacttqgt	gttaaaaccc	lgyakhtctg	aanccacttt	1320
	atcccttttg	aagagllknt	lannngannn	ctnqantgag	ttctagaaat	ggtataagat	1380
	lclacttttt	tcasagtaga	aacagagaa	aaaltctctt	ttatgacatg	tccctttata	1440
60	ttgankctct	tcacaaagaa	tttgggattt	tattatgann	atnqnaattg	catgtncagt	1500
	gaacgaagaa	lcnctgtttt	ctacagctta	gttcaaggac	agcaagllgna	tcclhktctg	1560
	ngctcaaaag	ttagacttga	ccataltcala	gannatncc	ttgtccggct	agagatgata	1620
	gctatngnan	atcctgcaga	cttgagaag	cagttgllhga	tnnattttga	aggagaacaa	1680
	ggagttgatg	agggagngnt	ttccaaagaa	ttttttcagc	tgyllytqna	gganctcttc	1740
65	antccagata	ttggllctgt	cccllccgal	gannctacaa	aattgttttg	gttttaatcca	1800
	tcttcttttg	aaactgaggg	tcagtttact	ctgactggng	tanctactgg	tctgnotatt	1860
	tacaataact	ghctctctnq	tgtacatttt	cccatggttg	ctctacngaa	gclaalgggg	1920

	aaaaaaggaa	cttttcogtyu	ottgggggao	tctcaacnag	tictatataca	gagtttaaan	1980
	gatttatttg	agletgaag	uatgttgaa	gatgacatga	tgatcanctt	ccagatatca	2040
	cagacagctc	tttttggtaa	cccaatgatg	talgatctaa	aggaatag	tgataaatt	2100
5	ccaattacaa	atgaaaacag	gaaggaalett	gtcaatcttt	attctgacta	ctttctcaat	2160
	aaatcagtag	aaaaacagtt	caaggctttt	cggagaggtt	ttcatatggt	gaccaahtga	2220
	tctcccctaa	agtaactatt	cagaccagaa	gaatttgaa	lqcttataty	hrgaagccgg	2280
	aatctagatt	tccaagcact	agaagaaact	acagaalett	acggttqcta	tcnaggggac	2340
	tctgtttctga	ttggggagtt	acgggaatct	gttcattcal	ttacagatga	acagaaatga	2400
10	ctctctcttg	agtttaccac	gygcnagac	agayaaactg	tgggngact	aggaatatta	2460
	nagatgatta	tggccaaaaa	tggccagac	acagaaaggt	tacctacahr	tcatacttgc	2520
	tttactgtgc	tttacttcc	ggaaactca	agcnaagaaa	aacttaaga	ganattgttg	2580
	aaggccatca	cgtatgucan	aggaattggc	atgctghaa			2619
	<210>	29					
15	<211>	4263					
	<212>	DNA					
	<213>	Homo sapiens					
	<400>	29					
20	ggcggttccc	cttctctcag	cagttagctct	atgyttttcag	ggcgggaaag	tgacaggtcc	60
	ttacatttga	cctgtgcagt	tgccttucac	ccggaaatcua	tagtcaactyl	racagagggcg	120
	gaggacttgg	gcncacagga	gcctcccagt	cccaacacgt	gugggtccgc	gcctggcccaa	180
	gcuaactctga	cctgtgaggt	tggggcggt	acccagcaat	tccctctgty	cagccggccgl	240
25	ttccaagggy	tcaggaaacg	ctgtgtttgt	tlcgtccggc	tagcnaaggg	gggtcngaga	300
	glantctgac	tgacccagac	gtggcaggtc	tgacggcgla	gcccagagacc	ggtgcccgyt	360
	gtaggaglcg	cagcctgggc	tgtnagcggc	tgctnggttag	acagacttgc	ttlctcttac	420
	agcatgtcat	ttccnaaatg	cactgtngtg	ctctctgctt	aagtcctala	ngaagacant	480
	gcgcuaacta	gacgggtctc	tatggctcgc	actgttatct	lgaactcaggt	cactgtctcat	540
	tgagcatatg	tatgaaaatg	ccttagggag	gaacactgga	gaaglatgtg	agactgcaga	600
30	agatttgaga	aggttctctt	ggaaaagctg	ttctgtttaa	atcgacagag	gctngcagac	660
	atttatghat	caaggaaatt	aacatctcaa	gactgtctga	taagynaaag	caagaahtca	720
	ggagagaagt	lactgtattg	gcaaacatga	agcatcnaag	tattgtccaa	tataaagaat	780
	actttgaaga	aaahggtct	ctctacatag	taattggatta	clgtgaagga	ggthgcttct	840
	ttaaacyaat	naatgctcag	aannggcctc	tgllhcaaga	agaccagatt	ttggactggl	900
35	ttgtgcagat	algttttggc	ctgaagcctg	tacatgatay	aaaaattctt	caanngagaca	960
	taaaglwaca	gaacatatll	ctaaccaaag	algggccagt	gcagctllhga	gatttttggaa	1020
	ttgtctgagt	lcttaattagt	actghagggc	tggtctgaaa	ttgcctaggg	actccatact	1080
	acttgtctcc	tgaaatctgt	gaaacaaagc	cttatnccaa	taaaagtga	atttgggcll	1140
	tgggtctgtyl	cctttatgag	tlgtctacac	ttaaacalgc	atttgaagct	gnaaacatga	1200
40	aaaacotggt	ackgaagata	atctctcgtat	cctttctctc	agtgtctcca	callctctct	1260
	atgactctcc	cagctllgctg	cctcagttat	lhaaaagaaa	tcclagggat	agaccatcag	1320
	tcaactccal	gtttctctag	gttctctatg	ctaaactcna	cgaaaagtll	ctctccctcc	1380
	agcttattgc	agaaatattt	tgtctaaatg	cactttcaaa	glhggagcca	cagctctctc	1440
45	cauyhaanag	accagatcca	ggacaaggly	lhaattcttt	tgctcclhgt	cagaaaatca	1500
	caaagcclyr	tgctaaatac	ggagtgcctt	taacalalaa	gaagtatgga	gctonaaagt	1560
	tucttgagaa	aaacaccccc	ccaaaactta	aacaggccca	lhaaatccc	gtgaagaaan	1620
	tgaattctcg	agaagaaatg	aaagaaatgt	clgngnangc	agcaaaahuy	agaaggttgy	1680
	aattttattga	gaagaaagag	aggttggayr	atcagatclg	gttctctgaag	yctngacaga	1740
50	lganogggca	agayaaagag	cggctggayr	ggtataatag	ggcnaagqaa	caagyalggc	1800
	ggaatgtttt	aagggtcggl	ggagcggtg	aagtaagggc	ttccttttll	ggcattggag	1860
	gggtgtctc	lhaatcccg	tgttctcthc	ggggccagta	lynaattac	catgcaattt	1920
	ttgacaaant	gcagcggtct	agagcagaag	alaahtgaag	aagatyghay	gggggaatct	1980
	atggtcgaht	gctcccagaa	agggaaanaag	gacacttlay	tgtagagaga	gcaaaacnag	2040
	tggaagaatt	actacagcgt	aaacyayayg	ctatgcagaa	lhaagccctga	gccgaagayr	2100
55	actgtgttta	tttggcnaqn	ctgaggcaaa	lhaagctnca	aaattttant	gagcgccaac	2160
	agattcaagc	caaacttcgl	ggtngnaata	aagaagctlyr	tggtaccaaa	ggaaahgaag	2220
	caactgaaga	gactcnaay	aggtcnaay	agatggagtc	actlaagggc	caaacaaatg	2280
	caugtgcctc	tgtaclaaay	gaacagctgg	agcgaaagag	aaaggaagcl	laktgaagag	2340
	aaaagaaant	atgggaagaa	clhctgtgtg	cgagggttaa	ahgtcagat	gttctctctg	2400
60	ctttggaact	acttgaacaa	ggttggllcl	cttcaagcca	gcayglyaag	cctgtcattt	2460
	ctgtgaactc	agcllhaaaa	gaagtgggac	tyyghayayg	tetaactgal	ccccaggaag	2520
	aaagaactga	aaagagttaac	agtgtattt	caagtaagcc	ahnaatcctg	cgttaggclaa	2580
	atgaaaactc	lhaagctcaa	gaggatgaay	ahnaaagcca	gcatcaahca	ggttctgtgt	2640
	agaacncttg	tcacaaagat	gaagagagat	atgagacayr	aatgacatt	tcclctgate	2700
65	gcaagaagly	ggagatggga	ggctcagctg	tgattctctc	cgalgaggtg	aaactggata	2760
	catccttctc	tgcaacccgaa	aaacatactg	tgngngnggt	tattaaahca	gattctaatg	2820
	gtctctccaa	aaaagclctgg	gggaaaaacc	claaagactc	tgtgtgaag	ahanttgag	2880

	aagcttgaatt	acagctatbn	acagaactac	tagaaaacac	atcitttttaa	agtguygttt	2940
	atgctgaagm	ggagaactac	anacocctac	ltaactgaay	agagaatctn	cagtgcaltt	3000
	nnnaagaaat	aanlcontoa	getantqttg	attctoctga	aaagaaaagt	nnnaagttta	3060
5	ctgaggtqtc	tcacaaantg	tcagaagym	atgtggaaga	acotgalgnt	ttggaanm	3120
	aagttctacn	anagocsaagt	agocacacaca	anqtgggag	tttgocacct	gttcttaaty	3180
	atgtgtggac	laynagagag	gaagcmqta	agganmtga	gttgragat	aaggctnctg	3240
	tgcagongag	tgaagllkgt	gaagataym	ttocagggm	cgtggacm	tcctgtanng	3300
	atcagagayn	tcctgcagta	ganjattote	cgcctctgg	clgtgatgta	ynagagtoag	3360
10	tcacagccaga	Atcgattttt	cagaangtng	ttcattctaa	ggactlgaac	ttagtlcaan	3420
	cagttcattg	ctcacaym	gaaccaatln	cnnttogalc	tcactctgal	tcocaccaa	3480
	aaactaagm	caagaattcc	tlactgattg	gactttcaac	tggtctqttt	galgnaaca	3540
	atccaaagat	gctnaggac	tgctcacttc	cagatcttct	caagctgltc	agaacctan	3600
	tggacgttcc	cactglggg	gacgttcaic	agacagctc	lgaatctgat	gnctggaag	3660
	atgaacmnt	taagaaggg	ctttctgatt	cgmagacac	tglttttgaa	gaactlqana	3720
15	cagatttaca	agagcttccg	gctctmntn	agcagclgt	tagggagcm	ccaggtgacy	3780
	aatnagtg	ggaggagm	tctgttttaa	anngacogca	lytnagacag	anngacagag	3840
	ggacagatgn	ncacagacag	gaggmncac	ccagcaynca	agccctclg	acagagcaatg	3900
	gcactcagat	aataghgacn	ctgagacca	hantgaatgt	gnatngaca	glgkctttaa	3960
	ccakttagag	gaactaagac	ltaacttgga	gcaggaantg	ggclctlgan	agttcttlg	4020
20	ggtttatgag	anngtaagm	ctatctahca	ggatgaagat	gaatatttg	anatttgctc	4080
	aacatagtt	gagcaatctt	tnngcaatga	gcacacagat	ctclctgcca	agattclgna	4140
	tttaglcntr	gcagatggag	ccatctcngg	agataalgnt	gaataatcc	cnngacattc	4200
	tttaatagtc	aaactgtaga	acacatttca	anttgctca	cnatcagaag	ttctclggan	4260
25	ata						4263
	<210> 30						
	<211> 1756						
	<212> DNA						
	<213> Homo sapiens						
30	<400> 30						
	tggggcgcm	ccgcgaagat	gacgttggm	ctnagcga	gmhngtga	gaagalctgg	60
	gtgcccgtgg	accacaym	ctcgttgccc	agatmntgt	ggccaaagm	gaaccaactc	120
35	cccannntca	togtcatggt	gggcctcccc	gcccgggym	agacctacat	clccannng	180
	ctgactcgrl	acctcaactg	gattggcgic	cccccaaaag	tgllcaacgt	cggggagtat	240
	nnccgggagg	ctgtgamyra	ntacagctcc	tacaactct	tcogccccgm	caatqnggaa	300
	gccalgaan	tcogggaagca	atgtgcnctt	getgccttga	ynctgtctaa	aagctacclg	360
	ggagaagag	ggymncaat	tgoggttttc	galgonacca	ataclactag	agagagaga	420
40	cnatgatcc	ttcattttgc	nnanngaat	gactttaaag	cncttttcat	cagclcgntn	480
	tgcgaagacc	ctacagttgt	ggcctcnaat	ntcatggaag	lfnuatctc	cagcccgat	540
	tacaagaccl	gnaactcggc	agaagccatg	gaugacttca	tgaagagym	caqttgctat	600
	gaagccagct	accagcccl	cgncccgac	aatgggac	gggaattgtc	getyalcm	660
	gtgattgac	tnngccggag	gttctgtgtg	nnnngtgc	aggaacnaat	ccagagcccg	720
	atcgtgtact	acclgalym	ctccacgtg	cagccgym	ccctctaccc	gtgcccgm	780
45	ggcgaymng	agcacaacct	ccaggcccg	atcggggcg	actcagggct	gtccagccgg	840
	ggcaagaagt	ltnccagtn	tctgagcaag	ttcglggan	agcagaacct	gnnggactg	900
	agntgttga	ccagccagcl	gnaagncac	atccagacgg	nnnaggcgct	ggcgctgccc	960
	tacyagcngt	ggaaggcgt	caatgagalc	gaogccggcg	tclylgagga	getgaactac	1020
	gaggagatca	ggacaccta	ccctgaggag	talgcnetgc	gggagcagga	caantctct	1080
50	tcacgctacc	ccaccgggm	gtcctacnng	gaactggtcc	ngcnettgga	gccagtgaic	1140
	atgganctgg	agoggcagga	gaatgtgclg	ntontctgcc	accagymnt	ccctgocetg	1200
	ctgcttgccl	antctctgga	taagagtga	gagymntgc	ccctacctgaa	algmactctt	1260
	nacacogtcc	tgaacttgc	gcctgtccct	catggctgcc	gtgtggaatc	catctacctg	1320
	aactgtngagt	cogtctgcac	acaccgggag	nggtcagagg	atgcaagym	gggacctaac	1380
55	ccgtctatga	gacncaatag	tgtcaacccg	ctagmnmn	ccgaacccac	caaaaayccl	1440
	cgcatacaaa	gctttgagya	gnalglggcc	tcacactgg	cngccctgcc	cagctgocctg	1500
	cccccgaay	tgccacgca	gctgcctgga	caaanctga	aaggctcccg	gagaymnet	1560
	gcctctcca	gganmctg	annganngt	gtcgttcca	ltaactttcc	atttctcag	1620
	cttagcttgt	gtcctgcct	cggcccgagg	caaaactat	ctgagymct	tcttcnggag	1680
60	aggttggnt	ngagcagogg	gggagccttg	gcnngayaga	acctatgctg	gnanngctctg	1740
	tgtccctn	ncogt					1756
	<210> 31						
	<211> 1661						
	<212> DNA						
	<213> Homo sapiens						
65							

&lt;400&gt; 31

	tggtgcagcc	gclgcgncg	attcaggatc	tcattgcac	ggcncncga	cgacgucng	60
	acgtgcattc	cogatttcct	lhgttccaa	gtccalutn	goactctaa	agcatcagct	120
5	gatttataat	ttctaaagg	aagaacagcc	ccccagaa	nanattacag	tlgl.tgggt	180
	tggtgctgt	ggcagggct	gtgcatcag	katcttaatg	aaggacttg	cagatgaact	240
	tgctctgtt	gatgtcatcg	anqncanatt	gaaggagag	atgatggatc	hccaaatgg	300
	cagccttllr	cttagaacac	caahgttqt	ctctggcaa	gactntaatg	caatncaaa	360
	ctccaagctg	gkcttatca	cggtgggyu	ncrtngcaa	gagggagaaa	gcgtctttaa	420
10	lllqntccag	cgtaacgtga	ncatatttaa	atccalnat	cctaattgtg	l.mnatacag	480
	ccgaaagcgc	nagttgetta	ttgtttcaaa	tcagtgagat	alchtgacot	acglggrttg	540
	gaagataagt	gyltttccca	aaaacccgtg	hcttgqangt	ggttgcaacu	tcgattcagc	600
	cagattccgt	taoctgatgg	ggnanaggct	gggagttca	ncattaagct	gtcalgggtg	660
	ggtccttggg	qnnocatggag	attctagttt	gcctgtatgg	agtggagag	atgttgcctg	720
	tgtctctctg	anqactctgc	acccagattt	agggactgat	aaagataagg	ncagtgga	780
15	agaggttcc	agcaggtgg	l.tgngagtgc	ttatgagglg	atcnaactca	aaggclacgc	840
	atcctggguk	cttggaactct	ctgtaycayn	tttgacagag	agtataalg	agatcttag	900
	gcgggtgcac	ccaglttcc	ccatgattaa	ggttclllk	ggaataaagg	atgalgtctt	960
	ccctagtttt	ccctgcattt	tggyacnqna	tggaatctca	gaccllgtgn	agtgactctt	1020
	gacttctgag	ynagagqccc	gtttgaagaa	gngtngngnt	acactttggg	ggal.ccnnaa	1080
20	ngagctgcaa	ttttaagllc	hctgatgtc	atatacttt	actgtctnng	ctacaacagg	1140
	atctagghn	gaggttgctc	atgllglkch	ttttatctga	ctgtgalla	ncqcaqtaat	1200
	attttaagat	ggactcngna	naacatcaac	tcctgaaglt	anqataaga	atggtllgtu	1260
	anctcnacag	ctatatcctg	alyctggntg	gtatttaact	tggtgaqlcl	tcacttggtt	1320
	agtgtgaaal	agttctgcca	ccctgagcgc	acccclgccc	atnctgtacg	tactgcaltt	1380
25	gccccttgag	ccaggtggat	gllkacnctg	tggttatata	ctccclggcl	ncctcaactga	1440
	acatgucnag	tcnncactt	tttccagtg	aglcacnctc	tgqnatccag	tgla.ccnna	1500
	caatatcatg	tbllytgcak	natcttcca	aaggatctta	lllllylynn	tatatcagta	1560
	glykcnatta	ccatataatg	taaaahyati	tanatacaaa	caatgcaacc	aculatccaa	1620
30	gtgttatacc	anctcaaac	cccaataaac	cttgaacayll	g		1661

&lt;210&gt; 32

&lt;211&gt; 4169

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

	ggcgggttcc	aggtgagngn	ncaggccgt	ggtcctgctt	lylyccclclg	acctgctgct	60
	gctgctgcta	ctgtacccac	cgcclgggk	ctgcggggcc	nanngctcgc	cggggagcc	120
40	cgacaggtcl	cccccaactc	cccggaagaa	gaagaaggat	allcygath	ccatgatgc	180
	agacatggcg	cgtcl.kctgy	ngnaatngna	gaagatgat	gacattgaag	aaygagakt	240
	hcaagagcac	aagagacctt	cagcacclgl	cynclctctc	aaqatngacc	caagcaagcc	300
	tgaaagclak	ttqnaactga	cgaaaaaagg	gaagactctc	algalylklg	tcactgtatc	360
	aggaagccot	actyayaygy	ngncaqngn	anttaacagc	ctctggcagg	gcagccllll	420
45	caatgcacac	tatgaactcc	agaggttcat	lylyyyahcn	gacgtgcta	tcttcatgct	480
	tcogcatggg	agctacngct	ggagatccan	ggactttttg	gtcggkcaag	acaggtgkge	540
	tcactgaact	ctggagggcc	aggl.gk.kct	cunccanngg	ggaggaagca	aagagaaaa	600
	taaaacnnng	ccaaacaagg	gcaaaaaaa	gaaggaagya	gal.chgnat	ctcgttcttc	660
	caaggaagaa	atctgaactg	ggaataaaag	agaagacctg	tgatggggca	gcaglyagcc	720
50	gctgtggggg	gacaggttga	cglggagng	hcttgcncn	gtcctgggg	tgggagtgg	780
	ctcaggcaat	tgcaacnng	atgacattct	agtgctctct	agaaagggtc	lyccanctgn	840
	ccagtttgtg	gtcaagaaal	laclgcllkn	hcgacttcan	qtaagaagac	agatgttttc	900
	taatlactac	tggaacttga	caaatctcatg	tttactctaa	aalclclclh	catggaatg	960
	tgactgtgll	gctttttccc	atttaccact	ggtgagtrct	caactctact	gagattccac	1020
	tcocctocaa	gcactgctg	l.gal.kggglg	gcctgctctg	atcagntagc	caattctgat	1080
55	cagagagngc	tttaaaactc	ttgaactta	tgagttaacl	ctccalynca	katagctcat	1140
	tttcaltak	tttaaggtaa	aatatgcttt	gtgaactcag	atgtctgtag	ccaggaagcc	1200
	aggggtgtga	aatccannat	ctahgcagga	natgcgggga	atnqaanata	tgtaacttga	1260
	aalccctnng	agttttgaat	ttctttgact	tgaactctac	tcactagtaa	gnggachctt	1320
60	ggtgtctgk	aggttttatg	tggtctgtaa	agttaggggt	tcctgtttgt	ttccttattt	1380
	aggaagaggt	acthctgkty	tnaggggghl	atctgttccc	ttcaatrtgn	cagttttana	1440
	ggatttaagt	aggggaatcag	agtcctttgc	agagtgtgac	agagagkcca	alacclnal	1500
	ttgtllctaa	ncattttctt	ttgataaagt	gctaatctct	gtgclttcgt	atagagtaac	1560
	atgatgtgct	acthgtgaty	trtgakltttg	ccgttccatg	tanagccctc	tgtgaatnag	1620
65	agltanqaca	cttatataca	gatgtcattt	ctaagaacla	aatctctttg	ggnaaaaccc	1680
	tcaattylga	ttttaatana	tttaannatg	ccacttacat	ggttagaaaa	tgtaactgtt	1740
	aaagaatggt	acaaagtga	aagtgatctc	clclclhgc	gonggtngka	gcttcttcca	1800
	gtggagagctg	ctgttaacaa	tttgtgcccc	caactcccc	tccttgcaca	tcnaccsaaa	1860

	aaaagtagcat	ttactttatgt	aaatgtactt	atgghgatgt	atgttttgtt	tggcclmna	1920
	gcattotgtt	cccttaatt	tgttagclgt	tcacatltcc	clmnaagaa	ccacacccctc	1980
	tgcattctca	gttattttgt	ttgqatggga	catttgccct	gcagltcccc	caccttccag	2040
5	gcatgctct	ctccagggtg	aggccctgt	gatclaccgt	actagggtat	taggcccctga	2100
	aaagagcttl	tcttgttcc	cttgcatctt	gaacctggag	cyygagctgt	lghaggccccc	2160
	gcccttggag	aaqnaactg	tctgacagtg	gyyagagagc	gcacacacct	ggtggcalka	2220
	acagatctct	gaatcatgac	gtggcttga	caagctctgt	clgtgggctt	ttctgttgtt	2280
	actcaggcca	ttttgatggg	gttactgtcc	tccatagcca	taatggccca	gtatawcca	2340
10	gctglhltga	tyaghtaatt	gclhkaatta	agcnaaggt	agcnaagcll	tcactccgcc	2400
	ctgtacclh	tgtttccact	taggagccct	cccatglccg	aatgttccga	tcghctcat	2460
	tgttccctgt	gcagtgtgac	ccnacttcc	clmgtagttl	ctgtgtgtct	gttatgtact	2520
	aggtactaca	aggtgncagg	acggtgtaga	tacagccct	gclatcgtaa	actcactga	2580
	ttcggctguy	gaagacaaat	ctcagtaalg	tacaaaglna	aatggccct	gttagaagha	2640
15	lgaagggggc	nyggtagggg	uaggtagaat	cltccctgar	raggttaagc	aaaccagagg	2700
	ccctctctga	gyycaagagg	aggagagggg	aaa lnaagta	ayyccngcag	agcnaacagt	2760
	ctgagclnag	acccctgtgac	tagaaglggt	agagggagag	gcagltuygan	ggccagcuyy	2820
	gaggtctggg	cccatgtcag	gucacaggtt	gagggagcta	gcacatggag	tttgttagga	2880
	gttlygncog	ccclgttnga	tcttattct	gatggggtng	gtglgnaagg	cagtcnagg	2940
20	tgcactggtt	gcacaggaga	actgatcaga	agaggaaccc	agcaggtgtg	agccctgagc	3000
	tgggaggtgc	tlncgtagtg	caggcactag	ctgaaggtgt	ccclmctcag	caggtgtatg	3060
	gtgaggtttg	aaocactglt	tcactgcaln	gtccctgclg	atggacatcl	gagtgttccg	3120
	acttttttgt	ggtatattca	gtyctgcagt	gyaatttttc	alcccaata	tlctgctaca	3180
	cttttgttta	tacttgaaag	gtaaattcc	agcagtagaa	ttattagagc	aaacggcaat	3240
25	lncacattttg	gtgtgtattg	ccnatttgc	ctcccaagt	gllhagtcag	cllcnatttg	3300
	ccacnctag	atclalnctt	gccagclh	ggcatcact	ttaccayllt	aatagattgl	3360
	aaaaccatct	cttaatttgc	lncctgaag	ccnccatct	gyagaggtgt	clhcnagtgt	3420
	lcnccgtaga	gyaggggata	cccagggagg	ccacclgctc	ccnccnagc	tgcattgaglc	3480
	ttccacgccc	agccacagcc	atgtggatln	gatttaaaan	ttccagccn	ccgcttcaa	3540
30	gcaatccclag	ttgacactga	gygngccaa	calnagctga	gclagaaac	agcllgccn	3600
	gtctgcagat	lcnctngcaa	agaaallgtt	gggtctggtt	cagtggctcn	agcctgtat	3660
	ccagctant	tgggagggcg	aggtgggtgg	atccgttgag	gtcnggagtt	tggagngagc	3720
	ctggccaaac	tnctgaagcc	ctglctctac	taaaaactag	ccgaglytng	tgggtggggc	3780
	ctgtactccc	agclactcn	gtggctgagc	cnngagaaag	gcttgaaccc	gyynggcnca	3840
35	ggttgcaghg	ngccaaagac	nggcaactgc	actcnagcct	ggalggggg	atgagactcl	3900
	glntccaaas	nnngaaacaa	aaattlllht	agagaalgt	catttgttll	lgtttttgag	3960
	acagggctctc	actctgtlgt	ctcactaga	glgcnagtag	gctcnaggct	cactgaaglc	4020
	tctacctacc	agctcaattg	actctnccac	cacagctcc	caaatagctg	agagaaatgt	4080
	ccgtgtttta	atgnaattgt	cttctttll	gtcttgttll	ctttaatate	taglyatctg	4140
40	ataaattclng	atgatctcll	ltgactatc				4169

<210> 33  
 <211> 859  
 <212> DNA  
 <213> Homo sapiens

45	<400> 33						
	catgccakgc	agcttacna	ccatcgagtc	tgggaactatg	ctggagahka	ctatgttcat	60
	agcctgggtt	cnagttaaac	agatgganng	atagtaayt	atgaatgtga	gggygkact	120
50	tgcunngag	aganaataga	tgccttacag	llnaggtatt	clhatttact	aaacaagccag	180
	ctggaatctc	agcgaatcta	ctgygnaanc	aagataghtc	ggatagayaa	ggacccagca	240
	ggggaatta	acnccntgaa	gaccaagttl	nnagaaacaa	ltngnaagt	tgataatcln	300
	gagcacnnc	taattgalct	ctctanngaa	aagcagtctg	tgganngnna	gtgcactcag	360
	ctaaacacn	nagtgcccaa	actcannnc	gagctcaann	aggaagcayg	nalgaanng	420
55	tglttgagag	ccnccnagt	ccctctgcag	nnnagctaa	aggaagagga	gaggggtctg	480
	aaggggaccc	gtgacccnna	ngatctgcag	atcnncngna	tccaggnagc	gctgctgac	540
	ctcatgttct	acctggagac	acagcagngg	atcaacnctc	tccctggcca	gacccggcag	600
	gaactccagg	aggggcagat	caacatcgcc	algccctcgg	clluyagccc	tgcctcttcg	660
	gggggcactg	ggaagtgtcc	ctcnngnag	ggccgcagca	agaggggcaa	gtgnacthca	720
60	gagcaacagc	catccctgag	actgttclcc	ctgacactgl	gagngtgtgc	tgggaccttc	780
	agctaaatgt	gmygttgggc	cccaataagt	acnagtgagg	acynnngccc	gocctcgtgg	840
	ccttagagat	ggatgagcc					859

<210> 34  
 <211> 1070  
 <212> DNA  
 <213> Homo sapiens

65



&lt;400&gt; 34

gagattgchg	gggtgcagc	gctgcctccg	agaccgagag	tgggtggagc	gggtcttcc	60
ggaaggggtgc	gataagggccg	ggcagaggtgc	ctgggatget	tctcccttc	cgagaggaag	120
agalcctatt	gggtagggcg	gggtgcagact	agcclgagc	gocgcgcgc	ggcaccctgc	180
gctcctggg	ggcctgggg	cccgccgagc	aggttggtta	ggggagcgag	gcyttttctc	240
ctggggctcg	agggcgccct	ctcagccct	gctcaccaga	agcgggagtc	ccgtggggtc	300
tgagagagca	gtttccttct	taatacacaat	aaatcctgc	tccctctgc	tcagacatct	360
acycagcgaa	atcgagcctg	gccttgaggg	tcacacctgc	gaggaagatg	cylgcgcaca	420
ttccagagcc	taagcctggc	gacotgattg	agctttctcg	cccllctctac	agacactggy	480
ccatctatgt	tgccgatgga	tatgtgttct	atctggcctc	tcacagtgag	gtcgcaggag	540
ctgggtgcag	cgctgtctct	tcgcgcctgc	ctgacaaggc	ctcctgagag	aaggaaclgc	600
tgtatgatgt	ggcggggagt	gacaggtacc	agglcgcaca	caaacalgc	gacaggtact	660
gycgcctgoc	ctgcacgaaa	atcaltccagc	ggcgccgagc	gctgtgtggc	caggaggtgc	720
tctacaggt	gacaggtgag	aactgcgagc	atctgtgaa	tgagctgctc	tatggagtgc	780
cccgccgtga	ccaggtcaga	gtatgtcatc	tcgtgtcagc	cgttgccagc	akgggtctgc	840
cagccctgag	ccttatttga	gtcatgtctc	caagaaacaa	gcccacaaag	caataactgc	900
aaaagactgt	ctgtccagcg	tcactttata	calcaggggc	gtctgtctcl	gctagagagt	960
ttgggggtttg	gtttgtggat	ttcatlgtgc	tttataataa	ggtttatttt	ccagaaclgc	1020
aataaagcgc	gacgtgggag	gattttattg	ggggggtgca	gccccaaaa		1070

&lt;210&gt; 35

&lt;211&gt; 460

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

cttttctcc	catgtctgca	ccgaggtgac	acggcggagc	cttctccgc	gctccgcgc	60
cagaagccgc	cgcgatgcgc	ctggtgcct	cctacctgct	gctctccctc	gggggcaact	120
ctctccctccg	cgcccaaggac	atcaagaaga	lcltgcgcag	cgtgggtatc	gaggtccgag	180
ccgacccgct	caacaaggct	atcgtgtgac	tgaatggaaa	gagctctgaa	gacgtcattg	240
ctcgggttat	tgcgaagctt	gacaggtgac	clgtctgtgc	gggtgtgac	gctctgtctg	300
ccccaggtc	lgtcggcct	gctgtgtgt	ctgcccctgc	lgtcgcagag	gagagagag	360
atgagaagaa	ggagggagtct	gaaggtctgc	atgatgacat	gggtctctgc	cttttctgatt	420
aatctctgc	tccctctgca	ataagcctt	ctctcctgc			460

&lt;210&gt; 36

&lt;211&gt; 4416

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

gcccgcacag	gttttatagg	atcacattga	caaaaglcgc	atggagtgtt	atgagtcagc	60
atattttatt	gttctctctc	cttcaatagt	tattacagta	atttctctct	tctctgtgct	120
tttcatgaaa	gaaacattat	atgatgaagt	lcltgcgcag	cagaaaagag	aaacaaagct	180
tattctctgc	aaanccgata	aanngaaagc	agaaaagaa	agagctctct	agaaagaaat	240
ccagaaatga	aaactctcgc	aatgtgctgc	ctcagagact	lcltgcgcag	lcltgcgcag	300
agatgctttg	gcagtagaag	atgatcaagt	tgcaatgtt	ccattgaatg	tcgttgaaac	360
ttcaagctgt	gttagggaaa	gaaaaagaaa	ggaaaagaaa	caaaagctgc	tgcttgaaag	420
gcaggtctac	aaagaaagtc	ccgcctctgc	gattcctggc	aaaaagctgc	aaacgtctgc	480
agttactaaa	cagcccccgc	ctcctctgca	agcagctgc	tcgaagagag	aaacagggca	540
gaagagctct	aaactgtgaa	gcgatgacca	ggataaaag	gltgcgcagc	tcctgtctgc	600
atcaaaaagg	caagaagcat	tgccctctgc	ccagagagct	aaacaaagaa	gtggatcagc	660
gaagagagaa	gcttcatcaa	agaaacaaaa	gacagaaat	gtctctgcag	atgacccct	720
tattcatgca	atctctctgc	lcltctctgc	ggataatgct	gactcaagtc	ctgtgtgagc	780
taagagagag	gttattgatt	tgcttaaaac	lgtcgcagta	gaagggatcc	agaaatctgc	840
gaclaaaaaa	ctgagacccg	aaactgacaa	agaaaatgcl	gaggtgagct	tttaagatct	900
tcttctgtcc	lgtgagagct	gtgtgttttc	tgaaagatgag	gctcttctgc	ttgtagactc	960
gctaaaggag	aggtctgtgt	taatacaaga	tgctctctgc	aggtcaagta	agggagaaat	1020
gactcctctt	atcacatcagc	ttcaagaaaa	ggacaagtta	ctctgtgtgc	tgaaagagag	1080
tgctgtctgt	aaagagagct	gtgtgtgtgc	gttaacccag	gaatgatga	cagagaaagc	1140
aaagagcaat	gtggttatat	caaggatgaa	agatctcaat	ggacattag	aaaggaacac	1200
taagtgtatt	caaaacaaaa	tacatgtcag	ttatcaagag	atctgtgtgc	tgcatgtgaa	1260
gttctctgca	gttctgtgagc	aggtgtgtgc	agagatagct	caattgtgagc	aggtgtgtgc	1320
tatactgaga	gatgtcaglc	gcaactctgc	aaatcaactg	gaaagcaagc	agtctgcaga	1380
actaaataaa	ctacgccagc	attatgtctg	gttgtgtgag	gagctgagct	agaaaacagc	1440
aaagctctgc	caagaggaag	tcacaaagaa	ggtgtgtgag	caagagagct	ctcgtgtgag	1500
ggttcaactc	caagagagct	aggtgtgtgc	gggtgtgtgc	cagagctaca	tcaggaagag	1560

	aacagcggaa	catgagggcag	caagagcaaga	tttacagaggt	aaatlhqtgg	unnagaaa	1620
	tgaagtacag	agtctgcata	gtatgcttac	agatcccttg	gtatcaaaa	aaatggttga	1680
	gcnaagacta	atccagttta	tggatccaga	gcagaahngg	glyancaazg	aagagctctct	1740
5	acaaatgmgag	gttcaggata	tlitggagca	gmitgaggcl	ttgaahgctc	aaatttcagca	1800
	gttcatttcc	cagatagcag	cccagacctc	cgcthcaqct	ctagcagaag	aattacataa	1860
	agtatttga	gaaagggata	agcagatana	acagacagaa	gatlcctttag	aaagtgaacg	1920
	tgatgttta	acaaagttaa	aaagaggact	taaggatata	cagaatatga	atllcttatt	1980
	aaaagctgaa	gtgcagaaat	tacagagccct	ggcanatgag	caggctgctg	ctgcacatga	2040
10	attgagagaag	atgnaacaaa	gtgttttatg	taaagalgat	aaaalaaat	tgctggaaga	2100
	gcaactatga	catgaatttt	caannanaat	ggaggaattt	aaatctctaa	atgacaaa	2160
	canagcattta	aatcagaay	tccagahyct	acagacictt	gtcttctaac	agcctaataa	2220
	ggahyttgtg	gaacaaatgg	aaaatatgat	lunagaaaaa	gatgagaagt	taaagantgt	2280
	ggagaaatga	cttgaaactg	gactlattca	ggtygganct	aaagunaggg	agctgaatgt	2340
15	ataaagaaca	gnaaattcal	ctctgacaaa	agaagtlcnu	gactlanaag	ctahgcaaaa	2400
	tgatcagggt	tccttttgct	ctctagttya	hgaacttaag	aaagtgalac	atgagahaga	2460
	tggaaagatc	aaagtclytg	aaagagttct	ggagggcaga	ctctctaaaag	lkqctaataa	2520
	ggagaaactc	gttcaggatt	tgaacacagg	aataaaggcl	ctaaaagang	aaatagygna	2580
	tglcragctt	gaacaggtct	aaaggttate	talctctctc	aaagttcagg	agcttcagaa	2640
20	ctttattaaa	qnaaaagagg	aaacagalga	tccatgahy	gctgtllctg	aaagahaga	2700
	gaagagacta	gcaaatacag	gnaagtgtgt	acaggatctt	caahgaagaaa	atgaatctll	2760
	aaaagcactat	gttcaggagag	tagcaahaca	taacttgana	gaggcctctt	ctgahacaca	2820
	gtttgaagaa	cttgagattg	tggtgaagaa	hahggaahat	gaaattgaaga	gattagaagc	2880
	catgctaaaa	gagagggaga	gtgalcttct	tagcaahaca	cagclgttnc	agahgtaca	2940
25	agatgaaaaa	naattgttta	agtcocaaa	tgagcagcti	hacaacaaa	actaccaaaa	3000
	ggcctctctc	tttccccctc	atgahgaatt	attaaaagta	atttcagaaa	gahggaaga	3060
	aataaglygt	ctctggaaicg	agtttagalhc	tttgaaggah	qaggttgahc	acagagggag	3120
	gnaaaacaa	gaagggcagc	hahnggtgga	ayctgtttgag	llggaaggcta	aaagagttct	3180
	caaaaaatta	tttccnaagg	tgletgtctc	ttctantttg	agttahngtg	aalgggttga	3240
30	tggatltgaa	aaaaagggan	aagaatghct	gagtggaant	tcagggtcng	aggaggliaa	3300
	ggttctagag	caaaagttga	hagaagctga	tgnaatgcac	actttgttac	ayntagagtg	3360
	tgaanaatac	aaatccctgc	ttgcagaaac	agaaggaaht	ttacagahgc	tacagahng	3420
	tgttgagcna	gaagaaaaah	antggaaagi	taaggtcgat	gaaacacaca	agactattaa	3480
	acaagatgcag	lcaatattga	cahcttcaga	acaahngcta	gagcynthaa	gaagggcnaa	3540
35	taaggahmtt	gaaaatctga	gaagagahng	aghaacattg	gaatggaaac	tgaasaagga	3600
	agagatggaa	gaaatctact	ahgttacaga	aghaahngag	ttgahggcac	aglttaatga	3660
	aaactctaca	aaactttagaa	ctgahcaaaa	tgaagahng	aaagtagahg	gtgattttgc	3720
	taaggtctca	cagtcacclg	agottatcca	gtcaaaaata	gtaaaagctg	clggagacac	3780
	tactgttatt	gaaatctagt	atglttcccc	agaacagggg	tcttctgaga	aggagacant	3840
40	gtctgtahgt	ctaaatcaga	ctgtaacana	gttccagcag	lkqcttcagg	cgntaaacca	3900
	acagctcaca	aaagagaaaag	agcctacca	ggtlyhtagag	tgaagkanti	gggaahctgt	3960
	tcaatttgagg	alaaahnaagg	callgtatta	tattttgnaa	nattaaagnc	ttattttatg	4020
	tttcaactct	tctaccltgt	cagaacacac	gaacagagtt	lhtcttttct	laatccttgt	4080
	tngactactg	atttaasgaa	gnaaaaaaaa	aaagcaactc	tgtagahccc	ttcagagttt	4140
45	agittttataa	taaaaactgt	ctgahnaatt	agaactllac	attctctgag	ataaacatgt	4200
	aatctlltat	cttattttgc	tcaataaaaa	hgttcagaag	alcaahngtg	taahgacat	4260
	gtaaaattta	acattttaat	aclyntgttg	taactyittt	tacttaacnt	tttgggaagi	4320
	aatgctctct	gaacttaant	caagaaacaa	hhtttttgtc	gclaatgtaa	caghtttttg	4380
	taatggogtc	agcaaataaa	aggaatgctta	ttattlc			4446
50		<210> J7					
		<211> 620					
		<212> DNA					
		<213> Homo sapiens					
55		<220>					
		<221> unsure					
		<222> 284..284					
		<223> n = a, c, g or t					
60		<220>					
		<221> unsure					
		<222> 594..594					
		<223> n = a, c, g or t					
65		<220>					
		<221> unsure					
		<222> 597..597					



<222> 563..563  
 <223> n = a, c, g or t  
  
 5        <220>  
       <221> unsure  
       <222> 640..640  
       <223> n = a, c, g or t  
  
 10       <220>  
       <221> unsure  
       <222> 681..681  
       <223> n = a, c, g or t  
  
 15       <220>  
       <221> unsure  
       <222> 689..689  
       <223> n = a, c, g or t  
  
 20       <220>  
       <221> unsure  
       <222> 708..708  
       <223> n = a, c, g or t  
  
 25       <220>  
       <221> unsure  
       <222> 714..714  
       <223> n = a, c, g or t  
  
 30       <220>  
       <221> unsure  
       <222> 728..728  
       <223> n = a, c, g or t  
  
 35       <220>  
       <221> unsure  
       <222> 730..730  
       <223> n = a, c, g or t  
  
 40       <400> 38  
 Axxxaatttg gcaagantga agaccgaacc lgaaxangaa aalyctgaag tgaagtttaa 60  
 agattyyctt ctgtcttga aaactatgat gttttclgaa gatgaggclt bttgtgttgt 120  
 agactyncln aaggagaagt ctgglgkhat acaagatgct ttanagaagt caagttaagg 180  
 ngnattgact acgchtatac atcagettca agaaaaggac aaglyantog ctgtgtgtga 240  
 ggaagntgct gctgcyaacn aagatcngtg taagcagltt acccaggaaa tnatgacaga 300  
 45 gaaaganaga aqcnatgtgg ttataacnng qatqanagay cyaatyqgaa cattagaaza 360  
 ggracataat gtatyycaan acaaaataca tgcagtyat caagagacyt aacagntgca 420  
 gatgaagtlt cagcaagttc gtgagcagat qgaggcagay atagcyoact tynagrayg 480  
 aatgggnata clngnqnat gcagtcagca acactacaaa tcaaclgaa agcaagcagt 540  
 ctgcagaaact aaataaacta agncaggatt atgctagglc ngtgaatgag cctnactnng 600  
 50 nacaggaaa gctacagcaa gaggaagtcn aagaagaatn clngncaagc agctaactcag 660  
 tggaggttcc caactacnng nacgctgng agaagghagg ggaggcgnlt cagngcctac 720  
 atcagggngn  
  
 55       <210> 39  
       <211> 571  
       <212> DNA  
       <213> Homo sapiens  
  
 60       <220>  
       <221> unsure  
       <222> 37..37  
       <223> n = a, c, g or t  
  
 65       <220>  
       <221> unsure  
       <222> 42..42  
       <223> n = a, c, g or t

60  
 120  
 180  
 240  
 300  
 360  
 420  
 480  
 540  
 600  
 660  
 720  
 730

5       <220>  
      <221> unsure  
      <222> 64..64  
      <223> n = a, c, g or t

10       <220>  
      <221> unsure  
      <222> 67..67  
      <223> n = a, c, g or t

15       <220>  
      <221> unsure  
      <222> 73..73  
      <223> n = a, c, g or t

20       <220>  
      <221> unsure  
      <222> 86..89  
      <223> n = a, c, g or t

25       <220>  
      <221> unsure  
      <222> 106..107  
      <223> n = a, c, g or t

30       <220>  
      <221> unsure  
      <222> 117..117  
      <223> n = a, c, g or t

35       <220>  
      <221> unsure  
      <222> 139..139  
      <223> n = a, c, g or t

40       <220>  
      <221> unsure  
      <222> 153..153  
      <223> n = a, c, g or t

45       <220>  
      <221> unsure  
      <222> 243..243  
      <223> n = a, c, g or t

50       <220>  
      <221> unsure  
      <222> 257..257  
      <223> n = a, c, g or t

55       <220>  
      <221> unsure  
      <222> 264..264  
      <223> n = a, c, g or t

60       <220>  
      <221> unsure  
      <222> 319..319  
      <223> n = a, c, g or t

65       <220>  
      <221> unsure  
      <222> 337..337  
      <223> n = a, c, g or t

      <220>

<221> unsure  
<222> 341..341  
<223> n = a, c, g or t

5        <220>  
         <221> unsure  
         <222> 353..353  
         <223> n = a, c, g or t

10       <220>  
         <221> unsure  
         <222> 362..362  
         <223> n = a, c, g or t

15       <220>  
         <221> unsure  
         <222> 373..373  
         <223> n = a, c, g or t

20       <220>  
         <221> unsure  
         <222> 379..379  
         <223> n = a, c, g or t

25       <220>  
         <221> unsure  
         <222> 384..385  
         <223> n = a, c, g or t

30       <220>  
         <221> unsure  
         <222> 419..419  
         <223> n = a, c, g or t

35       <220>  
         <221> unsure  
         <222> 421..421  
         <223> n = a, c, g or t

40       <220>  
         <221> unsure  
         <222> 427..427  
         <223> n = a, c, g or t

45       <220>  
         <221> unsure  
         <222> 433..433  
         <223> n = a, c, g or t

50       <220>  
         <221> unsure  
         <222> 440..442  
         <223> n = a, c, g or t

55       <220>  
         <221> unsure  
         <222> 444..444  
         <223> n = a, c, g or t

60       <220>  
         <221> unsure  
         <222> 448..448  
         <223> n = a, c, g or t

65       <220>  
         <221> unsure  
         <222> 450..450

<223> n = a, c, g or t  
<220>  
<221> unsure  
5 <222> 455..455  
<223> n = a, c, g or t  
<220>  
<221> unsure  
10 <222> 486..486  
<223> n = a, c, g or t  
<220>  
<221> unsure  
15 <222> 488..489  
<223> n = a, c, g or t  
<220>  
<221> unsure  
20 <222> 493..493  
<223> n = a, c, g or t  
<220>  
<221> unsure  
25 <222> 496..497  
<223> n = a, c, g or t  
<220>  
<221> unsure  
30 <222> 500..500  
<223> n = a, c, g or t  
<220>  
<221> unsure  
35 <222> 504..504  
<223> n = a, c, g or t  
<220>  
<221> unsure  
40 <222> 506..507  
<223> n = a, c, g or t  
<220>  
<221> unsure  
45 <222> 515..515  
<223> n = a, c, g or t  
<220>  
<221> unsure  
50 <222> 520..520  
<223> n = a, c, g or t  
<220>  
<221> unsure  
55 <222> 523..523  
<223> n = a, c, g or t  
<220>  
<221> unsure  
60 <222> 525..526  
<223> n = a, c, g or t  
<220>  
<221> unsure  
65 <222> 538..538  
<223> n = a, c, g or t

&lt;400&gt; 39

aaya	aatgc	cttttttate	cccaaatagc	rcagtttccc	anttaactlca	ctettacacc	60
tgg	nagngcl	ctntctcoct	lgtgrnnnnn	nnnnnnnnnc	cccccynncg	aatggtnctg	120
taact	gtggt	acaghetqnt	ttagggtttac	agncattqtc	tccllclccag	gaggclccgt	180
ttct	ggggga	acatcaactll	tttcaataan	agttagtgtcl	ccgcgcagcti	ttactatttt	240
tgnct	ggata	agttccngtg	aelattgagc	ottalgcac	tcacacagata	ccttclykat	300
ttca	klttgt	tcagttctna	gttttgtagg	tgittctnttl	naatgtgcay	kenactctct	360
gnott	ctgla	acntagggng	ghnnntccct	clnttgccttt	telagttccc	tttccmang	420
ntct	qntct	ccnccccagc	nnghnnannc	ccgcnaclctt	tcgcttclla	attcggtcta	480
gcct	nnnnc	cgnagnnggc	aaangnnngc	tgcancgcgc	lfnannagge	clgtgtqntt	540
cat	ggcctll	tanctttccc	tttctttctt	t			571

&lt;210&gt; 40

&lt;211&gt; 644

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; 415..435

&lt;223&gt; n - a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; 525..526

&lt;223&gt; n - a, c, g or t

&lt;400&gt; 40

atallctmga	gcagaatgag	gttttcaaaq	ctcaaatkca	gcagttccat	luncagatag	60
cagcccagat	ctccgcttca	gttclagccag	aagaattaca	lannqgtgatt	gcagaaaagq	120
atnagcagat	aaacacagct	gaagattctt	lagnagctga	acgtgacagc	ttanccaagta	180
aagaagagay	aottaaggat	alannagata	tgaatttcll	attanaagot	gaagtgcaga	240
aattacaggr	celggccat	gagcaggtct	clgctgcaca	tgaalllyng	agatgcac	300
acagtgctta	tgttaagaa	gttanaataa	gattgcclgg	agagcaacta	caacafyaca	360
tttcaaacac	notcaagaa	tttaagallc	tanntgacca	aaanannnra	ttanaticag	420
aggttcagaa	gttacagact	cttgtttctg	aacagactaa	taaggatggt	glynnaccca	480
tggaaaaatg	cattcaagaa	aagahagaaa	gttaaaagac	gtcgnngatt	acttgacact	540
ggaattatcc	ayttgcacac	taaagagagg	agclggtqca	tagacagaca	tcactctctg	600
acaaagagtt	caagacttac	aythagcaaa	tgatcagglc	cttg		644

&lt;210&gt; 41

&lt;211&gt; 566

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; 47..47

&lt;223&gt; n - a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; 59..59

&lt;223&gt; n - a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; 91..91

&lt;223&gt; n - a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; 104..104

&lt;223&gt; n - a, c, g or t

&lt;220&gt;

&lt;221&gt; unsure



<222> 441..442  
 <223> n = a, c, g or t

5  
 <220>  
 <221> unsure  
 <222> 448..448  
 <223> n = a, c, g or t

10  
 <220>  
 <221> unsure  
 <222> 457..457  
 <223> n = a, c, g or t

15  
 <220>  
 <221> unsure  
 <222> 525..525  
 <223> n = a, c, g or t

20  
 <220>  
 <221> unsure  
 <222> 539..539  
 <223> n = a, c, g or t

25  
 <220>  
 <221> unsure  
 <222> 564..564  
 <223> n = a, c, g or t

30  
 <400> 41  
 caacacacac tcaaggtctll caaacctggga tgcagagagag gacatctntca agtllatqtng 60  
 tgcactctln tgaacaaggg ctlyaaaaga ntcaatggtt totngagag ccogtaacaa 120  
 attcccgta ttggtatagg atttctctll ctcttcaaaa caacaccttca lggatctcat 180  
 ctgltgctct ttctcttlla ataggttcyg aagcctctga actllggag tgatagata 240  
 cygttgagcc ltttcaagct ggaratllln tttttctct tttagagct lttttcccg 300  
 35 tllcaantcc cgaacaglll kttcttgtt agcacccttg agaaglgccg cctccagag 360  
 ctcttctaca gacttgatct ttaacchctc tcatggalca ctctcttaag gtcttcaact 420  
 agagaggcaa aagaacacga acatttgnta gttttanget cgaactctt ttgltcagga 480  
 tgaattctct qttcttattg caktcaqctc ctcttcttta ggtgncacaa naataagyn 540  
 agtqtaaga aallcttcca cagnot 566

40  
 <210> 42  
 <211> 878  
 <212> DNA  
 <213> Homo sapiens

45  
 <220>  
 <221> unsure  
 <222> 595..595  
 <223> n = a, c, g or t

50  
 <220>  
 <221> unsure  
 <222> 756..756  
 <223> n = a, c, g or t

55  
 <220>  
 <221> unsure  
 <222> 766..766  
 <223> n = a, c, g or t

60  
 <220>  
 <221> unsure  
 <222> 815..815  
 <223> n = a, c, g or t

65  
 <220>  
 <221> unsure

<222> 818..818  
 <223> n = a, c, g or t

5  
 <220>  
 <221> unsure  
 <222> 827..827  
 <223> n = a, c, g or t

10  
 <220>  
 <221> unsure  
 <222> 831..831  
 <223> n = a, c, g or t

15  
 <220>  
 <221> unsure  
 <222> 853..853  
 <223> n = a, c, g or t

20  
 <220>  
 <221> unsure  
 <222> 866..866  
 <223> n = a, c, g or t

25  
 <400> 42  
 accttaaacct cctctgacck gaaqttccag ccataaatte ttttgccctt ktttcaatcc 60  
 atgcaacuat tccccataac tcaahktagn agggacagac acrhhtgqaa ataaklkkt 120  
 gagaacttct ttaycctcpa actcaacagc ctnc>ectgt tgotgcollk cattgttttt 180  
 ctctctctgg tgttcaactg cctccttcaa agaatckaa: bcattccaga gaccacttat 240  
 ttctttctcl cttcttgaaa ttactttll> baattcttca tgagggggaa aagaagatgc 300  
 ctatttgtag ttttgttggk taagctgctc aatttgggac ttaaaccaatt lgttttccatc 360  
 ttgtacakee tgtaacagct gtgtllkget agaaagatca clclmctct ctttttagcal 420  
 ggcttctaac ctctlcaatt cactttcctt tictltcaac acaatctcaa gkktttcaaa 480  
 clghgatgaa gaagaggcct clklcaantt atgttgtget acttctgaa catgtgcllk 540  
 taaaagattc attllkttct tgaagatcct gtamamctt cctgtattg yctkngtctt 600  
 35 tclckktctc ttccaaaaca gccllkraagg tatccatctg tttctctttt ccttttaaaa 660  
 agttctgaag cctctgaact ttgggaagtga kagataactg ttgagccctk tcaagccctgg 720  
 acattcttaa ttctctcttt aaaaagcctta attcngllk caaanccga aacagllkktc 780  
 ccccttgtaa gcaactttga yaaakctggc tccaancc ctcclanaga nttgatcttt 840  
 caacctttcc Aaaggattac ttccnaaag ttccllka 878

40  
 <210> 43  
 <211> 620  
 <212> DNA  
 <213> Homo sapiens

45  
 <220>  
 <221> unsure  
 <222> 391..391  
 <223> n = a, c, g or t

50  
 <220>  
 <221> unsure  
 <222> 400..400  
 <223> n = a, c, g or t

55  
 <220>  
 <221> unsure  
 <222> 411..411  
 <223> n = a, c, g or t

60  
 <220>  
 <221> unsure  
 <222> 414..414  
 <223> n = a, c, g or t

65  
 <220>  
 <221> unsure

<222> 418..418  
<223> n = a, c, g or t

5       <220>  
      <221> unsure  
      <222> 421..421  
      <223> n = a, c, g or t

10       <220>  
      <221> unsure  
      <222> 427..428  
      <223> n = a, c, g or t

15       <220>  
      <221> unsure  
      <222> 435..435  
      <223> n = a, c, g or t

20       <220>  
      <221> unsure  
      <222> 446..446  
      <223> n = a, c, g or t

25       <220>  
      <221> unsure  
      <222> 454..455  
      <223> n = a, c, g or t

30       <220>  
      <221> unsure  
      <222> 463..463  
      <223> n = a, c, g or t

35       <220>  
      <221> unsure  
      <222> 465..465  
      <223> n = a, c, g or t

40       <220>  
      <221> unsure  
      <222> 471..471  
      <223> n = a, c, g or t

45       <220>  
      <221> unsure  
      <222> 480..480  
      <223> n = a, c, g or t

50       <220>  
      <221> unsure  
      <222> 484..484  
      <223> n = a, c, g or t

55       <220>  
      <221> unsure  
      <222> 490..490  
      <223> n = a, c, g or t

60       <220>  
      <221> unsure  
      <222> 493..493  
      <223> n = a, c, g or t

65       <220>  
      <221> unsure  
      <222> 500..500  
      <223> n = a, c, g or t

5       <220>  
       <221> unsure  
       <222> 514..515  
       <223> n = a, c, g or t  
  
 10       <220>  
       <221> unsure  
       <222> 524..524  
       <223> n = a, c, g or t  
  
 15       <220>  
       <221> unsure  
       <222> 539..539  
       <223> n = a, c, g or t  
  
 20       <220>  
       <221> unsure  
       <222> 568..568  
       <223> n = a, c, g or t  
  
 25       <220>  
       <221> unsure  
       <222> 573..574  
       <223> n = a, c, g or t  
  
 30       <220>  
       <221> unsure  
       <222> 581..581  
       <223> n = a, c, g or t  
  
 35       <220>  
       <221> unsure  
       <222> 600..600  
       <223> n = a, c, g or t  
  
 40       <220>  
       <221> unsure  
       <222> 604..604  
       <223> n = a, c, g or t  
  
 45       <220>  
       <221> unsure  
       <222> 608..608  
       <223> n = a, c, g or t  
  
 50       <220>  
       <221> unsure  
       <222> 616..616  
       <223> n = a, c, g or t  
  
 55       <220>  
       <221> unsure  
       <222> 619..619  
       <223> n = a, c, g or t

60       <400> 43  
 accttaaacgt cctctgaccc tgaattccag ccacacacac ttttgccttt ttttcaaatc 60  
 catgcaacac ttccaccataa ctcaaattag aagggaacac cacccttgga aataattttt 120  
 tgagaacttc tttagcctcc aactcaacag ctccacacac ttgctgcctt tcattgtttt 180  
 tcttctcttg gtgttcaact gcacccctca aagaacacac ctcatccag agaccactta 240  
 ttctttctc tctttctgaa attacttta ataattcttc atgaggggga aaagaagatg 300  
 cctgtttggt tttttgttgt ttaagctgct caatttcgga cttaaacaaat ttgttttcal 360  
 cctgtacatc ctgtaacaga tgtgttttgc naagaacacac actcccccctt nccnttanca 420  
 65       nggggtancca acctcettta atacanttcc ttttacttca aannaaatct naggttctctn 480  
 caangggtan tynaaanan gcccttttca agtnnggttg tgcnaacttc tgaacatgng 540  
 ctttaagatc atttctctg aagatccngt acnttccagc nattggtatg ctccctctn 600

ttcnaaaanag cttaevngqng

620

5           <210> 44  
            <211> 623  
            <212> DNA  
            <213> Homo sapiens

10           <220>  
            <221> unsure  
            <222> 25..25  
            <223> n = a, c, g or t

15           <220>  
            <221> unsure  
            <222> 409..409  
            <223> n = a, c, g or t

20           <220>  
            <221> unsure  
            <222> 412..412  
            <223> n = a, c, g or t

25           <220>  
            <221> unsure  
            <222> 414..414  
            <223> n = a, c, g or t

30           <220>  
            <221> unsure  
            <222> 423..423  
            <223> n = a, c, g or t

35           <220>  
            <221> unsure  
            <222> 426..426  
            <223> n = a, c, g or t

40           <220>  
            <221> unsure  
            <222> 435..435  
            <223> n = a, c, g or t

45           <220>  
            <221> unsure  
            <222> 444..444  
            <223> n = a, c, g or t

50           <220>  
            <221> unsure  
            <222> 450..450  
            <223> n = a, c, g or t

55           <220>  
            <221> unsure  
            <222> 454..454  
            <223> n = a, c, g or t

60           <220>  
            <221> unsure  
            <222> 459..459  
            <223> n = a, c, g or t

65           <220>  
            <221> unsure  
            <222> 490..490  
            <223> n = a, c, g or t

<220>  
 <221> unsure  
 <222> 508..508  
 <223> n = a, c, g or t  
 5  
 <220>  
 <221> unsure  
 <222> 511..511  
 <223> n = a, c, g or t  
 10  
 <220>  
 <221> unsure  
 <222> 515..515  
 <223> n = a, c, g or t  
 15  
 <220>  
 <221> unsure  
 <222> 524..524  
 <223> n = a, c, g or t  
 20  
 <220>  
 <221> unsure  
 <222> 545..545  
 <223> n = a, c, g or t  
 25  
 <220>  
 <221> unsure  
 <222> 555..555  
 <223> n = a, c, g or t  
 30  
 <220>  
 <221> unsure  
 <222> 564..564  
 <223> n = a, c, g or t  
 35  
 <220>  
 <221> unsure  
 <222> 600..600  
 <223> n = a, c, g or t  
 40  
 <220>  
 <221> unsure  
 <222> 611..611  
 <223> n = a, c, g or t  
 45  
 <400> 44  
 accttaacct cctctgaccc tgaantctat ccatcacctc tttctgcttt ttttcaaaac 60  
 catgcaacca ttcaacataa ctcaaattag aagggacaga caactttgga actaattttt 120  
 tgagaacttc tttagcctcc aactcaacag ctccacactg ttactgactt tccLLggaag 180  
 tottgttcac ttgtctctgc agcatttttt cagttgatgc caatgcttcc attgcttccc 240  
 agttttttct ccgaaggtna ttgtttttct tctctcghg ttcaactgca tttttcaag 300  
 aatctcaact attccagaga ccaacttttt ctctctctct ttctgaaatt acttttcaat 360  
 attcttcatg aggggggaaaa gaagatgccc gctgggaatt tgglygttna ancgggccaa 420  
 ttnggnacct aaaaattttg gttncaactn gtatccccng taaaaactgt gttttgctaa 480  
 aaagataaon cccctctct ttaagpnnng nttonaaccl cttnattcat ttcttttct 540  
 tcaanaaaac tcaantctca aacngggatg uaaaagaggo tottcaayli aaggtgggcn 600  
 anttccggaa natggncttt aan 623  
 60  
 <210> 45  
 <211> 625  
 <212> DNA  
 <213> Homo sapiens  
 65  
 <220>  
 <221> unsur  
 <222> 392..392  
 <223> n = a, c, g or t

5       <220>  
      <221> unsure  
      <222> 400..400  
      <223> n = a, c, g or t

10       <220>  
      <221> unsure  
      <222> 417..417  
      <223> n = a, c, g or t

15       <220>  
      <221> unsure  
      <222> 421..421  
      <223> n = a, c, g or t

20       <220>  
      <221> unsure  
      <222> 424..425  
      <223> n = a, c, g or t

25       <220>  
      <221> unsure  
      <222> 437..437  
      <223> n = a, c, g or t

30       <220>  
      <221> unsure  
      <222> 439..439  
      <223> n = a, c, g or t

35       <220>  
      <221> unsure  
      <222> 456..456  
      <223> n = a, c, g or t

40       <220>  
      <221> unsure  
      <222> 467..467  
      <223> n = a, c, g or t

45       <220>  
      <221> unsure  
      <222> 469..469  
      <223> n = a, c, g or t

50       <220>  
      <221> unsure  
      <222> 473..473  
      <223> n = a, c, g or t

55       <220>  
      <221> unsure  
      <222> 475..475  
      <223> n = a, c, g or t

60       <220>  
      <221> unsure  
      <222> 496..496  
      <223> n = a, c, g or t

65       <220>  
      <221> unsure  
      <222> 499..500  
      <223> n = a, c, g or t

      <220>

	<221> unsure				
	<222> 516..516				
	<223> n = a, c, g or t				
5	<220>				
	<221> unsure				
	<222> 524..524				
	<223> n = a, c, g or t				
10	<220>				
	<221> unsure				
	<222> 535..535				
	<223> n = a, c, g or t				
15	<220>				
	<221> unsure				
	<222> 538..538				
	<223> n = a, c, g or t				
20	<220>				
	<221> unsure				
	<222> 560..560				
	<223> n = a, c, g or t				
25	<220>				
	<221> unsure				
	<222> 582..582				
	<223> n = a, c, g or t				
30	<220>				
	<221> unsure				
	<222> 592..592				
	<223> n = a, c, g or t				
35	<220>				
	<221> unsure				
	<222> 594..594				
	<223> n = a, c, g or t				
40	<220>				
	<221> unsure				
	<222> 604..604				
	<223> n = a, c, g or t				
45	<400> 45				
	accttaacac cctctgaccc tgaagtcacg ccatacattc ttttgccttc ttttcacac	60			
	catgcaccca ttcacacata ctcaaatag aagggacaga cacccttggg aataattttt	120			
	tgaagacttc tttagcctcc aactcaacag ctccacactg ttgctgcctt tcatgtttt	180			
	tttctctctg gtgtcaact gcactccttc aagaatctaa cknattccag agaccactta	240			
50	tttcttctc kctttctgaa attactttta ataactcttc atgagggggg aaggaagatg	300			
	cctglttgta gttttgttgt ttaagctgct caatttgggg cttaaacaat ttgttctct	360			
	ctgtacatc ctggtaacag ctgtgttctg cntagaaaag attactctcc ctctctntct	420			
	neannnggtt caaccctna aattacattt cctctctctt aaacaanant cttaagtctt	480			
	tcaaacctgt atgcacacac gctctcttca agttangtgc tgaactctcc tgaacatctg	540			
55	ctttaaagat catttctctn tgaacacat aaccacttcc cnglclgggc angncttccc	600			
	ttencttcaa aagagctca aggta	625			
	<210> 46				
	<211> 4416				
60	<212> DNA				
	<213> Homo sapiens				
	<400> 46				
	gcgcacagg gttttatagg atcacattga ccaagctacc atggagtttt atgagtcagc	60			
65	atattttatt gttctctctt ctccaatagt tattacagtc atttctctct tcttctggct	120			
	tttcatgaa gaaacattat atgaggaagt tottgcaaaa cagggagag aacaaaagct	180			
	tattctctacc aaaaacagata aaaaagaaagc agggagaaa aagaatctaa agaaagaaat	240			



	ccagaatgga	aacctccatg	ahccogactc	tgagagtqta	ctctnagact	ctnnattatc	300
	agntgecttg	gcagtaruag	atgati:agnt	tgcacctght	ccattgaetg	togttgaanc	360
	ttcaaghtagt	gttaggggaa	gcaaaaagaa	gganagaaa	caaaagcctg	tqcttgaaga	420
5	gcaggtcatc	anagaaagtg	atgcatcana	gattccnhgc	aaaaaagttag	aacctgtccc	480
	agttactaaa	cagcccaccc	ctccctcttg	agcagctgcn	togaagaayn	aaccagggca	540
	gaaguantct	aaaaatggan	gcgatgacca	ggatcaaaaag	gtgnaaactc	tcalqgtacc	600
	atcaaaaaag	caagaagcat	tgcncctcca	ccaagagant	aaacaagann	gtggatcagg	660
	gangaagaaa	gctkcatcna	agaaacaaaa	gncagaaaat	gtcttcgttag	ahqaacccct	720
	tattcmtqca	actacttata	ttcctttgat	ggatantgct	gactcnaqtc	ctgtggttara	780
10	taagagagay	gttcttqatt	tgcctaaaac	tgaaccaagta	gaagggatcc	anaaatctgg	840
	gaetnaaaaa	ctgaagagay	nnactgacaa	agaantgct	gaaglgcaat	ttaaagatct	900
	ccttctgkcc	ctgaagacta	tgatgttttc	tgaagalyan	gotcttlgky	ttgtagactc	960
	gctaaaggag	anctctgggt	taatacnaqa	tgtctttaaag	auqtoaatga	auqtaagaatt	1020
	gactaagctt	ataactcagg	ttcaagaaaa	ggnaagctta	clcgctgtctg	tgaagynaga	1080
15	tgnlqctnct	acaaaaggac	ggtgttaagca	gttaaacccag	gaatgalyan	cagagaaaqa	1140
	aagaagcaal	gtggttataa	caagynatna	agatcgaacl	ggaaacattag	aaaaqnaaca	1200
	taattgtattt	caaaaacaaa	tacatgtcag	ttahcangag	actcaacagn	tgcagatynh	1260
	gtltcagcna	gttcgtgagc	agatggaggc	agagatagnt	caottgaayc	aggaacaaatg	1320
	tatactgag	natgcagtoa	gcaacactac	nnatcaacty	ynangcaagc	agttctgcaga	1380
20	actaaataaa	clacgcacng	attatgctag	glttgtgaat	gagclgactg	agaaaacagc	1440
	aaagrtccag	caagaggagc	trcaaaaagaa	gaatgtctag	caagcagcta	clcaattgaa	1500
	ggttcaacta	canqaagctg	agagaagylg	ggatgaagtt	cagynctaca	tcagggaagc	1560
	ancagcgag	catgaggcag	caacncaaga	tttacagagt	aaatttctg	ccaaagaaaa	1620
	tgaagtcaag	ogtctgcata	gttaagctaac	agatnccctg	glatcnaaac	aaacgttlyan	1680
25	gcaagacta	atgcttttaa	tggaaatcaga	gcagynaaag	gtgaacaaay	agagctctct	1740
	acaaahgcag	gttcaggata	llhctgagcn	gaatgaggtc	ltgnaagctc	aaatlccagc	1800
	gttccattcc	cagctagcag	cccagacctc	cycttcaagt	ctagcagayc	nattacataa	1860
	agtgattgca	gaazaggyta	anagatana	acagactgyn	natctcttag	canghgcac	1920
	tgatcgtlha	acaaagtaag	aagaggaacl	kanagatata	cagantatga	atttcttatt	1980
30	aaaagctgaa	gtgcagayt	tncaggccct	ggcaaalgag	caggtctctg	clgncatga	2040
	attgynagag	atgcaacaaa	gtglttatgt	taangatgat	aaahhagnt	tgctggaaga	2100
	gcaactacaa	catgaaattt	caaacaaaaat	ggaagatatt	aagattctaa	ahgcacaaa	2160
	caahgcatta	aaatcagaag	llhnaagct	ccagactctt	glttctganc	agcctaataa	2220
35	ggatgttlyg	gaacaaatg	aaatctgat	tcagaynaat	gatgagaagt	haagactnt	2280
	ggaagaatta	cttgaacctg	gacttattoa	ggtggcaac	naagagagc	agctgaatgc	2340
	aataagynca	gaanaattcat	ctctgacaaa	agaggttcaa	gacttaaaag	ctangcaaaa	2400
	tgatcaggtt	tccttttgct	ctctagttag	agaactleay	naatgatcc	atgagaagaa	2460
	tgyanagatc	aagtcgttag	aagagclctt	ggagggcagaa	cttctcaayc	ttgctaacaa	2520
	ggagaaaac	gttcaggatt	tgaacaggaa	aataaagct	ctaaaagaag	aaataggaan	2580
40	tgtccagctt	gaazaggyta	naagcttato	tatcaactcc	aaagltcagg	agcttcagaa	2640
	cttalctaaan	ggaagaggc	aacagatgaa	haactgaag	gctgtttlyy	agagaaagaa	2700
	gaagaccta	yncaatacng	ggaagtgtt	acaggaltcl	caagaagaaa	atgaatcttl	2760
	aaahgcacat	gttcaggagc	hagncacaa	taacttgaaa	gaggcclctt	ctgcataaca	2820
	gtttgagagc	cttgagattg	tttgaaaag	aaagynnat	gaattgagaa	gylhagynag	2880
45	catgotaaaa	gagynagag	gtgatcttcc	tagcaaaan	canctgttac	aggtatgaca	2940
	agahgnaaac	aaattgttta	agtcncaat	tgaacagctt	aaacaacaaan	actnccanac	3000
	ggcatclct	ttcccccctc	atgaagaatt	attaanagtn	atttcagaaa	gagagaaagc	3060
	aataagtggt	clctggaatg	agttagatto	tttgaaggal	ynagttgna	accagaggaa	3120
	gaahcaaat	gaagggcagc	aaagggkyn	ayntgttag	ttggaggcta	aaqaagttct	3180
50	caaaaazett	tttccaaaag	tgtctgtccc	ttctaattly	agttatggtg	aattggttgc	3240
	tggatttgaa	aaaaaygna	aaqaatgtat	gnetggaact	tcaggytca	aggaggttaa	3300
	ggttctagag	cacaagttga	aagaagclga	lgnatgcaac	acattgttac	agctnagatg	3360
	tgaaaaatla	aaatccgtcc	ttgcagaac	agaaygaatt	ttccagaagc	tacagagaag	3420
	tgttgagcaa	gaagaaanta	aatggaagt	taaggtcgat	gaalccacac	agactattaa	3480
55	acagatgcag	tcactcllha	natcttngc	ccagagctta	gagcgattaa	gaaagagaaa	3540
	taagynhatt	gaaaatctga	gaagagaacg	agaactttg	gnaatggaac	tagaaagggc	3600
	agagatggaa	cgatctaccc	atgtttacaga	agtcagagag	tlgagggcna	agttcaatga	3660
	aaactcaca	aaacttagaa	ctgaanaaaa	lgnagacag	aaggttagctg	gtgatttgca	3720
	taagctcna	cagttacagc	agcttaacca	gtcaaaacl	gtanaagctg	ctggagacac	3780
60	tactgttatt	gaahatagtg	atgtttcccc	agaaacggag	ttctctgaga	agagagcaat	3840
	gttgttaagt	ctaaatcagc	ctgtaacaca	gttcaagcag	ttgcttcagg	cggtaaacca	3900
	acagctcaco	agggagaag	agcaactacca	ggtgttagag	tgaaatnatt	gggaaactgt	3960
	tcatttgagg	aknaaaagc	cattgtatta	ttttttgcca	aattaaagcc	lclatttathg	4020
	ttlccacctt	tcactttgt	cagaacactc	gaacagagbt	ttgttttttc	taactcttgt	4080
65	tagactacty	ctttaagaa	ggaacaaact	aagccaaact	tgtagacacc	ttcagagttt	4140
	agttttataa	taaaaaclgt	ttqaatath	agacctttac	attcttgaag	akaaacahgl	4200
	aactclttat	cttattttgc	tcaataaaat	tgtlcaagag	atcaagtggt	taaagacaat	4260

gtaaaattta	acattttaat	acigatgctg	tacactggtt	tacttcaaat	ttlgggaggt	4320
aactgootct	gacttcaact	caagaaaaca	cltttttgtt	gclaatgtaa	tcgttttttg	4380
taatggcgtc	agcaaataaa	aggatgctta	ttattc			4416



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> C12N 15/12, C07K 14/47, A61K 31/70, 35/12, 38/17, C07K 16/18, G01N 33/574, C12Q 1/68	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/20587</b> <b>(43) International Publication Date:</b> 13 April 2000 (13.04.00)
<b>(21) International Application Number:</b> PCT/US99/22873 <b>(22) International Filing Date:</b> 4 October 1999 (04.10.99) <b>(30) Priority Data:</b> 09/166,300 5 October 1998 (05.10.98) US 09/166,350 5 October 1998 (05.10.98) US <b>(71) Applicant:</b> LUDWIG INSTITUTE FOR CANCER RE- SEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US). <b>(72) Inventors:</b> OBATA, Yuichi; Chikusa-Ku, Nagoya 464 (JP). GOUT, Ivan; 91 Riding House Street, London W1P 8BT (GB). TURECI, Ozlem; Innere Medizin 1, D-66421 Hom- burg/Saar (DE). SAHIN, Ugar; Innere Medizin 1, D-66421 Homburg/Saar (DE). PFREUNDSCHUH, Michael; Innere Medizin 1, D-66421 Homburg/Saar (DE). SCANLAN, Matthew, J.; 1275 York Avenue, New York, NY 10021 (US). STOCKERT, Elisabeth; 1275 York Avenue, New York, NY 10021 (US). CHEN, Yao-Tseng; 525 East 68th Street, New York, NY 10021 (US). OLD, Lloyd, J.; 605 Third Avenue, New York, NY 10158 (US). JAGER, Elke; Hohl 2-28, D-60488 Frankfurt am Main (DE). KNUTH, Alex; Hohl 2-28, D-60488 Frankfurt am Main (DE).	<b>(74) Agent:</b> VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).  <b>(81) Designated States:</b> AU, CA, CN, JP, KR, NZ, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 12 October 2000 (12.10.00)	
<b>(54) Title:</b> CANCER ASSOCIATED ANTIGENS AND USES THEREFOR		
<b>(57) Abstract</b> <p>Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in renal cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with renal cancer. The invention provides, <i>inter alia</i>, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/US 99/22873

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 A61K31/70 A61K35/12 A61K38/17  
C07K16/18 G01N33/574 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL Entry AA858164; Accession number AA858164 13.03.1998 National Cancer Institute, Cancer Genome Anatomy Project; of66h01.s1 NCI_CGAP_Co8 Homo sapiens clone IMAGE:1435345; in relation to SEQ ID Nos. 1 and 12 XP002132221 see the abstract --- -/--	55,56, 60,68, 69,71, 72,75



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

23 June 2000

Date of mailing of the international search report

14.07.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Alt, G

## INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/US 99/22873

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL Entry HSAA10936; Accession number 188593 20.01.1997 The WashU-Merck EST Project zp75e04.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 626046; in relation to SEQ ID Nos. 1 and 12 XP002132222 see the abstract ---	55,56, 60,68, 69,71, 72,75
X	Database EMBL Entry AI139112; Accession number AI139112 25.09.1998 National Cancer Institute, Cancer Genome Anatomy Project; qc27h04.x1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:1710871; in relation to SEQ ID Nos. 1 and 12 XP002132223 see the abstract ---	55,56, 60,68, 69,71, 72,75
X	Database EMBL Entry MM1210701; Accession number AA415243 09.05.1997 The WashU-HHMI Mouse EST Project; vd25e08.s1 Knowles Solter mouse 2 cell Mus musculus cDNA clone 793574; in relation to SEQ ID Nos. 1 and 12 XP002132224 see the abstract ---	68,69
X	Database EMBL Entry HS437322, Accession number W00437 19.04.1996 The WashU-Merck EST Project yz99c04.r1 Homo sapiens cDNA clone 291174; in relation to SEQ ID Nos. 1 and 12 XP002132225 see the abstract ---	68,69
A	KAWAHARA, K. ET AL.: "Review: Potassium transport and potassium channels in the kidney tubules" JAPANESE JOURNAL OF PHYSIOLOGY, vol. 47, 1997, pages 1-10, XP000881680 see the whole document; in relation to SEQ ID Nos. 1 and 12 ---	1
A	WANG, W. ET AL.: "Renal K+ channels: Structure and function" ANNUAL REVIEW OF PHYSIOLOGY, vol. 59, 1997, pages 413-436, XP000881688 see the whole document; in relation to SEQ ID Nos. 1 and 12 ---	1
	---	

-/--

## INTERNATIONAL SEARCH REPORT

Int. .ional Application No

PCT/US 99/22873

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL Entry HSAA24402; Accession number AA211485 02.02.1997 zn55c06.s1 Stratagene muscle 937209 Homo sapiens cDNA clone IMAGE:562090 3' similar to TR:E245548 E245548 Chromosome XII Reading frame ORF YLR097C Hillier, L. et al.; in relation to SEQ ID No. 4 XP002140895 see the abstract	55,56, 60,68, 69,71, 72,75
X	SEMENKOVICH C F ET AL: "Human fatty acid synthase mRNA: tissue distribution, genetic mapping and kinetics of decay after glucose deprivation" JOURNAL OF LIPID RESEARCH,US,BETHESDA, MD, vol. 36, no. 7, July 1995 (1995-07), pages 1507-1521-1521, XP002105049 ISSN: 0022-2275 see Figure 1; in relation to SEQ ID No. 5	55,56, 60,68, 69,71, 72,75
X	US 5 665 874 A (KUHAJDA FRANCIS P ET AL) 9 September 1997 (1997-09-09)  see cDNA and protein OA-519 (SEQ ID No. 9) corresponding to columns 43-60; in relation to SEQ ID Nos. 5 and 16	55,56, 60,68, 69,71, 72,75
A	GANSLER, T. S. ET AL.: "Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival" HUMAN PATHOLOGY, vol. 28, 1997, pages 686-692, XP000909948 related to SEQ ID No. 5	1
P,X	WO 99 18989 A (BAYLOR COLLEGE MEDICINE) 22 April 1999 (1999-04-22) see page 109, SEQ ID No. 41; in relation to SEQ ID No. 15	48,49
P,X	WO 98 48020 A (FIORE PIER PAOLO DI ; ISTITUTO EUROP DI ONCOLOGIA S (IT); CAPRA MAR) 29 October 1998 (1998-10-29)  see pages 42-48 corresponding to SEQ ID Nos. 3 and 4; in relation to SEQ ID Nos. 7 and 18  --- -/--	55,56, 60,68, 69,71, 72,75

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/22873

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NAKAMURA, T. ET AL.: "A novel transcriptional unit of the tre oncogene widely expressed in human cancer cells" ONCOGENE, vol. 7, 1992, pages 733-741, XP000670282 see Figure 3; in relation to SEQ ID Nos. 7 and 18	55,56, 60,68, 69,71, 72,75
X	--- RICH, B.E. AND STEITZ, J.A. : "Human acidic ribosomal phosphoproteins P0, P1 and P2: Analysis of cDNA clones in vitro synthesis and assembly " MOLECULAR AND CELLULAR BIOLOGY, vol. 7, 1987, pages 4065-4074, XP000909977 see Figure 1C; phosphoprotein P2; in relation to SEQ ID No. 35	55,56, 60,68, 69,71, 72,75
X	--- SEKI, T. ET AL.: "Cloning of the cDNA encoding a novel importin alpha homologue, Qip1: Discrimination of Qip1 and Rchl from hSrp1 by their ability to interact with DNA helicase A1/RecQL" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 234, 1997, pages 48-53, XP000910159 see Figure 1 & Database EMBL; 10.04.1997; Entry HSAB2533; Accession number AB002533; in relation to SEQ ID No. 35	55,56, 60,68, 69,71, 72,75
A	--- JIANG, C. ET AL.: "Characterization of colorectal cancer related cDNA clones obtained by subtractive hybridization screening " JOURNAL OF CANCER RESEARCH AND ONCOLOGY, vol. 123, 1997, pages 447-451, XP000909986 see the whole document as far as related to phosphoprotein P2	1
A	--- WO 96 29409 A (UNIV LEIDEN ;LUDWIG INST CANCER RES (US)) 26 September 1996 (1996-09-26) the whole document	1
A	--- SAHIN ET AL: "Human neoplasms elicit multiple specific immune responses in the autologous host" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, 1 December 1995 (1995-12-01), pages 11810-11813, XP002091914 ISSN: 0027-8424 cited in the application the whole document	1
	--- -/--	



International Application No  
PCT/US 99/22873

International Application No  
PCT/US 99/22873

Category "	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>SCANLAN, M.J. ET AL.: "Antigens recognized by autologous antibody in patients with renal-cell carcinoma" INTERNATIONAL JOURNAL OF CANCER, vol. 83, 12 November 1999 (1999-11-12), pages 456-464, XP000867569</p> <p>see whole document in relation to SEQ ID Nos. 1, 4, 5, 7, 12, 15, 16, 18 and 35 of the application</p>	1
P,X	<p>&amp; Database EMBL, 06.July 1999; Entry AF155110; Accession number AF155110</p> <p>Scanlan, M.J. et al.; in relation to SEQ ID Nos. 1 and 12</p> <p>&amp; Database EMBL, 06.July, 1999; Entry AF155114; Accession number AF155114;</p> <p>Scanlan, M.J. et al.; in relation to SEQ ID Nos. 4, 5, 15 and 16</p> <p>&amp; Database EMBL; 06.07.1999; Entry AF155116; Accession number AF155116; in relation to SEQ ID No. 7</p> <p>-----</p>	<p>55-60, 68,69, 71,72,75</p>

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/22873

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 78, 79, 81-88, 90-107 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
  
1-12, 14-17, 19-22, 24, 26-35, 37-44, 46-50, 52-69, 71-79, 81-88, 90-107, 109-116 (subject 1, 4, 6 and 22 of non-unity motivation)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Claims Nos.: 1-4, 14-17, 20, 30-35, 39-41, 57-59, 75, 78, 79, 81, 83, 84, 98-101, 104, 109, 110, 112-114

1. The terms NA group 1, NA group 2, etc. and PP group 1, PP group 2, etc. are applicants own reference signs and have therefore no recognised meaning. Consequently, all claims in which these terms are used are unclear within the meaning of Article 6 PCT. For the purposes of the search the terms have been interpreted as shown in the description, pages 14 and 15.

2. Present claims 1, 2 (as far as points (g) - (i) are concerned), 3, 4, 14-17, 20, 30, 39-41, 57-59, 75, 78, 79, 81, 98-101, 104, 109, 110, 112-114 relate to an extremely large number of products and methods defined inter alia by reference to a desirable characteristic or property, namely in the case of

- 1) claims 1-4: "specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an HLA molecule"
- 2) claims 14-17 and 20, 78, 79, 81, 83, 84 and claims 98-101 as far as they relate to claims 14-17: "enriches selectively the presence of complexes of an HLA molecule and a human cancer associated antigen"
- 3) claims 30-35, 39-41: "binds selectively to a ..... polypeptide"
- 4) claims 57-59 and 75: "of sufficient length to represent a sequence unique within the human genome"
- 5) claim 104: "inhibits the expression or activity of the protein"
- 6) claims 109, 110, 112-114: "bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein"

The above mentioned claims cover all products and methods having or using a compound having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a few or even none of these compounds or methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the complete claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound or method inter alia by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely:

- group 1) of claims: antibodies reacting with a peptide encoded by SEQ ID 1 and nucleic acids hybridizing to SEQ ID No. 1
- group 2) of claims: polypeptides encoded by SEQ ID No. 1, host cells expressing them, complexes of said polypeptide with HLA, nucleic acid having SEQ ID No. 1.
- group 3 of claims: antibodies and fragments thereof reacting with polypeptides encoded by SEQ ID No. 1
- group 4 of claims: complete SEQ ID No. 1
- group 5 of claims: antibodies reacting with a polypeptide encoded by SEQ

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

ID No. 1

group 6 of claims: no search

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-12,14-17,19-22, 24, 26-35, 37-44, 46-50, 52-69,  
71-79, 81-88, 90-107,  
109-  
116 all partially as far as they relate to SEQ ID N  
os. 1 and 12

Pharmaceutical compositions or isolated molecules comprising a molecule having the sequence of SEQ ID No. 1 (cl. 42, 43, 55) or the corresponding protein (cl. 48, 68) and HLA binding fragments (cl. 56, 71, 72, 109), an expression vector comprising said DNA molecule (cl.61) and host cells comprising the expression vector (cl. 64) as well as related antibodies (cl. 115).

Fragments of SEQ ID No. 1 which are long enough to represent a sequence unique within the human genome (cl. 57, 75).

Kit for detecting the presence of a SEQ ID No. 1 molecule using nucleotide fragments of SEQ ID NO.1 (cl. 76)

Method of treatment consisting essentially of increasing the immune response to a molecule encoded by SEQ ID NO. 1 (cl. 78, 85, 88, 102) or in the administration of an antibody to such a molecule (cl. 95)

Methods for determining regression, progression or onset of a condition characterized by monitoring SEQ ID No. 1 or encoded molecules, fragments, etc. (cl.5)

Pharmaceutical compositions comprising an agent that enriches selectively the presence of complexes of HLA molecules with polypeptides encoded by SEQ ID No. 1 (cl. 14) and use in a method of treatment (cl. 98)

Composition comprising an agent binding to a polypeptide encoded by SEQ ID No. 1 molecule and fragments (cl. 30-34) or a conjugate thereof (cl. 39).

Method of treatment by inhibiting expression of a polypeptide encoded by SEQ ID No. 1 molecule (cl. 104).

Method of diagnosing using an agent binding to SEQ ID No. 1 or encoded molecule (cl.1)

2. Claims: 1-10,12,14-17,19-22, 24, 26-33, 35, 37-44, 46-50,  
52-69, 71-79, 81-88, 90-107,  
109-  
116 all partially as far as they relate to SEQ ID N  
os. 2 and 13

essentially idem as for subject 1, but related to SEQ ID  
Nos. 2 and 13

3. Claims: 1-10,12,14-17,19-22, 24, 26-33, 35, 37-44, 46-50,  
52-69, 71-79, 81-88, 90-107,  
109-

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N  
os. 3 and 14

essentially idem as for subject 1, but related to SEQ ID  
Nos. 3 and 14

4. Claims: 1-12,14-17,19-22, 24, 26-35, 37-44, 46-50, 52-69,  
71-79, 81-88, 90-107,  
109-  
116 all partially as far as they relate to SEQ ID N  
os. 4, 5, 15 and 16

essentially idem as for subject 1, but related to SEQ ID  
Nos. 4, 5, 15 and 16

5. Claims: 1-10,12,14-17,19-22, 24, 26-33, 35, 37-44, 46-50,  
52-69, 71-79, 81-88, 90-107,  
109-  
116 all partially as far as they relate to SEQ ID N  
os. 6 and 17

essentially idem as for subject 1, but related to SEQ ID  
Nos. 6 and 17

6. Claims: 1-12,14-17,19-22, 24, 26-35, 37-44, 46-50, 52-69,  
71-79, 81-88, 90-107,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 7 and 18

essentially idem as for subject 1, but related to SEQ ID  
Nos. 7 and 18

7. Claims: 1-10,12,14-17,19-22, 24, 26-33, 35, 37-44, 46-50,  
52-69, 71-79, 81-88, 90-107,  
109-  
116 all partially as far as they relate to SEQ ID N  
os. 8, 9, 19, 20

essentially idem as for subject 1, but related to SEQ ID  
Nos. 8, 9, 19 and 20

8. Claims: 1-10,12,14-17,19-22, 24, 26-33, 35, 37-44, 46-50,  
52-69, 71-79, 81-88, 90-107,  
109-

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N  
os. 10, 11, 21

essentially idem as for subject 1, but related to SEQ ID  
Nos. 10, 11 and 21

9. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 22

essentially idem as for subject 1, but related to SEQ ID No.  
22

10. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 23

essentially idem as for subject 1, but related to SEQ ID No.  
23

11. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 24

essentially idem as for subject 1, but related to SEQ ID No.  
24

12. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 25

essentially idem as for subject 1, but related to SEQ ID No.  
25

13. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N  
o. 26

essentially idem as for subject 1, but related to SEQ ID No.  
26

14. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 27

essentially idem as for subject 1, but related to SEQ ID No.  
27

15. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 28

essentially idem as for subject 1, but related to SEQ ID No.  
28

16. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 29

essentially idem as for subject 1, but related to SEQ ID No.  
29

17. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 30

essentially idem as for subject 1, but related to SEQ ID No.  
30

18. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N  
o. 31

essentially idem as for subject 1, but related to SEQ ID No.  
31

19. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 32

essentially idem as for subject 1, but related to SEQ ID No.  
32

20. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 33

essentially idem as for subject 1, but related to SEQ ID No.  
33

21. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,  
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 34

essentially idem as for subject 1, but related to SEQ ID No.  
34

22. Claims: 1-9,11,12,14-16,19-22, 24, 26, 28-31, 34, 35,  
37-42, 44, 46-48, 50, 52-54, 69, 71-79, 81-88,  
90-106,  
109-  
116 all partially as far as they relate to SEQ ID N  
o. 35

essentially idem as for subject 1, but related to SEQ ID No.  
35

23. Claims: 1-12,14-17,19-22, 24, 26-35, 37-44, 46-50, 52-69,  
71-79, 81-88, 90-107,

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

109-  
116 all partially as far as they relate to SEQ ID Nos. 36-46

Pharmaceutical compositions or isolated molecules comprising a molecule having the sequence of SEQ ID Nos. 36-46 (cl. 42) or the corresponding protein (cl. 48, 70) and HLA binding fragments (cl. 71, 72, 109), an expression vector comprising said DNA molecule (cl. 61) and host cells comprising the expression vector (cl. 64) as well as related antibodies (cl. 115).

Fragments of SEQ ID Nos. 36-46 which are long enough to represent a sequence unique within the human genome (cl. 57).

Kit for detecting the presence of a SEQ ID Nos. 36-46 molecule using nucleotide fragments of SEQ ID Nos. 36-46 (cl. 76)

Method of treatment consisting essentially in increasing the immune response to proteins encoded by SEQ ID Nos. 36-46 (cl. 78, 85, 88, 102) or in the administration of an antibody binding to the protein encoded by SEQ ID No. 36-46 (cl. 95)

Methods for determining regression, progression or onset of a condition characterized by monitoring SEQ ID Nos. 36-46 molecules or encoded fragments, etc. (cl. 5).

Pharmaceutical compositions comprising an agent that enriches selectively the presence of complexes of HLA molecules and molecules encoded by SEQ ID Nos. 36-46 (cl. 14) and use in a method of treatment (cl. 98)

Composition comprising an agent binding to proteins encoded by SEQ ID Nos. 36-46 (cl. 30, 32, 34) or a conjugate thereof (cl. 39)

Method of treatment by inhibiting expression of a protein encoded by SEQ ID Nos. 36-46 (cl. 104)

Method of diagnosing using an agent binding to SEQ ID Nos. 36-46 molecule or protein encoded (cl. 1)

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

Int. l. Application No  
PCT/US 99/22873

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5665874 A	09-09-1997	US 5759791 A	02-06-1998
		US 5872217 A	16-02-1999
		US 5864011 A	26-01-1999
		US 5759837 A	02-06-1998
		AU 682007 B	18-09-1997
		AU 4786493 A	14-02-1994
		CA 2140866 A	03-02-1994
		EP 0651636 A	10-05-1995
		JP 7509470 T	19-10-1995
		MX 9304501 A	29-04-1994
		WO 9402108 A	03-02-1994
		AT 151882 T	15-05-1997
		AU 632535 B	07-01-1993
		AU 5040690 A	13-08-1990
		CA 2045552 A	26-07-1990
		DE 69030494 D	22-05-1997
		DE 69030494 T	07-08-1997
		DK 454782 T	27-10-1997
		EP 0454782 A	06-11-1991
		ES 2101695 T	16-07-1997
		JP 2959837 B	06-10-1999
		JP 4504110 T	23-07-1992
		KR 174528 B	15-05-1999
		WO 9008324 A	26-07-1990
WO 9918989 A	22-04-1999	AU 1088399 A	03-05-1999
WO 9848020 A	29-10-1998	IT MI970905 A	19-10-1998
		AU 7077998 A	13-11-1998
WO 9629409 A	26-09-1996	US 5939526 A	17-08-1999
		AU 705768 B	03-06-1999
		AU 5429896 A	08-10-1996
		CA 2211448 A	26-09-1996
		EP 0815229 A	07-01-1998
		JP 11506904 T	22-06-1999
		NZ 306122 A	29-06-1999
		ZA 9602280 A	28-08-1996

**THIS PAGE BLANK (USPTO)**